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Glossary 
 
Adenoma  A benign epithelial neoplasm in which the tumor cells 
form glands or glandlike structures. Usually well 
circumscribed, tending to compress rather than  
infiltrate or invade adjacent tissue. 
 
Allele  Any one of a series of two or more different genes that 
may occupy the same locus on a specific chromosome. As 
Autosomal chromosomes are paired, each autosomal 
gene is represented twice in normal somatic cells. If  
the same allele occupies both units of the locus, the 
individual or cell is homozygous for this allele. If the 
alleles are different, the individual or cell is 
heterozygous for both alleles. 
 
Appendix A wormlike intestinal diverticulum extending from the 
blind end of the cecum; it varies in length and ends in 
a blind extremity. 
 
Benign  Denoting the non-malignant character of a neoplasm. 
 
Cancer  General term frequently used to indicate any of various  
types of malignant neoplasms, most of which invade 
surrounding tissues, may metastasize to several sites, 
and are likely to recur after attempted removal and to 
kill the patient unless adequately treated; especially, 
any such carcinoma or sarcoma, but, in ordinary 
usage, especially the former. 
 
Carcinoma  Any of various types of malignant neoplasm derived 
from epithelial cells, chiefly glandular 
(adenocarcinoma) or squamous (squamous cell 
carcinoma); the most commonly occurring kind of 
cancer. 
 
Colon  The large intestine extending from the caecum to the 
rectum. 
 
DNA Deoxyribonucleic acid (DNA) is the type of nucleic acid 
containing deoxyribose as the sugar component and 
found principally in the nuclei (chromatin, 
chromosomes) and mitochondria of animal and plant 
cells. Many forms are known, the most commonly 
described of which is double stranded / double helix. 
Chromosomes are composed of double-stranded 
DNA. 
 
Dysplasia Abnormal tissue development. 
 
 7 
Epigenetic Relating to epigenesis; the regulation of the 
expression of gene activity without alteration of genetic 
structure. 
 
Exophytic  Denoting a neoplasm or lesion that grows outward 
from an epithelial surface. 
 
Gene  A functional unit of heredity that occupies a specific 
place (locus) on a chromosome, is capable of 
reproducing itself exactly at each cell division, and 
directs the formation of an enzyme or other protein. In 
organisms reproducing sexually, genes normally 
occur in pairs in all cells except gametes, as a 
consequence of the fact that all chromosomes are 
paired except the sex chromosomes (X and Y) of the 
male. 
 
Germline A collection of haploid cells derived from the 
specialized cells of the primitive gonad. 
 
Growth factor Natural substances produced by the body (hormones) 
or obtained from food (vitamins, minerals) that 
promote growth and development by directing cell 
maturation and differentiation and by mediating 
maintenance and repair of tissues; abnormalities in 
growth factors may be involved in benign and 
malignant neoplasia. 
 
Malignant  In reference to a neoplasm, having the property of 
locally invasive and destructive growth and metastasis. 
 
Mass A lump or aggregation of coherent material. 
Commonly used as a synonym for tumor or neoplasm. 
 
Metastatic Relating to metastasis; the spread of a disease 
process from one part of the body to another, as in the 
appearance of neoplasms in parts of the body remote 
from the site of the primary tumour; results from 
dissemination of tumour cells by the lymphatics or 
blood vessels or by direct extension through serous 
cavities or subarachnoid or other spaces. 
 
Mismatch repair Replacement of mismatched base pairs by removal of 
the incorrect base and replacement with the correct 
base by DNA polymerase. 
 
Mucosa A mucous tissue lining various tubular structures 
consisting of epithelium, lamina propria, and, in the 
digestive tract, a layer of smooth muscle (muscularis 
mucosa). 
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Mutation  A change in the chemistry of a gene that is 
perpetuated in subsequent divisions of the cell in 
which it occurs; a change in the sequence of base 
pairs in the chromosome. 
 
Neoplasia / Neoplasm An abnormal tissue that grows by cellular proliferation 
more rapidly than normal and continues to grow after 
the stimuli that initiated the new growth cease. 
Neoplasms show partial or complete lack of structural 
organization and functional coordination with the 
normal tissue, and usually form a distinct mass of 
tissue that may be either benign (benign tumour) or 
malignant (cancer). 
 
Oncogenes Any of a family of genes that normally encodes 
proteins that are involved in cell growth or regulation 
but that may foster malignant processes if mutated.  
 
Pedunculated polyp Any form of polyp that is attached to the base tissue 
by means of a slender stalk. 
 
Polyp A general descriptive term used with reference to any 
mass of tissue that bulges or projects outward or 
upward from the normal surface level, thereby being 
macroscopically visible as a hemispheroidal, 
spheroidal, or irregular moundlike structure growing 
from a relatively broad base or a slender stalk; polyps 
may be neoplasms, foci of inflammation, degenerative 
lesions, or malformations. 
 
Rectum  The terminal portion of the digestive tube, extending 
from the rectosigmoid junction to the anal canal. 
 
Sessile polyp Any form of polyp that has a relatively broad base. 
 
Somatic cells The cells of an organism, other than the germ cells. 
 
Stricture A circumscribed narrowing of a hollow structure. 
 
Tumour suppressor gene A gene that encodes a protein involved in controlling 
cellular growth; inactivation of this type of gene leads 
to deregulated cellular proliferation, as in cancer. 
 
 
Glossary terms defined using Stedman’s Medical Dictionary. London: 
Lippincott Williams & Wilkins; 2006 via www.medilexicon.com  
Accessed 5 Feb 2014 
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Abbreviations 
 
ACPGBI Association of Coloproctology of Great Britain and Ireland 
AGREE Appraisal of Guidelines for Research and Evaluation 
Instrument - original version and version II (AGREE II) 
AHRQ Agency for Healthcare Research and Quality (of the United 
States) 
ALP Alkaline phosphatase 
ALT Alanine transaminase 
APC Adenomatous polyposis coli 
APR Abdominoperineal resection 
ASA American Society of Anesthesiologists 
ÄZQ German Agency for Quality in Medicine (Ärztliches Zentrum 
für Qualität in der Medizin) 
BAX B cell lymphoma (BCL)- 2-associated X protein 
BC Before Christ 
BRAF B homolog rapidly accelerated fibrosarcoma proto-oncogene 
CANISC Cancer Network Information System Cymru 
CBO Dutch Institute for Healthcare Improvement (founded as the 
Central Accompagnement Organization for Peer Review by 
the Dutch Association of Chief Medical Officers) 
CCP Centre for Clinical Practice at the National Institute of Health 
and Clinical Excellence 
CDKN2A Cyclin-dependent kinase inhibitor 2A gene; (methylated tumor 
suppressor gene p16) 
c-e Contrast-enhanced 
CEA Carcinoembryonic antigen (tumour marker) 
CECT Contrast-enhanced x-ray computed tomography 
CI 95% confidence interval 
CIN Chromosomal instability 
CNS Cancer nurse specialist 
COSD Cancer Outcomes and Services Dataset 
CRC Colorectal cancer 
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CRM Circumferential margin 
CRUK Cancer Research UK 
CT X-ray computed tomography 
CTAP X-ray computed tomography during arterioportography 
cTcNcM Clinical staging using the T-N-M classification 
CUP Cancer of unknown primary origin 
DCC Deleted in colon cancer 
DCO Death certificate only: cases represented in colorectal cancer 
data and identified only from death certificates 
DFS Disease-free survival 
DIPEX Database of Individual Patient Experience 
DNA Deoxyribonucleic acid 
DoH Department of Health 
DWI Diffusion-weighted imaging – a magnetic resonance imaging 
modality in which the intensity of each three-dimensional 
image element (voxel) reflects the rate of water diffusion at the 
corresponding location 
DWI MRI Diffusion-weighted imaging modality of magnetic resonance 
imaging 
EBM Evidence-based medicine 
EGFR Epidermal growth factor receptor 
ENCORE English National Cancer Online Registration Environment 
ESD Endoscopic submucosal dissection 
EUS Endo-anal ultrasound scan 
FAP Familial adenomatous polyposis 
FDG 
(F-18-FDG) 
18F-fluoro-2-deoxy-D-glucose – a radiopharmaceutical and 
biologically active tracer used in the medical imaging modality 
positron emission tomography 
FDG PET Positron emission tomography using the tracer 18F-
fluorodeoxy-D-glucose (FDG) 
FDG PETCT Positron emission tomography and x-ray computed 
tomography using the tracer 18F-fluorodeoxy-D-glucose (FDG) 
Gad MRI Gadolinium contrast-enhanced magnetic resonance imaging 
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GAIN Guidelines Audit and Implementation Network 
GDG National Institute of Health and Clinical Excellence guideline 
development group of health professionals 
GI gastrointestinal 
GILDA Gruppo Italiano di Lavoro per la Diagnosi Anticipata – a large-
scale multi-center European study to delineate the optimal 
surveillance strategy following resection of primary colorectal 
cancer 
G-I-N Guidelines International Network 
GMC General Medical Council 
GP(s) General Practitioner(s) 
GPRD General Practice Research Database 
GRADE Grading of Recommendations Assessment Development and 
Evaluation – a method of quality assessment and evidence 
grading developed by the GRADE Working Group 
commencing in 2000 
HES Hospital Episode Statistics - a data repository containing 
details of all admissions, out-patient appointments and 
Accident & Emergency attendances at NHS hospitals in 
England 
hMLH1 Human mutational homolog 1 
hMSH2 Human mutational homolog 2 
HNPCC Hereditary non-polyposis colon cancer 
HSW Health Solutions Wales (predecessor of the NHS Wales 
Informatics Service (NWIS)) 
HTA Health Technology Assessment programme of the National 
Institute for Health Research 
IACR International Association of Cancer Registries 
IARC International Agency for Research on Cancer (of the World 
Health Organization) 
ICBP International Cancer Benchmarking Partnership 
ICD-10 International Classification of Diseases version 10 
ICER Incremental cost-effectiveness ratio 
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IOUS Intra-operative ultrasound 
IP Interventional procedures 
IT Index test(s) 
I2 (I squared) I squared index is the percentage of total variation across 
studies in a meta-analysis that is due to heterogeneity rather 
than chance 
K-ras Kirsten rat sarcoma viral oncogene homolog 
lapUSS Laparoscopic ultrasound scan 
LETR ‘Linking Evidence To Recommendation’ 
LSHTM London School of Hygiene and Tropical Medicine 
MDCT Multidetector row x-ray computed tomography 
MDT Multi-disciplinary team 
MeSH Medical Subject Headings - a  thesaurus of medical terms 
used by many databases and libraries to index and classify 
medical information. It helps to overcome differences in UK 
and US English and different terminology applied to identical 
concepts 
met Solitary metastasis 
mets Metastases 
MLH1 Mutational homolog 1 
MMR Mismatch-repair 
MnDPDP 
MRI 
Mangafodipir trisodium contrast-enhanced magnetic 
resonance imaging 
MOSAIC Multicentre international study of oxaliplatin, 5-fluorouracil and 
leucovorin in the adjuvant treatment of colon cancer 
MRI Magnetic resonance imaging 
MSI Microsatellite instability 
NA Not applicable 
NATCANSAT National Cancer Services Analysis Team 
NBCA National Bowel Cancer Audit 
NBOCAP National Bowel Cancer Audit Project 
NCASP National Clinical Audit Support Programme of the NHS 
Information Centre (NHS-IC) 
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NCC(s) National Collaborating Centre(s) 
NCC-C National Collaborating Centre for Cancer 
NCCN National Comprehensive Cancer Network 
NCDR National Cancer Data Repository 
NCIN National Cancer Intelligence Network 
NCRI National Cancer Research Institute 
n-e Non-enhanced 
NGC National Guideline Clearinghouse (of the United States) 
NHG Dutch College of General Practitioners (Nederlands 
Huisartsen Genootschap) 
NHS National Health Service 
NHS-IC NHS Information Centre 
NWIS NHS Wales Informatics Service 
N-H-L Non-Hodgkin lymphoma 
NICE National Institute of Health and Clinical Excellence 
NICR Northern Ireland Cancer Registry 
NMSC Non-melanoma skin cancer 
No. / no. number of 
NPV Negative predictive value 
NSABP C-07 National Surgical Adjuvant Breast and Bowel Project study 07 
to evaluate the efficacy of different adjuvant chemotherapy 
regimens for Dukes stages B and C colon cancer 
NYCRIS Northern and Yorkshire Cancer Registry and Information 
Service 
ONS Office for National Statistics 
OPCS-4.5 Office of Population Censuses and Surveys Classification of 
Surgical Operations and Procedures version 4.5 
OR Odds ratio 
OS Overall survival 
p P-value: in statistical significance testing, the probability of 
obtaining a test statistic at least as extreme as the one 
observed assuming the null hypothesis is true 
PbR ‘Payment by results’ policy for the remuneration of health 
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service providers 
PEDW Patient Episode Database for Wales 
PET Positron emission tomography 
PETCT Positron emission tomography and x-ray computed 
tomography 
PICO Patient, intervention, comparison and outcome framework 
PPV Positive predictive value 
pre-op Pre-operative 
post-op Post-operative 
pTpNpM Pathological staging using the T-N-M classification 
p14 Tumor suppressor gene p14 
p16 Tumor suppressor gene p16 
p53 Tumor protein p53, in humans encoded by the TP53 gene 
QALY(s) Quality Adjusted Life Year(s) 
QoL Quality of Life 
QUADAS Quality Assessment of Diagnostic Accuracy Studies (quality 
assessment tool) 
RCT(s) Randomised controlled trial(s) 
REVMAN 5 Review Manager 5: the Cochrane Collaboration’s meta-
analysis software for preparing and maintaining Cochrane 
reviews (version 5) 
RS Reference standard 
RTDS Radiotherapy dataset 
R0 Resection for cure or complete remission in the R 
classification adopted in 1987 by the Union for International 
Cancer Control (UICC) denoting the absence or presence of 
residual tumour after treatment 
ROC Receiver-operator characteristic curve 
SACT Systemic Anti-Cancer Therapy Data Standard 
SBRT Stereotactic body radiotherapy 
SCPRT Short-course pre-operative radiotherapy 
SCR Scottish Cancer Registry 
SEMS Self-expanding metal stent(s) 
 15 
SIGN Scottish Intercollegiate Guidelines Network 
SPIO-MRI Superparamagnetic iron oxide nanoparticle contrast-enhanced 
magnetic resonance imaging 
spiral CT Spiral (or helical) cone beam x-ray computed tomography 
SR(s) Systematic review(s) 
SSCRGs Site-Specific Clinical Reference Groups 
SS-EPI-DWI Single shot echo planar diffusion-weighted magnetic 
resonance imaging 
SS SE-EPI Unenhanced single-shot spin-echo echo planar magnetic 
resonance imaging 
SUS ‘Secondary User Services’ (British Telecom database 
management system) 
TEMS Transanal endoscopic microsurgery 
TGF- Transforming growth factor beta 
TGFBR2 Transforming growth factor beta receptor type 2 
TNM Tumor–node–metastases 
TN True negative(s) 
TP True positive(s) 
UICC Union for International Cancer Control 
UK United Kingdom 
UKACR United Kingdom Association of Cancer Registries 
US United States 
USA United States of America 
USS Ultrasound scan 
v Versus 
WICSU Welsh Cancer Intelligence and Survival Unit 
XNMSC Excluding non-melanoma skin cancer 
1 Primary 
15-PGDH 15-prostaglandin dehydrogenase 
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1.0 Introduction  
 
1.1 Colorectal cancer 
Colorectal cancer (CRC) is the third most common cancer in the UK and the 
second leading cause of cancer deaths.[1] Colorectal cancer includes 
cancerous growths in the colon, rectum and appendix.[1] Most colorectal 
cancers arise from adenomatous polyps (adenomas). These neoplasms are 
usually benign, but some develop into cancer over time.[2] It is a common 
form of malignancy in developed countries but occurs much less frequently in 
the developing world.[1] 
 
Colon cancer is believed to be caused by a cascade of genetic mutations 
leading to progressively disordered local DNA replication and accelerated 
colonocyte replication. The progressive accumulation of multiple genetic 
mutations results in the transition from normal mucosa to benign adenoma to 
severe dysplasia to carcinoma. This is referred to as the adenoma-to-cancer 
sequence and is presented graphically in figure 1.1.[2] 
 
Figure 1.1: Genes & Growth Factor Pathways that drive the progression of 
colorectal cancer.[3] 
 
 
 
 22 
In the progression of colon cancer, genetic alterations target the genes that 
are identified at the top of the figure 1. The microsatellite instability (MSI) 
pathway is initiated by mismatch-repair (MMR) gene mutation or by aberrant 
MLH1 methylation and is further associated with downstream mutations in 
TGFBR2 and BAX. Aberrant MLH1 methylation and BRAF mutation are each 
associated with the serrated-adenoma pathway.[3] 
 
The question mark in figure 1 indicates genetic or epigenetic changes specific 
to metastatic progression that have not been identified. Key growth factor 
pathways that are altered during colon neoplasia are shown at the bottom of 
figure 1. CIN denotes chromosomal instability, EGFR epidermal growth factor 
receptor, 15-PGDH 15-prostaglandin dehydrogenase, and TGF- 
transforming growth factor .[3] 
 
An individual’s risk of developing cancer depends on many factors. It is 
dependent on increasing age with 83% of cases arising in people who are 60 
years or older.[4] Diet has also been shown to have an effect and a high 
intake of red and processed meat [5], as well as a high alcohol intake [5] 
increases the chances of developing bowel cancer.  
 
In contrast, high fibre content in the diet has been shown to reduce the risk of 
colorectal cancer.[5] Other known risk factors are obesity [6], physical 
inactivity [7] and cigarette smoking.[8] In addition people with a first degree 
relative with bowel cancer are at increased risk of developing it themselves.[9]   
 
Most cases of colorectal cancer occur in people with no family history of the 
disease (sporadic). Investigation of the genetic inheritance of two uncommon 
familial colon cancer syndromes, familial adenomatous polyposis (FAP) and 
hereditary non-polyposis colon cancer (HNPCC), led to dramatic 
breakthroughs in understanding the pathogenesis and molecular basis of the 
more common sporadic (non-syndromic) form of colon cancer.[2] 
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FAP was shown to be caused by germ line mutation of the APC gene 
(adenomatous polyposis coli). A patient with FAP carries this germ line 
mutation in one allele in all somatic cells, including colonocytes. This mutation 
underlies the development of hundreds of adenomatous polyps throughout 
the colon; colonic adenomas form when the second APC allele is damaged or 
lost in a colonocyte.[10–15] 
 
Spontaneous somatic APC mutation in colonocytes is believed to underlie the 
development of sporadic adenomatous polyps. APC gene mutations occur 
early in adenoma development.[16] APC mutations are found in about 50% of 
sporadic adenomas [17] and are thought to account for 80% of sporadic colon 
cancers.[18] Adenomas usually remain benign. Malignant transformation 
requires further genetic alterations.[18] 
 
The DCC (deleted in colon cancer) gene normally promotes apoptosis (cell 
death) and suppresses tumours. Loss of the normal DCC gene is believed to 
be important in the transition from an intermediate to a late adenoma.[19] 
 
The normal p53 gene product arrests the cell cycle following DNA injury to 
permit either DNA repair if the damage is correctable, or apoptosis if the 
damage is too severe. Mutation of the p53 gene is believed to be important in 
the transition from late adenoma to carcinoma. About 50% of lesions with 
high-grade dysplasia and about 75% of cancers exhibit loss of normal p53 
function.[20, 22] 
 
The K-ras gene encodes for a protein involved in signal transduction from the 
cell membrane to the nucleus.[23] Specific mutations of this gene result in 
constitutive activation of this signal pathway and increased colonocyte 
replication. These mutations are associated with exophytic growth of 
adenomas in the transition to carcinoma.[24] About 50% of colon cancers 
have K-ras mutations.[19] 
 
HNPCC was shown to be caused by mutations of one of the mismatch repair 
genes.[24]  Germ line mutations of the hMLH1 and hMSH2 genes account for 
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most of the cases. Cells with mismatch repair gene mutations cannot repair 
spontaneous DNA errors and progressively accumulate mutations throughout 
the genome with succeeding DNA replications. This progressive accumulation 
in oncogenes and tumour suppressor genes can result in colon cancer.[25] 
Mutations of the mismatch repair genes are believed to account for about 
15% of sporadic colon cancers.[18] 
 
Methylation (the addition of a methyl group) of DNA at specific sites such as 
at promoter regions can terminate gene expression without DNA mutation.[26] 
Colon cancer is sometimes associated with methylation and inactivation of the 
p14 gene, normally an upstream inducer of the p53 tumour suppressor 
pathway. This occurs in about 25% of colon cancers.[27] Methylation of the 
tumor suppressor gene p16, designated CDKN2A, occurs in about 35% of 
colon cancers.[28] 
 
Colon cancer can occur in a pedunculated polyp, sessile polyp, mass, or 
stricture. Small polyps rarely contain cancer. Only about 1% of diminutive 
polyps contain cancer.[29] Cancer in a sessile polyp may metastasize faster 
than cancer in a pedunculated polyp because of the closer proximity of the 
lymphatic drainage.[30] 
 
Colon cancers are classified as well-differentiated, moderately well 
differentiated, or poorly differentiated on the degree of preservation of normal 
glandular architecture and cytologic features. Progressively more poor 
differentiation is presumably a histological marker of further underlying genetic 
mutations, but the mutations associated with poor differentiation are currently 
unknown.[31-33] 
 
When staging the disease the term carcinoma in situ, or high-grade dysplasia, 
is pathologically confined to the mucosa without penetration of the muscularis 
mucosa. Invasive colon cancer is commonly staged from A to C according to 
the Dukes system [34] (Table 1.1). 
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 Table 1.1: Dukes classification of the stages of colorectal cancer[34] 
stage A Growth does not extend into peri rectal tissue. 
stage B Growth extends into peri rectal tissue but does not spread to lymph 
glands.  
  
stage C Growth metastasised to regional lymph nodes  
  
 
Colorectal cancer is more recently staged according to the tumor–node–
metastases (TNM) classification (table 1.2) [35].  
 
Table 1.2: The 7th edition of the TNM classification of colorectal cancer by the 
American Joint Committee on Cancer.[35] 
 T Stage Depth of primary tumour 
T1 Tumour is only in the inner layer of the bowel - submucosa 
T2 Tumour has grown into the muscle layer of the bowel wall – 
muscularis propria 
T3 Tumour has grown into the outer lining of the bowel wall – into 
subserosa or into non-peritonealised pericolic or perirectal tissue. 
T4 Tumour has grown through the outer lining of the bowel wall.  It 
may have broken through the membrane covering the outside of 
the bowel (the visceral peritoneum) – T4a 
It may have grown into another part of the bowel, or other nearby 
organs or structures. – T4b 
N Stage Lymph node metastasis 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 (N1a), 2-3  (N1b) pericolic or perirectal lymph 
nodes. Metastasis in the subserosa, mesentry, or pericolic-
perirectal tissue without regional nodal metastasis (N1c) 
N2 Metastasis in 4 or more pericolic or perirectal lymph nodes 
4-6 nodes (N2a) 
>7 nodes (N2b) 
M Stage Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis (one organ M1a), (>1organ M1b) 
 
The number system uses the TNM stages to group bowel cancers. There are 
5 stages in total but stage 0  - carcinoma in situ – is non-invasive. There are 4 
stages of invasive colon cancer.[35] 
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Table 1.3 The number system to stage colorectal cancer based on TNM [35] 
Stage  
I T1, N0, M0 or T2, N0, M0 
IIa T3, N0, M0 
IIb T4a, N0, M0 
IIc T4b, N0, M0 
IIIa T1-2, N1/N1c M0,      T1,N2a,M0 
IIIb T3, N1, M0 or T4, N1, M0 
IIIc any T, N2, M0 
IVa any T, any N, M1a 
IVb any T, any N, M1b 
 
The TNM and Dukes’ classification systems correspond with each other and 
are used in parallel by health professionals in the menagement of colorectal 
cancer (Table 1.4). 
 
Table 1.4: Correlation between TNM and Dukes classification systems[35] 
TNM stage Dukes stage 
Stage I Dukes A or B1  
Stage II Dukes B2  
Stage III Dukes C  
Stage IV - 
 
Pathologic stage, as classified by either scheme, is highly correlated with 
cancer prognosis.[36] 
 
In the diagnosis and treatment of colorectal cancer it is important that the 
investigations and treatment modalities patients receive adhere to certain 
standards and that patients have access to the most appropriate treatment for 
their condition. Clinical practice is about making choices. The answer to most 
clinical questions depends on the practitioner’s knowledge, skills and 
attitudes, the resources available, and the patient’s concerns, expectations, 
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and values.[37] Unfortunately there can be a variable gap between what is 
known from research and what is done in clinical practice. In the last 40 years 
attempts have been made towards a more systematic approach to the 
evidence that underpins medical practice. 
 
1.2 Evidence-based medicine (EBM) 
In 1972 the British epidemiologist Archie Cochrane highlighted the fact that 
most treatment-related decisions were not based on systematic review of 
clinical research. Rather they were based on ad-hoc selection of information 
from the vast scientific literature of variable quality, on expert opinion, or worst 
of all, on trial and error.[37] 
 
Cochrane proposed that researchers and practitioners collaborate  
internationally to systemically review all the best clinical trials by specialty.[38] 
An international collaboration was indeed established and in the early 1990s 
funds were provided by the UK National Health Service to establish the 
Cohrane Centre in Oxford. This work has been continued through the 
Cochrane collaboration which publishes systematic reviews of randomised 
controlled trials (RCTs) electronically in the Cochrane Database of Systematic 
Reviews within the Cochrane Library. Access in many countries is available 
free and online.[37,39]  
 
Also in the early 1990s, David Sacket and his colleagues from McMaster 
University in Ontario, Canada, coined the term ‘evidence-based medicine’ to 
mean ‘integrating clinical expertise and patient values with the best available 
external clinical evidence from systematic research to achieve the best 
possible patient management’.[40] 
 
Over the years ‘evidence-based medicine’ has evolved into ‘evidence-based 
practice’ to include a wider provision of healthcare but the principles remain 
the same and that is to improve the quality of healthcare provided through 
systematic searching and appraisal of the research evidence. 
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There are several controversial areas with regard to the diagnosis and 
treatment of colorectal cancer. This, together with NHS funding arrangements 
can lead to differences in the management and availability of different 
treatments to patients in different areas of the UK. 
 
Guideline development is one method by which this issue is currently being 
addressed and it is an attempt to ensure that the quality of the information on 
which healthcare decisions are based follows the principles of EBM. 
 
1.3 Guidelines 
A medical guideline is defined as a systematically developed statement to 
help clinicians and patients with decision-making regarding diagnosis, 
management, and treatment in specific areas of healthcare. The aim is to 
standardize medical care, to raise quality of care, to reduce risk, and to 
achieve the best balance between cost and effectiveness. Once a guideline is 
published quality standards can be developed to assist the implementation of 
the guideline and improve patient care nationwide.[41]    
 
Guidelines have been in use for thousands of years during the entire history 
of medicine. In the late 5th century BC, Hippocrates wrote the Hippocratic 
oath. One of its main principles, “Do no harm” or nonmaleficence, is today the 
cornerstone of medical ethics. Though originally intended to guide the practice 
of his pupils, the oath still holds relevance today and is taken by new doctors 
in many countries.[42] 
 
Guidelines are never mandatory by definition. However there are situations 
where by law a doctor whose practice deviates from certain guidelines may be 
faced with legal proceedings. Guidelines can therefore be classified into 
Statutory and Advisory. 
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1.3.1 Statutory guidelines  
 
General Medical Council guidance 
Statutory guidelines are subject to the Law and for doctors this type of 
guidance is produced by the General Medical Council (GMC). 
 
The purpose of the GMC is to protect, promote and maintain the health and 
safety of the public by ensuring proper standards in the practice of medicine. 
The GMC was established under the Medical Act of 1858. Over time a range 
of new legislation has been introduced that defines its powers and 
responsibilities. To practice medicine in the UK all doctors are required by law 
to be both registered with the GMC and hold a license to practice. Licensed 
doctors are required to demonstrate to the GMC that they are practising in 
accordance with the generic standards of practice set by the GMC.[43] 
 
Good Medical Practice (2006)[44] is the core guidance which the GMC 
produces for doctors regarding their fitness to practice. This guidance sets out 
the principles and values on which good practice and medical professionalism 
is founded. Quoting directly from the Good Medical Practice Document 2006 
“It is the responsibility of every doctor registered with the GMC to be familiar 
with Good Medical Practice (2006) and to follow the guidance it contains. It is 
guidance, not a statutory code, so every doctor must use their judgement to 
apply the principles to the various situations they are faced with. Every doctor 
must be prepared to explain and justify his or her decisions and actions. 
“Serious or persistent failure to follow this guidance will put your registration at 
risk.”[44] 
 
This is therefore a situation where a by law a regulatory body has the power 
to remove a doctor’s licence to practice if the doctor fails to justify 
appropriately the reasons from deviating from the set guidance. 
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1.3.2 Advisory Guidelines 
 
Although the production of advisory guidelines does not directly relate to an 
act of parliament in the same way as the GMC guidelines do, failure by a 
doctor to comply with advisory guidelines can also lead to dispute with an 
employer or in the case of patient harm or percieved harm to negligence 
proceedings. It is important to highlight that “a doctor is not guilty of 
negligence if he has acted in accordance with a practice accepted as proper 
by a responsible body of medical men skilled in the relevant art.” (Bolam test 
1957).[45] Therefore once again the doctor who goes against accepted 
professional guidance needs to be able to justify his actions appropriately. 
There are a variety of bodies that produce advisory guidelines. 
 
Guidance produced by Government (e.g. Department of Health (DoH), Welsh 
Assembly, Scottish Parliament) 
These are usually service related guidelines (e.g. referral pathways, referral 
timelines). They are usually consensus statements that are the result of 
working groups where invited specialist(s) have been asked to give their 
opinion(s) to policy makers. Adherence is often strongly recommended by 
employment contracts with health providers or government agencies and it 
may be a contractual obligation to abide. There may be financial incentives or 
penalties which are often used to ensure compliance. 
 
Guidance produced by local health-care providers (e.g. healthcare trusts or 
local networks) 
These are both service and clinical guidelines. Typical examples are local 
prophylactic antibiotic prescription guidance, thrombosis prophylaxis guidance 
or blood transfusion guidance. These may be evidence-based or based on 
other published guidelines (from national guideline developers or professional 
bodies such as professional colleges / associations) with appropriate 
adaptation to the local community being served.  They may also be 
consensus statements from local committees. These committees are usually 
made up of relevant specialist staff that volunteer their time to represent their 
department or specialty on the committee. Internationally there is a recent 
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trend for local hospitals to employ professional guideline developers to 
oversee their guideline and protocol development (Australia, USA).  
Adherence is strongly recommended and certain employment contracts 
include a clause regarding possible legal action (under employment law) 
against the employee who fails to adhere to local protocols or agreed 
processes.  
 
Guidelines produced by The National Institute of Health and Clinical 
Excellence (NICE). 
NICE is an independent body commissioned in 1999 by the Department of 
Health to produce guidelines for healthcare professionals treating patients in 
the NHS in England and Wales. NICE guidelines are evidence-based 
recommendations designed to promote good health and prevent ill health. 
The guidelines address both clinical-effectiveness and cost-effectiveness 
issues.[46] There are different types of NICE guidelines. 
 
Clinical guidelines  
Clinical guidelines cover aspects of the management of a particular disease or 
condition. The evidence supporting different treatments is examined to assess 
whether they are effective for patients. The guidelines make 
recommendations on which treatments should be made available in the NHS 
in England and Wales, in order to ensure the best care is available to all 
patients.  Clinical guidelines sit alongside, but do not replace the knowledge 
and skills of experienced health professionals and consider both the clinical 
effectiveness and also the cost effectiveness of cancer treatments.  
 
Service guidelines 
Service guidelines make recommendations on how NHS services for patients 
should be organised in England and Wales. Both the anticipated benefits and 
the resource implications of implementing the recommendations are 
considered.  
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Technology Appraisal guidance 
Technology appraisal guidance focuses on the clinical and cost effectiveness 
of one or more technologies, such as new drugs, surgical procedures and 
medical devices.  
 
Interventional Procedure Guidance 
Interventional procedures (IP) guidance covers the safety and efficacy of 
interventional procedures used for diagnosis or treatment.  
 
Public Health Guidance 
Public health guidance deals with promoting good health and preventing ill 
health.  
 
Guidelines produced by The Scottish Intercollegiate Guidelines Network 
(SIGN)  
SIGN develops evidence based clinical practice guidelines for the NHS in 
Scotland. SIGN guidelines are derived from a systematic review of the 
scientific literature. SIGN guidelines are produced by guideline development 
group members, with support from the SIGN Executive according to 
structured robust methodology.[46,47] 
Guidelines produced by The Guidelines Audit and Implementation Network 
(GAIN.)  
GAIN produces guidelines for the NHS in Northern Ireland. Its role is safety 
and quality improvement in Health & Social Care Services throughout 
Northern Ireland through the commissioning of regional audit and guidelines 
as well as the promotion of good practice through the dissemination of audit 
results, and the publication and facilitation of implementation of regional 
guidelines.[48] 
Guidelines produced by international guideline developing bodies 
Since the establishment of NICE in the UK other countries are also 
establishing guideline-developing bodies. In the US there is the Agency for 
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Healthcare Research and Quality.[49]  In The Netherlands, two bodies (CBO 
and NHG) publish specialist and primary care guidelines, respectively.[50] 
The German Agency for Quality in Medicine (ÄZQ) coordinates a national 
program for disease management guidelines [51, 52].  These organisations 
are members of the Guidelines International Network (G-I-N). [50] G-I-N is 
owner of the International Guideline Library – the largest web-based database 
of medical guidelines worldwide - and pursues a set of activities aiming at 
promoting best practice and reducing duplication in the guideline world. The 
USA and other countries also maintain medical guideline clearinghouses. In 
the USA, the National Guideline Clearinghouse (NGC) maintains a catalogue 
of high-quality guidelines published by various organizations. In addition, the 
National Comprehensive Cancer Network, an alliance of leading US cancer 
centres also provided reputable guidelines. 
Guidelines produced by professional medical organisations and societies  
Specialist working groups formed by members of the executive who have 
volunteered to sit on the guideline panel usually produce these guidelines. An 
alternative is that panel members are self-selected or nominated by their 
peers. The evidence provided varies with some societies producing very good 
quality evidence-based guidelines and others producing a higher number of 
consensus statements particularly when addressing topics where evidence is 
not available in the literature. 
 
1.4 Health Economics  
Health economics is concerned with issues related to efficiency, 
effectiveness, value and behaviour in the production and consumption of 
health and health care.[52] It is about improving the health of a population 
through the efficient use of resources.[53] 
 
No country can afford all the health care interventions that might benefit 
patients. Clinical need will always outstrip available resources so priorities 
have to be agreed. How this prioritisation process takes place varies from 
 34 
country to country but the need to prioritise in some way is clear. There just is 
not (and never will be) enough money to provide every possible service.[54] 
Health economics applies at all levels, including individual clinical decisions. 
Clinicians already take resources and value for money into account in clinical 
decisions, and the incorporation of good-quality health-economic evidence 
into clinical guidelines can help make this less arbitrary and more 
consistent.[53] 
 
In Britain, before NICE was established, these decisions were largely made 
behind closed doors. Although formal economic assessments were 
sometimes made they were rarely exposed (or explained) to the public, nor 
was the public involved in making the assessments.[54] 
 
More often, decisions about how NHS money was used were based on other 
factors. These included historical patterns of health care, assumptions about 
where (and how) additional investment might appropriately be made, pressure 
from special interest groups, political lobbying and perceptions about public 
preferences.[54] 
 
The creation of NICE made possible a fundamental change in how these 
issues were tackled by the NHS. For the first time, a national public body was 
charged with making authoritative recommendations about the availability of 
new and established treatments, and pathways of care, and doing so formally 
taking cost-effectiveness (or value-for-money) into account.[54] 
 
Few healthcare systems had tried to do this before. In those countries that 
did, such as in Australia, the process was mainly limited to new 
pharmaceutical products.[54] 
 
NICE guidelines assess the clinical effectiveness and cost effectiveness of 
treatments and ways of managing a particular condition. Cost effectiveness is 
the estimated costs of the treatment options in relation to their expected 
health benefits rather than the total cost or resource impact of implementing 
them.[54] 
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In evaluating healthcare and making its decisions on whether an intervention 
should be available to the NHS, NICE compares interventions by using an 
economic approach called ‘cost-utility analysis’. This considers the impact 
each intervention has on health compared to current care and how much it 
costs again compared to the costs of current care.[54] 
 
NICE health economics carry out the cost-effectiveness analyses with the 
units of effectiveness expressed in QALYs (Quality Adjusted Life Years). 
QALYs are an overall measure of health outcome that weighs the life 
expectancy of a patient with an estimate of their health-related Quality of Life 
(QoL) measured on a 0–1 scale.[54] 
 
The QALY captures the treatment on both ‘quality of life (QoL)’ and length of 
life. One QALY is the equivalent of one year in perfect health, or two years in 
50% of that health, or four years in 25% of that health, and so on. It provides a 
‘common currency’ that allows different interventions to be compared for 
different conditions.[54] 
 
The use of QALYs is widely recognised as a useful approach for measuring 
and comparing the efficiency of different health interventions. There are 
however well-documented methodological problems with QALYs, but this is 
also true of other approaches. If there is insufficient data to estimate QALYs 
gained, an alternative measure of effectiveness may be considered for the 
cost-effectiveness analysis (such as life years gained or cases averted, or a 
more disease-specific outcome).[54] 
 
The cost per QALY indicates how much extra it costs the NHS to buy the 
equivalent of one QALY of benefit from a new intervention over and above 
what it pays now for the benefits from existing treatments.[54] 
 
Economists also refer to this comparative ‘cost-per-QUALY’ as the 
‘incremental cost effectiveness ratio (ICER)’. The incremental cost-
effectiveness ratio (ICER) is an equation used commonly in health economics 
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to provide a practical approach to decision making regarding health 
interventions. It is typically used in cost-effectiveness analysis.[55]  
ICER is the ratio of the change in costs to incremental benefits of a 
therapeutic intervention or treatment.[56] 
 
The equation for ICER is: ICER = (C1 – C2) / (E1 – E2) where C1 and E1 are 
the cost and effect in the intervention or treatment group and where C2 and 
E2 are the cost and effect in the control care group.[55] Costs are usually 
described in monetary units while benefits/effect in health status is measured 
in terms of quality-adjusted life years (QALYs) gained or lost.[55] 
 
ICER provides a means of comparing projects or interventions across various 
disease states and treatments. As seen in the equation above, a ratio is 
created with the units of cost per benefits/effect unit. By using this ratio, 
comparisons can be made between treatment modalities to determine which 
provides a more cost-effective therapy.[55] 
 
For example, when one strategy is more effective but also more costly, then 
the magnitude of the incremental cost-effectiveness ratio (ICER) should be 
considered. The cost per QALY gained is calculated as the difference in mean 
cost divided by the difference in mean QALYs for one strategy compared with 
the next most effective alternative strategy. If one intervention appears to be 
more effective than another, the guideline development group will have to 
decide whether the increase in cost associated with the increase in 
effectiveness represents reasonable ‘value for money’.[54] 
 
Some people feel ICER studies provide an opportunity to help contain health 
care costs without adverse health consequences.[57] They also provide to 
policy makers information on where resources should be allocated when they 
are limited.[55] As health care costs have continued to rise, many new clinical 
trials are attempting to integrate ICER into results to provide more evidence of 
potential benefit.[58] 
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Others feel that basing health care interventions on cost-effectiveness is a 
type of health care rationing and have expressed concern that using ICER will 
limit the amount or types of treatments and interventions available to 
patients.[55]  
The aim of the cost-utility approach used by NICE is to use the budget of the 
NHS to ‘purchase’ the greatest number of QALYs possible i.e. to maximise 
the amount of health gained for the money available. [54] 
NICE has never identified an ICER above which interventions should not be 
recommended and below which they should.[60] 
However an ICER threshold range has been set (£20-30,000 per QALY) to 
indicate a point at which factors other than the ICER itself should be 
examined and debated as part of the judgment about the acceptability of the 
intervention as an effective use of NHS resources.[59,60] 
Such factors include: the degree of certainty around the ICER in the cost-
effectiveness analysis, a change in the quality of life inadequately captured in 
the representation of the health gain, and demonstrable benefits inadequately 
captured in the measurement of health gain.[59,60] 
The overall ‘rationing of healthcare’ debate, the use of QALY’s, and the ICER 
threshold debate remain and will probably remain at the forefront of 
healthcare related debates; however this is the situation in the UK at present. 
 
1.5 The guideline debate 
Opinion on the value of guidelines differs amongst physicians. Advocates of 
guidelines believe that they are a welcome development that brings 
improvement to clinical practice. They believe that finding, evaluating and 
implementing the results of medical research can, and often does, make 
patient care more objective, more logical, and more cost effective. [60] 
They maintain that the purpose of guidelines is to improve quality of 
healthcare provision, to make evidence-based standards explicit and 
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accessible, to make decision-making in the clinic and at the bedside easier 
and more objective, to educate patients and professionals about current best 
practice, and to improve the cost effectiveness of health services.[61] 
There are those however, who see guidelines as a potential danger. They fear 
that when guidelines are applied in a vacuum (that is in the absence of 
common sense and without regard to the individual circumstances and 
priorities of the person being offered treatment), the evidence based approach 
to patient care is a reductionist process with a real potential for harm, 
particularly when becoming the only accepted option for example in the 
context of a busy practice or a resource-strapped health-care provider. [60] 
Others just feel overwhelmed by the sheer number of guidelines available, 
finding it often conflicting or confusing. There are also those that worry that 
guidelines are an unnecessary external authority that removes autonomy from 
the individual clinician.[61] 
Some take the view that guidelines developed at national or regional level 
may not reflect local needs or have the ownership of local practitioners. 
Guidelines developed in or for secondary care may not reflect demographic, 
clinical or practical differences between this sector and the primary care 
setting.[61] 
 
Guidelines may produce undesirable shifts in the balance of power between 
different professional groups (for example between clinicians and academics 
or purchasers and providers) and guideline development may be perceived as 
a political act.[61]  
 
Others see it as an undesirable way to provide a yardstick for assessing 
professional performance, to delineate the division of labour (e.g. between 
GPs and hospital consultants), or even as a tool for external control.[61] 
 
Evidence-based medicine and guidelines are now so common in clinical 
practice that it is hard to remember a time before them.[62] Yet there are 
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those who question the validity of the development process and the quality of 
the evidence on which guidelines are often based.[61,62, 63] 
Doctors who are sceptical about the scientific basis of guidelines have two 
choices: they can follow guidelines even though they suspect doing so will 
cause harm, or they can ignore them and do what they believe is right for their 
patients, thereby risking professional censure and possibly jeopardising their 
careers.[63]  
This is no mere theoretical dilemma. There is evidence that even when 
doctors believe a guideline to be harmful and compromised by bias, a 
substantial number follow it.[63] 
It is important therefore for research in the field of guideline development to 
take place. In-depth analysis of the methodology and the body of evidence 
that support the recommendations will ensure thorough understanding of the 
process, its strengths and weaknesses. It will provide an opportunity for 
quality assessment and the platform for any necessary improvements.  
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2.0 Aims  
 
To research the evidence base on which the NICE guideline for the diagnosis and 
management of colorectal cancer is developed. This principle aim has been broken 
down into the following six study aims.  
 
1. To research the availability and quality of guideline methodology data 
that can inform all end users of guidelines produced by NICE on the 
guideline development process for the purpose of guideline appraisal 
(Chapter 4).  
 
2. To research the availability and quality of epidemiology data that can 
inform a guideline development group (GDG) on incidence, mortality, 
survival and prevalence of CRC for the purpose of the CRC guideline 
needs assessment report (Chapter 5). 
 
3. To research the availability and quality of current clinical practice data 
that can inform a GDG on aspects of CRC management for the 
purpose of the CRC guideline needs assessment report (Chapter 6). 
 
4. To research the availability and quality of the diagnostic data that make 
up the evidence to support the most effective method for diagnosing 
liver metastases from CRC to assess resectability (Chapter 7). 
 
5. To research the availability and quality of the therapeutic data that 
make up the evidence  to support the most effective method for the 
follow up of patients that have been diagnosed and treated for primary 
CRC (Chapter 8). 
 
6. To research the international nature of data supporting the NICE 
guideline on CRC and the influence this may have on the resulting 
recommendations (Chapter 9). 
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3.0 Methodology and Methods 
3.1 Research Methodology 
In 2009 NICE commissioned the National Collaborating Centre for Cancer 
(NCC-C) to develop a clinical guideline on the diagnosis and management of 
CRC.  This marked the beginning of a two-year project that culminated in the 
publication of the guideline in 2011.  
 
For the first time in parallel to the guideline development process the NCC-C 
introduced the opportunity for research into guideline methodology and for this 
reason granted full access to the entire guideline development process of the 
NICE CRC guideline. 
 
The research was carried out through active membership of both the NCC-C 
guideline development team and the NICE guideline development group 
(GDG) of health professionals established to produce the recommendations.  
Though participation in all aspects of the guideline development process were 
encouraged the researcher held a non-voting role during the final formulation 
of the recommendations similar to the members of the NCC-C guideline 
development team. 
 
This thesis is the result of the research endeavour described above. Six 
thematically distinct studies were designed prior to the commencement of the 
guideline development process. These all attempt to answer the principle aim, 
to research the evidence base on which the NICE CRC guideline is 
developed. The decision was taken to design multiple distinct studies so as to 
cover as many different aspects of the guideline development process as 
possible within the given time limitations of the project. Each study answers 
each of the six secondary aims and is presented in separate chapters.  
 
The detailed methods used to carry out each individual research study are 
presented within each study chapter. A summary of these methods is 
presented below.  
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3.2 Summary of research study methods 
Methods employed to address aims 1, 2 & 3 
 
Online data mining.  
Web based research was carried out with the purpose to identify the data that 
was relevant to answer each research aim. The details of the search engine, 
the search strategy, the search terms used, are included in the methods 
section of each of the relevant chapters (4,5,6).  
 
Methods employed to address aim 3 
 
Data request from national databases of patient information 
National databases of patient information were approached and anonymised 
data on current clinical practice was requested. Linkage studies combining 
data from multiple databases were also discussed and planned. Details of the 
search strategies are included in the methods section of chapter 6. 
 
Methods employed to address aims 4 & 5 
 
Systematic reviewing according to NICE methodology 
The review questions were broken down into appropriate search terms and 
the appropriate search strategies  were created. The international medical 
literature was systematically searched through multiple databases and 
registers.  
Study selection was carried out based on pre-determined inclusion and 
exclusion criteria.  
Study quality assessment was carried out using appropriate quality checklists 
for each type of study under consideration. The checklists were all validated 
tools used within the international guideline community and approved by NICE 
for use as part of their guideline development.  
The data was extracted and analysed. Where data synthesis was appropriate 
meta-analysis software was used (REVMAN 5). 
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Methods employed to address aim 6 
 
Review of ‘Linking Evidence To Recommendation’ (LETR) data 
Information on how the evidence that supported the guideline was linked to 
the final recommendations formulated by the guideline development group 
was collected through: 
 
i) participation in all the guideline development group (GDG) meetings 
throughout the two year development of the CRC guideline and 
experiencing in close proximity the process of developing 
recommendations from the body of evidence presented for each 
topic. 
ii) reviewing of all the final formal LETR sections of the CRC guideline 
document for each of the topics the guideline addressed for 
evidence of the recommendations having been influenced by the 
national setting of the evidence that supported that 
recommendation.  
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4.0 The availability and quality of methodology data for 
guideline appraisal 
 
4.1 Introduction 
 
Methodology is the systematic analysis of the methods applied to a field of 
study.[64] 
 
It offers the theoretical underpinning for understanding how a specific piece of 
research has been carried out. Many treat it as a synonym for method or body 
of methods.[64] 
 
Doing this shifts it away from its true epistemological meaning and reduces it 
to being the procedure itself, the set of tools or the instruments that should 
have been its outcome. [64] 
 
A methodology is the design process for carrying out research or the 
development of a procedure and is not in itself the instrument.[64] 
 
For Guidelines, there is a standardised way of appraisal and quality 
assessment of methodology by the use of the AGREE tool.[65] 
 
The Appraisal of Guidelines for Research and Evaluation (AGREE) 
Instrument (appendix 1) evaluates the process of practice guideline 
development.[65] 
 
It is a tool that assesses the methodological rigour and transparency in which 
a guideline is developed and it is used internationally.[65] 
 
The original AGREE Instrument has been updated and methodologically 
refined. [66] 
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AGREE II is not only used for appraisal but can also be used to provide a 
methodological strategy for the development of guidelines.[66] 
 
In addition, it can be used to guide what information and how that information 
ought to be reported in guidelines.[66] 
 
AGREE II is designed for guidelines developed by local, regional, national or 
international groups or affiliated governmental organizations.[67] 
 
Amongst the medical profession there are those who question the reasoning 
behind a guideline developing organisation such as NICE.[61] 
 
Some worry that guidelines produced by non-professional bodies may be 
intellectually suspect and a means of external control, policing, and removal of 
autonomy from the professional medical groups. [61] 
 
There is a fear amongst some of the professionals that such guidelines might 
be a way in which politicians and health-service managers who have made 
use of the rationale for evidence-based guidelines will use them to make 
judgements that serve their own political or economic agendas.[61] 
 
In this way they would be using evidence that proves interventions are 
effective “on average” but which omit the value of experience and professional 
insight.[61]  
 
Guidelines have been produced  for many years by the Royal Colleges and 
specialist  professional societies.[68] 
 
As the field of evidence based medicine has been evolving guideline 
development by such organisations has in the past been characterised by 
problems that  potentially undermine the quality and trustworthiness of the 
guidelines they produce.[68] 
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This includes lack of transparency, limitations in the process of systematic 
reviews, but more importantly a failure to use rigorous methodology.[68] 
 
The rapid proliferation of guideline production often means guidelines are 
produced in parallel either by professional associations with an overlap in 
interest or by professional associations and national guideline developing 
bodies.[68] 
 
This, apart from appearing unecessary and wasteful of resources, can  
potentially lead to confusion amongst the audience when guidelines are  
produced by different bodies on the same topic with differences in their 
recommendations.[68] 
 
In the UK National Health Service, all doctors, nurses, pharmacists, and other 
health professionals now have a contractual duty to provide clinical care 
based on best available research evidence. [61] 
 
Furthermore, whilst the medico-legal implications of “official” guidelines have 
rarely been tested in the UK, US courts have ruled that guideline developers 
can be held liable for faulty guidelines.[61] 
 
In addition, the same ruling states that doctors cannot pass off their liability for 
poor clinical performance by claiming that adherence to guidelines corrupted 
their judgment.[61] 
 
The ability to appraise the quality of a guideline irrespective of the authority 
that has produced it is vital. 
 
In order to do so it is important to be able to access and assess the quality of 
the guideline development process by which it was produced. This is done by 
appraisal of the methodology. 
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4.2 Aim 
 
To research the availability and quality of guideline methodology data that can 
inform all end users of guidelines produced by NICE on the guideline 
development process for the purpose of guideline appraisal.  
 
4.3 Methods 
 
Reasearch on the availability of NICE methodology data was carried out by 
online data mining of the NICE website according to a predetermined search 
strategy as outlined below.  
 
The methodology data retrieved was also reviewed for information regarding 
the quality strategy of the development process. It was specifically scanned 
for information on whether a standardised tool like the AGREE II, or a different 
tool or method, was used.  
 
The NICE methodology data retrieved was also further assessed for its 
availability and quality by comparison with similarly retreaved methodology 
data from other UK guideline developing bodies.  
 
Online Data mining  
 
NICE methodology data 
The search engine ‘google’ was used to search for available data regarding 
the NICE methodology. The search terms that were used were: ‘NICE’, 
‘guideline’, ‘methodology’, ‘development’, ‘process’ 
 
The information produced from the search was selected if it answered the  
following questions: 
Is this information about the NICE clinical guideline development 
process? 
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Is this information about the quality assessment of the guideline 
process with the AGREE tool or any other mentioned guideline quality 
appraisal/development tool? 
Is this information about quality assessment of the development 
process without a standardised instrument? 
An overall assessment was finally made by the reviewer regarding the ease of 
access to the data through the online data mining process. 
  
Methodology data from other UK  guideline producing bodies 
A systematic search was performed of the information presented on the 
websites of all current UK surgical societies, associations, and Royal 
Colleges. 
 
The list of surgical societies to be searched was drawn up by associating a 
society for each of the known surgical specialties and sub-specialties. One 
medical society was included on the list as it was felt that this medical 
specialty through endoscopy practice overlapped with surgical practice and 
should therefore be included.  
 
Search terms relating to the associations’ titles were entered into the ‘google’ 
search engine and the precise title and webpage address of the society was 
identified. In the case that surgical subspecialties were found to have more 
than one associated society, all were included in the search. 
 
Table 4.1: List of professional societies and Royal Colleges included in the 
search for methodology data. 
Organisation Web address 
Royal College of Surgeons of England www.rcseng.ac.uk 
Royal College of Surgeons of Ireland www.rcsi.ie 
Royal College of Physicians and Surgeons of Glasgow www.rcps.ac.uk 
Royal College of Surgeons of Edinburgh www.rcsed.ac.uk 
Association of Surgeons of Great Britain and Ireland ASGBI www.asgbi.org.uk 
Association of Coloproctology of Great Britain and Ireland ACPGBI www.acpgbi.org.uk 
Association of Upper Gastrointestinal Surgeons of Great Britain and 
Ireland AUGIS 
www.augis.org 
 49 
The Vascular Society of Great Britain and Ireland www.vascularsociety.org.uk 
Association of Breast Surgery UK  - ABS at BASO www.baso.org 
British Association of Surgical Oncology BASO www.baso.org 
Association of Laparoscopic Surgeons of Great Britain and Ireland www.alsgbi.org 
British Association of Day Surgery BADS daysurgeryuk.net 
British Hernia Society www.britishherniasociety.org 
British Orthopaedic Association www.boa.ac.uk 
British Trauma Society www.bts-org.co.uk  
www.trauma.org 
British Association of Otorhinolaryngologists ENT-UK www.entuk.org 
The British Association of Urological Surgeons www.baus.org.uk 
British Association of Plastic, Reconstructive and Aesthetic Surgeons 
BAPRAS 
www.bapras.org.uk 
British Association of Aesthetic Plastic Surgeons BAAPS baaps.org.uk 
Society for Cardiothoracic Surgery of Great Britain and Ireland www.scts.org 
British Society of Gastroenterology www.bsg.org.uk 
 
Each website was visited and carefully searched for data on guidelines and 
guideline methodology. The home webpage was searched as a first step 
followed by all linked webpages accessible through the home page option 
lists. All lists and linked pages were searched for data, not just those that 
immediately appeared relevant to guideline data such as lists  referring to 
‘research’ or ‘resources’. 
 
If no information on guideline or guideline methodology was available through 
this route then the home webpage ‘search’ option was used and the key 
words ‘guideline’ and ‘methodology’ entered as separate searches not as a 
limited combined search. 
 
If a society website was found to offer guideline documents but had no 
information available on the website about the guideline methodology then all 
guideline documents were opened and their contents page searched for a 
methodology section. Paper versions of guideline documents were not 
requested and societies were not contacted via telephone or mail for 
methodology data.No formal statistical software was necessary in the analysis 
of the results as numbers involved were small enough to analyse manually. 
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4.4 Results 
 
NICE methodology data 
 
Availability of methodology data 
The methodology and all related guideline methods and tools are publicly 
available and easily accessible online through the NICE website and the 
webpage of the guideline development manual.[69]  
 
The NICE guideline development process [69] 
Referral and remit 
The Department of Health asks NICE to produce a guideline on 
a particular topic. The topics for guidelines are based on 
recommendations from topic selection consideration panels.The 
topic referral is also associated with a remit that identifies the 
broad areas to be covered. 
 
National Collaborating Centres (NCC) 
NICE commissions one of the four National Collaborating 
Centres (NCC) to co-ordinate the development of a guideline. 
For the clinical guideline on the management of colorectal 
cancer this was the NCC for cancer (NCC-C). 
 
This is responsible for developing NICE guidelines for the NHS 
in England and Wales on treating and caring for people with 
cancer. The other national collaborating centres are the centre 
for acute and chronic disease, the centre for women and 
children, and the centre for mental health.  
 
A management board comprising representatives of relevant 
professional bodies oversees the work at the NCC-C. This 
currently includes representatives for a number of Royal 
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Colleges, the National Cancer Research Institute (NCRI), and 
other charity and academic bodies. 
 
The management board meets regularly and among its many 
functions is to oversee the guideline development process for 
each guideline.It advises the NCC-C on negotiating with NICE 
on quality issues. 
 
The guidelines team in the Centre for Clinical Practice at NICE 
supports and advises the NCC during the process. 
 
Guideline Development Group (GDG) 
A Guideline Development Group (GDG) is established to 
manage the work. The GDG is composed of health 
professionals who are involved in the treatment and 
management of patients with cancer. 
 
It also includes at least two patient/carer representatives. GDGs 
usually consist of 12-15 people. NICE is not represented on the 
GDG. 
 
The scope 
The remit is translated into the scope. The scope provides a 
framework within which to conduct the guideline development 
work. When developing the scope key clinical issues are 
selected by the scoping group. This group consists of 
representatives of the GDG, NCC-C technical team and NICE. 
 
Stakeholders 
Before the scope consultation takes place stakeholders are 
invited to a scoping workshop to discuss the key clinical issues 
identified by the scoping group. Stakeholder organisations are 
organisations with an interest in a particular guideline. They 
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register with NICE at the beginning of the guideline development 
process and contribute their views during consultation periods.  
 
In the NICE clinical guideline development process, 
stakeholders are: national patient and carer organisations, 
national organisations that represent healthcare professionals, 
companies that manufacture medicines or devices used in the 
clinical area covered by the guideline, providers and 
commissioners of health services in England and Wales, 
statutory organisations including the Department of Health and 
research organisations. 
 
After a consultation period the scope is finalised. The scope 
provides information to healthcare professionals, stakeholders 
and the public about the expected content of the guideline.  
 
Review questions 
The key clinical issues listed in the scope are next broken down 
into review questions. The exact number of review questions for 
each clinical guideline depends on the topic and the breadth of 
the scope. However, the number of review questions must be 
manageable for the GDG and the NCC technical team within the 
agreed timescale. 
 
For standard clinical guidelines that take 10–18 months to 
develop (from the time the scope is signed off to submission of 
the draft guideline), between 15 and 20 review questions is a 
reasonable number. This number is based on the estimate that, 
on average, it is feasible for a maximum of two systematic 
reviews to be presented at any one GDG meeting.  
 
Review questions are usually drafted by the NCC technical 
team. They are then refined and agreed by all GDG members 
through discussions at GDG meetings.  
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The different perspectives among GDG members will help to 
ensure that the right review questions are identified, thus 
enabling the literature search to be planned efficiently.  
 
Often the main questions need refining again once the evidence 
has been searched, and this may generate sub-questions. 
 
Review questions for economic analysis 
Questions are selected for economic analysis as a joint decision 
between the health economist and the other GDG members. 
The health economist is a core member of the GDG alongside 
the rest of the NCC technical team, and is involved at the 
earliest opportunity and attends all GDG meetings.  
 
The expertise of all of the GDG members is necessary to ensure 
that economic evidence is underpinned by the most plausible 
assumptions and the best available clinical evidence. Selection 
is based on potential value across all key clinical issues, quality 
of available evidence, and time available for economic modeling.  
 
There are likely to be large differences between clinical 
guideline topics in the amount, relevance and quality of the 
economic literature. In some topic areas there may be high-
quality data that can be used in economic models, whereas in 
other areas there will be little information. 
 
Defining the economic priorities for each clinical guideline starts 
during scoping, and proceed alongside development of the 
review questions. 
 
Systematic reviewing 
A systematic review is carried out for each question. Review 
questions are broken down into different parts and used to 
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devise a search strategy using the PICO (patient, intervention, 
comparison and outcome) framework.  
 
This can be constructed from terms relating to the population, 
combined with terms relating to the interventions and 
comparisons to be evaluated.  
 
The search strategy is discussed and approved by the GDG. 
The searches are then carried out by the information specialist. 
Core and subject-specific databases are searched. Other 
sources such as registers are also included.  
 
Before acquiring papers for assessment, the systematic 
reviewer sifts the evidence identified in the search in order to 
discard irrelevant material. Next, the remaining abstracts are 
scrutinised against the inclusion criteria agreed by the GDG.  
 
Abstracts that do not meet the criteria are excluded. Any doubts 
about inclusion should be resolved by discussion with the GDG 
before the results of the study are considered.  
 
Once the sifting is complete, full versions of the selected studies 
are acquired for assessment. Studies that fail to meet the 
inclusion criteria once the full version has been checked are 
excluded; those that meet the criteria are assessed.  
 
Because there is always a potential for error and bias in 
selecting the evidence, double sifting (that is, sifting by two 
people) of a random selection of abstracts is performed 
periodically.  
 
Once a study has been selected it is assessed using a 
methodology quality checklist. Data is extracted to a standard 
template for inclusion in an evidence table.   
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Meta-analysis may be needed to pool treatment estimates from 
different studies.  
 
Developing recommendations 
In developing recommendations the GDG must decide what the 
evidence means in the context of the review questions and 
economic questions posed.  
 
There are many reasons why it can be difficult for a GDG to 
reach a decision about a recommendation. The literature search 
may have found no evidence. The quality of the evidence may 
be poor. There may be conflicting evidence. The clinical 
evidence may not be directly applicable to the population 
covered by the guideline. 
 
The GDG may have to consider consensus methods to identify 
best practice. The reasoning behind all decisions are 
documented and presented in the full guideline. 
 
Final consultation and publication 
At the end of the process, and after further consultation with 
stakeholders, NICE’s Guidance Executive signs off the 
guideline.  
 
The Guidance Executive confirms that the NCC has developed 
the guideline in accordance with the terms of the remit from the 
Secretary of State for Health and the scope, and by following 
NICE’s process and methods.  
 
The guideline is then published and distributed to the NHS in 
England and Wales. 
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Figure 4.1: Summary of NICE clinical guideline development process [70] 
 
 57 
Quality of methodology data 
The following information was identified in the NICE methodology manual on 
the NICE website relating to guideline methodology quality assessment: 
 
“NICE methodology follows the AGREE II framework. NICE guideline 
development aims to be a transparent process using the principles of 
evidence-based medicine.” [46] 
 
“The NICE guideline development process has been drawn on the 
advice of international guideline development methodology experts, 
internationally acceptable criteria of quality, the expertise of the clinical 
guidelines team in the Centre for Clinical Practice (CCP) at NICE, and 
the experience of the staff at the national collaborating centres (NCCs) 
where the guidelines are produced on behalf of NICE.”[69]  
 
Methodology data from other UK guideline developing bodies 
 
Availability and quality of methodology data 
 
Table 4.2: Availability and quality of methodology data of UK surgical societies 
and Royal Colleges. 
 
 
Society Produce guidelines Guideline 
methodology 
available online 
or in guideline 
document 
 Guideline 
development quality 
checklists used e.g. 
AGREE tool 
Royal College of 
Surgeons of England 
Yes –more audit 
from the clinical 
effectiveness unit 
No No 
Royal College of 
Surgeons of Ireland 
Yes – 1st under 
development 
No No 
Royal College of 
Surgeons of Glasgow 
No – they provide 
links to SIGN 
No No 
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Royal College of 
Surgeons of Edinburgh 
No – they provide 
links to SIGN 
No No 
Association of Surgeons 
of Great Britain and 
Ireland ASGBI 
Yes No No 
Association of 
Coloproctology of Great 
Britain and Ireland 
ACPGBI 
Yes No No 
Association of Upper 
Gastrointestinal Surgeons 
of Great Britain and 
Ireland AUGIS 
Yes – but also refer 
to NICE and SIGN 
No No 
The Vascular Society of 
Great Britain and Ireland 
Yes No No 
Association of Breast 
Surgery UK  
ABS at BASO 
Yes No No 
British Association of 
Surgical Oncology BASO 
Yes – just breast No No 
Association of 
Laparoscopic Surgeons of 
Great Britain and Ireland 
ALS-GBI 
Yes  No No 
British Association of Day 
Surgery BADS 
Yes No No 
British Hernia Society No NA NA 
British Orthopaedic 
Association 
Yes No No 
British Trauma Society No access to 
website without 
membership 
NA NA 
British Association of 
Otorhinolaryngologists 
ENT-UK 
Yes No No 
The British Association of 
Urological Surgeons 
Yes No No 
British Association of 
Plastic, Reconstructive 
No NA NA 
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and Aesthetic Surgeons 
BAPRAS 
British Association of 
Aesthetic Plastic 
Surgeons BAAPS 
No NA NA 
Society for Cardiothoracic 
Surgery of Great Britain 
and Ireland 
No access to 
website without 
membership 
NA NA 
British Society of 
Gastroenterology 
Yes Yes Yes 
 
 21 website pages were visited and of those 19 allowed access without 
membership. Of those, 18 were websites of surgical societies and 
Royal Colleges and 1 was of a medical society of relevance to CRC 
 Of the 18 surgical society websites 14 produced guidelines for their 
members (77.8%) 
 No surgical society website provided information online about their 
guideline methodology 
 Of all 21 societies that produced guidelines only 1 society website 
provided information about their guideline methodology (5.2%). It was 
this same organisation that reported on their website about using the 
AGREE tool as a template for their guideline development and 
reporting 
 
4.5 Discussion 
The results show that NICE provides easily accessible information on the 
methodology of its guideline production. The guideline manual is an extensive 
and detailed document easily accessible online and clearly describing all 
processes relating to NICE guideline development. 
 
Guideline development at NICE has been set up after consultation with a 
variety of methodology and guideline experts and follows the AGREE tool in 
its development strategy, an international tool for guideline quality 
assessment and development. 
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The results however show very poor online reporting of guideline 
methodology by all surgical societies and Royal Colleges.   
 
Even though the majority of the organisations produce guidelines which are 
available online for their members and the public, they do not supply data on 
the methodology of these guidelines online.  
 
This does not mean that the guidelines produced are of poor quality but it 
does leave an uncertainty about their quality. 
 
The data is limited to societies relevant to surgery and may not be indicative 
of availability of methodology relating to guidelines produced by medical 
societies or indicative of the quality of the reporting of surgical professional 
bodies internationally.  
 
The results may also be a reflection of the fast pace of information technology 
advancement. The majority of these societies may be unable to keep up with 
accurate representation of the guideline data they provide via the technical 
medium of the internet.   
 
In addition, the pace of change and evolution is fast within the discipline of 
evidence based medicine. The importance of principles and details of 
guideline development are being highlighted with the passage of time and 
more importantly are being registered by the guideline community with time 
and with maturation of this entire field of research. 
 
The acknowledgment of methodology developments relies heavily on 
enthusiasts keeping up to date and applying these improvements to the 
guideline work they are doing. 
 
The data however does highlight an important gap in guideline presentation 
by surgical societies in the UK. The absence of methodology data from online 
guideline documents is serious. 
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With no methodology to refer to and to appraise it is difficult or impossible to 
draw conclusions about: 
 
i) The overall purpose of the guideline: it is important to be able to 
define the health question addressed and the target population. 
 
ii) The extent to which the guideline was developed by the appropriate 
stakeholders and to which it represents the views of its intended 
users. 
 
It is important that the guideline development group includes 
individuals from all the relevant professional groups, with an 
appropriate level of expertise and that the process of their selection 
is transparent.  
 
It is also important that the views and preferences of the target 
population have been sought. The target users of the guideline also 
need to be clearly defined. 
 
iii) The process used to gather and synthesise the evidence, the 
search dates, the search engines and databases employed, and the 
methods used to grade the evidence.  
 
It is important to be able to assess whether systematic methods 
were used to search for the evidence, that the criteria for selecting 
the evidence were clearly set out at the beginning and that the 
strengths and limitations of the body of evidence are clearly 
described.  
 
It is also important to be able to identify clearly the methods used to 
formulate the recommendations, and that there is an explicit link 
between the recommendations and the supporting evidence.  
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Additionally it is important that the side effects and risks have been 
considered in formulating the recommendations, and not just the 
health benefits.  
 
Finally it is important that the guideline has been externally 
reviewed by experts prior to its publication and that there is a 
procedure  provided for updating it in the future. 
 
iv) Likely barriers and facilitators to implementation, strategies to 
improve uptake, and resource implications of the application of the 
guideline.  
 
v) Editorial independence and whether the formulation of 
recommendations was biased with competing interests.  
 
There are also potential adverse medicolegal consequences when the importance 
of methodology is overlooked. The proliferation of guidelines has happened at 
least in part due to a growing “accountability culture”.  
 
The need to be able to refer to officially produced standards in any case where 
there is a legal challenge to medical practice has led to more and more guidelines 
to be produced.  
 
Guideline methodology in such situations becomes even more important as a 
means to assess quality as there is the risk that guidelines of uncertain quality 
could be used medico-legally (both in and out of context) to dictate what a 
competent practitioner ‘would have done’ in particular circumstances.  
 
Good quality guideline development aims to be evidence-based, systematic, and 
transparent. The purpose of guideline methodology is to ensure that this is the 
case. It provides the framework for standards in guideline development.  
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Guidelines are produced for many different diseases and encompass diverse 
diagnostics and interventions. Applying uniform methodology aims to provide 
standards of quality and transparency even though in some cases it creates 
methodological challenges for the developers. 
 
It is imperative that anyone involved in healthcare is educated in the principles of 
evidence-based medicine and in particular in guideline development and guideline 
appraisal. This way each guideline can be assessed on its own methodology and 
development process in the setting within which it is going to be implemented.  
 
It is always the responsibility of the individual clinician to decide on the individual 
patient’s management. Guidelines aim to assist in this process but never to replace 
the medical acumen and experience of the specialist or the wishes of the patient. 
In order to assess the quality of a guideline the reader must be aware of the 
principles of evidence-based medicine and apply a systematic appraisal to the 
guideline.  
 
Doctors should embrace and be educated to a high standard in the principles 
of evidence based medicine and especially in guideline appraisal so that they 
can responsibly assess for themselves the quality of any guideline and make 
a decision as to whether they will or will not apply it to their practice, or indeed 
change their practice to comply with guidelines. 
 
Doctors must at all times be confident that they are doing the right thing for 
their patients and not adhering uncritically to guidelines. 
 
The potential benefits of guidelines are only as good as the quality of the 
guidelines themselves. It is important to be able to assess the methodology 
used to develop the guidelines in order to be confident of the resulting 
recommendations. 
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5.0 Availability and quality of epidemiology data for a 
guideline needs assessment report 
 
5.1 Introduction 
 
A health needs assessment is a systematic method for reviewing the health 
issues facing a population. It aims to lead to agreed priorities and resource 
allocation that in turn aims to improve health and reduce any existing 
inequalities in health provision.[71] It is recommended practice for policy 
documents such as guidelines in order to inform and aid their better 
development as well as aid future strategic planning and implementation.[71] 
 
With every NICE clinical guideline it is recommended that a baseline needs 
assessment be made. The scope of the colorectal cancer guideline required 
the first half of the guideline needs assessment to include information on the 
epidemiology of the disease.[69]  
 
Epidemiological data is information on the factors affecting the disease in a 
way that makes it possible to infer possible trends. It is information regarding 
how the disease affects the population, the incidence, mortality, survival and 
prevalence.[72] 
 
The use of epidemiological data on colorectal cancer for the purpose of a 
guideline needs assessment is to place the disease in the context of a cancer 
diagnosis in general, to make comparisons to other types of cancers, to 
present a focused picture of how the disease effects the population. This sets 
the scene for the guideline development group members called to shape the 
guidance. 
 
Traditionally epidemiological information on cancer patients has been 
collected by the cancer registries. These are organisations for the systematic 
collection, storage analysis, interpretation and reporting of data on subjects 
with cancer.[73]  
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Population-based cancer registries collect data on all new cases of cancer 
occurring in a well defined population, usually resident in a particular 
geographical region. Their main objective is to produce statistics on the 
occurence of cancer in the defined population and to provide the framework 
for assessing and controlling the impact of cancer in the community.[73] 
 
The data items collected vary depending on the resources available but 
generally include the basic information about the patient and the tumour and 
may extend to include information about the treatment and the follow up.[73] 
 
The advancement of information technology has expanded the potential for 
data, storage, handling and analysis. The world wide web makes 
dissemination of any information much easier and faster than it has ever been 
in the past. As a result of both these changes the potential quantity of 
epidemiological information that could be accessible is large.  
 
Though this is undoubtably a welcome improvement an important issue that 
must accompany the increasing quantity of information is that of the quality of 
the information. Two main issues need to be considered when evaluating the 
quality of epidemiological data: its completeness and its validity.[73] 
 
Epidemiological data is collected in large databases and no such database is 
without error. According to international guidance regarding registration data 
all organisations handling such data should have quality control mechanisms 
to ensure continuous monitoring of data quality.[73,74] 
 
 5.2 Aim 
 
To research the availability and quality of epidemiology data that can inform a 
guideline development group on incidence, mortality, survival and prevalence 
of CRC for the purpose of the CRC guideline needs assessment report. 
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5.3 Methods 
 
Online data mining 
 
Availability of Epidemiological data 
The search engine  ‘Google’ was used to search for available epidemiological 
data on cancer and CRC. The search terms used were: ‘colorectal’, ‘cancer’, 
‘incidence’, ‘mortality’, ‘survival’, ‘prevalence’, ‘epidemiology’, ‘UK’. The 
information produced from the search was selected based on whether: 
 
i) the data related to the epidemiology of cancer and CRC in the UK. 
 
ii) the data was supplied by a reputable source (e.g. national cancer 
registry, other national body with appropriate references to the 
source of the raw data used.) 
 
iii) the data was collated, analysed, and presented in tables / graphs 
with accompanying explanatory text. 
 
iv) the data was appropriate for presentation to non-medically trained 
individuals as the guideline development group also included lay 
persons. 
 
The decision not to contact the registries directly for this information was 
taken a priori  as cancer in general and CRC more specifically is a disease 
with a major population impact in the UK it was therefore anticipated that 
epidemiological data would be available in an analysed and collated format 
through the public domain / internet.  
 
In addition a search for available data rather than a direct request for data 
would also provide the opportunity to scan the public domain for data of this 
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type potentially being provided by organisations other than the cancer 
registries. 
 
Quality of Epidemiological data 
 
The quality of epidemiological data was assessed by appraisal of the 
techniques used to create the data. Quality control is the mechanism by which 
the quality of the data is measured.[74] 
 
There are national and international standards that all registries adhere to. 
The International Agency for Research on Cancer (IARC) and the 
International Association of Cancer Registries (IACR) have published and 
made publicly available documents that outline the parameters that affect data 
quality and the responsibilities of cancer registries.[73,74] 
 
The UK Association of Cancer Registries (UKACR) plays a pivotal role in 
quality assurance of data provided by the registries through the development 
of national performance indicators. [75]  
 
A systematic online search was carried out for information / reports regarding 
the quality control process as reported by the organisation providing the data. 
The search engine ‘google’ was used to search using the terms : 
‘epidemiology’, ‘data’, ‘quality’ ‘control’ AND (a combination search using the 
term AND) the organisation identified in the availability search as providing 
the data. In addition the website of the relevant organisation was searched 
systematically by exploring every drop down list available through their home 
page and searching for epidemiology data quality reports. 
 
If the organisation that presented epidemiology data identified in the 
availability search handled already-aggregated data and performed secondary 
analyses or presented the data for information purposes then the search was 
tailored to seek data regarding the quality of the analyses or the presentation 
of the epidemiological data (i.e. methodological information rather than quality 
control of the registration process). 
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5.4 Results  
 
Availability of epidemiology data 
 
Sources of epidemiology data 
 
Cancer registries 
 
In the UK epidemiological data on cancer is collected by the 8 cancer 
registries across England, as well as the national registries in Wales, Scotland 
and Northern Ireland. Amongst the cancer registries the Northern and 
Yorkshire Cancer Registry and Information Service (NYCRIS) has been 
appointed lead cancer registry for colorectal cancer in England. The Welsh 
Cancer Intelligence and Survival Unit (WCISU) provides colorectal cancer 
data for Wales. The Scottish Cancer Registry (SCR) and the Northern Ireland 
Cancer Registry (NICR) provide the colorectal cancer data for Scotland and 
Northern Ireland respectively.[75] 
The registries produce incidence, mortality and survival summaries of their 
data for their geographical population catchment area annually and these are 
available as either text documents or summary tables from the website of 
each registry. 
 
Office of National Statistics 
 
In the UK cancer registries  submit a standard dataset of information to the 
Office for National Statistics (ONS), for the collation of national cancer 
statistical data.[76,77] ONS is the UK’s largest independent producer of 
official statistics and the recognised national statistical institute. [78] One of 
the key departments of ONS is involved in producing statistics covering life 
events (births, deaths and some health conditions). It is within this remit that 
cancer related statistics are produced. [79] These are published as reports, 
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bulletins or articles in the journal ‘Health Statistics Quarterly’ all available 
through the publication section of the ONS website[80]. 
 
National Cancer Intelligence Network  
 
The data collected by the registries is also accessed by other organisations, 
according to strict data access policies. The data is used for analysis and 
presentation / publication. One such organisation is the National Cancer 
Intelligence Network (NCIN). The NCIN was launched in 2008 and is a UK-
wide initiative, working to drive improvements in standards of cancer care and 
clinical outcomes by improving and using the information collected about 
cancer patients for analysis, publication and research.[81]  At the UK level, 
the NCIN co-ordinates information which is already aggregated by the 
registries. [82]  
 
The NCIN brings data together into a National Cancer Data Repository 
(NCDR). The 1990 - 2010 England NCDR Analysis Dataset brings together 
data from each of the English Cancer Registries for the period from 1990 to 
2010. The data consists of tumour level records submitted to the Office of 
National Statistics (ONS) by the English Cancer Registries together with a 
further sub-set of data covering additional data fields required for the 
purposes of analysis. The NCDR is held in a central location and is accessible 
by each of the cancer registries in line with NCIN's data access policies. 
Though NCIN includes English data only there is the capacity for the addition 
of the Celtic Countries NCDR Analysis Dataset.  The creation of the 
NCDR2010 dataset is a joint project between the NCIN, UKACR and 
ONS.[83] 
 
The NCIN uses the epidemiological data to coordinate UK-wide analyses as 
they become necessary. The NCIN annual reports include incidence, 
mortality, and survival figures and analyses that compare data across the UK 
by a variety of parameters (e.g. geographical location, age and others).[82] 
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It also uses the data to provide cancer information tools such as the cancer 
and prevalence e-atlases.[84,85] These aim to provide easily accessible basic 
information on incidence, mortality, survival [84] and prevalence [85] for the 
main types of cancers in males and females presented by UK region.   
 
 
Cancer Research UK 
 
Another organisation that handles the data from the registries and ONS is 
cancer research UK (CRUK), a leading UK charity. CRUK is dedicated to 
cancer research, and is funded entirely through public donations. Among their 
roles is providing publicly available relevant information necessary to 
understand the disease.[86] 
 
The epidemiology data from the registries and ONS is available on the CRUK 
website presented for cancer in general and specifically for each cancer type 
including colorectal cancer. The information is presented in tables and graphs 
with accompanying text that is easily understood by non-medically qualified 
individuals.  
 
CRUK has dedicated research teams including the Cancer Survival Group at 
the London School of Hygiene & Tropical Medicine (LSHTM) and the CRUK 
Statistics Team. They use the data to perform additional analyses as 
necessary, often in conjunction with the NCIN statistical teams.[86] 
 
Epidemiological data for cancer and colorectal cancer 
 
Life expectancy in the UK is increasing, due to a decrease in all-cause 
mortality. More elderly people are alive today than ever before.[87-92] 
 
Cancer is a major cause of morbidity in the UK. The lifetime risk of cancer is 
an estimation of the risk that a newborn child has of being diagnosed with 
cancer at some point during his or her life. It is based on current incidence 
and mortality rates and therefore is calculated under the assumption that the 
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current rates (at all ages) will remain constant during the life of the newborn 
child. The lifetime risk of cancer in the UK based on 2006 data was 1 in 3. 
One in three people will develop some form of cancer during their lifetime.[87-
93] It can develop at any age but is most common in older people. Around 
three-quarters of cases occur in people aged 60 and over (74%) and more 
than a third of cases in people aged 75 and over.[87-92] 
 
Incidence of Cancer 
 
Incidence of cancer refers to the number of new cancer cases arising in a 
specified period of time. Each year around 289,000 people are newly 
diagnosed with cancer. Breast, lung, colorectal, and prostate cancer account 
for over half of all the new cases (Figure 5.1).[94-97] 
 
If current cancer incidence rates stay the same, by 2025 there will be 100,000 
additional cases diagnosed per year due to the ageing population.[98]  
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Figure 5.1: The 20 most commonly diagnosed cancers in the UK, 2005. 
(excluding non-melanoma skin cancer (nmsc)).[99] 
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Incidence of Colorectal Cancer 
 
Colorectal cancer is the third most common cancer in the UK after breast and 
lung. Around 100 new cases of colorectal cancer are diagnosed each day. In 
2005 there were 36,766 new cases of large bowel cancer registered in the UK 
- around two-thirds (22,748) in the colon and one-third (14,018) in the rectum. 
The left side of the bowel is affected by cancer more often than the right. 
Tumours in the sigmoid colon, rectosigmoid junction and in the rectum 
together account for over half of all cases (Figure 5.2).[100-103] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colorectal cancer is the second most common cancer in women after breast 
cancer, with around 16,500 new cases diagnosed each year (Figure 
5.3).[100-103] 
 
More than 20,000 men are diagnosed with bowel cancer in the UK each year 
making it the third most common cancer in men after prostate and lung cancer 
(Figure 5.4).[100-103] 
 
 
Figure 5.2: Percentage distribution of cases by site within the large bowel, 
England 1997-2000[104] 
 
 
 
 
15% unspecified 
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Almost three-quarters of bowel cancer cases occur in people aged 65 and 
over. Until age 50, men and women have similar rates for bowel cancer, but in 
later life male rates predominate. In numerical terms, there are more male 
cases of bowel cancer up to the age of 80, after which female cases are in the 
majority, even though their rates are lower, as women make up a larger 
proportion of the elderly population (Figure 5.5).[100-103] 
Figure 5.3: The ten most common 
cancers in females in the UK, 2005.[99] 
 
 
Figure 5.4: The 10 most common 
cancers in men in the UK, 2005.[99] 
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Geographical analysis of cancer incidence in the UK showed similar 
distribution for colon and rectum with small variation (Figure 5.6).[100-103] 
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Figure 1.2: Numbers of new cases and age-specific incidence rates,
by sex,  bowel cancer, UK 2005
Figure 5.5: Numbers of new cases and age-specific incidence rates by 
sex, bowel cancer, UK, 2005.[105] 
 
Figure 5.6: Age-standardised incidence rates by sex, colorectal cancer, 
region of England, UK and Ireland, 1991-1999 [105] 
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Mortality from cancer 
 
In the UK in 2006, there were 154,162 deaths from cancer: one in four (27%) 
of all deaths in the UK; 29% for males and 25% for females. Deaths from 
cancers of the lung, bowel, breast and prostate together account for 47% of 
all cancer deaths (Figure 5.7).[106-108] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer caused a quarter of deaths in the over 65s in the UK in 2006, whereas 
cancer was responsible for more than a third (36%) of all deaths in the under 
65s.[106-108] 
 
In females under the age of 65 cancer causes 45% of deaths, while in males it 
is only 30%.[106-108]  
 
The overall cancer death rate has fallen by 10% over the last decade around 
12% for men and 9% for women.[106-108] 
 
The majority of deaths from cancer occur in the elderly. More than three 
quarters of cancer deaths (76%) occur in people aged 65 years and over. 
[106-108] 
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Figure 1.1: The 20 most common causes of death from cancer, UK, 2006Figure 5.7: 20 most common causes of death from cancer, UK, 2006.[109] 
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The cancer death rates rise with increasing age. Although there is a higher 
number of cancer deaths in the over 65s, cancer causes a greater proportion 
of deaths in younger people. [106-108] 
 
Mortality from Colorectal Cancer 
 
Colorectal cancer was the second most common cause of cancer death 
(10%) after lung cancer (Figure 5.7).[110-112] 
 
In 2006 there were 15,957 deaths from colorectal cancer in the UK, 
comprising 10,119 from colon and 5,838 from rectal cancer.[110-112] 
 
Colorectal cancer caused 8,511 deaths in men in 2006, accounting for 11% of 
all male cancer mortality (Figure 5.8).  
 
Colorectal cancer was responsible for 7,446 deaths and 10% of all cancer 
deaths in females (Figure 5.9).[111-113] 
 
 
 
 
 
 
 
 
 
 
 
 
Colorectal cancer mortality rates are substantially higher in men than in 
women – 23 per 100,000 males compared with 14 per 100,000 females in 
2006. [110-112] 
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Figure 5.8: The 10 most 
common causes of cancer 
deaths, males, UK, 2006.[110] 
Figure 5.9: The 10 most common 
causes of cancer deaths, females, 
UK, 2006.[110] 
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In contrast to incidence trends, bowel cancer mortality has been falling fairly 
continuously since the early 1990s (Figure 5.10).[110-112] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80% of bowel cancer deaths occurred in people aged 65 and over and almost 
two-fifths in the over 80s (Figure 5.11). [110-112] 
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Figure 5.10: Age-standardised incidence and mortality rates by sex, 
colorectal cancer, Great Britain, 1975-2005.[113] 
 
Figure 5.11: Number of deaths, and age-specific mortality rates, colorectal 
cancer, by sex, UK, 2006.[113] 
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In the ten years between 1997 and 2006, the bowel cancer age-standardised 
mortality rates in the UK fell by 17%. This fall in mortality affected all age 
groups with the largest fall in the 40–69 age groups for men and the 55-79 
age groups for women. [110-112] 
 
Bowel cancer mortality rates started to decrease in 1988 and since then the 
male rate has fallen by 30% and the female rate by more than a third (36%) 
(Figure 5.12).[110-112] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Within England, bowel cancer mortality rates are generally higher in the north 
of the country. [114] 
 
Survival from Cancer / Colorectal Cancer 
 
Survival estimates are the percentage of patients who are still alive a 
specified time after their diagnosis of cancer. The most common estimates 
are five and ten year survival rates.[115] 
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Figure 5.12: Percentage decrease in mortality rates, bowel cancer, by 
age and sex, UK, 1997-2006.[113] 
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Relative survival provides an estimate of the percentage of patients still alive 
a specified time from their diagnosis, taking into account the background 
mortality in the general population (i.e. the percentage of patients that would 
be expected to have died from other causes during the period if they did not 
have cancer). It is therefore an estimate of the proportion of patients that 
survive their cancer for the specified time period.[115] 
 
Survival has improved for most cancers in both sexes during the 1990s.[116-
119] There have been similar and significant improvements in survival for both 
colon and rectal cancer over the last 25 years.[120] The five-year relative 
survival rates for both male and female colon and rectal cancer have doubled 
between the early 1970s and early 2000 (Figures 5.13, 5.14, 5.15, 5.16).[121-
123] 
 
Five-year relative survival for male colon cancer rose from 22% in the early 
1970s to 52% in early 2000; for females it rose from 23% to 53%. Five-year 
survival rates for male rectal cancer rose from 25% in the early 1970s to 50% 
in early 2000 and from 27% to 52% for female rectal cancer. On average, 
increases in five-year survival of around 4% every five years for colon cancer 
and around 5-6% for cancer of the rectum occurred in both men and women. 
[121-123]  
 
Ten-year survival rates are only a little lower than those at five-years 
indicating that most patients who survive for five years are cured from this 
disease.[123] These improvements are a result of earlier diagnosis and better 
treatment but there is still much scope for further progress.[121-123] 
 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- - -    estimate survival 2000-2005  
___   1996-1999 
___  1991-1995 
___  1986-1990 
 
F 
- - -    estimate survival 2000-2005  
___   1996-1999 
___  1991-1995 
___  1986-1990 
Figure 5.14: Age-standardised relative survival in women diagnosed with 
colon cancer, England and Wales, 1986-1999.[124] 
 
Figure 5.13: Age-standardised relative survival in men diagnosed with 
colon cancer, England and Wales, 1986-1999.[124] 
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Figure 5.16: Age-standardised relative survival in women diagnosed with 
rectal cancer, England and Wales, 1986-1999.[124] 
 
Figure 5.15: Age-standardised relative survival in men diagnosed with 
rectal cancer, England and Wales, 1986-1999.[124] 
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Younger bowel cancer patients have a better prognosis than older patients. 
[121-123] As with nearly all cancers, relative survival for bowel cancer is 
higher in men and women under the age of 70, even after taking account of 
the higher background mortality in older people (Figure 5.13).[121-123] 
 
The reasons for this are likely to include a combination of better general 
health, more effective response to treatment and earlier diagnosis in younger 
people overall. Differences in underlying tumour biology may also play a part 
for some cancer sites.[125] 
 
Five-year survival in the age group 60-69 is slightly higher than the 40-49 and 
50-59 age groups though this difference is not statistically significant (Figure 
5.17).[123-125] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients who are diagnosed at an early stage have a much better prognosis 
than those who present with more extensive disease. Over 83% of patients 
diagnosed with Dukes stage A survive five years compared with less than 3% 
of patients with advanced disease (Table 5.1).[126] 
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Figure 5.17: Five year survival (%) of patients diagnosed with bowel cancer 
1996-1999, England and Wales.[125] 
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Prevalence for cancer and colorectal cancer 
 
Cancer prevalence refers to the number of people who have previously 
received a diagnosis of cancer and who are still alive at a given time point. 
Some of these patients will have been cured and others will not. Therefore 
prevalence reflects both the incidence of cancer and its associated survival 
pattern.[128] 
 
Overall, it is estimated that there are now 2 million cancer survivors in the UK, 
or approximately 3.3% of the population of the UK (Table 5.2).[128] This 
figure is rising at an estimated 3.2% per year. Overall, 10% of the total UK 
population over the age of 65 years is now a cancer survivor.[128] 
 
 
 
 
Dukes stage 
 
Approximate frequency 
at diagnosis 
Approximate 5-year 
survival 
A 11% 83% 
   
B 35% 64% 
   
C 26% 38% 
   
Metastatic disease 29% 3% 
Breast (female) 550,000 
Large bowel 250,000 
Prostate 215,000 
Lung 65,000 
Other 920,000 
All cancers 2,000,000 
Table 5.1: Approximate frequency and 5 year relative survival (%) by Dukes 
stage – England and Wales,1996-1999[127] 
 
Table 5.2: UK estimates of total cancer prevalence. (UK 2008 estimates 
based on diagnoses 1971-2004 applied to 2008 population; Thames cancer 
registry 2008.)[130] 
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These latest estimates are much higher than previous forecasts of cancer 
prevalence.[129] This is mainly because incidence has been rising whilst the 
death rates have continued to fall, leading to better survival. This trend is 
expected to continue over the coming years as a result of a number of factors, 
including an ageing population, earlier detection of cancer and continued 
improvements in treatment.[128-129] 
 
As the incidence of bowel cancer is high and survival rates have doubled over 
the last 30 years there are many people alive today who have been 
diagnosed with bowel cancer. An estimated 250,000 people are alive in the 
UK having received a diagnosis of bowel cancer (Table 5.2).[128] 
 
The NHS Bowel Screening Programme which has now been implemented 
nationally will dramatically influence the epidemiology of the disease and it will 
increase prevalence with more patients being diagnosed earlier and at an 
earlier stage giving them better prognosis and therefore increasing the 
prevalence of the disease. There could be up to 20,000 fewer deaths from 
bowel cancer over the next 20 years if just 60% of those eligible take up the 
invitation for bowel screening.[128] 
 
Quality of epidemiological data 
 
UK registry data quality 
 
Each Cancer Registry in the UK provides quality control information annually 
to the UKACR on a number of measures to allow comparisons of the 
timeliness, quality and completeness of their data. This information is collated 
and an annual report produced by the UKACR, consisting of a series of 
datasets, with accompanying explanatory commentary from the registries.[76] 
The UKACR annual quality results for 2008 from the 4 main registries 
providing colorectal data are presented in Table 5.3. 
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Quality and 
performance 
indicator 
Cancer 
peer review 
standard 
Target 
expected 
UK average NYCRIS 
England  
WICSU 
Wales 
SCR 
Scotland 
NICR 
N Ireland 
1. Registration and 
timeliness 
100% +/- 
2% 
100% +/- 2% 95.7% 95.7% 
 
103.1% 48.2% 103.3% 
2A. % change in 
registrations –  
male 
colorectal 
all xnmsc 
+/- 2% 
 
 
+/- 2% 
 
 
 
 
 
1.1 
1.2 
 
 
 
 
0.8 
-3.2 
 
 
 
5.9 
3.4 
 
 
 
 
-1.3 
-2.2 
 
 
 
2.1 
5.7 
2B. % change in 
registrations – 
female 
colorectal 
all xnmsc 
+/- 2% +/- 2%  
 
 
1.4 
0.6 
 
 
 
-1.2 
-4.7 
 
 
 
6.9 
2.9 
 
 
 
-0.8 
-0.5 
 
 
 
6.6 
0.9 
2C. childhood 
cancer incidence 
rates 
na na na na na na na 
2D. % death 
certificate only cases 
(DCO) 
colorectal 
 
 
 
2% 
 
 
 
2% 
 
 
 
2.3% 
 
 
 
0.4% 
 
 
 
1.9% 
 
 
 
0.6% 
 
 
 
0.4% 
Table 5.3: UKACR quality and performance indicators 2008 and results from the 4 registries that provide colorectal cancer data  
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2E. % “True” DCO 
colorectal 
 
2% 
 
2% 
 
1.4% 
 
1.0 
 
1.9 
 
0.6 
 
0.4 
2F. % zero survival 
colorectal 
   
 
3.3% 
 
 
2.2% 
 
 
2.5% 
 
 
1.3% 
 
 
0.7% 
2G. % 
microscopically 
verified 
colorectal 
 
  
 
87% 
 
 
 
88% 
 
 
 
88.9% 
 
 
 
90.8% 
 
 
 
84.9% 
 
 
 
91.4% 
 
 
 
90.5% 
2H. % non-
specificity of 
morphology code for 
cases 
microscopically 
verified 
colorectal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5% 
 
 
 
 
 
 
1.6% 
 
 
 
 
 
 
5.7% 
 
 
 
 
 
 
1.1% 
 
 
 
 
 
 
3.5% 
2I. 
mortality:incidence 
ratios 
colorectal 
 
 
 
 
 
 
 
0.44 
 
 
 
0.43 
 
 
 
0.44 
 
 
 
0.43 
 
 
 
0.45 
 
 
 
0.39 
3A. demographic 
and diagnostic 
details 
patients name 
patients address 
sex  
ethnicity 
date of death 
postcode 
 
 
 
 
 
 
 
 
100% 
  
 
 
100% 
99.9% 
100% 
50.2% 
100% 
99.8% 
 
 
 
100% 
100% 
100% 
42.3% 
100% 
100% 
 
 
 
100% 
100% 
100% 
30.2% 
100% 
100% 
 
 
 
100% 
100% 
100% 
0.2% 
99.9% 
100% 
 
 
 
100% 
99.1% 
100% 
0.0 
100% 
97.8% 
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date of birth 
unique health 
identifier 
diagnosis date 
site of primary  
type of growth 
behaviour of growth 
basis of diagnosis 
100% 
100% 
 
100% 
>95% 
>85% 
>98% 
>96% 
100% 
96.7% 
 
99.7% 
96.2% 
87.4% 
99.9% 
97.7% 
100% 
99.9% 
 
98.7% 
95.3% 
87.3% 
99.4% 
99.3% 
100% 
99.9% 
 
100% 
96.5% 
84.4% 
100% 
89.7 
100% 
91.3% 
 
100% 
96.1 
87.8% 
100% 
99.3% 
100% 
81.1% 
 
100% 
95.9% 
84.6% 
100% 
92.7% 
3B/C. treatment/ 
screening/stage 
information 
therapeutic surgery 
radiotherapy 
chemotherapy 
Dukes stage 
 
 
 
 
 
 
 
>74% 
 
 
 
 
 
 
 
 
 
 
45.6% 
17.8% 
19.5% 
66.4% 
 
 
 
43.6% 
20.5% 
24.0% 
75.9% 
 
 
 
54% 
na 
20.2% 
52.6% 
 
 
 
43% 
19.9% 
26.1% 
76.4% 
 
 
 
46.3% 
15.8% 
20.6% 
55.4% 
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When the search for quality control data was performed directly via the 
registry websites the only registry that provided the results of their quality 
control in tabulated format on their website was the NYCRIS registry. 
 
NYCRIS data quality 
NYCRIS the lead registry for colorectal cancer registrations in England 
produces an annual report which includes reporting of data quality. The report 
is presented and is easily accessible through the NYCRIS home webpage. 
The website also contains information regarding the quality assurance 
process in place at NYCRIS and this information is summarised below. 
 
NYCRIS has in-house quality assurance processes that aim to maintain high 
quality data. These comprise extensive routine monthly quality checks as well 
as one-off excercises and spot checks. In addition there is a comprehensive 
quality assurance process for reviewing each successive year of completed 
registrations.[131] 
 
Quality control procedures of the registration process include routine checking 
of staging against staging protocols, of registrations with multiple hospital 
episodes, and of registrations where two or more treatments are 
recorded.[131] 
 
NYCRIS uses monthly monitoring reports to estimate the completeness of a 
particular registration year based on the numbers of registrations made in 
previous years. NYCRIS liaises with other organisations in the geographical 
area that shows under-ascertainment (a commonly occuring problem) and 
identifies alternative means of retrospective cross-checking of cases, ideally 
prior to the completion of a particular registration year. This often requires 
pathology reports to check for missed cases. It is not clear why some cases 
are missed in routine process; changes in hospital personnel or changes in 
computer systems may have an impact. Reminders are sent regularly 
regarding the range of registerable conditions and monitoring of this aspect of 
data quality continues.[131] 
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Table 5.4 presents the key quality and performance indicators for NYCRIS 
compared to the average UK results based on cases diagnosed in 2007 as 
reported in the NYCRIS 2008-9 report available through the NYCRIS 
website.[132] 
 
 
 
Performance indicators NYCRIS UK average 
Dataset completeness Data item % complete Data item % complete 
Postcode 100.0 99.9 
Sex 99.9 100.0 
Date of Birth 100.0 100.0 
NHS number 99.4 99.0 
Topography (specific) 95.9 96.4 
Morphology (specific) 86.7 88.4 
Breast staging Na 49.0 
Cervix staging 92.1 64.7 
Colorectal staging 75.8 68.8 
Melanoma staging 92.9 58.4 
Grade (breast only) 89.9 86.3 
Death Certificate only 
cases 
% % 
All sites (male) 1.9 2.3 
All sites (female) 1.9 2.4 
Microscopic verification 
rates  
% % 
All sites (male) 86.1 84.4 
All sites (female) 90.2 85.9 
Mortality : Incidence 
ratios 
  
All sites (male) 0.55 0.53 
All sites (female) 0.53 0.50 
Table 5.4: NYCRIS performance indicators for 2007 diagnoses.[132] 
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ONS data quality 
ONS provides an extensive list of methodology and guidance documents 
regarding the statistical analyses it carries out. These are available to access  
through its webpage.[133,134]  
 
NCIN data quality 
The NCIN uses the data already aggregated by the cancer registries and 
ONS. For any additional statistical analyses performed the methodology is 
provided as part of the introduction to the analysis document. All analyses are 
available through the website.[135] 
 
CRUK data quality 
CRUK uses the data provided by the UK cancer registries and ONS. It does 
not provide any information on the quality of the registration data or the 
analyses from ONS. However it provides explanations on terminology used  
as part of the explanatory text accompanying the statistics.[136] 
 
5.5 Discussion 
 
The results show that epidemiology data on colorectal cancer is available and 
easily accessible through multiple sources via the world wide web. These 
sources are long established national organisations with an expertise in the 
data being handled. Therefore they are appropriate sources for delivering this 
information. In addition, the information is available without prior request. 
Either in graphical format or explanatory text information on the epidemiology 
of cancer and colorectal cancer can be accessed easily by both professionals 
and the public. This fact in itself makes the issue of the quality of the data and 
the ability to access and assess the quality of the data even more important. 
  
Quality  is a property of the data and a product of the techniques used to 
create the data. [74] The main source of data is the cancer registries that 
perform the main task of cancer data registration. Therefore the assessment 
of quality begins by the assessment of the quality of the registration process. 
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The main sources of data for a cancer registry include: 1) treatment facilities 
such as hospitals, hopsices, GP surgeries; 2) diagnostic services, especially 
pathology departments, imaging departments, haematological laboratories; 3) 
death certificates from the death registration system.[73] 
 
The information is collected both actively (registry staff visit the hospitals to 
collect information) and passively (hospital staff fill in registration forms 
provided by the registry for each cancer case). A mixture of both procedures, 
with an emphasis on the latter is followed in most registries creating large 
databases of information.[73] 
 
There can be error in any of the steps of the information gathering and 
processing exercise. No large-scale database can be perfect and quality 
control procedures are instituted to identify the areas and degree of 
imperfection, and thus assist in the interpretation of the data and any 
indicated procedural changes.[74]  
 
The results show that in the UK all registries have quality control procedure in 
place and aim to adhere to standards set by national and international bodies. 
This in itself is an important indication of quality. There is monitoring of the 
process irrespective of the results of the quality control process itself. 
 
With regard to the quality of the data two main issues need to be considered 
when evaluating the quality of the data of a cancer registry: its completeness 
and its validity.  
 
Completeness of the data includes completeness of cover. A population- 
based registry should, by definition, register every single case that occurs in 
its catchment population.[73] It is also important to ascertain the extent to 
which the registry eliminates registrations of cases from outside the 
catchment population and avoids multiple registrations of the same person or 
tumour.[73] Data completeness also included the completeness of detail i.e. 
ascertaining every item of data for every patient. Some data items may not be 
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applicable to every patient, there may be errors of commission (data being 
present where it should be absent), or errors of ommision, all making 
interpretation of the data difficult.[74] 
 
Validity of the data refers to the accuracy of the detail recorded. Error can 
occur in a multitude of ways: abstraction, transcription, coding. In additon, 
validity of the data refers to the accuracy in the reporting. Many variables, 
discontinuity of coding, changing file layouts, make the collation of data a 
difficult task. All this may be handled by staff that lack first-hand knowledge of 
the data and this may introduce error that is difficult to detect unless it gives 
rise to totally unexpected results. Finally, validity of the data also refers to the 
accuracy of the interpretation of the data. This requires understanding of the 
data, the data sources and how the data is processed.[74] 
 
The results show that UK cancer registries have developed internal quality 
control checks so that attention is drawn to missing information and 
inconsistent data. 
 
Case completion and ascertainment is rarely complete. Various methods, 
such as comparisons with death certificates and hospital records have been 
used to determine the degree of completeness of registration.[73] 
 
A unique registration number is assigned by the registry to each patient. If a 
patient has more than one primary tumour then the same number is given to 
each tumour. Multiple primaries are then distinguished on the basis of their 
incidence date and their topography (site of primary tumour) and morphology 
(histological type of the tumour). The incidence date is the date of first 
consultation or admission to hospital with a diagnosis of cancer as can be 
verified from the hospital records. If this is not available then it is the date of 
the first pathological report that confirms cancer. A special problem arises if 
cancer is first ascertained from a death certificate and attempts to follow back 
are unsuccessful. The date of death of such ‘death certificate only’ (DCO) 
cases is taken as the incidence date.[73] 
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The results show that all four registries had a very low death certificate only 
case load and less than the target of 2%.  
 
Other identification items such as name, sex, and date of birth are important  
to avoid multiple registrations of the same patient or tumour, to obtain follow 
up data and to conduct any kind of linkage. Address is essential to conduct 
analyses by area of residence.[73] The results show that all four registries had 
a very high completion rate for these parameters between 99-100%.  
 
An important deficiency is the recording of ethnicity. This parameter is 
important where distinct ethnic groups might carry different risk of cancer. 
Ethnicity registration varied between 0.2 and 52% which is a much lower 
registration completion than any of the other parameters. It affects all 
registries, which indicates that this is a national problem regarding the 
registration of this particular parameter rather than poor quality in any one 
step of the registration process of one registry. Further analyses of colorectal 
cancer epidemiology in combination with ethnicity data would need to take 
this into account but it does not effect the data within this analysis. 
 
The validity of the data can be assessed in various ways. The proportion of 
cases with microscopic verification of diagnosis is a very useful index, as is 
the proportion registered during life (not simply from death certificate).[73]  
 
The results show that all four registries have high proportion of cases with 
microscopic verification (between 84.9% and 91.4%). The Welsh registry with 
a score of 84.9% is slightly under the standard target of 87% and under the 
UK average of 88.9%; however overall these are high scores. 
 
Information on the most valid basis of diagnosis is of great interest in 
assessing the quality of the registration data. The minimum requirement of a 
cancer registry is to discriminate between tumours that were microscopically 
verified and those that were not. If possible, further information should be 
obtained to distinguish neoplasms that were diagnosed on the basis of a 
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clinical history only, clinical history plus other investigations (e.g. x-ray), 
exploratory surgery, autopsy, cytology, etc.[73]. 
 
The results show that all four registries had high percentage of registration of 
this parameter (89.7-99.3%). The Welsh registry was scoring below the 
standard target of 96% and less than the UK average of 97.7. However this is 
a steady improvement from previous years (84.6% in 2006, 88.5% in 2007). 
 
NYCRIS, was the only registry that actually displayed its quality control results 
on its webpage. This is good practice and certainly makes assessment of data 
both easy and possible concurrently when approaching a source for data. 
 
Overall, the quality of UK cancer and colorectal cancer epidemiology data is 
high primarily due to the high quality of the cancer registration process in the 
UK carried out by the cancer registries and the quality control procedures in 
place. 
 
 The establishment of the English National Cancer Online Registration 
Environment (ENCORE) as a single database recording all English cancer 
registrations will reduce the potential for error arising from the collation of 
information from multiple databases across the various English registries as 
well as provide a single point of contact for accessing the epidemiological 
data of interest. 
 
The quality of the data is also a reflection of the quality of the statistical 
analysis carried out by ONS and to a lesser degree by the statistical teams at 
CRUK and NCIN. The results show that these organisations present their 
methodology clearly through their websites. Either as separate documents (in 
the case of ONS), or as part of a specific analysis document (in the case of 
NCIN), or as part of their ‘frequently asked question’ webpage in the case of 
CRUK. The transparency of the methods of statistical analysis is very 
important. 
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It is important to know why a particular method has been used over an 
alternative and how a particular calculation has been carried out. 
 
The results present the data as age-standardised rates for incidence and 
mortality and it is on these age-standardised rates that survival and 
prevalence are estimated thereafter. 
 
Crude incidence rates are calculated using a simple formula in which the 
number of cases is divided by the corresponding population and multiplied by 
100,000. Since cancer is generally more common in the elderly, crude rates 
are greatly influenced by the proportions of older people in the populations 
being studies. For this reason, age-standardised rates are used when making 
comparisons of incidence rates (for example, over time, between sexes or 
between geographical areas).[137] 
 
Age-standardisation adjusts rates to take into account how many old or young 
people are in the population being studied. Thus when rates are age-
standardised, differences in the rates over time or between geographical 
areas do not simply reflect variations in the age-structure of the population. 
This is important when looking at cancer rates because cancer is a disease 
that predominantly affects the elderly. So if cancer rates are not age-
standardised, a higher rate in one country is likely to reflect the fact that it has 
a greater proportion of older people.[138] 
 
The data and the analyses presented do have limitations. All the epidemiology 
data presented has a time lag of about two years from the time of the search 
query. This is a common and accepted reality in data of this type. The process 
of registering a cancer is complex and there are a number of processes in 
place as discussed above to ensure the data is of high quality but this means 
there is usually a delay of about 18 months before the data is complete 
enough for them to be published. In addition, the statistical analyses are 
compiled from data produced by the regional cancer registries in England and 
the three national registries in Wales, Scotland and Northern Ireland which 
means there is another time lag before the statistical analyses can be 
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published as these have to wait until all of the data has been published by 
each country and its registry.  
 
In addition, mortality may be higher than case numbers because of the way death 
certification and cancer registration works, and what data is available and when.   
If a patient has died from cancer but the official documenting the death on the 
certificate cannot confirm what type of cancer caused the death, it may be 
recorded as a non-specific cancer type (Cancer of Unknown Primary -CUP). 
However, on receipt of the death certificate the cancer registries may then be able 
to identify other information about that history and determine what type of cancer it 
was, and update the record regarding their case diagnosis. The data would 
therefore show a patient recorded as having a known type of cancer for their case 
data, e.g. being a colorectal cancer case in the incidence data, but as a different 
cancer type in the mortality data, e.g. being a CUP death in the mortality data. This 
inconsistency will remain because the death certificate cannot be changed and the 
effect of this is potentially inflated mortality statistics for non-specific cancers like 
CUP at the detriment of the mortality statistics for specific cancers.[138] 
 
 
The epidemiology results were presented by the author to the guideline 
development group as part of the guideline needs assessment report. 
The results trigerred a discussion about the implication of these results 
internationally and how the UK compared to other countries. In the past studies 
have shown that UK nations have poorer cancer survival outcomes than 
comparable countries. However, the opinion of the GDG was that such 
international comparisons lacked uniformity in the countries they compared and 
this information should therefore not be searched nor included in the guideline 
document. 
 
Around the same time the International Cancer Benchmarking Partnership (ICBP) 
was being set up (2009) and its purpose mirrors the conclusion of the GDG on this 
matter. The ICBP is an international initiative involving 6 countries. Australia, 
Canada, Denmark, Norway, Sweden and the UK. The partners all have 
comparable wealth, a universal access to health care and long standing high 
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quality  population based cancer registration. Partner countries are invited to join 
only if they fulfil these three criteria. Meeting these three factors is important as it 
limits the variables that can affect cancer outcomes. The research is looking 
specifically at four cancers breast, colorectal, lung and ovarian which share a large 
burden of cancer disease in developed countries and which also display significant 
differences in survival amongst countries.[258] Comparing cancer services, 
processes and the public’s interactions with these across different countries can 
help identify possible  reasons for the observed differences. And by understanding 
critical differences  and similarities between UK nations and those countries with 
better survival rates it should be possible to build a picture of where improvements 
could be made.[258] 
 
Overall what the results show is that a reliable source of epidemiological data is a 
powerful tool that can provide clues as to how the lives of people with cancer are 
affected and can be changed. This can be used to improve early detection, 
diagnosis, treatment and follow up. As part of a guideline document it can either 
guide the direction of research or underpin future improvements based on specific 
findings.  
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6.0 Availability and quality of current clinical practice data 
on CRC management for the purpose of a guideline needs 
assessment report 
6.1 Introduction 
 
The scope of the NICE colorectal cancer guideline recommends that the second half 
of the needs assessment report includes information on current UK clinical practice 
with regard to the management of colorectal cancer.[139]  
 
The aim is to identify any concerning variability that exists in the management of the 
disease in order to help the guideline development group members formulate 
recommendations that are likely to have the greatest impact on clinical outcomes. 
[139] 
 
Variability in disease management is not always undesirable. It is often just a 
reflection of different populations, patient choice, or one center of excellence carrying 
out a technique in a slightly different way to another center of excellence.[71] 
 
It is unacceptable however if patients receive substandard care which deviates from 
basic principles due to the actions and practice of one individual clinician without 
backup and support from a multidisciplinary team.[71] 
 
In the UK variability in disease management is likely to exist in areas such as pre-
operative staging, often because of the different availability of imaging resources.[71] 
 
Also, where a sequence of therapeutic interventions is possible the sequence may 
differ, e.g. treatment for liver metastases either before or after the surgery for the 
primary tumour. [71] 
 
Variation is also likely to exist when considering different patient groups. For 
example when considering patients with multiple co-morbidities or the very elderly 
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who despite their age have low morbidity as assessed on the ASA physical status 
classification system. Some do and some do not get access to radical therapies.[71] 
 
The collection of clinical practice data is a relatively recent development. Before 
1987, only a 10% sample of admitted patient records were collected nationally. 
[140,141]  
 
The mechanisms for collecting the data have changed considerably over the years, 
often in response to changes in the organisation of the NHS.[140] 
 
There are additional clinical practice data sources that have been developed in 
recent years, such as national audit databases, disease registers, specialty datasets, 
and national specialist systems, all of which have been developed to provide high-
quality clinical data and improve the quality of care provided.[141] 
 
When considering the quality of current clinical practice data the two main issues of 
concern are the completion and the validity of the data. Both these parameters are 
intimately involved with the process of the data collection. Understanding the data 
collection process, its strengths and weaknesses, and having quality control 
processes in place for monitoring are vital in order to ensure data that is reliable. 
 
The issue of the quality of current clinical practice data is complicated however by 
the sheer diversity of this type of data. The data can range from imaging information, 
to operative information, to patient reported outcomes and many more types.  
 
Furthermore, quality issues are additionally complicated by the diversity of the 
databases. The location of these, their age, the software, the data collection process 
they encompass, the data access policies are some of the many variables relating to 
the databases. In order to ensure quality assurance a systematic approach with 
attention to the elimination of bias risk is key. 
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6.2 Aim 
 
To research the availability and quality of current clinical practice data that can 
inform a GDG on aspects of CRC management for the purpose of the CRC guideline 
needs assessment report. 
 
6.3 Methods 
 
For the purpose of a needs assessment current clinical practice data could 
potentially be sourced from many different specialist areas within the different 
settings of colorectal cancer management. In order to limit the breadth of this 
analysis the scope of the guideline was used as a guide to defining what the required 
current practice data should include.  
 
As the purpose of the needs assessment is to ‘set the scene’ for what is currently 
happening in the UK in colorectal cancer management it was deemed to be useful to 
identify sources of current clinical practice data relevant to each clinical topic the 
guideline was planning to address. 
 
6.3.1 Formulation of data queries (current clinical practice questions):  
 
The topics for the clinical questions that the guideline addresses are based on the 
guideline scope and are developed in consultation with the various stakeholders at 
the scoping workshop.  
 
Once the specific guideline topics emerged after the results of the scoping workshop, 
the guideline development group together with the NCC-C technical team (including 
the author) finalised the fifteen clinical questions for the NICE colorectal cancer 
clinical guideline.  
 
A background summary of key facts known about each clinical question was 
presented to the guideline development group by the lead group member for this 
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topic as chosen by the guideline chair. This was for the purpose of establishing the 
basic information available about each one topic prior to any systematic review 
performed.   
 
Each guideline question together with the background information provided was then 
used by the author as the basis from which the equivalent current clinical practice 
data query was formulated. 
 
6.3.2 Online data mining 
 
With the current practice questions formulated an online search was carried out to 
identify appropriate sources that could provide data to answer these specific clinical 
practice questions. 
 
The search was through the ‘Google’ search engine and used key words from the 
formulated current clinical practice questions. References of key documents or 
websites identified were then further explored for additional information. 
 
 Websites of national bodies, societies, research organisations, patient-groups and 
charities associated with the management of colorectal cancer were also searched 
with the purpose to identify data sources. 
 
6.3.3 Query of National databases of patient information for data 
 
Online data mining identified a range of potential data sources and the most 
appropriate data sources were approached for anonymised data. Discussions for 
potential linkage of multiple specialist databases were also carried out with database 
specialists in order to establish the feasibility of the data collection for the specific 
data queries.  
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6.4 Results  
 
6.4.1 Formulation of data queries (current clinical practice questions) 
The following section presents the fifteen guideline topics A-O with a 3-step 
breakdown of the development process from guideline question to formulated current 
clinical practice data query for each topic. 
Guideline topic A: diagnosing CRC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question:  
What initial investigation is currently being performed in units across the UK for 
patients with suspected CRC in order to establish a diagnosis? Are patients first being 
investigated with:  
barium enema, flexible sigmoidoscopy, barium enema and flexible sigmoidoscopy, 
colonoscopy, CT colonography 
Guideline question 
What is the most effective initial diagnostic intervention(s) for patients with suspected 
CRC to establish a diagnosis? 
 
Information linking the guideline question to current clinical practice.[142] 
The optimum diagnostic strategy for colorectal cancer has not yet been defined. 
Historically, the interventions used in each centre are guided by local expertise and 
preference. The aim of the investigation is to achieve adequate examination of the 
entire colon and rectum. In the past barium enema was the investigation of choice.  
There is no need for patient sedation and it carries a low incidence of serious 
complications. The introduction of the highly sensitive fibre-optic endoscopic 
examinations has seen a huge rise in flexible sigmoidoscopy (endoscopic investigation 
of the distal 50cm of the large bowel) and colonoscopy (complete endoscopic 
examination of the rectum and colon). Colonoscopy is considered the gold standard. 
Some centres may however offer patients a combined investigative pathway of flexible 
sigmoidoscopy followed by barium enema as an alternative way to image the entire 
colon. CT colonography (or CT colonoscopy, or virtual colonoscopy) is a recently 
developed modality that is less invasive and does not require sedation.  
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Guideline topic B: staging CRC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question(s):  
What modality is currently used in the UK to stage colon and rectal cancer?  
Do all patients get a CT chest-abdomen-pelvis? 
Which group of patients get staged with PET or PETCT? 
Which group of patients get staged with MRI?  
Which patients with rectal cancer receive EUS as part of their staging? 
 
Guideline question:  
For patients diagnosed with primary colorectal cancer, what is the most effective 
technique(s) in order to accurately stage the disease (excluding pathology)? 
 
Information linking the guideline question to current clinical practice. [142] 
The optimal modality may vary depending on the clinical situation. Historically, staging 
of CRC relied on physical examination including digital rectal examination. More 
recently staging relies mainly on CT, endo-anal ultrasound scan (EUS) and MRI.  In 
addition PET and PETCT have been introduced in the assessment of distant 
metastases. Availability of MRI, PET, PETCT and EUS in particular may differ from 
one centre to another and additionally there may be differing levels of local expertise 
with regard to the interpretation of these images; this may lead to variation in the 
staging process offered to patients. In addition, modalities may differ in their ability to 
accurately demonstrate distant metastases, assess early cancers (T1 muscularis 
propria invasion and wall penetration), define the mesorectal fascia and the 
circumferential margin (CRM), and to a certain degree predict the suitability for 
restorative surgery (low anterior resection rather than abdominoperineal resection).  
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Guideline topic C: prognostic factors for curative treatment of stage I/polyp cancers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Current clinical practice question:  
What treatment are patients currently having in the UK for stage I / polyp cancers?  
Local treatment (endoscopic or other)? 
Surgical segmental resection?  
  
Guideline question:  
For patients who have undergone local excision for stage I colorectal cancer, 
including polyp cancers, with/without neoadjuvant treatment for rectal tumours, 
which prognostic factors determine the most effective curative treatment? 
 
Information linking the guideline question to current clinical practice.[143] 
Patients with Stage I CRC have a five-year survival of >95% following surgery, 
segmental resection with clear surgical margins (removal of a segment of large 
bowel including its associated mesentery). Surgery is the curative treatment. 
Stage I colorectal cancer may also be identified in endoscopically resected polyps 
(malignant polyps). Less commonly, it may be found in polypoid lesions resected 
en-bloc with Endoscopic Submucosal Dissection (ESD) or Transanal Endoscopic 
Micro Surgery (TEMS). 
The UK Bowel Cancer Screening Programme has lead to increased frequency of 
malignant colonic polyps. Almost all locally removed malignant polyps are Stage I 
cancers. Endoscopic resection of malignant polyps may be sufficient as the only 
management but there is a risk of local recurrence or metastatic spread, 
particularly to local lymph nodes, since the mesentery, which contains the nodes, 
is not resected. These risks may be reduced by subsequent surgery, but the 
associated risks such as bleeding, infection or possibly death, and the effects on 
quality of life need to be balanced against the potential benefits.   
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Guideline topic D: self-expanding metal stents (SEMS) for malignant obstruction 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Guideline question 
For patients with acute large bowel obstruction as a first presentation of CRC  
A) Should all patients have a CT scan to confirm diagnosis and stage?  
B) What are the indications for stenting as a bridge to elective surgery? 
C) What is the optimal timing for stenting to occur? 
 
Information linking the guideline question to current clinical practice.[143] 
Up to 30% of CRC cases in the UK present in the emergency setting. Emergency 
surgery performed for obstructing lesions is associated with a high morbidity and 
also with peri-operative mortality ranging from 10-20% compared to 5% in the 
cases of elective cases. In addition, emergency surgery results in a higher rate of 
stoma formation, high intensive care use and prolonged hospital stay. The 
introduction of SEMS has provided the opportunity for endoscopic decompression 
of these patients in an attempt to reduce the risk of emergency surgery. Following 
decompression it is possible to correct electrolyte imbalance, evaluate the extent of 
disease, determine the presence of synchronous lesions and evaluate co-
morbidities, thus enabling the planning of the most appropriate elective surgery. 
The placement of a SEMS however is not without risk. It can be associated with 
colonic perforation, stent migration, malposition or may delay surgery further if the 
procedure is unsuccessful. The incidence of stent-related complication increases 
the longer the stent remains in situ. It has been suggested that the success rate for 
stent insertion is lower for tumours proximal to the sigmoid colon, but with the 
advent of newer devices able to pass through the endoscopic therapy channel the 
success of stent placement in the right colon is likely to increase. The potential 
hazards of SEMS placement must be balanced against the lower surgical mortality 
in cases of emergency surgery for right-sided colonic obstruction when compared 
to left-sided lesions. 
 
Current clinical practice question:  
Are all patients with a diagnosis of malignant bowel obstruction getting a CT scan?  
Who is getting a stent and who is getting emergency surgery?  
In how many patients is the bowel currently being defunctioned? 
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Guideline topic E:  pre-operative management for non-metastatic locally advanced 
colon and rectal tumours  
(locally advanced tumours are defined as those tumours that appear unresectable or 
borderline resectable at presentation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question: 
What pre-operative treatment are patients with locally advanced but non-metastatic 
colon and rectal cancer receiving?  
Are patients with colon cancer receiving pre-operative chemotherapy?  
Are patients with rectal cancer receiving pre-operative chemoradiotherapy? 
Guideline question 
For patients presenting with a) non metastatic locally advanced colon cancer is 
pre-operative chemotherapy followed by surgery more effective than immediate 
surgery and for patients presenting with b) locally advanced rectal cancer is pre-
operative radiotherapy, pre-operative chemotherapy or pre-operative 
chemoradiotherapy more effective than immediate surgery? 
Information linking the guideline question to current clinical practice.[143] 
Colon cancer occurs at several different sites along the large bowel with variation in 
the anatomy affected. For most of these sites, the main risk is peritoneal 
involvement which when it occurs is usually widespread. Any strategy to reduce the 
risk of recurrence needs to have a systemic approach. However it is not known 
whether pre-operative chemotherapy is able to reduce the risk of this type of 
recurrence. Pre-operative chemoradiotherapy is given to patients with locally 
advanced rectal cancer, with the intention of reducing tumour size to facilitate 
potentially curative surgery. There is concern that for a small proportion of patients 
their tumour may progress while on such therapy, thereby losing the window of 
opportunity for surgical resection. There is also concern that pre-operative 
chemoradiotherapy is being used for the treatment of very low rectal tumours to 
facilitate sphincter saving surgery (i.e. a low anterior resection versus an 
abdominoperineal resection). 
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Guideline topic F: the most effective sequence of chemotherapy and surgery for the 
treatment of patients with CRC and synchronous metastatic disease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question 
For patients with resectable synchronous metastatic disease are units offering 
pre- or post-operative chemotherapy or are they offering a combination of both? 
In these patients is the surgery staged or a combined procedure? 
In patients with non-resectable metastatic synchronous disease are units offering 
adjuvant chemotherapy and are they offering surgery for the primary tumour?  
 
Guideline question 
In patients with CRC presenting with overt synchronous metastatic disease, what 
is the effectiveness of treating metastatic disease before, after or at the same 
time as treating the primary tumour? 
 
Information linking the guideline question to current clinical practice. 
At presentation approximately 25% of patients with CRC have metastatic disease. 
In these patients it is thought that the outcome is worse than in those patients that 
present with metachronous metastatic disease.  
The first issue to be addressed is whether the primary tumour is causing 
obstruction. If this is the case then surgery either to resect or to bypass the 
tumour should be the primary treatment before considering both chemotherapy 
and surgery for the metastatic disease. In some cases a stent of the obstructing 
primary tumour may be possible. 
In patients with resectable metastatic disease they should undergo both surgery 
and systemic treatment with chemotherapy, as their disease is potentially curable. 
The questions are: chemotherapy prior to or after surgery? Should surgery be 
staged or combined? 
For patients with unresectable disease all treatments are palliative and the main 
issue is whether leaving the primary tumour in situ is harmful to the patient. 
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Guideline topic G: neoadjuvant radio- and chemoradiotherapy for rectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice questions 
Do all patients undergoing an abdominoperineal resection for low rectal cancer receive 
pre-operative radiotherapy?  
For patients allocated to receive pre-operative radiotherapy do they all receive long-
course chemoradiotherapy?  
If short-course radiotherapy is considered for some or all of these patients under what 
circumstances is this done?  
How is the decision made between short-course radiotherapy versus long-course 
chemoradiotherapy for patients with rectal cancer requiring an abdominoperineal 
resection (APR)? Is there a standard policy in the units / networks?  
Is a re-staging MRI or other imaging investigation performed after the completion of the 
pre-operative neoadjuvant treatment?  
Is a biopsy of the downstaged tumour site performed to confirm downstaged appearance 
on imaging? 
If the re-staging MRI identifies the original tumour to be completely downstaged to R0 
and the biopsy of the site is negative what decision is made then? Do units proceed with 
performing an APR as originally planned or do they offer regular follow-up with re-
imaging and re-biopsy? 
 
Guideline  question: 
For patients with operable rectal cancer, what is the effectiveness of short-course pre-
operative radiotherapy (SCPRT) and chemoradiotherapy? 
 
Information linking the guideline question to current clinical practice.[143] 
SCPRT and chemoradiotherapy are widely used to reduce the risks of local recurrence 
compared with surgery alone, but there is uncertainty over which schedule to use in 
which particular clinical setting. SCPRT is a brief (5 days) treatment with high dose per 
fraction radiotherapy. Short-term side effects are minimal though there is some risk from 
long-term morbidity. Chemoradiotherapy involves a protracted (minimum of 5 weeks) 
course of radiotherapy with concomitant chemotherapy. Short-term side effects are more 
marked and long-term effects can occur. Some cases respond completely.  
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Guideline topic H: adjuvant chemotherapy for stage II and III rectal cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question: 
Are patients with stage II and III colon and rectal cancer being offered adjuvant 
chemotherapy?  
Guideline question 
In patients with clinical or pathological stage II and III rectal cancer what is the 
effectiveness of adjuvant chemotherapy following surgery? 
Information linking the guideline question to current clinical practice.[143] 
Colonic and rectal tumours are anatomically in continuity and similar in 
histopathology. When metastatic, both respond to cytotoxic chemotherapy to a 
similar level.  
Patients are assessed pre-operatively for their risk of recurrence by clinical 
examination and imaging i.e. clinical staging (cTcNcM). Patients are assessed 
post-operatively for their risk of recurrence by virtue of the surgical specimen i.e. 
pathological staging (pTpNpM).  
Although it is assumed that the effects of post-operative adjuvant chemotherapy 
achieved in colon cancer will be the same as in rectal cancer, there has been less 
direct evidence to support this in patients who have received pre-operative 
radiotherapy or chemoradiotherapy. Also historical trials in the post-operative 
setting have used a combination of chemotherapy concurrent with radiotherapy, 
which has made the assessment of the impact of adjuvant chemotherapy more 
difficult. 
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Guideline topic I: adjuvant chemotherapy for high risk stage II colon cancer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Guideline topic J: adjuncts for patients with unresectable metastatic disease 
 
 
 
 
 
 
 
 
 
Current clinical practice questions: 
Are patients with high-risk stage II disease being offered adjuvant chemotherapy? 
If so how are units defining high risk in patients with stage II disease?  
poorly differentiated tumours 
extra-mural vascular invasion 
T4 tumours (local extension or perforation) 
obstructed tumours 
small number of lymph nodes harvested (which means the patient has been 
inadequately staged) 
microsatellite instability 
mucinous tumours 
tumour budding 
 
  
 
Guideline question 
For patients with high-risk stage II colon cancer what is the effectiveness of 
adjuvant chemotherapy after surgery? 
 
Information linking the guideline question to current clinical practice.[143] 
The benefit of adjuvant chemotherapy was first demonstrated for patients with 
stage III disease. In the MOSAIC and NSABP C-07 studies 40% and 29% 
respectively of patients had stage II disease. The remainder had stage III 
disease. It is recognised that patients with stage II disease have a better 
prognosis than those with stage III disease and therefore the benefit of adjuvant 
chemotherapy is likely to be less. It is known that the prognosis of patients with 
stage II disease is variable and efforts have been made to identify those at higher 
risk of relapse.  
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Guideline topic J: adjuncts for patients with unresectable metastatic disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Current clinical practice question: 
Are patients with unresectable metastatic disease who have had a positive 
response to systemic chemotherapy being offered adjunct local treatments to 
prolong their disease-free interval?  
If so which one? 
 
Guideline question 
What is the most effective additional treatment (adjuncts) to systemic 
chemotherapy to achieve cure or long-term survival in patients with apparently 
unresectable metastatic disease? 
 
Information linking the guideline question to current clinical practice.[144] 
Where metastatic disease is considered unresectable, systemic combination 
chemotherapy, with or without biological agents, is the standard of care. Long-
term cure is unlikely but median survival can be prolonged to approximately 2 
years. Provided a good response is seen in patients with unresectable liver, 
lung or peritoneal disease following chemotherapy, then local procedures can 
be attempted to try to prolong the disease-free interval. These local procedures 
have been most applied to the liver where radiofrequency ablation (RFA) is the 
most commonly used local treatment, although conclusive data on the benefits 
have not yet been published. There are even less data on alternative local 
procedures such as microwave, laser, cryotherapy, radio-embolisation or 
stereotactic body radiotherapy (SBRT). Some of these local procedures can 
also be applied to lung metastases, depending on the size and position of 
individual lesions.  
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Guideline topic K: imaging of liver metastases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question: 
What imaging investigation are patients with hepatic metastases offered in their 
assessment as candidates for curative liver resection? 
PETCT 
MRI 
PETCT and MRI 
Do units have specific policies for this decision? 
 
Guideline question 
In a patient with colorectal cancer metastasised to the liver which imaging 
modalities most accurately determine the number and extent of metastases pre-
operatively? 
 
Information linking the guideline question to current clinical practice.[144] 
In the UK the diagnosis of liver metastases is usually derived from a CT scan 
performed as part of the original staging or during follow-up after potentially 
curative surgery for the primary cancer. Currently the two imaging modalities used 
to assess the presence, number and extent of liver metastases in order to decide 
whether a lesion is operable are MRI with liver contrast enhancement and PETCT 
scans. Most patients prepared for surgery will have both of these investigations at 
some point in their pre-surgical assessment. PETCT is considered by many to be 
more accurate in detecting liver metastases. However it is an expensive 
investigation, and not widely available. Patients need to travel long distances to 
gain access to a PETCT scanner. MRI is much more widely available and has 
smaller costs. 
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Guideline topic L: imaging of extra-hepatic metastases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Guideline topic M: chemotherapy regimens for patients with advanced and 
metastatic colorectal cancer 
 
 
 
 
Current clinical practice question: 
What imaging investigation are patients with extra-hepatic metastases offered in 
their assessment as candidates for metastasectomy? 
PETCT 
MRI 
PETCT and MRI 
 
Guideline question 
In a patient with colorectal cancer and extra-hepatic metastases (e.g. lung, brain, 
peritoneum), which imaging modality most accurately determines the extent of 
metastases? 
 
Information linking the guideline question to current clinical practice.[144] 
The common sites of extra-hepatic metastases are distant lymph nodes, 
peritoneum and lungs. Rare sites of metastases include adrenal glands, central 
nervous system and bones. Having detected extra-hepatic disease, it is important 
to determine the extent of disease to offer the appropriate treatment strategy. 
Information is obtained by means of contrast-enhanced CT scanning of chest, 
abdomen and pelvis. Further information is also obtained using MRI and PETCT, 
both for lesion characterisation and also for evaluation of extent and site of extra-
hepatic tumour burden. However, little is known as to which is the most useful 
investigation or the correct sequence of investigations to accurately determine the 
extent of tumour burden in these patients. 
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Guideline topic M: chemotherapy regimens for patients with advanced and 
metastatic colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question: 
What chemotherapy combinations / sequence are patients with metastatic 
colorectal cancer being offered? 
 
Do units have specific policies for this decision? 
 
Guideline question:  
What is the effectiveness of oxaliplatin- and irinotecan-based chemotherapy 
regimens for patients with advanced and metastatic colorectal cancer? 
 
Information linking the guideline question to current clinical practice.[144] 
Both oxaliplatin and irinotecan have assumed important roles in the management 
of colorectal cancer – both in combination with fluoropyrimidines and also, for 
irinotecan, as a single agent. When combinations of oxaliplatin and a 
fluoropyrimidine are compared against irinotecan combinations then generally the 
results are equal, albeit with differing toxicities. Irinotecan appears to have activity 
both in combination with a fluoropyrimidine and as a single agent. The 
combination regimens seem to have less toxicity, and appear to demonstrate a 
trend to better outcomes than when used as a single agent. 
Currently, for patients with advanced metastatic disease, both oxaliplatin and 
irinotecan can be used to extend disease-free and overall survival. There are a 
number of less frequent circumstances (for example liver-limited metastatic 
disease), where alternative strategies are used but these are with the intention of 
long-term disease control, rather than palliation. Defining the optimal strategy for 
sequencing of these agents remains a difficult management issue. 
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Guideline topic N: follow-up for CRC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current clinical practice question: 
Are all patients with CRC offered follow-up after their treatment? 
Is follow-up dependent on pathological stage of disease? 
What imaging modality is used for follow-up and how frequently? 
What serological tests are offered for follow-up and how frequently? 
What endoscopic surveillance is offered and how frequently? 
 
 
 
Guideline question: 
In asymptomatic patients who have undergone treatment with curative intent for 
CRC, what are the optimal method(s), frequency and duration of follow-up? 
 
Information linking the guideline question to current clinical practice.[145] 
Whether systematic follow-up for CRC can alter long term clinical outcome 
remains controversial. It is also not clear to what extent follow-up can be tailored 
to the risk of recurrence as defined by pathological stage. A practicing clinician 
can accumulate a large cohort of follow-up patients and this surveillance can 
consume significant resources. In addition, what constitutes good clinical practice 
in terms of follow-up has not been established and there is enormous variation in 
terms of frequency, duration, clinical setting and interventions employed. Many 
centres use a policy of CT scanning at variable intervals, with or without serial 
serum CEA estimation to detect liver and/or lung metastases during the first few 
years after initial curative resection. Colonoscopy at various time intervals serves 
the purpose of surveillance for local recurrence of tumour or metachronous 
tumours. There is also the issue of the effect that follow-up has on quality of life. 
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Guideline topic O: information for patients with CRC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Guideline question:  
For patients with colorectal cancer, what are the information needs associated 
with bowel function?  
 
Information linking the guideline question to current clinical practice.[145] 
Treatment for colorectal cancer often causes a change in bowel function. This 
can be distressing for patients and have other adverse effects, including dietary 
restrictions and changes in body image and sexual function. Patients want to 
know what to expect after surgery, what is normal and when they should seek 
further medical advice. Clear and effective communication of information can 
improve well-being and quality of life. There is paucity of data on this topic from 
trial data and information that has traditionally been available to patients has 
been delivered by interested healthcare professionals who have compiled the 
information based on their own professional experience. However the key 
question is: ‘what do patients identify as their information needs on the topic of 
bowel function in relation to CRC?’. 
 
Current clinical practice question: 
What information is currently available to patients with a diagnosis of CRC on 
the topic of bowel function? 
Nationally produced leaflet? 
Locally produced leaflet? 
Access to relevant support websites? 
No information 
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6.4.2 Data sources  
With the current clinical practice data queries formulated the online search identified 
the following national databases as potential sources of answers. 
 
Hospital Episode Statistics (HES)  
 
HES is a records-based system that covers all NHS trusts in England, including 
acute hospitals, primary care trusts and mental health trusts and contains details of 
all admissions, outpatient appointments and A & E attendances. This data is 
collected during a patient's time at hospital and is submitted to allow hospitals to be 
paid for the care they deliver. [146] 
The data collected relate to patients (including age, sex, ethnicity and location of 
residence), clinical details (including diagnoses, operative procedures, consultant 
and specialty), administrative details (such as NHS trust, GP, admission and 
discharge date, source of referral).[146] 
 
Hospital Episode statistics (HES) was originally conceived in 1987 following a report 
on collection and use of hospital activity information (Korner report). HES aims to 
collect a detailed record for each hospital ‘episode’ of admitted patient care. 
[140,141] 
 
For many years clinical practice data for HES was collected from in-patients by the 
completion of the Korner forms, which were often used as a poor, sometimes 
illegible, discharge summary for the general practitioner.[141] 
 
Highly skilled clinical coders are required to convert clinical diagnostic terms gleaned 
from the notes or Korner returns into data entries under the International 
Classification of Diseases version 10 (ICD-10). Their skills are also required to 
convert interventions into data entries under the Office of Population Censuses and 
Surveys Classification of Surgical Operations and Procedures version 4.5 (OPCS-
4.5) through the Trusts’ Patient Administration Systems to a British Telecom 
database management system called Secondary User Services (SUS).[141] 
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Since the introduction of ‘Payment by Results’ (PbR) the terms have also been put 
through a ‘grouper’ to create the necessary Health Resource Groups for the 
purposes of reimbursement. Extracts of SUS data are anonymised and cleaned and 
made available by the NHS Information Centre (NHS-IC) for secondary use as HES 
data.[141] 
 
As HES data is very complex, any standard report can only show basic information 
such as number of episodes with a certain primary diagnosis or primary procedure. 
As might be expected, patients often present with more than one diagnosis or have 
more than one procedure performed. [146] 
The team of professionals at the National Cancer Services Analysis Team 
(NATCANSAT) use data science to provide analysis based on combinations of 
procedures and diagnoses as required. Data Science is the application of analytical 
and computing skills using large quantities of data.[147] 
As well as managing large datasets, NATCANSAT also manipulate, link and analyse 
the data in order to present the information in interesting, innovative and ultimately 
useful ways. This enables the data to be used in order to answer specific needs or 
queries.[147] 
 
The Patient Episode Database for Wales (PEDW)  
 
PEDW records all episodes of in-patient and day-case activity in NHS Wales 
hospitals. This includes planned and emergency admissions, minor and major 
operations, and hospital stays for giving birth. Hospital activity for Welsh residents 
treated in hospitals in England is also included.[148] 
 
The data are collected and coded at each hospital. The records are then 
electronically transferred to the NHS Wales Informatics Service (NWIS) - previously 
known as Health Solutions Wales (HSW) - where they are validated and merged into 
the main database.[148]  
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The National Bowel Cancer Audit Project (NBOCAP)  
 
The overall aim of clinical audits is to improve patient outcomes by improving 
professional practice and the general quality of the services delivered.[149] 
 
The bowel audit project began in the late 1990’s following an approach by the Joint 
Consultants Committee to several specialist groups including the Association of 
Coloproctology of Great Britain and Ireland (ACPGBI) regarding a quality control 
initiative.[150] 
 
The intention was to establish a series of professionally led studies that would define 
outcomes and benchmarks in specific areas of care. ACPGBI initiated an audit of 
malignant large bowel obstruction and this paved the way for successive audits of 
Colorectal Cancer outcomes throughout the UK over the last decade.[150] 
 
In 2000 the ACPGBI published the first edition of the NBOCAP and has since 
published audit findings annually aiming to improve the quality of care and survival of 
patients with bowel cancer.[150] 
 
The National Cancer Services Analysis Team (NATCANSAT), which was 
established in 1996, provided among other services medical informatics services to 
the NHS, including involvement in cancer clinical audits. The NATCANSAT website 
initially provided access to the software that enabled the health-care professionals to 
collect data for the Colorectal Database of the Association of Coloproctology of 
Great Britain and Ireland.[149] 
 
The national bowel cancer audit (now abbreviated as NBCA) is a collaborative 
clinical audit run jointly by the NHS Information Centre and the ACPGBI.[151] 
 
The NHS Information Centre manages a number of audit projects in a number of 
priority areas including cancer. It is the single largest provider of clinical audits. Each 
audit is backed by appropriate professional bodies, which provide clinical leadership 
and direction. The aim is to deliver each audit, which includes project management 
of the complete process, from development of the data requirements, gaining 
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national authorisations, collection and secure storage of the data, analysis of 
findings, and continuing review to ensure improvement.[151] 
 
It also provides the infrastructure for the audits, including: providing a secure clinical 
audit database and technical infrastructure to ensure patients' data is safe and 
secure; co-ordinating the various approaches to clinical audit across NHS 
organisations and professional bodies; and ensuring that the clinical data collected is 
risk adjusted and aligned with national priorities.[151] 
 
For NBOCAP, the NHS Information Centre's National Clinical Audit Support 
Programme (NCASP) provides the necessary project management and the technical 
infrastructure described above. It works in collaboration with a range of NHS 
organisations and professional bodies to provide the infrastructure for the collation, 
analysis and feedback of local clinical data needed to support effective clinical audits 
across the NHS.[149]  ACPGBI provides clinical leadership and direction for the 
audit.[150] 
 
The audit includes all NHS Trusts in England and Health Boards in Wales.  
All participating trusts submit their data via the Clinical Audit Platform. The Welsh 
data is submitted directly from the Cancer Network Information System 
Cymru (CANISC) to the Clinical Audit Platform.[152]   
 
Participation in the audit has always been voluntary but is strongly encouraged by 
the ACPGBI. Since its inception, there has been constant improvement in the levels 
of participation from hospital trusts and improvement in case ascertainment and data 
completeness.[153] 
 
There are 38 essential data items that are collected as part of the audit. These are 
listed in table 6.1 
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Table 6.1 The 38 data items of the NBOCAP database.[153] 
 
 NBOCAP Data item Additional comments 
1 Organisation code  
2 NHS number  
3 Local patient identifier  
4 Date of Birth  
5 Height  
6 Weight  
7 Sex  
8 Postcode  
9 Date of diagnosis  
10 Colonoscopy result Normal-cancer not seen 
Abnormal-cancer or polyp seen 
Inadequate-bowel not visualised 
Not done 
11 Colonoscopy incomplete - reason Obstructing cancer 
Poor bowel prep 
Patient intolerance 
Technical reason 
other 
12 CT result M0  
M1 
uncertain 
13 MRI result T stage 
14 MRI result N stage 
15 MRI result Margins threatened – yes / no 
16 MDT discussion Yes / no 
17 Seen by specialist nurse Yes / no 
18 Primary cancer site 10 sites appendix to rectum 
synchronous cancer not recorded  
anal cancers not recorded 
19 Height of tumour above anal verge  
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20 Distant metastases None 
Present  
Uncertain 
21 Date surgical procedure carried out  
22 Surgical urgency Elective 
Scheduled (=expedited) 
Urgent (in 24h) 
Emergency (life saving) 
23 ASA grade  
24 Surgical access Open 
Laparoscopic then open 
Laparoscopic converted to open 
Laparoscopic completed 
25 Surgical procedure  
26 Radiotherapy treatment (rectal only) None 
Neoadjuvant short 
Neoadjuvant long 
Adjuvant 
Definitive with no plan for surgery 
Palliative 
27 Venous invasion Yes / no 
28 Number of lymph nodes examined  
29 Number of lymph nodes found positive  
30 Circumferential margin involved Yes / no 
31 Dukes stage  
32 T stage  
33 N stage  
34 M stage  
35 stoma Not performed 
Ileostomy temporary 
Ileostomy permanent 
Colostomy temporary 
Colostomy permanent 
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36 Date of death  
37 Discharge date  
38 Major surgical complications 
(The definition of a major complication 
is one that required re-operation, or, 
interventional radiology, or ITU/HDU 
care, or delayed discharge for more 
than 72 hours.) 
None 
Leak 
Abscess 
Bleed 
Obstruction 
Stoma – as a second procedure 
Re-admission within 14 days 
other 
 
 
 
The linked National Cancer Data Repository (NCDR)  
 
The National Cancer Information Network (NCIN) was set up to co-ordinate the 
collection, analysis and appropriate distribution of patient cancer data by building, 
maintaining and quality assuring a new national repository of cancer data. [154] 
 
The National cancer data repository (NCDR) contains merged data on all cancer 
patients in England from the following sources:[83] 
 
8 English Cancer Registry Data (1990-2010) 
(This dataset provides details of cancer diagnoses and demographic 
information about cancer patients.) 
 
ONS Minimum Cancer Dataset (1985-2010) 
(Basic information from the Office for National Statistics database of 
cancer registrations in England, allowing the repository to be reconciled 
to official national statistics.) 
 
Hospital Episode Statistics (April 1997-March 2010 
  124 
(Data on inpatient and day case hospital episodes for patients with a 
diagnosis of cancer in the admitted patient Hospital Episodes Statistics 
database. This dataset provides clinical information about diagnoses 
and operations as well as further demographic and administrative 
details.) 
 
National Clinical Audit Data 
(Data from the national bowel, lung, and head & neck cancer clinical 
audits. These data provide a range of detailed information on diagnosis 
and treatment of patients for specific cancers). 
 
General Practice Research Database 
(An indirect linkage between the NCDR and the General Practice 
Research Database (GPRD) also exists and applications for linked 
data may be made to GPRD. GPRD collects data on over 3.6 million 
active patients (approximately 13 million total) from around 488 primary 
care practices throughout the UK. This linkage provides vital 
information on primary care that is not included in the other available 
datasets.) 
 
The NCDR database is updated yearly. The addition of Celtic Countries NCDR 
Analysis Dataset is also now included. Each of the English cancer registries holds a 
copy of the database. Applications for data from the repository may be made in line 
with NHS data access policies. The details of any request should be discussed with 
the relevant cancer registry at an early stage.[83] 
 
NCIN seeks to improve collaboration and coordination between UK cancer registries 
and other organisations involved in collecting and analysing information about 
cancer patients and to raise national standards of timeliness, comprehensiveness 
and consistency. NCIN also requires cancer registries to take on national lead roles 
for specific sites of cancer.[155] 
 
The Northern and Yorkshire Cancer Registry and Information Service (NYCRIS) is 
playing a significant role within the new National Cancer Intelligence Network (NCIN) 
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and making use of new sources of information about cancer patients being provided 
through NCIN e.g. Hospital Episode Statistics (HES).[156] 
 
Within NCIN, NYCRIS has national responsibility for leading on colorectal and 
haematological cancers. Its purpose is to deliver a comprehensive, electronically 
acquired and linked, high quality cancer dataset that meets the needs of all its 
stakeholders. This repository for electronic data will become a holding area for all 
electronic datasets and will allow assessment of data quality and availability. The 
linked National Cancer Data Repository aims to provide a more extensive source of 
patient data through the merging of both clinical practice data through HES and other 
available patient data through other national databases. NYCRIS is working on 
linkage and cleaning of HES data.[156] 
 
NYCRIS offers an ad-hoc information request service. This processes an average of 
350 information requests each year. NYCRIS also provides information in response 
to individual requests.[156] 
 
Database of Individual Patient Experience (DIPEX) 
 
The Health Experience Research Group at the University of Oxford with funding from 
the Department of Health has created a database of personal and patient 
experiences through in-depth qualitative research into over 50 different illnesses and 
health conditions including bowel cancer. The results of the research are published 
on two websites – www.healthtalkonline.org and www.youthhealthtalk.org. 
 
The methodology includes rigorous and systematic research methods to sample, 
collect and analyse interviews with individuals of all ethnic groups over the age of 
sixteen. These methods provide a high quality evidence-based approach to patient 
experience and ensure that a full range of patients’ perspectives are analysed in 
terms of what someone might expect to experience when diagnosed with a particular 
condition or illness.[157] 
 
Users of the database will find accounts – presented through video, audio and 
written material – on issues such as reaction to diagnosis, consultation with the 
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doctor, effect on work, social life and relationships, decisions on treatment options 
and side-effects of treatments.[157] 
NHS patient survey programme 
Another possible source of current practice data is national patient surveys 
particularly for data regarding survivorship, which is so important for patients 
diagnosed with cancer.  
 
Survivorship focuses on the health and life of a person with cancer post treatment 
until the end of life. It covers the physical, psychosocial, and economic issues of 
cancer, beyond the diagnosis and treatment phases. Survivorship includes issues 
related to the ability to get health care and follow-up treatment, late effects of 
treatment, second cancers, and quality of life. Family members, friends, and care-
givers are also considered part of the survivorship experience.[158] 
 
The National Surveys of NHS Patients programme set up in 1997 comprises a series 
of surveys designed to contribute to monitoring the performance of the NHS as seen 
from the patient’s perspective. The programme systematically gathers the views of 
patients about the care they have recently received. The information collected aims 
to allow systematic comparisons of experiences over time and between different 
parts of the country.[159] 
Under the auspice of the NCIN annual cancer patient experience surveys are 
conducted collecting a large amount of data on how patients rate their cancer 
journey.[160]
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6.4.3 Data retrieval feasibility assessment  
 
A number of national databases were identified as potential sources of current 
clinical practice data relating to the colorectal cancer guideline questions. 
 
NATCANSAT for HES data, WCSU for Welsh hospital episode statistics data, and 
NYCRIS for NCDR access were initially approached for a feasibility assessment. 
 
The clinical practice questions for all topics were presented to the data specialists 
and their assessment on the feasibility of data retrieval for each question was 
sought.  
 
NYCRIS as the lead cancer registry for colorectal cancer could provide access to all 
these databases by performing linkage of databases where appropriate.  
 
The following are the results of the feasibility analysis from NYCRIS. 
 
Topic A – diagnosis of CRC cancer 
In order to answer this question patient demographic data needed to be combined 
with endoscopy and radiology data.  
Potential data sources:  
The NYCRIS registry database could provide the cancer demographic data. The 
HES Outpatient episodes database could provide endoscopy dates and radiology 
dates.  The NBOCAP database could also potentially provide information of similar 
nature.  
Initial assessment of feasibility 
Project possible due to the NYCRIS/HES/NBOCAP linked database. 
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Topic B: Staging of CRC cancer.  
In order to answer this question patient demographic data needed to be combined 
with radiology data.  
Potential data sources 
The NYCRIS registry database could provide the cancer demographic data. The 
HES Outpatient episodes database could provide radiology dates.  The NBOCAP 
database could also provide information of similar nature.  
Initial assessment of feasibility 
Project potentially possible due to the NYCRIS/HES/NBOCAP linked database. CT 
data is known to be of excellent quality. MRI / PET / EUS data has not been 
assessed in this way and there is uncertainty as to how complete this information is 
within the databases. The project needs further clarification after a trial data request 
exercise. 
 
Topic C: prognostic factors for curative treatment of stage I/polyp cancers 
In order to answer this question patient demographic data needed to be combined 
with endoscopy data (if patients had endoscopic removal of their polyps), day case 
unit data (if patients had local procedures as day cases), and main theatre data (if 
patients had segmental resections).  
Potential data sources 
The NYCRIS registry database could provide the cancer demographic data. The 
HES main database could provide operation dates and the HES – out-patient 
episodes database could provide endoscopy dates and day case procedure dates. 
The NBOCAP database could overlap some of this information e.g. the main 
operation dates.  
Initial assessment of feasibility 
Project possible due to the NYCRIS/HES/NBOCAP linked database.  
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Topic D: self-expanding metal stents (SEMS) for malignant obstruction. 
To answer this question patient demographic data needs to be combined with 
radiology data, endoscopy data, and main theatre operative data. 
Potential data source 
Demographic data on patients with CRC cancer can be provided by the NYCRIS 
database. CT data with dates can be provided by the HES database. The service of 
colonic stent insertion in some trusts is provided by radiology departments and in 
some by endoscopy departments so this data would need to be sought by requesting 
information both from the HES main and the HES outpatient databases. Operative 
data can be provided by HES and could also be provided by the NBOCAP database. 
Initial assessment of feasibility 
Project possible. Good data from the NYCRIS/HES/NBOCAP linked database 
 
Topics E,F,G,H,M Chemotherapy, radiotherapy, histopathology topics 
Topic E: Pre-operative management for non-metastatic locally advanced colon and 
rectal tumours. 
Topic F: The most effective sequence of chemotherapy and surgery for the treatment 
of patients with CRC and synchronous metastatic disease. 
Topic G: Neoadjuvant radio- and chemoradiotherapy for rectal cancer. 
Topic H: Adjuvant chemotherapy for stage II and III rectal cancer. 
Topic I: Adjuvant chemotherapy for high risk stage II colon cancer. 
Topic M: Chemotherapy regimens for patients with advanced and metastatic 
colorectal cancer. 
Potential data source 
No data immediately available. National databases being formed.  
Initial assessment of feasibility. These projects are not currently possible.  
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Topic J,K,L Hepatic and extrahepatic metastases 
 
Topic J: Adjuncts for patients with unresectable metastatic disease. 
Potential data source 
No national data available. 
Initial assessment of feasibility  
Project not possible. 
 
Topic K: Imaging of liver metastases 
Topic L: Imaging of extra-hepatic metastases 
For the imaging of hepatic and extra hepatic metastases the information request is 
exclusively radiology data combined with patient demographic data. 
Potential data source 
NYCRIS/HES/NBOCAP linked database 
Initial assessment of feasibility 
Project possible. 
 
Topic N: Follow-up for CRC 
Potential data source 
No data within the national databases. There has been a colorectal cancer audit 
carried out by Stamatakis et al in 1987 and 1997 in the Wales and Trent regions 
which showed that huge variation exists in the follow-up protocols followed with no 
change shown in the decade between the two audits.  
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Initial assessment of feasibility 
Not feasible through national databases.  
 
Topic O: Information for patients with CRC 
Potential data source 
DIPEX database, National patient survey. 
Initial assessment of feasibility 
Theoretically possible although it depends whether or not the experiences 
documented in these databases cover the topic of information required by patients. 
 
6.4.4 Data actually recovered for each formulated clinical practice question 
 
No relevant data was recovered for any of the formulated clinical practice questions. 
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6.5 Discussion 
One of the findings of this study was that of subtle mismatch between the clinical 
question and the clinical practice question.  A good example is topic C where the 
guideline question focuses on prognostic factors and the clinical practice question 
focuses on types of treatment for stage I / polyp cancers.  
This is not a failing of understanding or an accidental deviation from the question the 
guideline aims to address by the author.  
The clinical practice question was developed by the author gradually after research, 
and discussion with the GDG members on a particular topic. It aims to highlight what 
is currently a genuine practice question.  
The fact that it deviates in some topics from the actual clinical question the guideline 
is seeking to answer raises the concern that perhaps in some instances the 
questions set early on in the guideline development process are not the most 
clinically relevant. 
On a number of occasions after the questions of the guideline had been set some  
GDG members felt that the questions needed revision. However the NICE 
methodology on question setting was inflexible in what could be amended after a 
certain time period had elapsed. 
The guideline development process is long and timeframes are tight for the 
development of each topic. Therefore changes to the original questions are not 
permitted after the first few stages of the development process. 
Though this is understandable it raises the concern that in some cases resources 
and time are devoted to answering the wrong question.  
A more flexible methodology with regard to the formulation of the guideline questions 
might be a future consideration by NICE.  
Alternatively, a lengthier time period devoted to scoping the guideline questions even 
before the guideline evidence searching begins might avoid such mismatch in the 
future. 
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In addition, the results show that for the purpose of a needs assessment report 
supporting a national clinical guideline the use of current practice data collected in 
national databases in the UK was not straightforward. This was despite initial 
indication through the online data mining search of a number of data sources 
showing promising potential for providing the answers to the formulated queries. 
National databases have the potential to be a major source of current practice data, 
particularly if the information from multiple databases can be linked in order to 
provide concise answers to particular questions. The HES and PEDW national 
databases showed initial potential in providing answers to some of the data queries.  
Successive audit reports have indicated considerable problems with HES data 
completeness, accuracy of clinical coding and engagement of clinicians [161,162] 
even following the introduction of PbR.[163] Generally speaking, clinical coders are 
well trained and very accurate in converting clinical terms into codes.[164] The 
problem is that it is difficult for them to extract the correct information from 
unstructured clinical notes.[141] If HES data were to be used then the issue of the 
data quality would have to be addressed. 
 
The National Bowel Cancer Audit was another potential source of current practice 
data relevant for the needs assessment. Though voluntary in its participation the 
audit has high participation rate from all the hospitals and year on year the data has 
had steady improvement in its completeness. 
 
However, there are challenges that remain with the data quality and one such issue 
is that of handling of missing data. The audit data set does not allow the distinction 
between patients who have not undergone a surgical procedure and those for whom 
the data item is missing. Siimilar issues arise for diagnostic and staging procedures. 
 
Multiple imputation is used to fill in any missing information but this remains a 
significant challenge for the national bowel cancer audit and other similar databases. 
 
National audits are designed to measure the quality of patient care and 
improvements over time. Healthcare professionals and organisations can use the 
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information contained in the audits to look at the national picture and identify areas 
for improvement as well as to learn from best practice.[165] 
 
A number of the data items of the national bowel cancer audit could potentially 
provide answers to some of the formulated data queries but would need to be 
combined with data from HES and PEDW in order to give more complete answers.  
 
It was clear that the variety of the data from the different databases and the issues of 
data quality made the project of answering the formulated data queries that much 
more complex. The data would require careful analysis to ensure quality standards 
were met.  
 
For these reasons the most exciting and promising finding was that NYCRIS, the 
lead registry for colorectal cancer was not only an official access point for all these 
databases but was additionally performing groundbreaking work in the improvement 
of the quality of the data as well as attempting linkage analyses of data from different 
databases in order to provide answers that were important clinically. 
 
The NCDR which links all these and other databases together provides exciting 
opportunities for novel hypothesis-led studies, as well as the possibility of enhancing 
other datasets. NYCRIS has a leading role in the development of the NCDR. 
 
The unfortunate and rather disappointing result that NYCRIS was not able to deliver 
any of the planned analyses was due to the timing of the specific data request which 
came at a time of massive change for NYCRIS and all the cancer registries. 
Unfortunately there was a lack of resources and the initial enthusiasm for addressing 
the needs of the project did not lead to results as expected. 
 
Over recent years, cancer registries have been subject to a number of outside 
influences that have caused them to adapt the way they are organised and to revise 
their working practices. The roles of registries have developed from traditional 
registration into cancer information and intelligence provision, with registries having 
an increasingly important role to play in taking forward the national cancer agenda.  
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NYCRIS, in recognising the task ahead set out a long-term development plan over 
three years 2008-2011. This plan encompassed all developments across the 
organisation including the upgrade of electronic data processing, changes in the 
registration process, an increase in the information and research outputs, and an 
increase in staff resources.[155] 
 
The time period of this project overlapped with this period of intense change at 
NYCRIS. In addition linkage analyses of national databases as a research tool are in 
their infancy and require time, staff and funding. 
 
Therefore for topics that could have potentially been answered with data from the 
HES, PEDW and NBOCAP linked databases the conclusion from these results is 
that the data is collected at a national level, attempts are currently being made to 
address and to improve the quality of the data but access to the data via NYCRIS at 
present also needs to be improved. 
 
For radiotherapy and chemotherapy related queries the results show that data 
collection was even less advanced.  
 
An important finding is the inability to access radiotherapy data at a national level at 
all.  Radiotherapy is a major modality in the treatment of cancer and also represents 
a significant sector within the NHS, in terms of both workforce and capital 
investment. Information on radiotherapy activity is recorded in various ways by 
different radiotherapy departments, with no nationally agreed dataset or data 
return.[154] 
 
This has since been addressed through an initiative of the NCIN in partnership with 
the NHS information centre. The development of the radiotherapy dataset (RTDS) 
allows for the routine collection of clinically and managerially relevant activity data 
from radiotherapy facilities with good quality reporting, in order to commission or 
monitor radiotherapy services in an evidence-based manner. The data is collected 
by the staff at NATCANSAT on behalf of the NCIN.[166,167] 
 
Prior to the inception of the RTDS, very limited radiotherapy data were collected, and  
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there were a wide variety of definitions of each of the currencies in use. The RTDS  
seeks to standardise these currencies, and to introduce new currencies which are  
aligned with other activities in the NHS. [166] 
  
Despite the recent lack of central information on radiotherapy, each patient’s data is 
stored on a database linked to the radiotherapy treatment machine (these systems 
are referred to generically as Oncology Management Systems), which generate an 
essential clinical record of the radiation delivery to each patient. These systems have 
been in use for several years. [166] 
  
A decision was taken early in the RTDS development to use these systems as the  
main source for the dataset, in order to avoid duplication of effort in entering the  
radiotherapy treatment details onto hospital patient administration systems (PAS),  
and to benefit from the excellent data quality in the technical radiotherapy data  
resulting from the use of the system which actually controls patient treatment.[166] 
 
Another important result finding is the absence of a national chemotherapy 
database. Information on chemotherapy delivery is rudimentary, largely because 
some providers of chemotherapy services are still using paper-based systems to 
prescribe and record activity.[154] This has since been addressed with the 
development of the Systemic Anti-Cancer Therapy (SACT) Data Standard and 
dataset as an initiative by NCIN and the NHS Information Centre (NHS IC).[168] 
 
Data on the treatment of patients with chemotherapy will be managed by the 
Systemic Anti-Cancer Therapy (SACT) Data Standard. With the advent of electronic 
prescribing systems it is possible to record this complex information on patient 
management in a standardised way. The SACT data standard defines terms that are 
used in chemotherapy prescribing for individual patients. It also specifies a reporting 
dataset.[168] 
 
The standard covers all patients receiving cancer chemotherapy in or funded by the 
NHS in England. The data standard relates to all cancer patients, both adult and 
paediatric, in acute in-patient, day-case, out-patient settings and delivery in the 
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community. It covers chemotherapy treatment for all solid tumour and 
haematological malignancies, including those in clinical trials.[168] 
 
In the clinical setting its primary use will be in prescribing and administering 
chemotherapy. The reporting dataset will be used at both local and national levels to 
generate ‘secondary uses’ information to provide quality data to support service 
development and commissioning.[168] 
 
In addition the results show that the need for survivorship data was not met by the 
databases and survey data currently available. Though there has been steady 
expansion and improvement of the type of data collected and the collection process 
itself through initiatives of the NCIN this field of clinical data has been chronically 
underdeveloped and therefore requires more time for data to be collected. 
 
Since the inception of HES the NHS has changed considerably, requirements for 
data have changed, monitoring of service and outcomes has become a high priority.  
 
The Cancer reform strategy established the National Cancer Intelligence Network 
(NCIN), under the umbrella of the National Cancer Research Institute (NCRI), with 
objectives, inter alia, of nationally promoting efficient and effective data collection 
throughout the cancer patient journey in order to secure improvements in standards 
of cancer care and clinical outcomes. This also provided the opportunity for the 
development of appropriate regulations for data access and data processing.[154] 
 
The NCDR, the radiotherapy dataset, the chemotherapy dataset are examples of 
some of the work already carried out. These are new developments and will take 
time to assess in terms of data quality but they are important steps in the 
improvement of national cancer data collection.  
 
Further work is ongoing. The NCIN is working together with the NHS information 
centre (NHS-IC) to develop a new National Cancer Dataset. This will replace the 
current National Cancer Dataset and will include both the Cancer Registration 
dataset and additional site specific data items relevant to the different tumour types. 
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It will be aligned with the other mandated national cancer datasets (Cancer Waits 
and Radiotherapy) and with the Systemic Anti Cancer Therapy dataset (SACT).[169] 
 
The new dataset, which is called the Cancer Outcomes and Services Dataset 
(COSD), will support the current needs of the NHS to provide information on 
incidence, mortality and survival and also service and outcomes. The intention is to 
collect data already used for patient management and clinical care and which where 
possible should mostly be available from existing NHS electronic systems such as 
PAS, pathology and MDT systems. These data will then be sent to the regional 
cancer registries who will link these and other multiple data sources at patient level 
using the NHS number to complete the full dataset.[169] 
The 12 NCIN Site-Specific Clinical Reference Groups (SSCRGs) have been 
engaged to ensure that good quality cancer data is available to inform and to 
promote improvements in standards of cancer care and clinical outcomes, as well as 
enabling the use of cancer information to support audit and research 
programmes.[169] 
 
The English regional cancer registries are involved with the work of the SSCRGs by 
taking up cancer registration lead roles. Initial work undertaken by each lead registry 
provided a site-specific "baseline assessment". Registries are now developing their 
roles as cancer registration site-specific leads through dedicated programmes of 
work.[170] 
 
At present there is a huge expansion in national database systems. Funding, human 
resources and technical support are being diverted to this chronically neglected field 
of health management and this is a welcome improvement.   
Although there has been significant multi-directional progress in the national 
collection mechanism for this type of data in recent years what these results show is 
that this progress was insufficient and in its infancy with regard to radiotherapy, 
chemotherapy and survivorship when the present research was taking place and 
therefore the required data collection for the guideline needs assessment report was 
not feasible.  
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However the formulated queries are important as they are attempting to capture the 
current picture in the delivery of colorectal cancer care and to support a national 
guideline in its attempt to produce recommendations which can actually be 
implemented.  
This will be considerably obstructed if that current picture cannot be presented. It is 
absolutely necessary to the implementation of the guideline to know what baseline 
practice there is. It is impossible for any cancer centre, unit or network to know how 
well it is doing on delivering care to patients without such key information. Attempting 
to collect a small sample of this information by means of questionnaire studies has a 
low return and small local audits and studies are underpowered and unable to 
provide strong evidence. This information needs to be collected at national level.  
 
Though the absence of a result is disappointing, it is an important finding in itself. 
Though requests for linkage analyses may come from a variety of authorised 
sources for the development of policy or for the purposes of commissioning, a 
request from a guideline development group is an additional viewpoint regarding the 
needs for health informatics in the NHS. It will hopefully strengthen the plea for faster 
improvements to be made in this area. 
 
The systematic process used in health needs assessment reports provides the ideal 
opportunity for communication across professional disciplines and patient groups, 
gathering evidence about the target patient population, and making use of an 
evidence-based approach to effect health management changes and improvements. 
 
The value of a health needs assessment lies in the contribution it can make to 
improving data quality. This is important in meeting quality indicators, in developing 
disease registers, and in providing information for an evidence-base of need which 
can support enhanced service provision by creating the basis from which resource 
and service provision assessments can begin and from which the guideline 
programme can be developed and implemented. 
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In addition, the analysis of data which reflects current practice in a variety of ways is 
in itself a key capability for motivating improvements in quality. Only when the 
databases are challenged to provide a variety of answers will it become clear 
whether they can demonstrate appropriate standards of data quality and are 
adequate for the intended purposes. 
Patient data will only be effective if it is collected, analysed and presented in ways 
that are useful to patients, commissioners, service providers and other interested 
parties.  
 
There is a responsibility to patients to ensure that their data, which is routinely 
collected and stored, is appropriately accessible for research and aids the provision 
of answers to important clinical questions that could help improve their overall 
management.  
 
Perhaps the unanswered data request of the colorectal guideline needs assessment 
report can serve as an example of one of the ways in which current-practice data 
that is collected in the UK might be used with advantage in the future. 
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7.0 The availability and quality of diagnostic data that 
make up the evidence to support the most effective 
method for diagnosing liver metastases from 
colorectal cancer to assess resectability 
 
7.1 Introduction 
 
The field of diagnostic tests is highly dynamic. New tests are developed at a 
fast rate and the technology of existing tests is continuously being 
improved.[171-174] 
 
Exaggerated and biased results from poorly designed and reported diagnostic 
studies can trigger their premature dissemination and lead physicians into 
making incorrect treatment decisions.[171-174] 
 
A rigorous evaluation process could not only reduce the number of unwanted 
clinical consequences relating to misleading estimates of test accuracy, but 
also limit health care costs by preventing unecessary testing.[171-174] 
 
In studies of diagnostic accuracy, the outcomes from one or more index tests 
(IT) under evaluation are compared with outcomes from the reference 
standard (RS), both measured in subjects who are suspected of having the 
condition of interest.[171,175-177] 
 
The term ‘index test’ (IT) refers to any method for obtaining additional 
information on the health status of a patient. It includes information from 
history and clinical examination, laboratory tests, imaging tests, function tests, 
histopathology.[171,175-177] 
 
The condition of interest or target condition can refer to a particular disease or 
any other identifiable condition that may prompt clinical actions, such as 
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further diagnostic testing or the initiation, modification, or termination of 
treatment. [171,175-177]  
 
In this framework, the reference standard (RS) is considered to be the best 
available method for establishing the presence or absence of the condition of 
interest.[171,175-177] 
 
The reference standard can be a single method, or a combination of methods, 
to establish the presence of the target condition. It can include laboratory 
tests, imaging tests, and pathology, but also the dedicated clinical follow-up of 
patients.[171,175-177] 
 
The term accuracy refers to the amount of agreement between the 
information from the test under evaluation, referred to as the ‘index test’, and 
the reference standard. [171,175-177] 
 
Diagnostic accuracy can be expressed in many ways including sensitivity and 
specificity, likelihood ratios, diagnostic odds ratio, and the area under a 
receiver-operator (ROC) characteristic curve.[171,175-177] 
 
There are several potential threats to the internal and external validity of a 
study of diagnostic accuracy.  The QUality Assessment of Diagnostic 
Accuracy Studies tool (QUADAS) has been systematically developed to try to 
guide the assessment of diagnostic studies.[178] 
 
The original QUADAS tool was developed through a collaborative project 
between the Centre for Reviews and Dissemination of the University of York, 
and the Academic Medical Centre at the University of Amsterdam. It was 
funded through the Health Technology Assessment (HTA) programme and 
was published in 2003.[178] 
 
Since its development QUADAS has been used in a large number of 
systematic reviews. A modified version of QUADAS, with items related to the 
quality of reporting removed, has been adopted for use by the Cochrane 
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Collaboration and is recommended for use in all Cochrane reviews. QUADAS 
has also been recommended for use by NICE in the assessment of diagnostic 
data.[178] 
 
In current UK oncological practice the diagnosis of liver metastases is 
determined from a CT scan performed as part of the original staging or during 
follow-up after potentially curative surgery for the primary cancer.  
 
Currently the two imaging modalities used to assess the presence, number 
and extent of liver metastases in order to decide whether a lesion is operable 
are MRI with liver contrast enhancement and PETCT scans.  
 
Most patients assessed for surgery will have both of these tests at some point 
in their pre-surgical preparation. PETCT is considered by many to be more 
accurate in detecting liver metastases. However it is an expensive 
investigation and not widely available. Patients need to travel long distances 
to get to a PETCT scanner. MRI is much more widely available and has 
smaller costs. 
 
7.2 Aim 
 
To research the availability and quality of the diagnostic data that make up the 
evidence to support the most effective method for diagnosing liver metastases 
from colorectal cancer to assess resectability. 
 
7.3 Methods 
 
A systematic review and meta-analysis was performed by one reviewer (the 
author). Training in systematic review methodology was provided by the 
department of evidence based healthcare at Oxford University and the review 
was performed according to NICE methodology.   The author selected the 
relevant titles and abstracts from the results of the database search, decided 
which studies met the inclusion criteria,graded their methodological quality, 
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extracted the relevant data and entered it into the REVMAN 5 software 
package for analysis.  
 
7.3.1 The PICO 
 
The traditional PICO framework (patient, intervention, comparison and 
outcome) used for researching review questions is slightly different for 
diagnostic topics compared with the more traditional interventional / 
therapeutic topics. 
 
The PICO for a diagnostic topic maintains the population (P) and outcome (O) 
items but includes the index test(s) (I) whose diagnostic accuracy is being 
investigated instead of the intervention more traditionally included in a 
therapeutic PICO. It also includes the reference standard used to prove the 
accuracy of the index test instead of the traditional comparator (C) item. 
 
Table 7.1: The PICO for the systematic review on CRC liver metastases 
Population Index Tests (instead 
of intervention) 
Reference standard 
(instead of comparator) 
Outcome 
Patients with  
colorectal cancer 
 
AND 
 
 
 
Potentially 
operable liver 
metastases 
MRI (with liver 
contrast agent) 
 
PETCT 
 
 
 
CT(with contrast) 
 
 
Laparoscopic 
ultrasound scan 
 
Histology of the 
resected specimen 
 
Follow-up with imaging 
of those lesions that 
were not operated 
 
Manual palpation of the 
liver 
 
Intra-operative 
ultrasound scan of the 
liver 
Sensitivity 
 
 
Specificity 
 
 
 
Survival 
 
 
Change in 
management 
 
 
The Population 
 
The patients in the studies should be adults (>18 years) of both sexes with 
known metastatic colorectal neoplasm who are candidates for liver resection. 
In practice this most commonly means that patients have had a diagnosis of 
colorectal cancer made on histological biopsy from colonoscopy and they are 
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potential candidates for liver resection based on the findings of a CT 
chest/abdomen/pelvis.  
 
Ideally this should be mentioned specifically in the methods of the study. 
However if studies do not mention specifically how the diagnosis of the 
colorectal cancer and the liver metastases is made they would not be 
excluded from the review. 
 
Synchronous and metachronous metastases will be included as well as 
patients who have had neoadjuvant chemotherapy. 
 
The studies should exclude patients who have contraindication to the contrast 
media used or to the imaging modalities e.g. pacemakers for MRI or those 
with advanced liver cirrhosis, or any contraindication to a surgical resection. 
 
The Index test 
 
Studies using all types of liver contrast-enhanced MRI were included. Only 
studies of fusion PET-CT technology were included.  
 
Studies comparing PET or PET followed by a CT to CT or to MRI were 
included but only the CT and/or MRI results were entered into the meta-
analysis.  
 
No exclusion of any types of CT scanners or laparoscopic ultrasound devices 
were made on technological grounds.  
 
Reference Standard 
 
There are multiple reference standards, as not all patients will proceed to 
surgery after their index test is performed.  
 
For the patients who have no resection the reference standard is follow-up 
imaging.  
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What defines malignancy or benign pathology on the follow-up scan needs to 
be stated clearly in the studies. 
 
Usually for malignancy this is defined as any sign of progression in the size of 
a lesion or regression in size as response to treatment. For benign pathology 
the definition is no change in the size of a lesion on the scan. 
 
It is important that the period of follow-up is also defined and clearly stated in 
the studies. 3-6 months is acceptable clinically. 
 
A period any shorter than this might allow insufficient time for progression of a 
lesion which as a result might be undetectable at follow-up. 
 
A period any longer might result in the follow-up scan identifying a new 
metastasis rather than the one under surveillance.  
 
For those patients who proceed to liver resection the gold standard reference 
test is histological analysis of the resected specimen.  
 
In some cases patients will have a combination of manual palpation of the 
liver, intra-operative ultrasound scan and the histology of the resected 
specimen. 
 
Some patients who proceed to surgery may prove to have in-operable 
disease at laparotomy such that no resection is undertaken. 
 
For these patients the reference standard will be manual palpation with or 
without intra-operative ultrasound scan followed by scanning in the post-
operative period if appropriate. 
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Outcome 
 
The primary outcome was the sensitivity together with the positive predictive 
value that can be derived from it. The sensitivity is of primary importance as 
this determines whether metastatic malignant disease is detected or missed 
(true positives / true positives + false positives).  
 
This was supplemented by specificity reporting to see how balanced the index 
test is in correctly identifying the patients with negative results and not 
committing patients to laparotomy unnecessarily (true negatives / true 
negatives + false positives). Positive predictive value and accuracy values 
were also calculated. 
 
Secondary outcomes were overall survival and change in management. 
Although not traditionally associated with diagnostic accuracy studies they are 
clearly important in clinical decision-making and are necessary in performing 
cost analyses and economic modelling. 
 
7.3.2 Search  
 
Table 7.2 lists the databases that were searched for this PICO and Table 7.3 
lists the truncation symbols that were incorporated into the search. The author 
closely observed the NCC-C information specialist create and perform the 
detailed search having received training in the creation of search strategies 
through the department of evidence based healthcare at oxford university. 
 
In addition hand searching of references in the selected study papers was 
performed by the author. 
 
The start date for the search was 1995 since advice from experts in radiology 
indicated that imaging prior to this date produced results, which would be 
inconsistent with the quality of modern scanning technology. 
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There was no language filter applied; however translation of foreign language 
papers was only requested if the abstract was deemed of critical importance 
to the review. No translations were required for this review.  
 
Table 7.2: List of databases searched for the systematic review on colorectal 
liver metastases with search dates 
 
Database name Dates 
Covered 
References 
retrieved 
Finish date of 
search 
Medline 1995-2009 108 01/10/09 
Premedline 1995 -2009 21 01/10/09 
Embase 1995-2009 95 07/10/09 
Cochrane Library 1995-2009 23 21/09/09 
Cinahl 1995-2009 1 13/10/09 
BNI 1995-2009 0 01/10/09 
Psychinfo 1995-2009 0 01/10/09 
Web of Science (SCI & 
SSCI) and ISI Proceedings 
1995-2009 128 13/10/090 
Biomed Central 1995-2009 1 07/10/09 
Total References retrieved 
(after de-duplication) 
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The search strategy was as follows: 
 
Colorectal cancer AND Liver mets AND Imaging 
1. exp colorectal neoplasms/ 
2. ((colorect$ or colo rect$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or 
tumo?r$ or carcinoma$ or adenocarcinoma$)).tw. 
3. ((colon or colonic) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ 
or carcinoma$ or adenocarcinoma$)).tw. 
4. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or 
tumo?r$ or carcinoma$ or adenocarcinoma$)).tw. 
5. 1 or 2 or 3 or 4 
6. exp Liver Neoplasms/ 
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7. (liver adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).tw. 
8. exp Neoplasm Metastasis/ 
9. liver metastas*.tw. 
10. hepatic metastas*.tw. 
11. hepatic lesion*.tw. 
12. exp Neoplasm Recurrence, Local/ 
13. 8 or 6 or 11 or 7 or 10 or 9 or 12 
14. 13 and 5 
15. exp Diagnostic Imaging/ 
16. exp Tomography, X-Ray Computed/ 
17. exp Magnetic Resonance Imaging/ 
18. exp Ultrasonography/ 
19. imaging modalit*.tw. 
20. (contrast enhanced CT* or CT*).tw. 
21. exp Positron-Emission Tomography/ 
22. PET*.tw. 
23. contrast enhanced MR*.tw. 
24. (CT adj (helic* or spiral*)).tw. 
25. PET-CT*.tw. 
26. exp Neoplasm Staging/ 
27. exp "Sensitivity and Specificity"/ 
28. 27 or 25 or 21 or 26 or 17 or 20 or 15 or 22 or 18 or 24 or 16 or 19 or 23 
29. 28 and 14 
 
Table 7.3: The truncation symbols incorporated into the search for colorectal 
liver metastases.[179] 
Symbol Definition 
* All words beginning with a particular stem 
$ For all words beginning with a particular stem 
? Overcoming spelling differences and searching for singular and plurals 
AND For all the words 
OR Searches for at least one of the words in the search string 
ADJ For words next to each other in the order specified 
() For words in brackets first / For each word and mapping to MeSH 
“ For words next to each other in the order specified 
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7.3.3 Study selection 
 
Study selection followed the steps that are displayed in Figure 7.1. 
 
Figure 7.1: Flow chart showing the selection criteria for included evidence for 
the systematic review on colorectal liver metastases 
 
 
             Reasons for exclusions 
 
 Reviews had to be systematic and include meta-
analysis (10 narrative reviews were excluded). 
 
 English language papers only unless abstract 
indicated the paper was pivotal to the question 
(2 foreign language papers excluded). 
 
 
 Guidelines needed to be explicit in the 
presentation of their evidence to be included (2 
foreign guidelines excluded). 
 
 Studies needed to fit the PICO (16 papers 
excluded because on further evaluation they did 
not comply with the PICO e.g. all 4 papers on 
lapUSS). 
 
 
 Studies must present enough data for 2x2 table 
to be extracted or if not they must present 
balanced summary results e.g. sensitivity and 
specificity, not sensitivity alone (2 papers 
excluded). 
 
 If the population data or the modality data is 
combined e.g. CT and USS data collected 
together or population with colorectal and gastric 
cancer the data must be distinguishable to each 
separate category (6 papers excluded). 
 
 
 Papers only after Jan 2005 included as 2 meta-
analyses covered the period prior to this (30 
papers excluded). 
 
 data not duplicated in another peer review paper 
of the same authors (2 papers excluded). 
 
 
287 possibly 
relevant 
papers 
identified 
 
193 
papers 
excluded 
based on 
title & 
abstract 
2 papers 
could not 
be 
obtained 
 
   
92 papers 
obtained for 
appraisal 
 
 
70 papers 
excluded 
   
22 papers 
included in 
evidence 
table 
  
 
 
 
7.3.4 Critical appraisal of included studies 
 
The QUADAS quality assessment tool was used to assess relevant study 
design characteristics of each study. This was in the form of a NICE 
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methodology checklist [180] adapted from the original paper [181] and is 
presented in Appendix 2. 
 
The questions in the checklist are aimed at establishing the validity of the 
study under review. That is, making sure that it has been carried out carefully, 
and that the conclusions represent an unbiased assessment of the accuracy 
and reliability of the test being evaluated. Each question covers an aspect of 
methodology that is thought to make a difference to the reliability of a 
study.[180] 
 
Checklist items are worded so that a ‘yes’ response always indicates that the 
study has been designed and conducted in such a way as to minimise the risk 
of bias for that item. An ‘unclear’ response to a question may arise when the 
answer to an item is not reported, or not reported clearly. ‘N/A’ is used when a 
study of diagnostic test accuracy cannot give an answer of ‘yes’ no matter 
how well it has been done.[180] 
 
The checklist consists of 14 items and these are listed below [180]. 
 
1. Was the spectrum of participants representative of the patients that will 
receive the test in practice? If it is not there is a potential for spectrum 
bias. 
 
2. Are selection criteria clearly described? If they are not then there is a 
potential for selection bias. 
 
3. Does the reference standard classify the target condition correctly? 
The use of an inappropriate reference standard can bias estimation of 
the diagnostic accuracy of the index test.  
 
4. Is the time interval between the reference standard and the index test 
short enough so that there is no change in the condition? If not then 
there is the potential for disease progression bias of the accuracy 
results. 
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5. Was verification with the reference standard given to the whole sample 
or a random selection? If not then there is the potential for partial 
verification bias (also known as work-up bias, [primary] selection bias 
or sequential ordering bias).  
 
6. Did participants receive the same reference standard regardless of the 
index test result? If not then there is the potential for differential 
verification bias. 
 
7. Was the reference standard independent of the index test (was not part 
of it)? When the result of the index test is used in establishing the final 
diagnosis, incorporation bias may occur. This item will only apply when 
a composite reference standard is used to verify disease status.  
 
8. Was the index test described clearly? Variation in measures of 
diagnostic accuracy can sometimes be traced back to differences in 
the execution of index tests. 
 
9. Was the reference standard described clearly? Variation in measures 
of diagnostic accuracy can sometimes be traced back to differences in 
the execution of the reference standards. 
 
10. Was the result of the index test interpreted without knowing the result 
of the reference standard? This issue is similar to the ‘blinding’ of the 
people who assess outcomes in intervention studies. 
 
11. Was the result of the reference standard interpreted without knowing 
the result of the index test? This issue is also similar to the ‘blinding’ of 
the people who assess outcomes in intervention studies. 
 
12. Was the same data available as in practice? The availability of 
information on clinical data during the interpretation of test results may 
affect estimates of test performance. If clinical data will be available 
when the test is interpreted in practice, then these should also be 
 153 
available when the test is evaluated. However, if the index test is 
intended to replace other clinical tests, then clinical data should not be 
available. 
 
13.  Were indeterminate results reported? A diagnostic test can produce 
these with varying frequency. If these are not reported this may lead to 
the biased assessment of the test characteristics. Whether bias will 
arise depends on the possible correlation between indeterminate test 
results and the true disease status. If indeterminate results occur 
randomly and are not related to the true disease status of the individual 
then, in theory, these should not have any effect on test performance. 
 
14.  Were withdrawals from the study explained? If participants lost to 
follow-up differ systematically from those who remain, for whatever 
reason, then estimates of test performance may be biased.  
 
The above items of the QUADAS checklist can be grouped into four domains. 
These are patient selection, index test, reference standard, flow (of patients 
through the study) and timing (of the index test and reference standard). [182] 
 
QUADAS should not be used to generate a summary “quality score”. If a 
study is judged as “low” on all domains relating to bias then it is appropriate to 
have an overall judgment of “low risk of bias” for that study. If a study is 
judged "high" or "unclear" on one or more domains then it may be judged “at 
risk of bias” or as having “concerns regarding applicability”. [182] 
  
A summary of the results of the QUADAS assessment is advised for all 
included studies. This could include summarising the number of studies that 
found low, high or unclear risk of bias/concerns regarding applicability for 
each domain. If studies are found consistently to rate well or poorly on 
particular items then reviewers may choose to highlight these.[182] 
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7.4 Results  
 
The data was extracted individually from all 22 studies included in the review 
and are presented in detail in the evidence tables of Appendix 3. 
 
7.4.1 Quality Assessment 
 
Design of the included studies  
 
From the 22 studies included in the review [183-204] none were systematic 
reviews of randomised controlled studies or other study designs.  
 
There were two randomised controlled trials [191,199], and twenty case 
series.  
 
There were 15 prospective (P)(184-7,190,192,194,196-8,200-4), and 5 
retrospective (R)(183,188-9,193,195) case series. 
 
QUADAS quality assessment applied individually to the 22 studies 
 
Table 7.4 lists all 22 studies and how they were assessed for each of the 
QUADAS items. 
 
In all the studies (100%) the patients were appropriately selected and the 
selection criteria were clearly described.  
 
All studies (100%) described clearly the index test that was used.  
 
All studies (100%) had multiple reference tests.  
 
These were appropriate for the classification of the target condition, they were 
applied to the whole study group rather than a random selection, they were 
not part of the index test, a different reference test was used depending on 
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the result of the index test, but the same reference test was used for each 
group of index test results. 
 
However, 45.5% of studies did not report how the reference test was 
performed. 
 
55% of studies did not report the time between index and reference test.  
 
A large proportion of studies did not report on ‘blinding’.  
 
82% did not report whether the reference test results were interpreted without 
knowledge of the index test results and 41% did not report on whether the 
index test results were interpreted without knowing the results of the reference 
test. 
 
82% of studies did not report their indeterminate results. 
 
73% of studies did not report their withdrawals from the study. 
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Error! 
Study Were patients 
representative 
Selection 
criteria 
clearly 
described 
RS 
classifies 
target 
condition 
correctly 
Time 
between 
RS and 
IT short 
enough 
so no 
change 
Was 
verification 
with the 
RS given 
to whole 
sample or 
randon 
selection 
Same RS 
independent 
of the IT 
result 
Was the RS 
independent 
of the IT  - 
was not 
part of it 
IT 
described 
clearly 
RS 
described 
clearly 
IT results 
interpreted 
without 
knowing 
the result 
of the RS 
RS results 
interpreted 
without 
knowing 
the reuslts 
of the IT 
Same 
data 
available 
as in 
practice 
Indeterminate 
results 
reported 
Withdrawals 
explained 
design 
Akiyoshi[183] y y y y y n y y n u u y n n R 
Arulampalam[184] y y y u y n y y y u u y n y P 
Ashraf [185] y y y u y n y y n u u y n y P 
Bartolozzi[186] y y y u y n y y y y y y y y P 
Bhattacharjya[187] y y y y y n y y y y y y y n P 
Cantwell[188] y y y y y n y y n u u y n n R 
Chua[189] y y y u y n y y n n n y n n R 
Coenegrachts[190] y y y y y n y y y y u y n n P 
Kim[191] y y y y y n y y y y y y y y RCT 
Koh[192] y y y y y n y y n y u y n n P 
Kong[193] y y y u y n y y n u u y n n R 
Liu[194] y y y u y n y y y u u y n n P 
Nanashima[195] y y y u y n y y n u u y n n R 
Orlacchio[196] y y y u y n y y n y y y n n P 
Rappeport[197] y y y y y n y y y y u y n n P 
Regge[198] y y y u y n y y y y u y n n P 
Ruers[199] y y y y y n y y y y u y n n RCT 
Schwartz[200] y y y y y n y y y y u y n y P 
Selzner[201] y y y u y n y y n y u y n n P 
Truant[202] y y y y y n y y y y u y y n P 
Vidiri[203] y y y u y n y y n u u y n y P 
Wiering[204] y y y u y n y y y y n y n n P 
 
 
 
Table 7.4: Summary QUADAS quality analysis of the 22 studies in the systematic review for colorectal liver metastases 
RS: reference standard, IT: index test
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7.4.2 Meta-analysis 
 
Per patient analysis 
12 studies reported CT data per patient, 9 studies reported MRI data per 
patient, 7 studies reported PETCT data per patient.  
 
CT data 
 
The sensitivity of CT ranged from 47% to 100%. The positive predictive value 
(PPV) for CT ranged from 86%-100%. Specificity for CT ranged from 0 to 
100%. The accuracy for CT ranged from 50% to 98%. 
 
Though there has been no weighting to the following summary values the 
overall sensitivity and PPV for CT from the 12 studies as calculated from a 
summary 2x2 table is presented in Table 7.5. 
 
Table 7.5: CT per patient summary values and 2x2 table values 
 
SENSITIVITY 87% 770 / 882 
PPV 95% 770 / 770+41 
ACCURACY 87% 770 + 266 / 1189 
Total TP=770 Total FP=41 Total FN=112 Total TN=266 Total =1189 
TP: total positive results; FP: false positive results; FN: false negative results; TN: 
total negative results; Total: total number of patients investigated by CT  
 
MRI data 
 
The sensitivity of MRI ranged from 50% to 100%. Specificity ranged from 0% 
to 100%. In a number of studies specificity estimates are not possible as there 
were no benign lesions identified at all in the population. PPV ranged from 
91% to 100%. The accuracy for MRI ranged from 48% to 100%. 
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Though there has been no weighting to the following summary values the 
overall sensitivity and PPV for MRI from the 9 studies as calculated from a 
summary 2x2 table is presented in Table 7.6. 
 
Table 7.6: MRI per patient summary values and 2x2 table values 
 
SENSITIVITY 80% 336 / 336 + 86 
PPV 96% 336 / 336 +13 
ACCURACY 91% 336+142 / 577 
Total TP=336 Total FP=13 Total FN=86 Total TN=142 Total =577 
TP: total positive results; FP: false positive results; FN: false negative results; TN: 
total negative results; Total: total number of patients investigated by MRI 
 
PETCT data 
 
The sensitivity for PETCT ranged from 91% to 100%. Specificity ranged from 
60% to 100%. In a number of studies specificity estimates are not possible as 
there were no benign lesions identified at all in the population. The PPV 
ranged from 93% to 100%.  Accuracy ranged from 91%-100%. 
 
Though there has been no weighting to the following summary values the 
overall sensitivity and PPV for PETCT from the 6 studies as calculated from a 
summary 2x2 table is presented in Table 7.7. 
 
Table 7.7: PETCT per patient summary values and 2x2 table values 
 
SENSITIVITY 94% 273 /273+19 
PPV 94% 273 / 273+19 
ACCURACY 94% 273+153/453 
Total TP=273 Total FP=8 Total FN=19 Total TN=153 Total = 453 
TP: total positive results; FP: false positive results; FN: false negative results; TN: 
total negative results; Total: total number of patients investigated by PETCT 
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Per lesion analysis  
7 studies reported CT data per lesion, 12 studies reported MRI data per 
lesion, 6 studies reported PETCT data per lesion.  
 
CT data 
 
The sensitivity of CT ranged from 67% to 97%. The PPV for CT ranged from 
63%-100%. Specificity for CT ranged from 0 to 67%. In a number of studies 
specificity estimates are not possible as there were no benign lesions 
identified at all in the population. This finding might be expected in a 
population that is so highly selected for suspicion of malignancy. The 
accuracy for CT investigation ranged from 64% to 84%. 
 
Though there has been no weighting to the following summary values the 
overall sensitivity and PPV for CT from the 7 studies as calculated from a 
summary 2x2 table is presented in Table 7.8. 
 
Table 7.8: CT per lesion summary values and 2x2 table values 
 
SENSITIVITY 74% 704 / 956 
PPV 90% 704 / 792 
ACCURACY 78% 704+114 / 1048 
Total TP=704 Total FP=78 Total FN=252 Total TN=114 Total = 1048 
TP: total positive results; FP: false positive results; FN: false negative results; TN: 
total negative results; Total: total number of lesions identified by CT 
 
MRI data 
 
The sensitivity of MRI ranged from 81% to 100%. Specificity ranged from 59% 
to 100%. In a number of studies specificity estimates are not possible as there 
were no benign lesions identified at all in the population. PPV ranged from 
81% to 100%. The accuracy for MRI ranged from 71% to 100%. 
 160 
Though there has been no weighting to the following summary values the 
overall sensitivity and PPV for MRI from the 12 studies as calculated from a 
summary 2x2 table is presented in Table 7.9. 
 
Table 7.9: MRI per lesion summary values and 2x2 table values 
 
SENSITIVITY 88% 1139 / 158 
PPV 96% 704 / 792 
ACCURACY 87% 1139+229 / 1571 
Total TP=1139 Total FP=45 Total FN=158 Total TN=229 Total = 1571 
TP: total positive results; FP: false positive results; FN: false negative results; TN: 
total negative results; Total: total number of lesions identified by MRI 
 
PETCT data 
 
The sensitivity for PETCT ranged from 61% to 100%. Specificity ranged from 
60% to 100%. In a number of studies specificity estimates are not possible as 
there were no benign lesions identified at all in the population. The PPV 
ranged from 94% to 100%.  Accuracy ranged from 61%-100%. 
 
Though there has been no weighting to the following summary values the 
overall sensitivity and PPV for PETCT from the 6 studies as calculated from a 
summary 2x2 table is presented in Table 7.10. 
 
Table 7.10: PETCT per lesion summary values and 2x2 table values 
 
SENSITIVITY 79% 410 / 522 
PPV 99% 410 / 415 
ACCURACY 97% 410+96 / 523 
Total TP=410 Total FP=5 Total FN=112 Total TN=96 Total = 523 
TP: total positive results; FP: false positive results; FN: false negative results; TN: 
total negative results; Total: total number of lesions identified by PETCT 
 
Summary sensitivity and specificity for all imaging modalities both for per 
patient and per lesion analyses are plotted and presented in Figures 7.2 and 
7.3. 
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Figure 7.2: Per patient forest plot for colorectal liver metastases meta-analysis 
 
 
 
Figure 7.3: Per lesion forest plot for colorectal liver metastases meta-analysis 
 
In many of the studies shown above specificity is not estimable. This is 
because these studies found no negative (benign) lesions. This is a plausible 
finding from meta-analysis of highly selected populations with patients already 
having suspicion of liver metastases on a previous scan. 
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7.5 Discussion 
 
The results show that in a per patient analysis PETCT has consistently higher 
sensitivity in all the studies compared to MRI and CT. When pooling the data 
the summary sensitivity and accuracy for PETCT is 94% for both and is higher 
than MRI (80%,91%) and CT (87% for both). 
 
In the per lesion analysis it is MRI that shows higher sensitivity compared with 
CT and PETCT. The pooled data shows MRI as having a combined sensitivity 
of 88% and accuracy of 87%, CT a sensitivity of 74% and accuracy of 78% 
and PETCT a sensitivity of 79% and accuracy of 97%. 
 
Before any conclusions can be drawn from these results there are a number 
of methodological issues that need to be highlighted. 
 
The higher diagnostic sensitivity of MRI in the per lesion analysis is potentially 
biased due to the data being clustered. 
 
The parallel analysis of the data ‘per patient’ and ‘per lesion’ is advocated for 
clustered data, otherwise also known as longitudinal or correlated. There is a 
tendency of the measurements within a cluster to respond in a similar way, 
which introduces statistical complexity.[205] 
 
When using a digital survey technique, such as PETCT, CT, or MRI, patients 
may present with multiple sites of tumour in their bodies. In sicker patients the 
presence of a lesion in a certain site increases the chances of observing a 
lesion in another site (positive correlation). [205] 
 
Radiological experiments using the above mentioned modalities involve the 
collection of multiple observations for each patient studied. For a variety of 
reasons, different observations from the same patient are more likely to be 
correlated, while observations from different subjects can be considered 
statistically independent.[205] 
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Conventional statistical techniques are based on the assumption that all 
observations are independent of each other. Any conclusions made for 
correlated observations within a cluster based on the above assumption will 
therefore not be valid. The extent of the problem depends heavily on the 
magnitude of the correlation as well as on the number of observations within 
the cluster.[205] 
 
One way of handling the problem of clustering is to provide a summary 
measure for each subject, i.e. the proportion of positive sites per patient (per 
patient analysis) and base the analysis solely on this measure. This implies 
that the subject, and not the measurements within the subject, is taken as the 
unit of analysis.[205] 
 
Reduction of the data to one observation per subject is convenient because 
independence among units of analysis is achieved and standard analysis 
methods are thus applicable. There is loss of information however owing to 
the aggregation of data within each subject.[205] 
 
When the correlation between the observations in the same patient is positive, 
ignoring the correlation might result in an erroneous conclusion.[205]  
 
Another methodological issue that has an effect on these results is the 
heterogeneity of the studies. 
 
Systematic reviews bring together studies that are diverse both clinically and 
methodologically. Therefore heterogeneity in the results is to be expected.  
 
Heterogeneity is likely to arise through a variety of causes including the 
population characteristics, diversity in doses, length of follow-up, study quality. 
What matters is the extent to which this heterogeneity affects the conclusions 
of the meta-analysis.[206] 
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Unless we know how consistent the results are, we cannot determine the 
extent to which the findings of the meta-analysis can be generalised.[206] 
 
The challenge is to consider all the potential sources of heterogeneity for a 
planned systematic review and decide at the outset whether its effect on the 
overall outcome is such that the source of the heterogeneity needs to become 
an exclusion criterion. 
 
If the decision is made to pool the studies despite the heterogeneity then this 
issue can potentially be addressed by carrying out subgroup analyses post 
meta-analysis and thus testing in this way whether the results are any 
different having removed the potential source of bias. 
 
For this review the sources of heterogeneity were considered. However, 
despite these it was still felt appropriate to include all studies and pool the 
data. A subgroup analysis would then be considered for each source of 
heterogeneity post meta-analysis. 
 
Sources of heterogeneity that potentially could have affected the outcome of 
this review and could have under- or over-estimated the diagnostic accuracy 
of a modality are: the design of the studies, the quality of the studies, the 
inclusion of studies that did not exclude patients who had received 
neoadjuvant chemotherapy prior to their imaging, the size of the metastatic 
liver lesions, the number and experience of the radiologists reading the 
imaging results, the technological characteristics of the scanners, and 
population characteristics such as the presence of co-incident diabetes or 
other co-morbidities that could potentially give a particular group of patients 
an advantage or a disadvantage over another group of patients. These 
sources of heterogeneity will be discussed individually below. 
 
Study Design 
Diagnostic accuracy studies are less well understood and their design 
methodology is less robustly developed compared with therapeutic studies. 
The design across studies is known to be heterogeneous.[207-208] 
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The results from this review show that the great majority of studies included 
were prospective (n=15) and retrospective (n=5) case series and that there is 
a relative absence of randomised controlled trials (n=2) from this particular 
field of radiological oncology.  
 
Although randomisation is usually the gold standard in the design of 
therapeutic trials for the investigation of diagnostic questions, it is often not 
straightforward. Randomisation is more appropriate for the investigation of the 
secondary outcomes of survival and change in patient management 
decisions. In fact one of the two randomised controlled studies that the search 
identified did in fact have these parameters as the primary outcome.[199] 
 
For this review question in particular most studies had all patients and all 
potential lesions assessed by all index modalities under investigation so that 
their diagnostic abilities could be directly compared and they did not 
randomise any patient groups to one type of imaging modality. 
 
Prospective rather than retrospective data collection is preferred in trial design 
because defining reference standard criteria and setting time periods allowed 
between tests and references standards is more precise and set in advance 
for the entire cohort but this is not always possible within clinical practice and 
so the type of data collection among studies is mixed. 
 
There are also ethical limitations to diagnostic study design. For example 
giving every patient the same reference standard of histological examination 
of the resected specimen would be unethical if the index test has shown that a 
particular patient is inoperable or indeed has a benign lesion and therefore 
resection is contraindicated.  
 
Study size also varies. The smallest study has 15 patients [194] and the 
largest 467 patients. [196] 
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Study quality 
The quality of individual studies as assessed by the QUADAS tool also varied. 
Quality assessment is an integral part of any systematic review. If the results 
of the individual studies are biased and these are synthesised without any 
consideration of quality then the review will also be biased.[181]  
 
This is particularly important for reviews of diagnostic accuracy studies as the 
methods for systematic data pooling and meta-analysis with the traditional 
application of weight to the different studies are still under development for 
diagnostic accuracy studies and this adds further potential source for bias. 
 
One of the main findings of the quality assessment with the QUADAS tool was 
that of poor reporting of items in the individual studies. It is a recognised 
problem particularly in the field of diagnostic accuracy studies. 
 
One of the items addressed by QUADAS is the time interval between index 
tests and reference standards. This time period potentially means that the 
disease may have progressed and misclassification of lesions may occur 
(disease progression bias). The length of period that may cause such bias is 
different between conditions. For cancer up to one month between tests and 
between 3-6 months for follow-up of a lesion is commonly accepted. 55% of 
studies failed to report the time elapsed between index and reference tests. 
 
A number of items on the QUADAS checklist address the issue of ‘blinding’. 
Lack of ‘blinding’ of investigators participating in a trial is an established 
source of potential bias for all types of studies. Test review bias occurs when 
persons interpreting the test under investigation have knowledge of the gold 
standard / reference test result. Diagnostic review bias occurs when 
interpretation of the gold standard test is made with knowledge of the test 
under investigation. Clinical review bias occurs when there is availability of 
other relevant clinical information (e.g. symptoms, co-morbidities), which may 
also affect estimates of test performance.[209-210]  
 
 167 
82% of studies did not report on whether the participating investigators 
interpreted the reference test without knowing the results of the index test and 
41% of studies failed to report whether the investigators interpreted the index 
test without knowing the results of the reference standard. 
 
The final items on the QUADAS checklist record whether studies report their 
withdrawals and indeterminate results. Authors may deal with these cases by 
considering them as positives, negatives or by excluding them from the 
analysis.  
 
Each of these methods could potentially alter the reported test performance.  
Considering these cases positive increases sensitivity, considering them 
negative increases specificity. In any case, a high number of indeterminate 
results diminishes the value of a test. This review found that 75% of studies 
did not report their withdrawals and 85 % of studies failed to report 
indeterminate results.  
 
Overall, the results of the quality assessment show that the majority of studies 
are of poor quality mainly due to poor reporting and to weaknesses in their 
design. This is in agreement with findings of previous reviews and 
unfortunately weakens the potential impact of the results. 
 
A subgroup analysis of the better versus the poorer studies was not 
performed, as the poor quality was so extensive. 
 
Neoadjuvant chemotherapy 
It has been suggested that the use of chemotherapy up to a month prior to a 
PET-based examination may reduced the sensitivity of PET technology in 
detecting tumours[211], although others have challenged this 
shortcoming[212]. 
 
Patients may have had chemotherapy prior to their imaging either to 
downstage their primary tumour or as post-operative treatment for their 
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primary tumour. This may have an effect on the liver lesions if they are 
metastatic.  
 
Lesions that are responding to chemotherapy treatment may not appear as 
well defined on PET-based scanning. The metabolism of the lesion is 
changed and this results in lesser or no appearance on the PET or PETCT 
scan. This could lead to higher number of false negatives for these modalities. 
Chemotherapy does not affect the identification of malignant pathology by CT 
or MRI.  
 
Of the 22 studies included in this review 4 studies comment on 
chemotherapy-exposed patients [189,197,198,201] and of those only 2 
actually give diagnostic data.  
 
In the study by Chua et al [189] no data is provided for chemotherapy 
exposed and naive patients but the group comment that chemotherapy did not 
impact on the diagnostic accuracy of PETCT (p=0.178). 
 
In the study by Regge et al [198] 19 patients out of 125 that were included in 
the study had neo-adjuvant chemotherapy but no details are given with regard 
to the timing of the chemotherapy and no separate data is given for this 
subroup of patients. 
 
The Rappeport study [197] report that 4 out of the 35 patients had prior 
chemotherapy. The 4 patients had 14 liver metastases (7 more than 1cm). For 
liver metastases larger than 1cm, PET had a sensitivity of 43% (3/7) 
compared to 76% (34/45) in patients without recent chemotherapy. For liver 
metastases up to 1cm the result was 0% (0/7) versus 8% (1/12). Even when 
patients with recent chemotherapy were excluded from the analyses, CT and 
SPIO-MRI were significantly more sensitive than PET (p=0.001) There is no 
mention about the chemotherapy effect on PETCT.  
 
In the study by Selzner et al [201] 18 patients received chemotherapy within a 
month prior to PETCT. A comparison of the false negatives revealed that FDG 
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uptake was absent in the liver metastases in 5 patients (28%) in the group 
with recent chemotherapy (sensitivity 72%) and in 1 in 58 of patients (5%) in 
the group without recent chemotherapy (sensitivity 98%, p=0.14 Fisher’s 
exact test). 
 
Overall the data available is very limited and therefore subgroup analysis 
looking at the association of neo-adjuvant chemotherapy and the diagnostic 
accuracy of PETCT was not carried out for this review. 
 
Varied size of liver lesions 
There is evidence from previous PET studies that PET technology is not as 
efficient at picking up micrometastases as it lacks the anatomical definition of 
CT and MRI.[213] 
 
A subgroup analysis attempting to distinguish the diagnostic ability of the 
modalities in association with lesion size would be an appropriate way to 
handle this source of bias. 
 
Of the 22 studies included in this review 7 comment on diagnostic accuracy in 
association with lesion size (186,187,198,203,204,193,197). Lesions are 
grouped into small lesions of <1cm in diameter, intermediate size lesions of 1-
2cm, or larger lesions of >2cm. 
 
In the study by Bartolozzi et al [186], in the lesion by lesion analysis for 
lesions 1cm the difference in sensitivity among spiral CT (38%), unenhanced 
MRI (51%), and MnDPDP-enhanced MRI (83%)  was even more manifest 
than in the overall comparison of diagnostic sensitivity. All lesions undetected 
by MnDPDP-enhanced MRI and discovered by the reference test did not 
exceed 1cm in diameter. 
 
In the  Regge study [198] the reference standard detected 191 lesions, 35.1% 
of which were 10 mm in size; per-lesion sensitivity was 71.7, 74.9 and 82.7% 
for CT, unenhanced MRI and MnDPDP-enhanced MRI, respectively. Although 
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the sensitivity of MnDPDP-enhanced MRI for 10 mm lesions was higher than 
both CT and unenhanced MRI (67.7 versus 47.7% versus 53.8%, 
respectively), multivariate analysis showed that lesion size was not 
significantly associated with such differences. 
 
In the study by Vidiri et al [203] of the 13 lesions that were 1cm CT identified 
4, unenhanced MRI identified 2, and contrast-enhanced MRI 9.  The group did 
not perform statistical analysis on these results. For both the small lesions 
group, and the larger lesions group the performance of the modalities was 
very similar with CT and MRI identifying 10 lesions of 1-2cm, enhanced MRI 
identifying 12, and all modalities identifying 20 lesions of the 21 lesions that 
were larger than 2cm. 
 
In the study by Wiering et al [204] the comparison is between CT and PET 
with only the CT data relevant to this review. CT identified 10 of the 63 lesions 
that were 1cm (16%), 123 of the 172 lesions that were 1-2cm (71%), and 
124 of the 128 lesions that were greater than 2cm.  Both CT and PET in this 
study missed the majority of lesions smaller than 2cm, both missed 25% of 
lesions 1-2cm in size, and detected equally satisfactorily the lesions larger 
than 2cm.  
 
In the study by Bhattarajha et al [187] the sensitivities of CT and contrast 
enhanced MRI for lesions 1cm are 52% and 57% respectively and for 
lesions >1cm the sensitivities are 77.4% and 86.3%. No formal subgroup 
analysis or conclusion is presented. 
 
The study by Kong et al [193] is one of two only studies where there is a direct 
comparison of PETCT and MnDPDP-enhanced MRI. In this study it is 
reported that MRI correctly identifies more lesions in 8 scans compared with 
PETCT. The lesions not detected by PETCT were all 1cm apart from one 
that was 1.5cm. PETCT correctly identified more metastatic lesions than MRI 
in one case and correctly identified as a metastasis one equivocal MRI case. 
 171 
Based on these descriptive results and with no reported statistical analysis the 
group conclude that MRI is superior to PETCT for the identification of small 
liver metastases and should remain therefore a prerequisite for surgical 
planning in patients with liver metastases. 
 
The Rappeport study [197] is the second of the two studies that directly 
compare MRI to PETCT (as well as to PET and CT). Only one of 19 
metastases that were 1cm in size was correctly identified by PET, 5 were 
identified by PETCT, whereas CT detected 13, and SPIO-MRI 10. Of the 52 
metastases that were >1cm PETCT identified 42, PET 37, and SPIO-MRI 48. 
Overall, all modalities were more sensitive in detecting liver metastases that 
were >1cm compared with 1cm. No formal statistical analysis is made of 
these results. Overall the group conclude that PETCT equalled MRI imaging 
in accuracy for liver metastasis detection but made no further specific 
conclusion about association to liver lesion size. 
 
As is evident from the presentation of the data from the 7 individual studies a 
conclusion that is repeated across the studies is that contrast-enhanced MRI 
is better than non-enhanced MRI and CT at identifying micrometastases. The 
subgroup analysis that would have been of interest comparing PETCT to 
contrast enhanced MRI was not carried out for this review as only two studies 
actually gave PETCT data specific for the identification of micrometastases. 
Both these studies, which individually are relatively small (Kong n=65 [193], 
Rappeport n=35 [197]) report contrast enhanced MRI having better diagnostic 
ability at identifying micrometastases compared with PETCT but no statistical 
analysis is done to confirm the significance of this result. 
 
The number and experience of the readers  
The diagnosis formulation is based on different radiologists across all the 
studies reading the images. They have different levels of experience and 
different abilities. The diagnostic ability of each modality is only as good as 
the diagnostic ability of the reader of the images produced.  
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A radiology consultant of 15 years of experience with an interest in colorectal 
radiology who sub-specialises in MRI only radiology and works at the national 
specialist centre may have a different diagnostic ability to a consultant of <5 
years in general radiology who works in a district general hospital. Some 
studies may counteract this effect by having the images read by more than 
one radiologist, and where the two disagree, then base the final diagnosis on 
their consensus opinion. 
 
Out of the 22 studies in this review only 9 studies comment on the number of 
radiologists that read the index tests, only 1 study mentioned the experience 
of the radiologist, and only 2 studies provided kappa statistics to quantify the 
level of agreement between the two or more radiologists. Subgroup analysis 
based on this parameter therefore was not carried out for this review. 
 
Technological aspects of the index test 
The imaging modalities are heterogeneous in their technologies both in the 
principle of their diagnostic method and in how they are developed over the 
years. Slice thickness, amount and type of contrast used, strength of 
magnetic field applied are some of the characteristics that have changed over 
time.  
 
The different scanners, as they develop technologically and as different 
centres use slightly different scanners, contribute to the heterogeneity of the 
included studies. All the aspects of the technology of each modality 
mentioned below can potentially affect the outcome.  
 
For CT the type of scanner (helical, multi-section helical), the section 
thickness (<5mm or >5mm), the amount of contrast agent (<45g iodine or 
>45g iodine), the number of phases (1=portal or 2=arterial and portal) are all 
characteristics that contribute to heterogeneity. 
 
For MRI the magnetic field strength, the type of contrast agent used (non-
specific or liver specific, non-enhanced, gadolinium enhanced, SPIO-
enhanced), the sequences, the type of coil used (body coil or phased array 
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coil), the section thickness are all characteristics that can also contribute to 
heterogeneity. 
 
For PET the system type (dedicated full ring or other), the amount of tracer 
used, the type of analysis (qualitative or quantitative), the data acquisition 
characteristics (timing of scanning and time of scanning per table position) are 
characteristics that contribute to heterogeneity. 
 
For this review the data was too varied to make subgroup analysis worthwhile 
on this topic. 
 
Population characteristics  
Differences between populations in demographic and clinical features may 
produce measures of diagnostic accuracy that vary considerably; this is 
known as spectrum bias. Reported estimates of diagnostic test accuracy may 
have limited clinical applicability (‘generalisability’) if the spectrum of 
participants tested is not representative of the patients on whom the test will 
be used in practice.[180] 
 
For this review all studies were consistent in including a representative group 
of patients. All studies included looked at data relating to patients both female 
and male, with a confirmed diagnosis of colorectal cancer only, and either 
confirmed lesions or lesions suspicious of liver metastases. Studies which 
reported on diagnostic accuracy of the modalities of interest but did not 
distinguish between liver metastases from colorectal cancer and other 
cancers were excluded. The age of the population, their co-morbidities, the 
referral patterns, the diagnostic settings are also similar between the studies 
and the population of interest. Therefore heterogeneity in the sources of the 
study population can be accepted as minimal. 
 
However, a population characteristic that may potentially introduce 
heterogeneity is if patients included were diabetic. PET works on the principle 
of altered metabolism of glucose in patients with cancer. Most studies include 
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patients who have well-controlled diabetes but this is theoretically still a 
source of spectrum bias. 
 
There are other sources of bias which add to the methodological issues 
relevant to these results. 
 
Selection bias 
Selection bias refers to the distortion of a statistical analysis resulting from the 
method of collecting samples. If the selection bias is not taken into account 
then certain of the conclusions drawn may be incorrect.[214] 
 
The start date for the search of the medical literature that was carried out for 
the purpose of this systematic review was set as 1995. This was on the 
advice of experts in radiology who suggested that to include CT, MRI and 
PET technologies prior to this date would not be appropriate. Though PETCT 
specifically is a much more recent technology than CT or PET, the start date 
for the search was not brought forward based alone on the availability of this 
imaging method but instead the a priori decision was taken to include only in 
the meta-analysis studies which reported comparisons using PETCT and not 
those using the older PET scanners. 
 
Although two previous meta-analyses had pooled data with a search end date 
of 2004 the search for this review was not started post 2004 because this 
would not have been a strong enough guarantee of the absence of PETCT 
studies prior to 2004. All these a priori decisions potentially include selection 
bias but in the context of advancing technology they were deemed 
appropriate for this review. 
 
Differential verification bias 
All the studies are subject to differential verification bias. This is because 
some of the index test results are verified by a different reference standard. 
This is a problem as the reference standards differ in their definition of liver 
metastasis. Histopathology has a far more precise definition of malignancy 
and is the gold standard compared with repeating the imaging and defining 
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malignancy based on change in size of a lesion. However for this particular 
area of oncology and surgery it would be unethical to submit a patient 
unnecessarily to the risks of surgery or indeed to the risks of a biopsy in the 
liver for benign or inoperable malignant lesions. Therefore it is acceptable that 
the studies were set up in this way even though the results are subject to 
verification bias. 
 
Incorporation bias 
This occurs when results of the test under study are actually used to make the 
final diagnosis.[210] The QUADAS results show that all studies included had 
a different reference test to the index test used so are not subject to 
incorporation bias. 
 
Publication bias 
As the data used in studies of test accuracy are often collected as part of 
routine clinical practice (and in the past have tended not to require formal 
registration) it has been argued that test accuracy studies are more easily 
conducted and abandoned than RCTs. They may therefore be particularly 
susceptible to publication bias.[210] It has been demonstrated however, that 
the unique features of the test accuracy study make the application of tests of 
funnel plot asymmetry potentially misleading.[210] It should be noted that the 
power of all statistical tests for funnel plot asymmetry decreases with 
increasing heterogeneity. Given the limitations of current knowledge, to ignore 
the possibility of publication bias would seem unwise; however, its 
assessment in reviews of test accuracy is complex [210] and it has not been 
undertaken for this review. 
 
 
Secondary outcomes 
A further methodological concern regards the reporting of secondary 
outcomes. 6 studies in this review report on change in management 
[183,184,189,194,199,201]. 3 studies [183,184,199] include PET and the 
other 3 studies [189,194,201] include PETCT as the index test. All of the 
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studies agree that it is the PET-based modality that is responsible for the 
change in management.  
 
However, all of the studies incorporate the extra-hepatic diagnostic element of 
these modalities in the results and in fact report that it is the detection of extra 
hepatic disease by these modalities which accounts for 25-40 %[189,194] in 
the change in management.  
 
In a review such as this which addresses a question on hepatic metastases 
specifically it is not appropriate to include and to analyse results that are the 
reflection of more complex data collection. It is sometimes possible to 
separate multiple sets of data from a study if the authors’ presentation allows 
for this. For example, this is often the case when studies present diagnostic 
data of a particular imaging modality for both lower GI cancer patients and 
patients with upper GI cancers.  
 
In this review and with regard to the secondary outcome of change in 
management it has not been possible to separate the hepatic data from the 
extra-hepatic data in any of the studies and indeed it would not be clinically 
appropriate to do so.  
 
Patient management is most often multifaceted. Attempting to decipher which 
scanner is best for detecting whether hepatic metastases are within the limits 
of what is resectable provides an answer to an essential part of the decision-
making pathway for patients with metastatic colorectal cancer. But when 
considering the patient’s overall management this step is linked to the parallel 
exclusion of the presence of extra-hepatic metastases, particularly pulmonary 
and peritoneal, as this is a potential contraindication to surgery.  
 
The secondary outcomes of survival and change in management cannot be 
reported on in association with hepatic metastases in isolation in this review. 
This is in agreement with previous meta-analyses which have shown that in 
their great majority the design of diagnostic studies in this field provide results 
which cannot be analysed with regard to one type of metastasis in isolation. 
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This is important when considering the overall diagnostic impact of a specific 
modality. 
 
As a consequence the feasibility of conducting any comprehensive analysis of 
cost-effectiveness to accompany this review is also therefore limited as it 
would need to take into account not only the diagnostic accuracy of the 
imaging modality in detecting hepatic metastases, but also the subsequent 
treatment decisions and patient outcomes.  
 
As the search of the clinical literature revealed that most of the relevant 
studies identified do not report information on change in patient management 
in relation to the information obtained by the imaging test and as the decision 
to resect is based on a number of different considerations, there is insufficient 
information to model the link between the imaging results and the treatment 
decision. 
 
In conclusion, from the evidence all modalities are comparably very good at 
detecting liver metastases with sensitivities above 75%. However, PETCT 
reported higher sensitivity than the other modalities in the per patient analysis. 
Contrast-enhanced MRI appears to have superiority in detecting micro-
metastases as indicated by a small proportion of the studies.  
 
However, these results are significantly affected by the overall poor quality of 
the pooled studies, which are subject to multiple sources of bias. This is 
mainly due to poor reporting of study design parameters and an overall 
variation in study design.  
 
Therefore the available evidence is unclear as to whether MRI or PETCT 
should be used after a CT scan to confirm the patient with liver metastases 
suitable for surgery, and further research is necessary.  
 
A prospective trial should be conducted to investigate the most clinically 
effective and cost-effective sequence in which to perform MRI and PETCT, 
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after an initial CT scan, to determine whether metastases are resectable in 
patients with colorectal cancer that has metastasised to the liver.  
 
The diagnostic accuracy of a given modality in identifying either hepatic or 
extra hepatic metastases is an appropriate and desirable study outcome. 
However these diagnostic events are clinically linked when considering 
surgery for liver metastases. Therefore, in trying to identify which modality is 
best for staging patients for liver surgery it might not be the direct diagnostic 
accuracy of each modality that is important but rather the downstream effect it 
has on subsequent clinical decisions and on overall survival. 
 
Therefore the outcomes of interest for future research should include 
reduction in inappropriate laparotomies, change in management decisions, 
and improvement in overall survival.  
 
Subgroup data collection is necessary, particularly based on lesion size, if 
uncertainty for the need for multi-modality treatment (PETCT and MRI) is also 
to be resolved. The effect of neo-adjuvant chemotherapy and reader 
agreement should also be included in the data collection for subgroup 
analysis to be possible. 
 
Some patients with colorectal cancer and liver metastases have a significant 
chance of cure with accurate and focused treatment. At the same time those 
patients whose disease is too advanced should not have the quality of their 
remaining life reduced by unecessary operations.  
 
Therefore delineating the most successful pre-operative staging modality for 
patient selection for surgery is of utmost importance. 
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8.0 The availability and quality of the therapeutic data 
that make up the evidence to support the most effective 
method for the follow-up of patients who have been 
diagnosed and treated for primary CRC 
 
8.1 Introduction 
 
Valid guidelines create their evidence components from systematic reviews of all the 
relevant worldwide literature. Some recommendations may be derived from evidence 
of high validity and others from evidence that is much more liable to error.[215] 
Sources of evidence can range from small laboratory studies or case reports to well-
designed large clinical studies.[216] 
 
Checklists assessing important methodology parameters relevant to the quality of a 
systematic review [217] or a randomized controlled trial [218] for example have been 
traditionally used by some guideline-producing organizations such as NICE in order 
to assess systematically the internal validity of evidence being used. 
 
The checklists, through a series of questions, aim to establish the quality of the 
internal validity of the study under review. That is, to make sure that it has been 
carried out carefully, and that the outcomes are likely to be attributable to the 
intervention being investigated. Each question covers an aspect of methodology that 
research has shown makes a significant difference to the conclusions of a study. 
 
Evidence grading schemes have been used for over 25 years. Since the 1970’s a 
growing number of organizations have employed various systems to grade the 
quality (level) of evidence and the strength of guideline recommendations.[216] 
 
Some grading systems are based on study design alone without explicit 
consideration of other important factors in determining the quality of evidence. Some 
systems are excessively complex.[216] A commonly used system is presented in 
table 8.1. 
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Table 8.1: The University of Aberdeen system for the grading of evidence [219]: 
 
 
Grading of evidence 
Ia Evidence obtained from meta-analysis of randomized controlled trials 
Ib Evidence obtained from at least one randomized controlled trial 
IIa Evidence obtained from at least one well-designed controlled study without 
randomization  
IIb Evidence obtained from at least one other type of well-designed quasi-
experimental study 
III Evidence obtained from a well-designed non-experimental descriptive study, 
such as comparative studies, correlation studies and case studies 
IV Evidence obtained from expert committee reports or opinions or clinical 
experiences of respected authorities 
 
Grading of recommendations 
A Evidence categories Ia and Ib 
B Evidence categories IIa, IIb, III 
C Evidence category IV 
 
Unfortunately, different organizations use different systems to grade evidence and 
recommendations. The same evidence and recommendation could be graded as “II-
2”, “B”, “C+”, “1”, or “strong evidence, strongly recommended” depending on which 
system is used. This is confusing and impedes effective communication.[216] 
 
Additionally with this system of evidence grading any data that has been derived 
from a systematic review of randomized controlled trials for example could potentially 
be given the top grade – level I – of evidence based on this parameter alone. 
 
However recent methodological research has lead to a more extensive method of 
quality assessment and evidence grading. GRADE (Grading of Recommendations 
Assessment Development and Evaluation)[220] is a new system of grading 
evidence.  
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The GRADE Working Group in 2000 developed a common, sensible and transparent 
approach to grading quality of evidence and strength of recommendations. Many 
international organizations have provided input into the development of the approach 
and have started using it.[220].  
 
Before assessing the quality of the evidence with GRADE, systematic reviewers and 
guideline developers identify all outcomes of a study or review, including benefits, 
harms, and costs. Reviewers will then assess the quality of evidence for each 
important outcome.[221] The GRADE-pro software is used to compare studies both 
in terms of internal validity and also of outcomes presented.[216] 
 
With this method a systematic review of randomised controlled trials may have been 
conducted with high quality but when in addition to its internal validity assessment all 
of the outcomes within the review are assessed it may be that despite a high quality 
systematic review some of the outcomes are given a low grading.[216] 
 
Table 8.2 presents the way in which evidence from any given review of the literature 
is classified by GRADE. 
 
Table 8.2: The GRADE system of classification of the quality of evidence.[216] 
High quality Further research is very unlikely to 
change our confidence in the estimate 
of effect 
Moderate quality Further research is likely to have an 
important impact on our confidence in 
the estimate of effect and may change 
the estimate 
Low quality Further research is very likely to have 
an important impact on our confidence 
in the estimate of effect and is likely to 
change the estimate  
Very low quality Any estimate of effect is very uncertain  
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The approach to rating the quality of evidence with GRADE begins with the study 
design and then addresses five possible reasons to rate down the quality of 
evidence and three possible reasons to rate up the quality.[221] 
 
The five reasons to rate down the quality of evidence are: risk of bias, imprecision 
(relating to how narrow or wide the confidence intervals are or how sparse the data 
is), inconsistency (or heterogeneity), indirectness (or applicability), and publication or 
reporting bias.[221]  
 
The three reasons to rate up the quality are: if the magnitude of the treatment effect 
is very large; if there is evidence of a dose-response relation; or if all plausible biases 
would decrease the magnitude of an apparent treatment effect (if, for instance, only 
sicker patients receive an experimental intervention or exposure, yet they still fare 
better, it is likely that the actual intervention or exposure effect is even larger than the 
data suggest.[221] 
 
GRADE identified these reasons because they address nearly all issues that bear on 
the quality of evidence. These categories were arrived at through a case-based 
process by members of GRADE, who identified a broad range of issues and factors 
related to the assessment of the quality of studies. All potential factors were 
considered, and through an iterative process of discussion and review, concerns 
were scrutinized and solutions narrowed by consensus to these five categories.[221] 
 
For recommendations the GRADE system offers two grades: “strong” or “weak”. 
When the desirable effects of an intervention clearly outweigh the undesirable 
effects, or clearly do not, guideline panels offer strong recommendations. On the 
other hand, when the trade-offs are less certain (either because of low quality 
evidence or because evidence suggests that desirable and undesirable effects are 
closely balanced), weak recommendations become mandatory.[216] 
 
The GRADE system is today used widely. The World Health Organization, the 
American College of Physicians, the American Thoracic Society, UpToDate (an 
electronic resource widely used in North America - http://www.uptodate.com), the 
Cochrane Collaboration and NICE are among the organisations which have adopted 
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GRADE. NICE specifically recommends  the use of GRADE in the assessment of 
therapeutic data / evidence. 
 
One such topic of therapeutic evidence included in the NICE colorectal cancer 
guideline is that of the most appropriate follow-up strategies for CRC. After definitive 
treatment for CRC is completed, the attention of clinicians turns to follow-up 
strategies designed to detect tumour recurrence at a stage when further curative 
procedures can be used. Follow-up strategies have also been developed in order to 
detect curable metachronous (i.e. occurring at different times) tumours. There is 
overlap between these two strategies.[222] 
 
The opportunity cost of the resources involved is considerable.[223,224] Clinicians 
justify follow-up by claiming that recurrences are being detected earlier than would 
otherwise occur and that patient outcomes are improved as a result.[223] Routine 
follow-up has the potential to create psychological harm for patients and any such 
disadvantages need to be outweighed by improved clinical outcomes that matter to 
patients.[225] 
 
Whether systematic follow-up can alter long-term clinical outcomes for CRC remains 
controversial. Whilst some commentators have concluded that follow-up is 
worthwhile [224], others have questioned its effectiveness.[223,225] 
 
It has not yet been shown whether assessment of the body of evidence for a 
particular topic of a guideline using the new method of evidence grading does in fact 
make a difference to the results presented to a GDG and thus help to identify better 
the strengths and weaknesses of the given evidence.  
 
8.2 Aim  
 
To research the availability and quality of the therapeutic data that make up the 
evidence to support the most effective method for the follow-up of patients who have 
been diagnosed and treated for primary CRC. 
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8.3 Methods 
 
A systematic review was performed of the most recently published studies on the 
topic of the effectiveness of follow-up strategies in CRC patients treated with curative 
intent.  
 
The systematic review was carried out by one reviewer (the author) who selected the 
relevant titles and abstracts from the results of the database search, decided which 
studies met the inclusion criteria, and graded their methodological quality.  
 
The body of evidence was assessed and classified using both the traditional NICE 
methodology checklists (Appendices 4 and 5) and GRADE. For the assessment with 
GRADE the relevant data was extracted and entered into GRADE pro software.  
 
8.3.1 The PICO 
 
The PICO for a therapeutic review follows the traditional framework of population – 
intervention – comparison – outcomes as detailed in table 8.3 below. 
 
Table 8.3: The PICO for the systematic review on the follow-up of CRC 
Population Intervention Comparison Outcomes 
Asymptomatic 
patients who have 
undergone 
treatment with 
curative intent for 
CRC, including 
patients treated 
for metastatic 
cancer 
Intensive 
packages 
including: 
Clinical 
examination 
CEA tumour 
marker tests 
Imaging 
Colonoscopy 
Timing / duration 
Do nothing 
Less intensive 
packages 
Survival 
Recurrence 
Quality of life 
Metachronous 
primaries 
Late effects 
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Population 
 
Males and females of any age with histologically-proven adenocarcinoma of colon or 
rectum, staged as T1,2,3,4 and treated with curative intent.  
 
The decision was taken to include also patients who were treated for metastatic 
colorectal cancer but with curative intent. This is because advances in the treatment 
of metastatic disease mean that more patients have the chance of cure than ever 
before.  
 
Evidence shows that neoadjuvant combinational chemotherapy may downstage up 
to 22% of unresectable liver metastases, hence increasing the proportion suitable for 
liver resection with curative intent.[227]  
 
It has also been shown that early systemic chemotherapy for asymptomatic 
metastatic colorectal cancer improves the interval to symptomatic deterioration, 
compared with delaying chemotherapy until symptoms develop.[228] 
 
Intervention 
 
The liver is the most common site of metastases from colorectal cancer. A number of 
strategies have been proposed to detect liver metastases at an early stage in order 
to identify patients suitable for curative liver resection. 
 
These include monitoring of blood tests (liver function, serum carcinoembryonic 
antigen (CEA)) and routine imaging of the liver [229,230] at various intervals during 
the first few years after initial curative resection.  
 
Patients with resected colorectal cancer are also at risk for metachronous neoplasms 
in the colon and rectum (including second primary cancers) and of intra-luminal 
recurrent disease.  
 
Patients with surgically resected Stage I, II and III cancers, and Stage IV cancer 
resected for cure (isolated hepatic or pulmonary metastasis) are candidates for 
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endoscopic surveillance, and the first preference is colonoscopy. The baseline is the 
‘clean colon’ examination. There is variation in the literature on guidance for the 
optimal timing of this.  
 
The duration to be recommended for intensive surveillance programmes is also 
unclear. The most important phase of follow-up is the first 2 - 3 years after primary 
tumour resection, as during this time the majority of recurrences will become 
apparent.[231-232]  
 
The conventional ‘model’ was that follow-up stopped after 5 years and the patient 
was discharged as ‘cured’. The perspectives of this model are changing.  
 
Specifically, in common with the principle of long-term survivorship, there is a 
continuing need to audit and quantify late effects from cancer treatment – for 
example, anorectal dysfunction from pelvic radiation. 
 
In addition, it is now recognized that the incidence-rate of second primary colorectal 
cancers after the index case is constant over 15 years (with the possible exception of 
the first two years).[233] 
 
Comparator  
 
The variation in follow-up programmes used by clinicians is considerable.[233-7] 
Which of these is the optimal one remains unclear and provisional conclusions 
change with advancing technology. 
 
The optimal setting for the follow-up of patients after curative treatment for colon and 
rectal cancer is also unclear. In many units patients attend a colorectal clinical led by 
the colorectal specialist supported by a colorectal cancer nurse specialist (CNS).  
 
There is debate whether patients can be followed in the community using for 
example a telephone follow-up scheme or a GP-led surveillance regimen.   
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The studies included in this review compare different follow-up strategies. These 
included comparisons of follow-up versus no follow-up, follow-up strategies of 
varying intensity and follow-up in different healthcare settings. 
 
Outcome 
 
The primary outcome is overall survival. However there are a number of secondary 
outcomes that are equally important. 
 
These include disease-specific survival, time to diagnosis of recurrence, incidence of 
surgery (with curative intent) for recurrence, interval between planned visits for 
assessment for recurrences, quality of life, harms, and costs of surveillance and 
investigations. 
 
8.3.2 Search 
 
Table 8.4 lists the databases that were searched for this PICO. The truncation 
symbols incorporated in the search are the same as those that have been presented 
previously relating to the search carried out in chapter 7 (Table 7.2).  
 
The author closely observed the NCC-C information specialist create and perform 
the detailed search having received training in the creation of search strategies 
through the department of evidence based healthcare at Oxford university. 
 
Members of the guideline development group for the NICE colorectal cancer 
guideline with professional experience in the area of colorectal cancer follow-up 
suggested that the literature search need not extend further back than 2005. 
 
This was because there was a wealth of studies on the topic but these had been 
repeatedly reviewed and synthesised in recent years. Therefore the a priori decision 
was taken to perform a systematic review of the literature starting in 2005. 
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Table 8.4: List of databases searched for the systematic review on colorectal cancer 
follow-up with search dates 
 Dates 
Covered 
No. of references 
retrieved 
Finish date 
of search 
Medline 2005-2009 79 18/08/09 
Premedline 2005-2009 18 19/08/09 
Embase 2005-2009 68 19/08/09 
Cochrane Library 2005-2009 76 17/08/09 
Cinahl 2005-2009 5 19/08/09 
BNI 2005-2009 9 19/08/09 
Psychinfo 2005-2009 2 19/08/09 
Web of Science (SCI & SSCI) and 
ISI Proceedings 
2005-2009 14 19/08/09 
Biomed Central 2005-2009 2 19/08/09 
Total References retrieved (after 
de-duplication) 
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The search strategy was as follows: 
Colorectal Cancer And Follow UP 
1. exp colorectal neoplasms/ 
2. ((colorect$ or colo rect$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or 
tumo?r$ or carcinoma$ or adenocarcinoma$)).tw. 
3. ((colon or colonic) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ 
or carcinoma$ or adenocarcinoma$)).tw. 
4. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or 
tumo?r$ or carcinoma$ or adenocarcinoma$)).tw. 
5. 1 or 2 or 3 or 4 
6. exp Follow-Up Studies/ 
7. (follow up$ or follow-up$).tw. 
8. surveillance*.tw. 
9. monitor*.tw. 
10. 6 or 7 or 8 or 9 
11. 10 and 5
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8.3.3 Study selection 
 
Study selection followed the steps displayed in the flow chart of Figure 8.1. 
 
Figure 8.1: Flow chart showing the selection criteria for included evidence for the 
systematic review on colorectal follow-up 
 
 
Reasons for exclusions: 
 
 Opinion papers or narrative reviews that 
were not systematic were excluded (10). 
 
 Papers not relevant to PICO were excluded 
(46). 
 
 Reports of experimental tests for follow-up 
were excluded (8). 
 
 Guidelines were excluded if the grading of 
evidence was unclear (3). 
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possibly 
relevant 
papers 
identified 
 
120 
papers 
excluded 
based on 
title & 
abstract 
   
70 
papers 
obtained for 
appraisal 
 
67 
papers 
excluded 
   
3 
papers 
included in 
evidence 
table 
  
 
 
 
 
8.3.4 Critical appraisal of included studies 
 
Methodology checklists 
 
The NICE methodology checklists for systematic reviews (Appendix 4) and 
randomised controlled studies (Appendix 5) were used to assess internal validity in 
the traditional way. 
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The checklist on systematic reviews includes three sections. The first examines the 
internal validity of the study. It has five topics of investigation which focus on the 
study question, the description of the methodology, the description of the literature 
search, the assessment of study quality and the presence of heterogeneity. The 
second section assesses bias and its effect on the overall study result. The third 
section refers to the types of studies included in the review and how the overall 
conclusion answers the key question asked. 
 
The answers are chosen from a list of six options (well covered, adequately 
addressed, poorly addressed, not addressed, not reported, not applicable). 
 
The checklist on randomised controlled trials also includes three sections. The first 
section examines the internal validity of the studies. It has ten topics of investigation 
which focus on the study question, the randomisation, the concealment method, the 
‘blinding’ methods, the similarity between the treatment and control groups at the 
start of the trial, the maintenance of the trial principles (that the treatment remains 
the only difference between the groups), the outcomes, the drop-out rate, the 
intention-to-treat analysis, and that results are comparable between different sites if 
the trial is of multi-centre type. The answers are chosen from the list of six options 
similar to the checklist for systematic reviews described above. The second section 
assesses bias and its effect on the overall study result. It also assesses applicability. 
The third section refers to the details of the study such as patient numbers, 
characteristics, comparators, follow-up period, outcomes, size of effect, funding. 
 
GRADE 
 
Table 8.5 summarises the GRADE approach to rating the quality of evidence, which 
begins with the study design (trials or observational studies) and then lists five 
possible reasons to rate down the quality of the evidence and three possible reasons 
to rate up the quality. 
 
This is the basis on which the GRADE pro software carries out the calculation of the 
GRADE score and produced a final overall quality score for each study outcome. 
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Table 8.5: Rating of evidence by GRADE[221] 
 
Study design Initial quality of 
the body of 
evidence 
Lower if Higher if Quality of a 
body of 
evidence 
Randomised 
trials 
 
High  Risk of bias Large effect 
 
+1 large 
+2 very large 
 
High (four plus 
) 
  Inconsistency Dose response 
 
+1 evidence of 
a gradient 
 
Moderate 
(three plus 
) 
Observational 
studies 
 
Low  Indirectness 
 
 
 
Imprecision 
 
 
 
 
Publication 
bias 
 
 
 
All plausible 
residual 
confounding 
 
+1 would 
reduce a 
demonstrated 
effect 
 
+1 would 
suggest a 
spurious effect 
if no effect was 
observed 
Low (two plus 
) 
 
 
Very Low (one 
plus ) 
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8.4 Results  
 
The study selection resulted in 3 studies being included for data extraction. These 
were two systematic reviews of RCTs [222, 238] and one randomized controlled trial. 
[239] 
 
8.4.1 Quality assessment by NICE methodology checklists 
 
Quality Assessment of systematic reviews by NICE methodology checklists 
 
Below are the summarised responses to the checklist questions both for systematic 
reviews as collected using the NICE methodology checklists (Appendix 4), followed 
by the evidence summary produced by the reviewing author without use of the 
GRADE pro software. 
 
Question addressed 
The two systematic reviews included both addressed a focused question that is 
directly relevant to the guideline PICO. 
 
Applicability 
Both systematic reviews refer to populations similar to that of the guideline PICO. 
That is asymptomatic patients with colorectal cancer who have been treated with 
curative intent. Patients may or may not have had adjuvant treatment. The 
populations are not identical as in the population of the studies no patients with 
metastatic disease were included although the PICO of this systematic review also 
aimed to address patients with metastatic cancer as long as their treatment was with 
curative intent. It was considered that this difference in the populations was not 
significant enough to affect the applicability of the study results.  
 
Methodology 
Both systematic reviews included clear and thorough descriptions of their 
methodology, which was appropriate. Only RCTs were included. 
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Literature searches of the two systematic reviews were appropriate and rigorous.  
 
Study quality assessment 
Both reviews assessed the quality of each individual study they included.  
 
Heterogeneity 
There is clinical heterogeneity of the follow-up regimen used by the different trials 
and this affects both systematic reviews equally. Some of the trials compared 
intensive follow-up with less intensive follow-up and some with no follow-up at all. In 
addition the intensity of the intensive follow-up regimen was variable and indeed the 
intensive regimen of one study was equal to the less intensive regimen of another 
study. In addition the trials span a considerable time period in which the surgery and 
oncological management of colorectal cancer has changed. In some studies patients 
were receiving adjuvant chemotherapy and radiotherapy and in others not. This adds 
to the clinical heterogeneity. 
 
Overall Assessment 
Both systematic reviews fulfilled all the criteria of the quality assessment checklists. 
None of the quality issues identified were thought likely to alter the conclusions of the 
reviews. 
 
Quality Assessment of the randomised controlled trial by NICE methodology 
checklists. 
 
Below are the summarised responses to the checklist questions for RCT as collected 
using the NICE methodology checklists (Appendix 5), followed by the evidence 
summary produced by the reviewing author without use of the GRADE pro software. 
 
Question addressed 
The RCT by Wang et. al. addressed a focused question that was directly relevant to 
the guideline PICO. 
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Recruitment / Applicability 
The population of the study was similar to that of the PICO but excluded patients 
with metastatic CRC. There were clearly stated inclusion and exclusion criteria that 
were appropriate for the question being addressed. 
 
Randomisation 
All consecutive patients with newly diagnosed colorectal cancer who consented were 
randomised to the two trial groups. This was clearly explained and appropriate. 
 
Allocation concealment 
This was described clearly and was appropriate by means of sealed envelopes that 
contained cards allocating patients to one or the other arm of the study. 
 
Maintenance 
The status of the two study groups was comparable. The patients in both groups 
received similar management throughout the study period and the treatment they 
received was the only addition to their management.  
 
The follow-up period was also clearly addressed in the study. The drop out rate was 
mentioned and within a normal range for a study of this nature. The analysis was on 
an intention-to-treat basis. 
 
‘Blinding’ 
In the study write up there was no reference to any ‘blinding’ having being 
undertaken. 
 
Outcomes 
All outcomes measured were relevant and measured in a standard, valid and reliable 
way. Complications were included in the outcomes. 
 
Overall Assessment 
This RCT fulfilled most criteria of the quality assessment checklist. It was not 
considered likely that the criterion which was not fulfilled (‘blinding’) would alter the 
conclusions of the study, although it potentially introduces bias.
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Evidence Summary (without the use of the GRADE pro software) 
 
Intensive versus less intensive follow-up: 
 
There is significant overall survival benefit at 5 years with intensive follow-up. 
The number of all recurrences detected is similar with both intensive and less 
intensive follow-up. 
The number of curative procedures attempted for recurrence is significantly more 
with intensive follow-up. 
There is no disease-specific survival benefit with intensive follow-up. 
Significantly more asymptomatic recurrences were detected in the group which 
received intensive follow-up.  
The time to recurrence is significantly less in patients receiving intensive follow-up.  
 
Generally: 
 
CEA blood test offers survival advantage.  
Liver imaging offers survival benefit, CT of the liver improves survival, ultrasound 
scanning of the liver versus none offers survival advantage. 
Colonoscopy leads to survival benefit versus no colonoscopy. Intensive colonoscopy 
versus less intensive colonoscopy does not offer survival advantage. 
Clinic visits for follow-up versus no clinic visit offer survival benefit. 
 
Complications:  
 
1 study reported adverse events from follow-up relating to colonoscopy: 2 
perforations and 2 GI bleeds from a total of 731 colonoscopies.[239] 
 
Quality of Life (QoL):  
 
1 study showed a small but significant increase in QoL with follow-up.[240] 
1 study showed no difference in QoL in patients followed up in GP versus hospital 
setting.[241] 
 196 
8.4.2 Quality Assessment by GRADE 
 
The quality assessment by GRADE is presented in evidence tables produced by the 
GRADE pro software. These are included in Appendix 7.  
 
There are 8 tables each presenting the assessment of evidence by GRADE for the 8 
comparisons found in the studies identified by the literature search.  
 
A question is presented per table as the formulated follow up comparison query. The 
table then presents the relevant associated outcomes for each question with data 
derived from the three studies included in this review.  
 
The penultimate column for each table represents the overall GRADE quality score 
for that outcome. 
 
The systematic review by Jeffery et al presented the results as odds ratios but the 
review by Tjandra et al presented the results in the form of p values.  
 
For ease of comparison of results between the two systematic reviews where p 
values were reported in the Tjandra publication the odds ratio has been calculated 
and this is the result that has been entered in the GRADE software.  
 
Calculations performed for this conversion are tabulated at the end of the GRADE 
evidence tables (Appendix 7). 
 
These results did not have a numerical confidence interval reported and this is 
missing from the grade tables but the grading of precision and statistical significance 
has been made based on the confidence interval representation on the forest plots. 
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Evidence summary using the GRADE pro software. 
 
Intensive v less intensive follow-up 
 
There is moderate quality evidence of significant overall survival benefit at 5 years 
with intensive follow-up.[222, 238] 
 
When looking at disease specific survival there is low quality evidence of survival 
benefit with intensive follow-up. The result is imprecise and not statistically 
significant.[222] 
 
There is moderate quality evidence that the number of all recurrences detected is 
similar with both intensive and minimal follow-up.[222,238] 
 
There is low quality evidence that significantly more asymptomatic recurrences were 
detected in the group that received intensive follow-up. The result is statistically 
significant though the total number of events in the pooled comparison is low and 
this can introduce imprecision to the result.[222,238] 
 
The time to recurrence is significantly less with intensive follow-up but the evidence 
is of low quality mainly as the studies pooled are too heterogeneous.[222,238] 
 
There is low quality evidence that the number of curative procedures attempted for 
recurrence is significantly greater with intensive follow-up.[222,238] 
 
Clinic visits versus no visits or fewer clinic visits 
 
Clinic visits versus no clinic visits showed a survival benefit in the clinic group but the 
result is imprecise, is not statistically significant, and the quality of the evidence is 
low.[222] 
 
In the ‘more clinic visits’ versus ‘fewer clinic visits’ comparison a survival benefit was 
shown in the group attending more clinic visits both in terms of overall survival and 
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number of recurrences but again the result is imprecise and the quality of the studies 
low (recurrences) and very low (overall survival).[222] 
 
More versus less frequent tests 
 
There is evidence of moderate quality to support the contention that generally when 
more tests are done they do give a significant survival advantage over fewer tests 
done but the number of recurrences detected as a result is no different in the two 
groups.[222] 
 
Carcinogenic Embryonic Antigen (CEA) (blood test) 
 
When included in the follow-up protocol CEA estimation gives an overall survival 
advantage versus no CEA testing. However this result should be interpreted with 
caution. 
 
The review by Jeffery et al reports this result as of no statistical significance. Only 
one randomised control trial [242] contributes to this result and overall the quality of 
the evidence is low. The RCT is small (107 patients) and the result is imprecise with 
a wide confidence interval.  
 
The review by Tjandra et al reports a statistically significant result. Two RCTs have 
been pooled for this result [242,243] but the quality of the evidence is very low. 
There is serious imprecision. The confidence interval is only given as a diamond 
representation on the forest plot and not as a numerical value but the total number of 
events is low (less than 300). 
 
The number of recurrences detected is not higher in the CEA group but this was not 
a significant result and the quality of the evidence is low.[222,238] 
 
There is evidence of equally low quality that a higher number of curative operations 
are done for recurrence when CEA is included in the follow-up rather than no 
CEA.[238] 
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When looking at the intensity of CEA testing i.e. more versus less CEA there is low 
quality evidence of a survival advantage with more frequent CEA 
measurements.[238] 
 
There is low quality evidence that the number of recurrences detected is not affected 
by CEA estimation.[238]  
 
There is also low quality evidence that the number of curative re-operations 
performed is greater in the group with more frequent CEA measurements.[238] 
 
Liver imaging 
 
There is evidence of moderate quality that liver imaging in general gives a significant 
survival advantage. There is also evidence of moderate quality showing no 
difference in the number of recurrences detected between follow-up that included 
liver imaging and follow-up with no liver imaging.[222] 
 
There is evidence of low quality that ultrasonography improves survival, evidence of 
low quality that it increases the number of recurrences detected and evidence of low 
quality that it increases the number of curative re-operations. All of the above were 
compared with control patients in whom no ultrasonography was performed at follow-
up.[238] 
 
There is evidence of moderate quality that CT improves survival (but no statistical 
significance was reached), evidence of moderate quality that it increases the number 
of recurrences detected and evidence of low quality that it increases the number of 
curative re-operations. All of the above were compared with control patients in whom 
no CT was performed at follow-up.[238] 
 
Colonoscopy 
 
There is evidence of moderate quality that colonoscopic surveillance leads to a 
survival advantage over no colonoscopic surveillance.[238] 
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There is evidence of low quality showing that there is no difference in the number of 
recurrences detected with the addition of colonoscopy, and equally low-quality 
evidence showing that more curative operations for recurrence were carried out in 
patients who had colonoscopic surveillance during follow-up.[238] 
 
When looking at the intensity of colonoscopy i.e. more versus less colonoscopy there 
is evidence of low quality that intensive colonoscopic surveillance does not offer any 
advantage in overall survival versus less intensive colonoscopic surveillance. 
[238,239] 
 
The evidence is again of low quality that frequent colonoscopic surveillance 
increases the number of recurrences detected.[238,239] 
 
Evidence of equally low quality suggests frequent colonoscopy does increase the 
number of curative operations attempted for recurrence.[238,239]  
 
There is also evidence of low quality that the time to the diagnosis of a recurrence is 
reduced and that the survival time after recurrence is diagnosed is increased.[239] 
 
Complications: 
 
1 study reported adverse events from follow-up: 2 perforations and 2 GI bleeds from 
a total of 731 colonoscopies.[239] 
 
Quality of life: 
 
1 study (597 patients) reported a small but significant increase in the quality of life of 
patients associated with more frequent follow-up visits.[240] A different study (203 
patients) reported no difference in quality of life, anxiety, depression, or patient 
satisfaction in patients followed up in different settings (general practice versus 
hospital).[241] 
 
 201 
8.5 Discussion 
 
These results show that overall more parameters are taken into account when 
assigning a quality value to a piece of evidence with GRADE compared to the sole 
use of internal validity checklists. 
In addition all individual outcomes reported within a systematic review are graded by 
the GRADE method whereas internal validity checklists assess the overall quality of 
the systematic review methodology and its principle outcome and not each individual 
outcome. 
In addition, these results show that in the case of this guideline topic on the follow-up 
of CRC this has helped highlight a number of low- and very low-quality outcome 
results within systematic reviews of high quality.  
This is very important for guideline developing group members as it gives a clear 
presentation of low quality results that perhaps would have easily been mistakenly 
accepted as high quality only because they were presented within a review with 
robust methodology. 
Internal validity checklists used prior to GRADE are not incorrect and indeed have a 
valid place in the assessment of evidence. 
When assessing the quality of a study or systematic review the majority of internal 
validity checklists focus on the study question and the study methodology. 
 
The NICE methodology checklists used in the initial quality assessment of this 
systematic review provided a thorough quality assessment of the methodology of the 
studies.  
 
The checklist for the systematic reviews begins with an assessment of the review 
question as the first step. It would be difficult to assess how well the study has met 
its objectives or how relevant its conclusions are to the guideline without this. 
 
The next item on the checklist is the description of the methodology, which is also 
important. One of the key distinctions between a systematic review and a general 
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review is the systematic methodology used. A systematic review should include a 
detailed description of the methods used to identify and evaluate individual studies. If 
this description is not present, it is not possible to make a thorough evaluation of the 
quality of the review. 
 
Assessment of the literature search follows, as this needs to be sufficiently rigorous 
to identify all the relevant studies. A systematic review based on a limited literature 
search (e.g. Medline only) is likely to be heavily biased. Any indication that hand 
searching of key journals, or follow-up of reference lists of included studies were 
carried out in addition to electronic database searches is additional evidence of 
quality methodology. 
 
Inclusion and exclusion criteria are also important markers of study quality and it is 
the next item on the checklist. A well-conducted systematic review should have used 
clear criteria to assess whether individual studies have been well conducted before 
deciding whether to include or exclude them. In addition studies covered by a 
systematic review should be selected using inclusion criteria that include, either 
implicitly or explicitly, the question of whether the selected studies can legitimately 
be compared. It should be clearly ascertained, for example, that the populations 
covered by the studies are comparable, that the methods used in the investigations 
are the same, that the outcome measures are comparable and the variability in effect 
sizes between studies is not greater than would be expected by chance alone. 
 
As a result of the quality assessment of the two systematic reviews with the NICE 
checklists it was concluded that the two reviews had robust methodology. Sources of 
bias were identified and these were minor differences between the population of the 
PICO and the population of the systematic reviews and additionally the 
heterogeneity introduced through the sheer variability of the follow-up protocols but 
neither of these were considered critical in the overall quality of the systematic 
reviews. Therefore their results were presented in the evidence summary. The 
individual outcome results presented in the evidence summary did not have any 
further quality assessment. All the results were presented with an assumption that 
the quality of the systematic reviews from which they were derived transferred to all 
the results presented in the evidence summary. 
 203 
 
The checklist for randomised controlled studies has a similar purpose and begins 
with addressing recruitment and randomisation. Random allocation of patients to 
treatment or no treatment is fundamental to this type of study.  
 
The next item on the checklist is allocation concealment. This also seeks to eliminate 
selection bias during the process of recruitment and randomisation, and it is a 
marker of study quality. Centralised allocation, computerised allocation systems or 
the use of coded identical containers would all be regarded as adequate methods of 
concealment, and may be taken as indicators of a well-conducted study.  
 
The next issue addressed is whether the treatment and control groups are similar at 
the start of the trial. Patients selected for inclusion in a trial should be as similar as 
possible, in order to eliminate any possible bias. The study should report any 
significant differences in the composition of the study groups in relation to gender 
mix, age, stage of disease (if appropriate), social background, ethnic origin or co-
morbid conditions. These factors may be included in the reporting of the inclusion 
and exclusion criteria rather than being reported separately.  
 
Maintaining equal management of both groups during the duration of the trial is also 
an important way to eliminate the introduction of bias. The only difference between 
the groups should be the treatment under investigation. If some patients received 
additional treatment, even if of a minor nature or consisting of advice and counselling 
rather than a physical intervention, this treatment is a potential confounding factor 
that may invalidate the results.  
 
The follow-up period is equally important in the maintenance of good quality 
throughout the study period. The drop out rate for a study is the percentage of the 
individuals or clusters recruited into each treatment arm of the study who dropped 
out before the study was completed. The number of patients who drop out of a study 
should give concern if the number is very high. It is an indication of attrition bias. 
Some regard should be paid to why patients dropped out, as well as how many. It 
should be noted that the drop-out rate may be expected to be higher in studies 
conducted over a long period of time.  
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Analysis by intention to treat means that all the subjects are analysed in the groups 
to which they were randomly allocated. In practice, it is rarely the case that all 
patients allocated to the intervention group receive the intervention throughout the 
trial, or that all those in the comparison group do not. Patients may refuse treatment, 
or contra-indications arise that lead them to be switched to the other group. If the 
comparability of groups through randomisation is to be maintained, however, patient 
outcomes must be analysed according to the group to which they were originally 
allocated, irrespective of the treatment they actually received.  
 
The outcomes of the study also need to be appropriate and relevant and measured 
in a standard, valid and reliable way.  
 
The final issue addressed by the checklist is that of ‘blinding’. ‘Blinding’ refers to the 
concealment of group allocation from one or more individuals involved in a clinical 
research study. It seeks to reduce performance and ascertainment bias after 
randomisation.[244] 
 
If bias is introduced during a trial because of differential treatment of groups or 
biased assessment of outcomes, no analytical techniques can correct for this 
limitation. Differential treatment or assessment of participants potentially resulting in 
bias may occur at any phase of a trial. The optimal strategy to minimize this bias is to 
‘blind’ as many individuals as possible in a trial.[244] 
 
If possible, trial researchers should ‘blind’ 5 groups of individuals involved in trials: 
participants, clinicians (surgeons), data collectors, outcome adjudicators and data 
analysts.[244] 
 
‘Blinding’ is not an all-or-nothing phenomenon; researchers may ‘blind’ any of the 
involved groups. Thus, it is far preferable for researchers to explicitly state which 
individuals in the trial were ‘blinded’. The higher the level of ‘blinding’, the lower is the 
risk of bias in the study.[244] 
 
 205 
In the RCT by Wang et al [239] there was no reference at all to methods of ‘blinding’ 
having been applied to any of the individuals involved in the trial and this is the only 
major criticism of the trial. 
 
Randomized controlled trials of surgical interventions are frequently more difficult to 
‘blind’ than RCTs of medications, which typically achieve ‘blinding’ with placebos. 
Whereas medical trials usually incorporate placebo medications to achieve ‘blinding’, 
surgical treatments often result in incisions and scars that may differ between 
groups. 
 
Furthermore, if a trial aims to compare surgical therapy to non-operative 
management, it will often be impossible to conceal group allocation from at least 
some of the individuals involved in a trial (such as the patients and surgeons). Thus, 
surgeons must interpret the results from trials that have not been ‘blinded’ with 
caution. 
 
When data collectors or outcome adjudicators cannot be ‘blinded’, researchers 
should ensure that the outcomes being measured are not only reliable but as 
objective as possible. Consideration might also be given to the use of duplicate 
assessment of outcomes and reporting the level of agreement achieved by the 
assessors. 
 
With the use of the NICE checklist the lack of ‘blinding’ was recorded in the quality 
assessment of the Wang trial but the checklist does not aid quantification of this any 
further.  
 
With GRADE the quality of the study and the quality of the data for each PICO 
outcome of the topic is used.  
 
The GRADE-pro software generates an evidence ‘quality score’ for each outcome 
from responses to several specific questions about the methodological quality of the 
study and the data. It emphasizes outcomes.  
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Each of the two systematic reviews included 8 RCTs in total. They had 7 in common 
and 1 different.  
 
Jeffery et al included an RCT that had quality of life as its primary outcome [241] but 
excluded the GILDA trial [244] as published results were on fewer patients than the 
number they initially set out to recruit (1240 patients rather than target of 2920) and 
follow-up is short (recruitment started in 1998 and the trial is still ongoing).  
 
Tjandra et al in their meta-analysis did not include the trial looking at quality of life 
[241] but included the preliminary results of the GILDA trial [244]. However, the 
group did do a sub-group analysis excluding the GILDA results and found that the 
trial exclusion did not alter the overall result of their meta-analysis. 
 
7 of the 8 RCTs in Jeffery and all of the RCTs in Tjandra had unclear reporting of 
their allocation concealment relevant to their randomisation process. Each outcome 
derived from these studies has therefore been downgraded for this reason. 
 
Both reviews in addition to 5-year survival carried out a number of comparisons 
addressing different associated outcomes. Some of these are statistically significant 
and in others the pooled groups are either too small, and therefore the result is 
imprecise, or too heterogeneous and therefore the result is inconsistent. 
 
When this information is entered into the GRADEpro software the outcome result is 
given a reduced score. If the outcome is afflicted by only one type of bias then the 
quality grade is reduced to moderate from high. If the outcome is afflicted by both 
imprecision and inconsistency then the quality score is low. 
 
In the case of the survival outcome in association with the clinical setting of the 
follow-up the outcome results were given a quality score of ‘very low’ because there 
was unclear allocation concealment, there was inconsistency (heterogeneity), and 
serious imprecision (CI includes 1 and the total number of events was less than 
300). 
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Using CI as a measure of precision is accepted statistical practice. The reference to 
the number of accrued events is however less widespread but is one of the quality 
items recommended through the GRADE pro software.  
 
A low number of accrued events is considered to increase the risk of treatment effect 
overestimation.[245] This goes against the purpose of a trial looking alternative 
interventions which is to generate an estimate of effect that closely approximates the 
true effect and is not misleading. Harm may result from misleading findings if these 
are the supporting evidence for clinical guidelines. There is no clear answer as to 
how many events accrued is enough but a figure of between 200 and 400 has been 
suggested by a team of experts in this field as a reasonable rule of thumb.[245]  
 
The number 300 is recommended by the GRADE working group as a threshold 
number of events below which imprecision should be considered and is included in 
the guidance to reviewers as part of the GRADE pro software. 
 
Another instance of a very low quality result is that from the Tjandra review of overall 
survival in association with the inclusion of CEA testing in the follow-up protocol. This 
outcome result is methodologically interesting as both of the systematic reviews by 
Jeffery et al and Tjandra et al report results on this outcome but their results differ. 
 
The two systematic reviews differ in the inclusion of the Secco RCT[243]. The 
inclusion of the second RCT by Secco et al in the pooled analysis by Tjandra et al is 
problematic. The review by Jeffery et al excluded this trial from the pooled 
comparison and commented that they felt survival data could not be extracted. 
 
The review by Tjandra et al has included this trial in the analysis. The Secco 
publication and their results was reviewed for this analysis and the views expressed 
in this thesis are in agreement with the opinion expressed in the review by Jeffery et 
al.  
 
From the data in the publication it is not possible to extract survival data even though 
the conclusion from the Kaplan Meier analysis is that there is a significant survival 
advantage between the groups they compare.  
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For the Tjandra group to have been able to pool these two studies it can only be 
assumed that the group wrote to the Secco group authors and received further data. 
However this is not mentioned in the publication. Therefore caution is recommended 
when considering these results 
 
It is a common assumption that systematic reviews are always at the top of the 
pyramid of evidence grading. When assessing the quality of a study the majority of 
internal validity checklists focus on the study question and the study methodology. 
But in this way the emphasis is on the quality of the study itself and not on the 
evidence in it. So a study that is of high quality with regard to its methodology may 
mislead someone in thinking that all the conclusions and indeed all the evidence it is 
based on is also of high quality. [216] 
 
What a GRADE analysis shows is that this might not always be the case. GRADE 
helps to clarify the quality of the evidence.[216] 
 
The advantage of GRADE over other evidence grading systems is that it provides 
comprehensive criteria for downgrading and upgrading quality of evidence with 
explicit evaluation of the importance of all outcomes within the studies.[216] 
 
This helps provide a clear separation between body of evidence and strength of 
recommendations, with additionally a transparent process that defines and exposes 
progression from the evidence to the recommendations.  
 
The quality score provided by GRADE helps quantify the confidence in the evidence, 
which in turn helps guideline panels formulate transparent recommendations. If the 
evidence is of high quality then the recommendation might be that patients ‘should’ 
be treated by the method supported by the evidence. If the evidence is of lower 
quality then the recommendation might be that the patients ‘should probably’ be 
treated by this method but implying or clearly stating that this might not be 
appropriate in all cases.[220] 
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The topic on CRC follow up is complicated with many different tests and strategies 
featuring in a wealth of different quality therapeutic data. GRADE was shown in 
these results to provide an important role in providing the GDG with a clear 
presentation of the true quality of the different outcomes from all the studies. Despite 
the wealth of studies the results vary from those of moderate quality to those of very 
low quality and it is the latter that have serious methodological weaknesses and 
therefore these results need to be interpreted with caution.  
 
Transparency should be a key goal for any guideline development group and 
GRADE contributes to the development of methodologically transparent guideline 
recommendations. 
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9.0 The international nature of evidence and the 
influence this has on the formulation of guideline 
recommendations 
 
9.1 Introduction 
 
Evidence for clinical guidelines is made up of studies from across the world. 
This potentially diverse geographical source of the evidence can create a 
concern that a clinician might be forced by guidelines to rely upon evidence 
that is only doubtfully relevant.[246] 
 
Confidence might be lost in the guidance if it is thought to be formulated in the 
absence of evidence that is clearly applicable to the case in hand, and with 
evidence generated perhaps in a different category of patients in another 
country, at some other time, and in different circumstances.[246] 
 
This would be far from ideal and indeed it might be considered to be biased-
medicine rather than evidence-based.[246] 
 
It is also possible that different guideline developers might use the same body 
of evidence to produce different guidelines for a different population or setting.  
 
It is vital that recommendations with any guideline are clear, and are based on 
the best available evidence.  
 
Interpreting the evidence to make recommendations is at the heart of the work 
of the Guideline Development Group (GDG). It is not a straightforward task 
and it is challenging.[54] 
 
The GDG must decide what the evidence means in the context of the review 
questions and the economic questions posed, and decide what 
recommendations can usefully be made to healthcare professionals.[54] 
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In a NICE guideline an important aim is to show clearly how the GDG moved 
from the evidence to the recommendation. This is best done in a section 
called ‘linking evidence to recommendations’ (LETR).[54] 
 
This section may also be a useful way to integrate the findings from several 
evidence reviews that are related to the same recommendation(s).[54] 
 
In this section the GDG’s view of the strength of a recommendation should be 
clearly reported. Points to address include the prioritisation of outcomes, the 
trade-off between clinical benefits and harms, the trade-off between net health 
benefits and resource use and the quality of the evidence.[54] 
 
With reference to the latter in particular, there should be discussion of how the 
presence of potential biases and uncertainty in the clinical and economic 
evidence has influenced the recommendation, and why.[54] 
 
This may include consideration of whether the uncertainty is sufficient to 
justify delay in making a recommendation to await further research, taking into 
account the potential harm of failing to make a clear recommendation.[54] 
 
9.2 Aim  
 
To research the international nature of data supporting the NICE guideline on 
CRC and the influence this may have on the resulting recommendations. 
 
9.3 Methods 
 
Information on how the evidence that supported the guideline was linked to 
the final recommendations formulated by the guideline development group 
was collected through: 
 
 212 
i) participation in all the guideline development group (GDG) meetings 
throughout the two year development of the CRC guideline and 
experiencing in close proximity the process of developing 
recommendations from the body of evidence presented for each 
topic. 
ii) review of all the final formal LETR sections of the CRC guideline 
document for each of the topics the guideline addressed for 
evidence of the recommendations having been influenced by the 
national setting of the evidence that supported that 
recommendation.  
 
9.4 Results 
 
Of the fifteen topics and questions which the NICE colorectal cancer guideline 
addressed there was only one that was found to be a demonstration of a 
guideline recommendation potentially influenced by the national setting and 
origin of the supporting evidence. This guideline topic was on the staging of 
CRC and is presented below. 
 
The summary of the systematic review evidence is presented as part of this 
thesis as it is necessary to the understanding of the topic and the detailed 
evidence that was presented to the guideline development group before they 
made their assessment and formulated the recommendation. The author of 
this thesis did not perform this systematic review. It is the work of colleague 
reviewer Dr Susan O’Connell, permanent staff of the NCC-C technical team 
and member of the NICE CRC guideline development group.  
 
The objective of this thesis chapter is not the exercise of performing a relevant 
systematic review but instead the critical appraisal of the process that links 
the evidence of a systematic review to the formulated recommendations and 
the analysis of the consequences and implications.  
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8.4.1 Guideline topic identified demonstrating influence of the 
recommendation by the national setting of the supporting evidence  
 
Guideline question [247] 
 
“For patients diagnosed with primary colorectal cancer, what is the most 
effective technique(s) in order to accurately stage the disease (excluding 
pathology)?” 
 
Evidence summary for rectal cancer [247] 
 
“From two systematic reviews (Kwok et al.[248], Bipat et al.[249]) it appears 
that endorectal sonography/endorectal ultrasound had the highest sensitivity, 
specificity and accuracy of the modalities investigated (CT, endorectal 
sonography/endorectal ultrasound and MRI).” [247] 
 
“Kwok et al. [248] reported a pooled sensitivity, specificity and accuracy for 
endorectal sonography of 93%, 78% and 87% respectively for wall 
penetration and 71%, 76% and 74% respectively for nodal involvement.” [247] 
 
Bipat et al. [249] reported summary estimates of sensitivity and specificity for 
endorectal ultrasound of 94% and 86% respectively for muscularis propria 
invasion, 90% and 75% respectively for peri-rectal tissue invasion and 67% 
and 78% respectively for lymph node involvement compared with sensitivity 
and specificity for MRI of 90% and 69% respectively for muscularis propria 
invasion, 82% and 76% respectively for peri-rectal tissue invasion and 66% 
and 76% respectively for lymph node involvement. [247] 
 
“For muscularis propria invasion, endorectal sonography specificity was 
significantly higher than that of MRI (p=0.02); for peri-rectal tissue invasion, 
endorectal ultrasound sensitivity was significantly higher than that of CT 
(p<0.001) and MRI (p=0.003).” [247] 
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“Specific UK evidence was provided from the Mercury Study group [250,251] 
investigating MRI in the staging of rectal cancer. The accuracy of MRI for 
predicting the status of circumferential resection margin (presence/absence of 
tumour) by initial imaging or imaging after pre-operative treatment was 88% 
[95% CI: 85-91%], sensitivity was 59% [95% CI: 46-72%] and specificity was 
92% [95% CI: 90-95%].” [247] 
 
“For patients undergoing primary surgery with no pre-operative treatment 
(n=311), accuracy of prediction of a clear margin was 91% [95% CI: 88-94%], 
sensitivity of 42% and specificity of 98%.” [247] 
 
“For patients undergoing pre-operative chemoradiotherapy or long-course 
radiotherapy the accuracy of prediction of clear margins on MRI was 77% 
[95% CI: 69-86%], sensitivity was 94% and specificity was 73%.” [247] 
 
“Two studies investigated the use of FDG PET (Kantorova et al [252], Llamas-
Elvira et al [253].” [247] 
 
“For lymph node involvement the reported sensitivity ranged from 21-29%, 
specificity ranged from 88-95% and accuracy ranged from 56-75% and for 
liver involvement sensitivity was 78%, specificity was 96% and accuracy was 
91%.” [247] 
 
“Inter-observer agreement was not addressed in all studies, though the 
studies which did evaluate inter-observer agreement (Fillipone et al.[254], 
Tatli et al.[255],  Kim et al. [256]) reported good to excellent agreement for 
interventions being investigated.”[247] 
 
 
Recommendations for staging of rectal cancer [247] 
 
“Offer contrast enhanced CT of the chest, abdomen and pelvis, to estimate 
the stage of disease, to all patients diagnosed with colorectal cancer unless it 
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is contraindicated. No further routine imaging is needed for patients with colon 
cancer.” [247] 
 
“Offer magnetic resonance imaging (MRI) to assess the risk of local 
recurrence, determined by anticipated resection margin, tumour and lymph 
node staging, to all patients with rectal cancer unless it is contraindicated.” 
[247] 
 
“Offer endorectal ultrasound to patients with rectal cancer if MRI shows 
disease amenable to local excision or if MRI is contraindicated.” [247] 
 
“Do not use the findings of a digital rectal examination as part of the staging 
assessment.” [247] 
 
Linking evidence to recommendations [247] 
 
“The GDG placed a high value on accurate staging at presentation because 
this information informs the optimum treatment strategy for patients with 
colorectal cancer. The evidence consisted of two good quality systematic 
reviews and several low-quality case series studies.” [247]  
 
“In patients with rectal cancer, the GDG were aware that the available 
evidence had shown EUS to have higher sensitivity, specificity and accuracy 
compared to MRI or CT for identifying those patients whose tumours are 
suitable for local resection. The GDG noted that EUS is not appropriate in 
bulky, obstructing tumours and does not visualise the total extent of nodal 
disease in the pelvis.” [247] 
 
“It was also noted that the evidence may reflect non-UK practice because 
EUS is not widely used in the UK.” [247] 
 
“There was also significant inter-observer variation in the performance of 
EUS.”  [247] 
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“The GDG therefore recommended MRI be used for the initial assessment of 
patients with rectal cancer and that EUS be considered if the MRI suggested 
disease which was amenable to local resection.” [247] 
 
8.4.2 The national setting of the studies included in the evidence 
summary 
 
The national setting of the studies included in the evidence is presented in 
Table 9.1.  
 
Table 9.1: The national setting of studies included in the evidence summary 
for the guideline topic on the staging of rectal cancer 
 
Study (first author and date) National setting 
Kwok [248] New Zealand 
Bipat  [249] The Netherlands 
Mercury Study Group [250,251] UK 
Kantorova [252] Czech 
Llamas-Elvira [253] Spain 
Fillipone [254] Italy 
Tatli [255] USA 
Kim [256] Korea 
 
 
The two systematic reviews by Kwok [248] and Bipat [249] pooled 83 and 90 
studies respectively. The Kwok group was based in New Zealand and the 
Bipat group in The Netherlands.  
 
For the two systematic reviews Table 9.2 presents the national setting of the 
individual studies pooled in the reviews.  
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Table 9.2: The national setting of the studies pooled by the two systematic 
reviews and included in the evidence summary of the guideline topic on the 
staging of CRC cancer 
. 
National setting of study Number of studies from 
Bipat review [249] 
Number of studies 
from Kwok review 
[248] 
UK 7 4 
Austria 1 1 
Germany 11 11 
Italy 17 10 
Sweden 5 6 
Finland 1 1 
France 2 1 
The Netherlands 2 1 
Switzerland  1 1 
Denmark 3 3 
Ireland 1 0 
Belgium 0 1 
Croatia 0 1 
Russia 1 1 
USA 20 19 
Japan 11 12 
Australia 1 2 
Korea 4 2 
Canada 0 1 
Total 88 
*unable to obtain data 
for 2 studies 
78 
* unable to obtain 
data for 5 studies 
 
 
 
 
 218 
9.5 Discussion 
 
These results show that the GDG made a recommendation that was in part 
influenced by the national setting of the evidence which emerged from the 
systematic search of the literature. 
 
The results of the literature search identified two high quality systematic 
reviews which concluded that the modality that was shown to have the highest 
diagnostic accuracy in staging rectal cancer was endoanal ultrasound. 
 
This accuracy was higher than that of the MRI scan. This was clearly 
acknowledged by the GDG in the relevant LETR paragraph. 
 
Despite this the GDG made a decision to recommend that patients with rectal 
cancer in the UK are offered an MRI to stage rectal tumours and that an 
endoanal ultrasound is to be offered only to those patients in whom MRI has 
shown the tumour to be amenable to local excision or where MRI is 
contraindicated.  
 
One of the reasons given in the LETR paragraph for this decision was the fact 
that endoanal ultrasound is ‘non-UK practice’. 
 
It appears that the UK Mercury study [250, 251], a high quality study 
researching the diagnostic accuracy of MRI in relation to the staging of rectal 
cancer, was upgraded in the evidence pool by the GDG despite the fact that 
in absolute terms the MRI results it presented did not show MRI to be a more 
accurate diagnostic modality compared with EUS. 
 
Though this decision is not entirely based on the national setting of a 
particular study (the GDG also considered the low inter-observer variability as 
a reason for their decision) this case is an example where the national setting 
of evidence does play a significant role in the formulation of their decisions. 
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This may be the case because the difference in diagnostic accuracy between 
the modalities is actually rather small. Had it been a more remarkable 
difference in diagnostic accuracy between EUS and MRI then perhaps it 
would have been more difficult to overlook a result of diagnostic accuracy and 
give preference to the option that had local origins. 
 
Another reason which may have lead the GDG to show preference to local 
results is the opinion that the results of the Mercury study [250, 251] are more 
applicable and transferable to the population that the guideline intends to 
serve.  
 
The results are more applicable because of the characteristics of the study 
population, which sampled patients from the local UK population. The results 
are also more applicable because they have been produced by modalities 
with technological characteristics similar to those modalities used regularly in 
UK clinical practice.  
 
In addition, there has been a long and concentrated effort in the UK to 
standardise the performance and reporting of MRI scans. Dr Gina Brown, 
Consultant Radiologist at the Marsden Hospital  has produced a lot of detailed 
work in standardising scanning techniques and has produced a detailed 
proforma so that all radiologists nationally can report their findings including 
all the relevant details. This is to give every possible chance that the 
diagnostic accuracy reported in trials like the Mercury trial are replicated 
nationally. [259] The same is not currently available for EUS. The combination 
of the reduced availability of specialists to perform the test confidently coupled 
with the absence of standardised ways to perform and report the scans could 
result in an inability to achieve similar results to the trial.  
 
In this way the GDG may also have downgraded evidence from foreign 
national settings due to an opinion that those studies were carried out within 
health systems very different from that in the UK. 
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The US is an example where the health system is in the majority private, EUS 
is performed by surgeons rather than radiologists, and payment for the 
service is arranged differently (pay for service). A large proportion of studies 
included in the systematic reviews by Bipat [249] and Kwok [248] were 
performed in the US.  
 
These are also differences found to a lesser degree within countries of the 
European Union where the presence of national health systems coexists with 
a variable degree of private health provision along with variable access 
policies to either of these. This can create very different working environments 
and research environments which influence the results of foreign studies and 
the evidence that can be drawn from them. 
 
In addition there are many cultural differences with regard to health and the 
investigations and treatment of ill-health across the world. The example of the 
EUS modality lends itself to demonstrate this due to its invasive nature and 
per rectum administration. 
 
Some populations are more accepting of certain modes of treatment that 
others may find too invasive to tolerate and would rather reserve such 
treatment as the last resort in the investigation or treatment pathway. It is 
perhaps an expression of cultural differences through health experiences. 
 
This may perhaps be a subtle reason why EUS was less favoured among a 
UK guideline development group if the investigation was considered a less 
favourable option by the population the GDG members are used to treating. 
 
The members of the guideline development group know that MRI is more 
available than EUS in the UK. They are also aware that the available 
expertise for the performance of the two tests is very different in the UK. MRI 
interpretation is readily available by specialist radiologists whereas the 
performance and interpretation of EUS is only available from a small number 
of specialist radiologists in tertiary care hospitals.  
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There is a chance that the members of the GDG have made their decision in 
order not to disrupt the ‘status quo’ of current service provision.   
 
There is also the possibility that certain members of the GDG have a conflict 
of interest that has not been taken into account. There are members of the 
GDG who have specialist interest in imaging and this representation may be 
stronger than that regarding interest in EUS.  
 
Any conflict of interest of members of GDG is reported and recorded as part 
of the NICE guideline development methodology and there is a policy of 
transparency with regard to this matter. However this is usually regarding 
active participation in ongoing trials or links with industry and this more subtle 
potential conflict of interest may be overlooked. 
 
There is also a simple sense of familiarity with results of local research which, 
for the members of the GDG, may be difficult to escape when making their 
decision; and so when a study conducted locally offers slightly less accurate 
diagnostic efficacy from a modality but which gives results that are not very 
different from those produced in other national settings the GDG members 
have an automatic preference for what is familiar. 
 
Guidelines are produced to improve medical practice and patient care. In a 
study by the World Health Organisation on identifying barriers to the 
implementation of guidelines it was identified that physicians, in addition to 
quality evidence, also need local evidence in order effectively to change their 
practice. This is because they need to validate the transferability of the 
findings in their own practice.[257] 
 
There are methodological implications that follow from the decision of the 
GDG however since any of the reasons presented above may introduce bias 
to the process. 
 
Upgrading or downgrading evidence based on the national setting of the 
evidence is not incorrect however and at times it is necessary. It requires skill 
 222 
and experience from members of a GDG panel in order to make accurately 
the right recommendation for the relevant population. Because the decision 
can expose the process to the risk of bias it is important that the process itself 
is by design as transparent as possible. 
 
It must be clear at all times what the evidence has shown and how this has 
been interpreted by the particular GDG. 
 
Theoretically guideline recommendations should be based on the best 
available evidence. They should be free from financial constraints and be the 
result of a pure methodological process. 
 
The results have shown that recommendations are not always pure and 
without influence. They are pragmatic decisions about the UK population 
within the framework of the NHS. They are however based on the best 
evidence available. Especially when the differences in the data between 
studies are not very substantial and management recommendations are 
potentially controversial, then decisions can become more subjective than 
objective and subject to the influence of the national setting of the studies 
under consideration. 
 
Provided that there is a process such as the ‘linking evidence to 
recommendation’ section of the NICE guidelines so that all readers and users 
of the guideline know how the evidence was interpreted, then influence on the 
recommendations by the national setting of the evidence under review is not a 
weakness but might even be seen as a necessary approach towards the 
proper assessment of the vast quantities of evidence reported in the literature. 
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10.0 Conclusions and future work 
 
The results of this thesis show that guideline development at NICE follows an 
evidence-based process that complies with internationally accepted principles 
of evidence-based medicine and guideline development.  
 
This process is continually reviewed and updated in order to ensure quality 
and transparency. It is well regarded both nationally and internationally for 
these reasons. 
 
No guideline development process is free of bias and some steps of the NICE 
guideline development process are more robust than others.  
 
One such example is that the technical team assigned to the development of 
each NICE guideline includes only one reviewer who performs the systematic 
reviews.  
 
It is strongly advised in systematic review methodology literature [260] that 
reviewing is carried out by at least two reviewers. They work independently to 
screen abstracts, extract data and assess risk of bias, thereby reducing the 
chance of reviewer bias and increasing reliability. 
 
The most likely reasons for NICE to divert from this principle of guideline 
methodology are time and cost constraints.  
 
The NICE colorectal cancer guideline took two and a half years to develop 
which is average for NICE clinical guidelines.  
 
This is a lengthy process considering that information is made available at 
such speed and with such ease of access. Guidance is therefore often 
desired at a fast pace.  
 
Guidelines are also gaining popularity and developers are facing a huge 
expansion in their output.  
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Therefore,  the cost of the development process for each guideline must be 
balanced against the need and resulting costs of producing a larger number of 
guidelines.  
 
It is understandable that a guideline development body desires to reduce both 
the development time and the costs.   
 
However, this is such an important factor in reducing reviewing bias that it 
would be advisable that the methodology specialists at NICE  address this in 
the future.  
 
It is especially important as NICE want to be regarded as leaders in the field 
of guideline development. 
 
It is also important as many other countries use NICE guidance and NICE 
guideline methodology as a template for their own guideline development.   
 
This is either directly through the services of NICE International or by 
following NICE methodology in the set up of their own guideline developing 
bodies.  
 
Most especially it is important because reducing reviewing bias increases the 
reliability of the results and strengthens the resulting recommendations. 
 
This thesis has also shown that there  is variability in the availability and 
quality of the evidence that underpins the NICE guideline and this has the 
potential of introducing further bias.  
 
Transparency is imperative at all levels of the development process so that 
there can be no confusion about the quality of the results and the strength of 
the recommendations. 
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The NICE guideline development process is transparent. The methodology is 
clear and easily available. Conflicts of interest are declared by the members 
of the guideline development groups.  
 
In addition, the formulation of the recommendations by the panel of experts is 
explicitly presented in the ‘linking evidence to recommendations’ paragraph at 
the end of each recommendation.  
 
However it is important to understand and highlight that a guideline is not a 
regulation, nor a statuatory obligation. It is the opinion of the committee that 
formulates the recommendations based on the evidence provided to them.  
 
This evidence may be biased, interpreted under certain influences, or simply 
lacking as demonstrated by the work in this thesis.  When this is the case then 
the recommendations must be presented and accepted by all as being weak.  
 
Even in the face of strong evidence, and a strong recommendation it is also 
important for clinicians to understand that a guideline is still guidance and not 
an over-arching inflexible obligatory rule that they need to adhere to in fear of 
being accused of professional misconduct.  
 
This is particularly important as NICE has currently been given the remit by 
the department of Health and NHS England to develop quality standards. 
 
NICE quality standards are concise sets of prioritised statements designed to 
drive measurable quality improvements within a particular area of health or 
care.[261] 
 
They are derived from the best available evidence such as NICE guidance 
and other evidence sources accredited by NICE. They are developed 
independently by NICE.[261] 
 
NICE works with independent Quality Standards Advisory Committees 
(QSAC) to develop the quality standards. Standing members are drawn from 
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the NHS, health, public health and social care professionals, patients/service 
users and carers and academia.  
 
The members of the QSAC do not represent their organisations but are 
selected for their expertise, experience of working with multidisciplinary and 
lay colleagues and understanding of evidence based care. A number of topic 
experts are invited to join the standing members for each quality standard 
topic.[261] 
 
The aspiration is that the quality standards will enable health, public health 
and social care practitioners to make decisions about care based on the latest 
evidence and best practice.[261] 
 
There is also the aspiration that the standards will help people receiving 
health and social care services, their families and carers and the public in 
general to find information about the quality of services and care they should 
expect from their health and social care provider.[261] 
 
It is also hoped that  service providers will refer to the standards in order to 
quickly and easily examine the performance of their organisation and assess 
improvement in standards of care they provide.[261] 
 
Commissioners  might also be able to refer to the standards so that they can 
assess whether the services they are purchasing are high quality and cost 
effective and focused on driving up quality.[261] 
 
However, the term ‘standard’ gives the impression of something more binding 
than guidance. This creates the anxiety that what started as guidance is 
converted into something that practitioners feel less able to deviate from.  
 
Considering the finding of this thesis, that the evidence underpinning NICE 
guidance is varied in its availablity and quality, coupled with the knowledge 
that NICE guidelines are the primary evidence undepinning the development 
of the standards, gives reason for concern. 
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There are two main components to a quality standard: the quality statement 
and the quality measure.[261] 
 
The quality statement generally describes high-priority areas for improvement. 
They are aspirational but achievable. Each statement specifies one concept 
or requirement for high quality care  or service provision, for example a single 
intervention, action, or event.[261]  
 
The quality measure that accompanies every statement is intended to be able 
to assess the quality of care or service provision specified in the 
statement.[261] 
 
NICE quality standards are not mandatory nor are they targets. The audience 
of these quality standards needs to be aware of this fact and therefore 
approach these standards accordingly.[261] 
 
Future work in understanding the development of the quality standards and 
particularly how NICE guidance is translated into a NICE quality standard is 
required.  
 
A specific area of research should include how each guideline 
recommendation is converted to a standard.  
 
It would be of interest to explore whether all recommendations are converted 
into a standard and how the strength of the recommendation is evident in the 
resulting standard.  
 
In addition it would be interesting to research how transparent the 
methodology relating to the development of quality standards is.  
 
Particularly looking at the reporting of bias in the evidence and how this 
remains transaparent in the developing standard.  
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The results of this thesis have also shown that there is poor reporting of 
methodological data by many of the UK surgical societies and Royal Colleges 
which produce guidelines.  
 
Though this is not an indication that these guidelines are of poor quality, it 
does prohibit their appropriate appraisal by their users. This is another area 
where future work can be done so improvements can be made. 
 
Appropriate attention must be given by professional societies and Royal 
colleges to the online publication of methodology data.  
 
Ideally this should be overseen by guideline development specialists if they 
havent already been involved in the development process.   
 
However, the results of this thesis demonstrate that there are many specialist 
considerations that are involved in guideline development.  
 
Even if the results of this thesis purely represent a failure of online 
presentation of methodology data it has been demonstrated that this is a 
highly specialist discipline that demands both time and resources so that the 
resulting guidelines can be of high quality.  
 
There are a variety of tools such as GRADE, and AGREE that are the 
products of lengthy research in this discipline. These assist in the 
development and appraisal of the guidelines.  
 
The quality assessment of therapeutic study data with GRADE in this thesis 
highlighted the importance of assessing all outcomes reported within a study.  
 
It is a common assumption that systematic reviews are at the top of the 
pyramid of evidence quality. These results have shown that it is possible to 
have some very low quality outcome results within a systematic review of high 
quality. 
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If this is not identified in a systematic fashion then it may be mistakenly 
overlooked leading to potentially inaccurate recommendations. 
 
A deep sense of responsibility towards the principles of evidence based 
medicine, enthusiasm and resources are required in equal measures in order 
to be able to keep up with such developments in this field. 
 
If the professional bodies want to be guideline producing bodies of quality 
then appropriate resources will need to be directed to this endeavour, perhaps 
more than what has been devoted to in the past. 
 
Considering the time and resources that go into guideline production perhaps 
it might be a future consideration of professional societies and Royal Colleges 
not to engage in the development of guidelines in the same way that thay 
have been doing so in the past.   
 
Rather than developing guidelines directly a better investment of resources 
might be  the stringent appraisal of the guidelines produced by NICE. 
 
In addition, it may be better value to invest time and resources in a more 
active engagement with the stakeholder process of the NICE guidelines. 
 
Stakeholders have the opportunity through the NICE development process to 
engage and influence the guideline production from its infancy.  
 
This perhaps is currently not utilised until later stages in the guideline 
development when it is much more difficult to influence  the course of a 
particular guidance. 
 
This may mean that there is less chance of contradictory guidelines being 
produced by guideline producing bodies. 
 
It  may also be more effective for these organisations to invest in the 
education of their members with regards to guideline appraisal. 
  230 
Guidelines are increasing in popularity and a larger number of them are being 
produced both nationally and internationally. 
 
It is important for medical practictioners to know what to look for in guidelines 
and their methodology in order to assess the strength of the 
recommendations and whether they warrant changing clinical practice. 
 
They are more likely to look to their professional bodies and the Royal 
Colleges for such education which at present does not include education in 
guideline appraisal. 
 
In addition, with the emergence of quality standards it will become even more 
important to be able to assess evidence and guidelines so as to be able to 
further decide whether the quality standards are indeed quality markers and 
not  transcripts of weak guideline recommendations. 
 
Another finding of this thesis was that a lot more investment is required in the 
field of data storage and analysis.  
 
In attempting to improve treatments and therefore survival from cancer it is 
important to have all possible information available and easily accessible for 
analysis.  
 
The regional cancer registries collect information and have quality control 
measures in place. There are a variety of other regional and national 
databases that collect and store patient data.  Some have voluntary data 
collection which poses data quality challenges.  
 
The improvements made in terms of the setting up of NCIN and the national 
registration database in England is a step in the right direction but so much 
more needs to be done in this field. 
 
Though there have been important improvements in the collection and 
handling of patient data and particularly clinical practice data over the last five 
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years it is quite clear from the results of this thesis that accessing data is 
complicated and remains too slow. 
 
 This is not acceptable and significant further work and resources need to be 
directed towards this area. 
 
The results of this thesis have identified poor methodological quality in 
diagnostic accuracy studies despite a wealth in the number of studies 
available.  
 
This is just one example where repeatedly there is an expense of patients 
time and effort in addition to the cost of running trials without a satisfactory 
result. 
 
The guideline was unable to make a recommendation on the topic of imaging 
for heaptic colorectal metastases despite a number of studies being available.  
 
Linkages among multiple databases are increasingly used to merge clinical 
data with administrative data to provide the power and depth of data needed 
to address clinical research questions extended through time.  
 
Linking these large databases to clinical research data can also be used to 
study outcomes such as health care utilisation or survival over long periods of 
time without having to track individual study participants themselves.  
 
Doing so requires that critical issues related to privacy and protection of data 
and human research subjects be addressed.  
 
Further potential impedements to such linkages exist including availability and 
accuracy of variables that could be used to correctly link an individual’s record 
in one database to other databases, and the technology available to perform 
complex data linkages.[262] 
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However, when this is carried out successfully, then the result is significant. 
The data does exists and is stored in the UK. What is needed is to be able to 
have the adequate technology and staff to adequately ‘clean’ the data from 
parameters that could bias the linkage and actually perform the linkage of the 
databases.  
 
The result output is potentially large,  it does not involve patients being 
exposed to additional risk, and the cost will compare favourably to running 
patient studies and trials for many years. 
 
Guideline recommendations often conclude that further research is required in 
order to answer a particular clinical question. Further research need not mean 
traditional clinical trials only. 
 
It is important that linkage studies are used to provide answers to guideline 
questions.  In the same way it is important that guidelines and their need for 
evidence-based answers is used as a drive for improvement in this chrinically 
under-resourced and under-invested area of health research. 
 
Over the years guidelines have become a common feature of medical practice 
and many organisations are producing them. 
 
Their purpose is to improve the quality of healthcare provision and to create 
and maintain standards of care. 
 
It is the over-arching conclusion of this thesis that guideline production 
through systematic searching of the evidence and with a transparent 
presentation of the results and strength of the recommendations is an 
outstanding addition to the high quality practice of modern medicine. 
 
It must however be used with appropriate training in guideline appraisal and 
confidence that it is a guidance that can be subject to a variety of bias and 
cannot and should not dictate clinical judgment and practice in totality. 
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The AGREE checklist 
 
Domain 1: Scope and Purpose  
1. The overall objectives of the guideline are specifically described Score 1-7 
2. The health questionscovered by the guideline are described Score 1-7 
3. The population whom the guideline is to apply is described Score 1-7 
Domain 2: Stakeholder involvement  
4. The guideline development group includes individuals from all 
relevant professional groups 
Score 1-7 
5. The views and preferences of the target population (patients, 
public etc.) have been sought 
Score 1-7 
6. The target users of the guideline are clearly defined Score 1-7 
Domain 3: Rigour of development  
7. Systematic methods were used to search for the evidence Score 1-7 
8. The criteria for selecting the evidence are clearly described Score 1-7 
9. The strengths and limitations of the body of evidence are clearly 
described 
Score 1-7 
10. The methods for formulating the recommendations are clearly 
described 
Score 1-7 
11. The health benefits, side effects, and risks have been 
considered in formulating the recommendations. 
Score 1-7 
12. There is an explicit link between the recommendations and the 
suporting evidence 
Score 1-7 
13. The guideline has been externally reviewed by experts prior to 
its publication 
Score 1-7 
14. A procedure for updating the guideline is provided Score 1-7 
Domain 4: Clarity of presentation  
15. The recommendations are specific and unambiguous Score 1-7 
16.The different options for management of the health issue are 
clearly presented 
Score 1-7 
17. Key recommendations are clearly identifiable Score 1-7 
Domain 5: Applicability  
18. The guideline describes facilitators and barriers to its 
applications 
Score 1-7 
19. The guideline provides advice and / or tools on how the 
recommendation can be put into practice 
Score 1-7 
20. The potential resource implications of applying the 
recommendations have been considered. 
Score 1-7 
21. The guideline presents monitoring and/or auditing criteria Score 1-7 
Domain 6: Editorial independence  
22. The views of the funding body have not influenced the content of 
the guideline 
Score 1-7 
23. Competing interests of guideline development group members 
have been recorded and addressed. 
Score 1-7 
Reviewers overall assessment of the quality of the guideline Score 1-7 
Recommend this guideline for use Yes 
modification 
No 
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Evidence Tables for the SR on diagnostic imaging for hepatic 
metastases from colorectal cancer 
Citation 1: Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Koyama M, Tanaka H, 
Matsueda K, Muto T. Comparison of pre-operative whole-body positron emission tomography 
with MDCT in patients with primary colorectal cancer. Colorectal Disease 2009; 11:464-469 
Design: retrospective Country: Japan 
Aim: to evaluate the additional value of FDG PET versus multidetector row CT (MDCT) in patients with 1 CRC 
Inclusion criteria  
65 patients with histologically proven colorectal cancer 
patients with suspected liver or lymph node metastases 
or patients with CEA >5ng/ml 
or patients with low rectal cancer awaiting pre-op chemoradiotherapy to check lateral lymph node metastases 
Exclusion criteria: Not specifically mentioned 
Population  
65 patients (36 men, 29 women) 
Interventions  
MDCT versus FDG PET 
Outcomes  
Sensitivity, specificity, PPV, NPV, Accuracy 
Results 2x2 table 
 Liver mets + Liver mets - total 
CT+ 22 1 23 
CT - 0 42 42 
total 22 43 65 
 
Sensitivity 100% (22/22 ) (CI 85%-100%) 
Specificity 98% (42/43 ) (CI 88%-100%) 
PPV 96% (22/23 ) (CI 78%-100%) 
NPV 100% (42/42) (CI 92%-100%) 
Accuracy 98% (64/65 ) (CI 92%-100%) 
 
 Liver mets + Liver mets - total 
FDG PET+ 20 0 20 
FDG PET - 2 43 45 
total 22 43 65 
 
Sensitivity 91% (20/22 ) (CI 91%-99%) 
Specificity 100% (43/43 ) (CI 92%-100%) 
PPV 100% (20/20 ) (CI 83%-100%) 
NPV 96% (43/45) (CI 85%-99%) 
Accuracy 97% (63/65 ) (CI 89%-100%) 
FDG PET failed to identify liver metastases detected by MDCT in two patients. 
General comments  
CT appears sufficient for detection of metastases in the liver. The strength of PET is in its ability to screen for 
extra-hepatic metastases and this is what leads to the change in management. 
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Citation 2: Arulampalam THA. FDG PET for the pre-operative evaluation of colorectal liver metastases 
Eur.J.Surg.Oncol. 2004; 30:286-291 
Design: prospective  
Country: Royal Free Hospital, UK 
Aim: To assess accuracy of whole body FDG PET in the pre-operative staging of patients with CRC liver mets. 
Inclusion criteria  
Patients referred to a single surgeon for consideration for resection of colorectal liver metastases. 
Sep 1999-May 2002 
Patients had both FDG PET and spiral CT. 
Exclusion criteria  
Population  
31 patients were studied. (median age 67, range 41-82), 15 male. 
28 patients had a lesion on both PET and CT. This was considered the index lesion and only these patients 
were considered for assessment for resection. Follow up was for 21 months (range 5-33) 
No loss to follow up. 
Interventions  
FDG PET 
CT 
Outcomes  
Results  
Accuracy of FDG PET and CT in detecting additional metastatic lesions in 28 patients with confirmed colorectal 
liver metastases. 
 Liver mets + Liver mets - total 
CT+ 8 1 9 
CT - 9 10 19 
total 17 11 28 
Sensitivity 47%  
Specificity 91% 
PPV 89%  
NPV 53% 
 
 Liver mets + Liver mets - total 
FDG PET+ 17 1 18 
FDG PET - 0 10 10 
total 17 11 28 
Sensitivity 100%  
Specificity 91%  
PPV 94%  
NPV 100%  
11 patients were confirmed to have solitary liver metastases correctly demonstrated by both modalities. 
10 patients were noted to have multi-focal liver metastases. All were correctly diagnosed by PET. CT was only 
able to identify multiple lesions in 5 patients. In 4 of these patients PET showed lesions that were not amenable 
to surgery. In the 5th patient laparotomy was performed. The 2nd PET lesion was not found but later identified 
on follow up imaging at 3 months.  There was altered patient management in 12 patients (39%) (including 
extra-hepatic results). 
General comments: FDG PET greatly adds to the decision making power of the surgical oncologist. 
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Citation 3: Ashraf K. Colorectal carcinoma, pre-operative evaluation by spiral computed tomography. Journal 
of the Pakistan Medical Association 2006; 56:149-153 
Design: cross sectional prospective 
Country: Pakistan 
Aim: to assess the capability of spiral CT in pre-operative evaluation of colorectal carcinoma. (local spread, 
lymph node mets and liver mets). 
Inclusion criteria  
Patients with biopsy proven colorectal cancer undergoing surgery 
All patients must have had the CT scan within 1 month prior to surgery 
Exclusion criteria  
Patients who had previous treatment for colorectal cancer or had a concurrent disease process which could 
result in false reading of the CT scan 
Population  
52 patients (32 male, 20 female,) 
mean age was 58, range 22-87 
Interventions  
Spiral CT scan, 7mm, with gastrograffin 
1 radiologist reading the images 
not ‘blinded’ to the location of the primary tumour or the biopsy result. 
Outcomes  
Results  
 Liver mets + Liver mets - total 
CT+ 16 2 18 
CT - 2 32 34 
total 18 34 52 
 
Sensitivity 89%  (CI 63.9%-98.1%) 
Specificity 94% (CI 78.9%-99.0%) 
PPV 89% (CI 63.9%-98.1%) 
NPV 94% (CI 78.9%-99.0%) 
Accuracy 92% 
 
General comments  
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Citation 4: Bartolozzi C, Donati F, Cioni D, Procacci C, Morana G, Chiesa A, Grazioli L, Cittadini G, Cittadini G, 
Giovagnoni A, Gandini G, Maass J, Lencioni R. Detection of colorectal liver metastases: a 
prospective multicentre trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral 
CT. Eur.Radiol. 2004; 14:14-20 
Design: prospective, multi-institutional trial 
Country: Italy 
Aim: to compare unenhanced MRI, MnDPDP-enhanced MRI and spiral CT in detecting hepatic CRC mets. 
Inclusion criteria: Adult patient with hepatic colorectal cancer metastasis, Patient scheduled for partial 
hepatectomy or intra operative radio frequency thermal ablation 
Exclusion criteria Pregnant or lactating woman, Severe biliary or renal insufficiency, Severe hepatic, 
dysfunction (Child class C), General contraindication to MRI, Inclusion in another study 7 days prior to 
enrolment 
Population: 44 consecutive patients with colorectal hepatic metastases were examined with all 3 above 
modalities. 3 blinded readers interpreted the images 
Interventions: unenhanced MRI, MnDPDP-enhanced MRI, spiral CT 
Outcomes  
primary endpoint: Sensitivity  
Secondary outcome: Lesion conspicuity, quality of lesion delineation, confidence in diagnosis 
Results  
Per patient analysis 
 Liver mets + Liver mets - total 
CT+ 22 3 25 
CT - 19 0 19 
total 41 3 44 
 
Sensitivity 53.6% 
Specificity NA   
PPV 88.0% 
NPV NA  
Accuracy 50.0%  
 
 Liver mets + Liver mets - total 
MRI + 21 2 23 
MRI - 21 0 21 
total 42 2 44 
 
Sensitivity 50.0% 
Specificity NA   
PPV 91.3% 
NPV NA   
Accuracy 47.7%  
 
 Liver mets + Liver mets - total 
MnDPDP MRI + 33 2 35 
MnDPDP MRI - 9 0 9 
total 42 2 44 
 
Sensitivity 78.6% 
Specificity NA   
PPV 94.2% 
NPV NA   
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Accuracy 75.0%  
 
Per lesion analysis 
 Liver mets + Liver mets - total 
CT+ 91 3? 94 
CT - 37 0? 37 
total 128 3? 141 
 
Sensitivity 71% 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA  
 
 Liver mets + Liver mets - total 
MRI + 92 2?  
MRI - 36 0?  
total 128 2?  
 
Sensitivity 72% 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA  
 
 Liver mets + Liver mets - total 
MnDPDP MRI + 115 2?  
MnDPDP MRI - 13 0?  
total 128 2  
 
Sensitivity 90% 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA  
 
Lesion size IOUS CT MRI MnDPDP MRI 
<10mm 47  18(38%)  24(51%)  39(83%) 
10-20mm 31 28 (90%) 24 (77%) 31(100%) 
>20mm 45 45 (100%) 44 (98%) 45(100%) 
All  128 (*) 91(71%) 92 (72%) 115 (90%) 
* 47+31+45 = 123 not 128. This total features in all the text and tables. Either the 128 is a typographic error and 
all their calculations of sensitivities are based on the wrong figure or one of the sums is a typographic error. 
MnDPDP MRI is more sensitive than both CT (P=0.0007) and unenhanced MRI (P<0.0001) in the per lesion 
analysis. In the very small lesions the sensitivity difference is even more manifest. In the per patient analysis 
MnDPDP MRI sensitivity was higher than CT (p=0.0023) and unenhanced MRI (p=0.0013). 
General comments: MnDPDP MRI is better than CT and unenhanced MRI. 
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Citation 5: Bhattacharjya S. B. Prospective study of contrast-enhanced computed tomography, computed 
tomography during arterioportography, and magnetic resonance imaging for staging colorectal 
liver metastases for liver resection. Br.J.Surg. 2004; 91:1361-1369 
Design: prospective 
Country: UK 
Aim: To compare the value of contrast-enhanced CT, CT during arterioportography, and magnetic resonance 
imaging for staging patients with colorectal liver metastases. 
Inclusion criteria  
Consecutive patients between January 1996 – December 2001 with known or suspected colorectal liver 
metastases. 
Exclusion criteria: Pulmonary metastases; intra-abdominal extra-hepatic disease (laparoscopy was performed 
before the laparotomy in 54 patients - suspicious nodules were biopsied, sent for frozen section, and 
confirmation of extra-hepatic disease contraindicated liver resection); local recurrence or metachronous 
primaries (all patients had colonoscopy to exclude this); medical contraindications to MRI (pacemaker, 
claustrophobia); medical contraindication to surgery 
Population  
120 patients with known or suspected colorectal liver metastases. 
64 men / 56 women mean age 62 (29-74) 
31 synchronous metastases – 89 metachronous metastases 
85 patients had all three modalities and were finally included in the study population. 
120 patients referred for consideration for resection. 
120 had CT of chest, abdomen and pelvis 
13 excluded after CT as either unfit for surgery or had pulmonary metastases 
15 did  not have an MRI due to contraindications 
92 have MRI 
54 of the 107 patients who had a CT and were fit for surgery proceeded to have laparoscopy (as part of another 
study being carried out in the unit) 
7 were excluded because of peritoneal metastases 
100 patients proceed to laparotomy, bimanual palpation and IOUS. 
11 underwent laparotomy but no resection as they either had positive lymph nodes (4 – included in the study) 
or additional metastases or unfavourably positioned metastases. 
89 patients went on to have liver resection 
Interventions: Spiral contrast-enhanced CT (dual phase), contrast-enhanced MRI (gadolinium) 
CTAP, MRI and CTAP were performed within 3 weeks of CT. 
Gold standard: intraoperative ultrasound (IOUS), bimanual palpation, histology of resected specimen. 
 
The films were reviewed by one of two consultant hepatobiliary radiologists. They were ‘blinded’ to the clinical 
history, the surgical and the pathological findings. The IOUS was performed by surgeons competent in this 
imaging modality and they were aware of the pre-operative findings. The pathologist that performed the 
histology of the resected specimens was ‘blinded’. 
Outcomes  
Per lesion basis analysis: Sensitivity, Specificity, Positive predictive value 
Per patient basis analysis 
Results  
 
The results for CTAP have been excluded from this summary as not relevant to our PICO. 
It has also not been possible to extract all the information for the 2x2 tables but the summary diagnostic values 
have been presented. 
 
Per lesion analysis 
 Liver mets + Liver mets - total 
CT+ 176 20 196 
CT - 65   
  265 
total 241   
Sensitivity 73% 
Specificity 96.5%   
PPV 89.8% 
NPV NA   
Accuracy NA 
 
 Liver mets + Liver mets - total 
GAD MRI+ 154 22 176 
GAD MRI - 34   
total 188   
Sensitivity 81.9% 
Specificity 93.2%   
PPV 87.5% 
NPV NA   
Accuracy NA  
 
Lesion size TOTAL CT GAD MRI 
<10mm 42 22 of 42 
(52%) 
16 of 28 
(57%) 
>10mm 199 154 of 199 
(77.4%) 
138 of 150 
(92%) 
All  241 176  of 241 
(73%) 
154 of ? 
(86.3%) 
 
Per patient analysis 
 Liver mets + Liver mets - total 
CT+  16  
CT - 21   
total   85? 
 
Sensitivity 73.0% 
Specificity NA   
PPV NA 
NPV NA  
Accuracy Area under ROC curve 0.73 
 
 Liver mets + Liver mets - total 
GAD MRI+  18 103 
GAD MRI - 16   
total 101  85? 
 
Sensitivity 82% 
Specificity NA   
PPV NA 
NPV NA  
Accuracy Area under ROC curve 0.82 
 
Detection of liver metastases by various imaging modalities on an individual patient basis stratified by number 
of lesions 
 
Modality Number of patients 
examined 
Number correctly 
identified 
Number 
understaged 
Number 
overstaged 
Solitary liver met     
CT 40 35 1 4 
  266 
MRI 41 28 1 2 
2 liver mets     
CT 28 24 3 1 
MRI 22 19 1 2 
3 liver mets     
CT 16 8 4 4 
MRI 16 14 1 1 
4 liver mets     
CT 7 4 0 3 
MRI 7 3 2 2 
5 liver mets     
CT 2 1 1 0 
MRI 2 1 1 0 
≥ 6 liver mets     
CT 7 1 6 0 
MRI 7 4 3 0 
 
Based on these results MRI is significantly superior to spiral CT (p=0.043) in staging colorectal cancer liver 
metastases on an individual patient basis once the number of metastases exceeds 4. 
No single modality diagnosed all hepatic metastases and a multi-modal imaging approach is recommended. 
General comments: The diagnostic accuracy of these modalities is similar.  
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Citation 6: Cantwell CP, Setty BN, Holalkere N, Sahani DV, Fischman AJ, Blake MA. Liver Lesion Detection 
and Characterization in Patients With Colorectal Cancer: A Comparison of Low Radiation Dose 
Non-enhanced PETCT, Contrast-enhanced PETCT, and Liver MRI. J.Comput.Assist.Tomogr. 
2008; 32:738-744 
Design: retrospective. Country: Boston,USA 
Aim: To compare low radiation dose non-enhanced (n-e) FDG PETCT, contrast-enhanced (c-e) FDG PETCT 
and gadolinium-enhanced liver-specific MRI in detecting and characterising liver lesions in patients with 
colorectal cancer. 
Inclusion criteria: Patients with colorectal cancer who had a gadolinium-enhanced MRI within 6 weeks of the 
PETCT scan. The follow-up diagnosis of the liver lesion must have been established either through histology of 
resected specimen or through imaging follow-up of at least 6 months for lesion stability or growth. 
Patient should have had at least 1 but no more than 10 liver lesions 
Note: previous hepatic resection and previous chemotherapy was allowed. 
Exclusion criteria: More than 10 liver lesions (possibility of lesion overlap). 
Population: 33 non-consecutive patients  (22 men, 11 women, mean age 63 years) 
retrospective review of imaging database of patients with colorectal cancer  with suspected liver metastases 
from one institution in Boston Massachusetts from Jan 2004 to Dec 2005 
Interventions: Low radiation dose non-enhanced FDG PETCT, contrast-enhanced FDG PETCT, gadolinium-
enhanced liver MRI. Data was analysed by 2 radiologists. Patient demographic data was blinded as was clinical 
data. All data was interpreted in consensus. 
Outcomes: Sensitivity, Specificity, accuracy 
Results  
Per lesion analysis 
 Liver mets + Liver mets - total 
Gad MRI + 98 0 98 
Gad MRI - 2 10 12 
total 100 10 110 
Sensitivity 98%   
Specificity 100% 
PPV 100% 
NPV 83%  
Accuracy 98% 
 
 Liver mets + Liver mets - total 
c-e PET CT+ 85 0 85 
c-e PET CT - 15 10 25 
total 100 10 110 
Sensitivity 85%   
Specificity 100%  
PPV 100%  
NPV 40%  
Accuracy 86% 
 
 Liver mets + Liver mets - total 
n-e PET CT+ 67 4 71 
n-e PET CT - 33 6 39 
total 100 10 110 
 
Sensitivity 67%  
Specificity 60%  
PPV 94%  
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NPV 15%  
Accuracy 66% 
 
No statistically significant difference in lesion detection was found between enhanced PETCT and MRI. 
Both PETCT and MRI had a higher detection rate than non-enhanced PETCT. 
For lesion characterisation MRI was significantly more accurate than enhanced and non-enhanced PETCT. In 
turn enhanced was better than non-enhanced PETCT. 
General comments  
Contrast enhanced PETCT is better than unenhanced PETCT.  
MRI and contrast enhanced PETCT are comparable in their detection rate 
MRI is better than contrast enhanced PETCT with regard to lesion characterization. 
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Citation 7: Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, Bomanji JB, Ell PJ. The impact of 
F-18-FDG PETCT in patients with liver metastases. European Journal of Nuclear Medicine and 
Molecular Imaging 2007; 34:1906-1914 
Design: retrospective  
Country: UCLH London, UK 
Aim: To assess the performance of PETCT versus contrast enhanced CT in the detection of colorectal liver 
disease. 
Inclusion criteria  
All patients who presented to one institution with suspected metastatic disease who underwent both PETCT 
and CT within 6 weeks of each other were retrospectively analysed covering a 5 year period. 
Exclusion criteria  
Population  
131 patients 
67 men, 64 women 
mean age 62 (range 30-85 years) 
75 had primary CRC 
56 had other malignancies 
patients were either pre-chemotherapy or minimum 6 weeks post-chemotherapy 
Interventions  
CECT (contrast enhanced CT) 
FDG PETCT 
Outcomes  
Sensitivity, specificity, PPV, NPV 
Subgroup analysis for those patients that had undergone chemotherapy (as this has the potential to alter the 
PETCT results) 
Results  
Colorectal malignancy results only  
 
Per patient analysis 
 Liver mets + Liver mets - total 
PET CT+ 63 2 65 
PET CT- 4 6 10 
total 67 8 75 
 
Sensitivity 94%  (CI 85%-98%) 
Specificity 75%  (CI 34%-96%) 
PPV 97%  (CI 89%-99%) 
NPV 60%  (CI 26%-87%) 
Accuracy NA 
 
 Liver mets + Liver mets - total 
c-e CT+ 61 6 67 
c-e CT- 6 2 8 
total 67 8 75 
 
Sensitivity 91%  (CI 81%-96%) 
Specificity 25% (CI 3%-65%) 
PPV 91% (CI 81%-96%) 
NPV 25% (CI 3%-65%) 
Accuracy NA 
 
Subgroup analysis for patients that had and did not have chemotherapy prior to PETCT scanning. 
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Sensitivity -
chemo 
89%  (CI 51%-99%) 
Sensitivity – 
no chemo 
95%  (CI 85%-98%) 
Specificity - 
chemo 
100% (CI 29%-100%) 
Specificity – 
no chemo 
60%  (CI 14%-94%) 
PPV - chemo 100% (CI 63%-100%) 
PPV –  
no chemo 
97%  (CI 87%-99%) 
NPV - chemo 75% (CI 19%-99%) 
NPV –  
no chemo 
50%  (CI 11%-88%) 
Accuracy NA 
Chemotherapy did not affect with statistical significance the diagnostic accuracy of FDG PETCT p=0.178 
General comments  
FDG PETCT is more accurate than c-e CT in the detection of metastatic liver disease both from colorectal 
cancer and from other malignancies (only colorectal results presented here). 
When the detection of extra-hepatic disease was also taken into account there was a change in management 
from the use of PETCT of about 25% (33 patients). 
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Citation 8: Coenegrachts K, De GF, ter BL, Walgraeve N, Bipat S, Stoker J, Rigauts H. Comparison of MRI 
(including SS SE-EPI and SPIO-enhanced MRI) and FDG PETCT for the detection of colorectal liver 
metastases. Eur.Radiol. 2009; 19:370-379 
 
Design: prospective 
Country: Belgium and the Netherlands 
Aim: To compare prospectively the FDG PETCT and MRI in 24 consecutive patients suspected of having 
colorectal liver metastases. 
Inclusion criteria  
USS shows new non-cystic focal lesion 
And / or  CEA >3.4ng/ml for non-smokers, >4.3 ng/ml for smokers 
ALT>41 U/L for males, >31 U/L for females 
ALP >129 u/l 
And /or bilirubin >1.2mg/dl 
Time interval between MRI and FDG PETCT was at most 3 weeks. 
Note: patients who had previously received chemotherapy for their colorectal malignancy were included, 
including those in whom the treatment was within a month of the FDG PETCT. 
Exclusion criteria  
Contraindications to MRI e.g. pacemaker, metallic implants 
Population  
14 men, 10 women with suspected colorectal cancer liver metastases 
mean age 65.3 +/- 10.8 years 
consecutive presentation between Oct 2005-Jan 2008 
Interventions  
FDG PETCT, MRI 
All patient data was blinded. Blinded evaluations were made by 2 radiologists independently. In case of 
disagreement a consensus opinion was reached. 
Reference standard: for lesions that were operated on - intra-operative ultrasound scan and the histology 
result. For lesions that were not operated on – follow-up was with repeat MRI. 
Outcomes Sensitivity, Positive Predictive Value PPV  
Results  
Per patient analysis 
 Liver mets + Liver mets - total 
EPI MRI+ 24 0 24 
EPI MRI - 0 0 0 
total 24 0 24 
 
Sensitivity 100%  
Specificity NA  
PPV 100%   
NPV NA 
Accuracy 100% 
 
 Liver mets + Liver mets - total 
SPIO MRI + 24 0 24 
SPIO MRI - 0 0 0 
total 24 0 24 
 
 
Sensitivity 100%   
Specificity NA 
PPV 100%  
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NPV NA 
Accuracy 100% 
 
 Liver mets + Liver mets - total 
PET CT + 23 0 23 
PET CT - 1 0 1 
total 24 0 24 
 
Sensitivity 96%   
Specificity NA 
PPV 100%  
NPV NA 
Accuracy 96% 
 
Per lesion analysis 
MRI and PETCT concordant in 9 patients. MRI identified more liver mets than PETCT  
 Liver mets + Liver mets - total 
EPI MRI+ 77 0 77 
EPI MRI - 0 0 0 
total 77 0 77 
 
Sensitivity 100%  
Specificity NA   
PPV 100%   
NPV NA 
Accuracy 100% 
 
 Liver mets + Liver mets - total 
SPIO MRI + 69 0 69 
SPIO MRI - 8 0 8 
total 77 0 77 
 
Sensitivity 90%  
Specificity NA   
PPV 100%   
NPV NA 
Accuracy 90% 
 
 Liver mets + Liver mets - total 
PET CT + 47 0 47 
PET CT - 30 0 30 
total 77 0 77 
 
Sensitivity 61%  NPV NA 
Specificity NA   Accuracy 61% 
PPV 100%     
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Citation 9: Kim HJ, Kim KW, Byun JH, Won HJ, Shin YM, Kim PN, Lee MS, Lee MG. Comparison of 
mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of 
hepatic metastases in colorectal cancer patients. AJR.American Journal of Roentgenology. 2006; 
186:1059-1066 
Design: block randomisation trial 
Country: South Korea 
Aim: to evaluate the validity of mangafodipir trisodium- versus ferucarbotran-enhanced MRI in the detection 
and characterisation of hepatic lesions in colorectal cancer patients. 
Inclusion criteria  
Patients known to have or suspected of having hepatic metastases form colorectal cancer on the basis of prior 
helical CT examinations 
Patients scheduled to have laparotomy for their hepatic mets or an intervention such as ablation. 
Exclusion criteria :>5 hepatic metastases on CT, contraindications to MRI (pacemaker or aneurysm clip) 
Population  
41 patients 
48 patients between June 2003 – Feb 2004 enrolled. 7 patients further excluded for multiple mets or histology 
confirming hepatocellular or cholangiocarcinoma. 
Interventions  
1.5 T MRI with either 
 mangafodipir trisodium (MnDPDP) (a type of liver-specific contrast like gadolinium) 
 ferucarbotran (a type of contrast used in SPIO MRI) 
Outcomes  
Results  
PER LESION ANALYSIS 
 Liver mets + Liver mets - total 
MnDPDP MRI + 37 2 39 
MnDPDP MRI -  1 0 1 
total 38 2 40 
 
Sensitivity 97% 
Specificity NA 
PPV 95% 
NPV NA 
Accuracy 37/40= 93% 
 
 Liver mets + Liver mets - total 
SPIO MRI+ 31 0 31 
SPIO MRI - 1 0 1 
total 32 0 32 
 
Sensitivity 97% 
Specificity NA 
PPV  100% 
NPV NA 
Accuracy 31/32= 97% 
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Citation 10: Koh DM, Brown G, Riddell AM, Scurr E, Collins DJ, Allen SD, Chau I, Cunningham D, Desouza 
NM, Leach MO, Husband JE. Detection of colorectal hepatic metastases using MnDPDP MR 
imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur.Radiol. 2008; 
18:903-910 
Design: prospective. Country: Royal Marsden Oncology Hospital, UK 
Aim: To compare the diagnostic accuracy of MnDPDP MRI and diffusion weighted MRI alone and combined. 
Inclusion criteria  
Consecutive patients with suspected colorectal liver metastatic disease 
Pathologically proven adenocarcinoma of the colon or rectum 
At least one liver lesion detected on CT scan or ultrasound that was diagnostic or suspicious of liver metastasis 
Patients were candidates for liver resection (i.e. disease-sparing at at least two contiguous liver segments) 
Exclusion criteria  
Contraindication to MRI 
Previous history of other malignancies.  
In 5 patients no metastatic disease was diagnosed on MRI nor at follow up hence these patients were excluded 
from the analysis.  
Population  
38 consecutive patients originally referred for consideration into the study 
5 patients had no evidence of metastatic disease at MRI or follow up so they were excluded. 
33 patients were the final study population. 
23 males, 10 females. 
Mean age 57 years old (range 45-67) 
Interventions  
MnDPDP MRI (liver-specific contrast-enhanced MRI), DWI (diffusion weighted imaging) MRI, and the 
combination of both. 
DWI is sensitive to the molecular diffusion of water in biological tissues and recent advancements have enabled 
high quality DWI images of the liver to be obtained. Breath-hold single shot echo planar diffusion-weighted (SS-
EPI-DWI) MRI has been shown to be superior to SPIO liver-specific contrast-enhanced MRI.  
Outcomes: ROC curve analysis with summary sensitivity and specificity. 
Results  
Average sensitivity and specificity from two observers reading the images of the different modalities. 
 Sensitivity Specificity 
MnDPDP MRI 81.3% 93% 
DWI MRI 78.3% 95% 
MnDPDP + DWI  MRI 92.2% 97% 
 
 Accuracy as Area under curve  
from observer 1 
Accuracy as Area under curve 
from observer 2 
MnDPDP MRI Az=0.92 (0.86-0.96) Az=0.88 (0.82-0.93) 
DWI MRI Az=0.83 (0.76-0.89) Az=0.90 (0.84-0.95) 
MnDPDP + DWI  MRI Az 0.94 (0.89-0.98) Az=0.96 (0.91-0.99) 
There was no significant difference in the averaged sensitivities between MnDPDP and DWI modalities 
For the combined MnDPDP + DWI  the sensitivity was better compared with MnDPDP alone (p=0.01) 
And there was a trend of improved sensitivity compared with DWI (p=0.06) 
Accuracy was good but significantly improved for observer 2 who was more experienced in reading DWI 
images. 
General comments  Combination of MnDPDP and DWI improved sensitivity without loss of specificity. 
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use of F-18-FDG PETCT in colorectal liver metastases-comparison with CT and liver MRI. 
European Journal of Nuclear Medicine and Molecular Imaging 2008; 35:1323-1329 
Design: Retrospective  Country: Royal Marsden, UK 
Aim: to compare FDG PETCT with liver-specific contrast-enhanced MRI (Mn-DPDP) for the presence and 
number of liver metastases in patients with colorectal liver metastases being considered for surgery. 
Inclusion criteria: Patients who had colorectal cancer and known or suspected liver metastases that were 
thought operable  from 2004-2006 and who also had PETCT and MRI with a median time between studies  
<1month 
Exclusion criteria: Patients with chemotherapy <3months before PETCT. 
Population: 65 patients (42 men) median age 65 years with CRC and known or suspected liver metastases. 
Retrospective identification of patients from 2004-2006 who presented to the Royal Marsden Hospital. 
Interventions PETCT, Mn-DPDP MRI. Proof of metastases in lesions operated upon came from 
histopathology or from MRI for those not operated on. 
Outcomes: Per patient and per lesion analysis. Sensitivity, Specificity, False positives. 
Results  
Per patient analysis: 
 Liver mets + Liver mets - total 
MnDPDP MRI+ 60 0 60 
MnDPDP MRI - 1 4 5 
total 61 4 65 
 Mn-DPDP MRI 
Sensitivity 98% 
Specificity 100% 
 
 Liver mets + Liver mets - total 
PET CT+ 60 0 60 
PET CT - 1 4 5 
total 61 4 65 
 PET CT 
Sensitivity 98% 
Specificity 100% 
 
Per lesion analysis 
 Liver mets + Liver mets - total 
MnDPDP MRI+ 163 0 163 
MnDPDP MRI - 2 6 8 
total 165 6 171 
 Mn-DPDP MRI 
Sensitivity 99% 
Specificity 100% 
 
 Liver mets + Liver mets - total 
PET CT+ 155 0 155 
PET CT - 10 6 16 
total 165 6 171 
 PETCT 
Sensitivity 94% 
Specificity 100% 
MRI and PETCT Concordant 85% of lesions 
MRI and PETCT  Discordant 15% of lesions 
MRI detected total 30 lesions  / mean 3.8 per patient 
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PETCT detected 20 lesions / mean 2.5 per patient 
The lesions not detected by PETCT were all <1cm apart from 1 
PETCT correctly identified more metastases than MRI in 1 case and confirmed metastases in an equivocal MRI 
lesion. 
General comments: PETCT has high sensitivity and specificity for the presence of liver metastases and 
should be included early in the initial pre-surgical evaluation and could potentially guide the use of MRI. 
However MRI is superior for small liver metastases and remains a prerequisite for surgical planning.  
  277 
 
Citation 12: Liu YN, Huang MX, An Q, Wei JM. The Impact of PETCT on Therapeutic Strategy of Patients with 
Colorectal Cancer Metastasis. Hepatogastroenterology. 2009; 56:968-970 
Design: prospective  Country: China 
Aim: to assess the impact of PETCT on the therapeutic strategy of patients with colorectal cancer metastases. 
Inclusion criteria  
Patients that had suspicion of liver metastases on CT scan and CEA after resection for colorectal cancer. 
Exclusion criteria  
Population: 15 patients who all had contrast-enhanced CT scan and CEA and had suspicion of liver 
metastasis. 7 men, 8 women 
Interventions: contrast-enhanced CT, PETCT 
Outcomes: Sensitivity, Specificity, Change in therapeutic management 
Results  
 Liver mets + Liver mets - total 
PETCT+ 5 patients  
9 lesions 
0 5 patients 
9 lesions 
PETCT - 0 10 patients 10 patients 
total 5 patients 
9 lesions 
10 patients 15 patients 
9 lesions 
 
 PETCT 
Sensitivity 100% 
Specificity 100% 
 
 Liver mets + Liver mets - total 
CT+ 4 patients 
6 lesions 
0 4 patients 
6 lesions 
 
CT - 1 patient 
3 lesions 
10 patients 11 patients 
3 lesions 
total 5 patients 
9 lesions 
10 patients 15 patients  
9 lesions 
 
 PETCT 
Sensitivity 80% 
Specificity 100% 
PETCT is statistically more sensitive than CT p=0.0009 - SIGNIFICANT 
General comments:  PETCT is  more sensitive than contrast-enhanced CT in detecting liver metastases from 
colorectal cancer. Taking into account the extra-hepatic disease as well, the results of which are not presented 
in this review, there is a change in therapeutic strategy in 40% of patients based on the results of the PETCT. 
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Citation 13: Nanashima A, Taheshita H, Sawai T, Sumida Y, Abo T, Tanaka K, Nonaka T, Sengyoku H, Hidaka 
S, Yasutake T, Nagayasu T. Pre-operative Assessment of Liver Metastasis Originating from 
Colorectal Carcinoma: Is Super Paramagnetic Iron Oxide Particles-Magnetic Resonance Imaging 
(SPIO-MRI) Useful for Screening? Hepatogastroenterology. 2008; 55:1750-1753 
Design: retrospective 
Country: Japan 
Aim: To examine retrospectively the accuracy of diagnosis for metastatic lesions per patient and per lesion by 
enhanced CT and SPIO-MRI in one institution in Japan over a 7 year period. 
Inclusion criteria  
Data from 47 consecutive patients with metastatic liver carcinoma who underwent hepatectomy between 2000 
and June 2007 were collected retrospectively. During this period enhanced CT and SPIO-MRI were performed 
routinely 2 weeks before hepatic resection. 
The reference standard was intra-operative ultrasound scan or palpation and histological findings in the 
resected specimen. 
Exclusion criteria  
Population  
32 male, 15 female, mean age 61.4 years (24-85) 
10 synchronous liver metastases (coincident with primary colorectal tumour) 
35 metachronous liver metastases 
Interventions Enhanced CT (dual phase multi detector), SPIO-MRI 
Outcomes:  Accuracy, Sensitivity, Positive predictive value, Negative predictive value 
Results  
 Per patient analysis: 
40 of 47 patients with liver metastases were accurately diagnosed by both modalities. 
Sensitivity 85% CT and SPIO-MRI 
Positive predictive value 100% CT and SPIO-MRI 
Negative predictive value 100% CT and SPIO-MRI 
The 7 patients who were missed had small liver metastases 5-8mm. 
 Per lesion analysis 
Comparison of diagnosis of liver metastases between enhanced CT and SPIO-MRI in patients with liver 
metastases undergoing liver resection. 
  Histology Histology 
  Liver mets (-) Liver mets (+) 
Enhanced CT Liver mets (-) 15 3 
Enhanced CT Liver mets (+) 18 92 
SPIO-MRI Liver mets (-) 17 1 
SPIO-MRI Liver mets (+) 12 98 
 
 Enhanced CT SPIO-MRI 
Sensitivity 92/110 (84%) 98/110 (89%) p=0.32 
Positive predictive value PPV 92/92 (99%) 98/99 (99%) 
Negative predictive value NPV 15/18 (83%) 17/18 (94%)   p=0.6 
Liver mets undetectable by CT in 18 lesions included 4 lesions of 5mm, 5 of 6mm, 5 of 7mm, 3 of 8mm, 1 of 
9mm. 
Liver mets undetectable by SPIO-MRI in 12 lesions included 4 lesions of 5mm, 4 of 6mm, 2 of 7mm, 2 of 8mm.  
Conclusions 
Undetectable cases had small tumours less than 8mm 
In the per lesion analysis SPIO-MRI appears superior to CT but this is not statistically significant. In the per-
patient analysis there was no difference between the two modalities. 
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Design: prospective. Country: Italy 
Aim: to compare the diagnostic accuracy of FDG PET versus CT versus PETCT in the detection of liver 
metastases during tumour staging in patients with a diagnosis of colorectal cancer for the purposes of correct 
surgical planning and follow up. 
Inclusion criteria / Exclusion criteria 
Population: 467 patients from April 2005 to Dec 2007 with the diagnosis of CRC and suspected liver mets. 
301 men, 166 women. mean age 64.4 +/-10.2 years 
Interventions:  CT, FDG PET, PETCT 
Outcomes  
Results: 426 cases (91.2%) there was concordance among the three modalities 
 Liver mets + Liver mets - total 
CT+ 336 6 342 
CT - 30 95 125 
total 366 101 467 
Sensitivity 91.07%  (CI 88.02%-94.12%) 
Specificity 95.42%  (CI 91.84%-99.0%) 
PPV 98.08%  (CI 96.55%-99.6%) 
NPV 80.65%  (CI 74.43%-86.86%) 
Accuracy 92.29%  (CI 89.87%-94.71%) 
 
 Liver mets + Liver mets - total 
PET+ 336 11 347 
PET - 20 100 120 
total 356 111 467 
Sensitivity 94.05%  (CI 91.52%-96.58%) 
Specificity 91.6%    (CI 86.85%-96.35%) 
PPV 96.64%  (CI 94.68%-98.59%) 
NPV 85.71%  (CI 79.92%-91.51%) 
Accuracy 93.36%  (CI 91.10%-95.62%) 
 
 Liver mets + Liver mets - total 
PETCT+ 336 3 339 
PETCT - 7 121 128 
total 343 124 467 
Sensitivity 97.92%  (CI 96.39%-99.44%) 
Specificity 97.71%  (CI 95.15%-100%) 
PPV 99.10%  (CI 98.08%-100%) 
NPV 94.81%  (CI 91.07%-98.56%) 
Accuracy 97.86%  (CI 96.55%-99.17%) 
There is statistically significant difference between the sensitivity, specificity and accuracy of PETCT v PET 
(P<0.05). There is also statistically significant difference between the sensitivity and accuracy of PETCT v CT 
(P<0.05). There is no difference between PET and CT.  
Comments: PETCT has excellent diagnostic performance. It may modify patients treatment / have lower cost.  
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Citation 15: Rappeport ED, Loft A, Berthelsen AK, von der Recke P, Larsen PN, Mogensen AM, Wettergren A, 
Rasmussen A, Hillingsoe J, Kirkegaard P, Thomsen C. Contrast-enhanced FDG PETCT vs. 
SPIO-enhanced MRI vs. FDG PET vs. CT in patients with liver metastases from colorectal 
cancer: A prospective study with intra-operative confirmation. Acta Radiol. 2007; 48:369-378 
Design: prospective 
Country: Denmark 
Aim: To compare PETCT with SPIO-MRI, PET, CT in the detection of liver metastases and extra-hepatic 
tumour from colorectal cancer. 
Inclusion criteria  
Exclusion criteria  
Diabetes 
Contraindications to MRI imaging 
Timing of imaging not feasible before surgery 
Extra-hepatic metastases confirmed on histology 
Population  
35 consecutive patients with suspected liver metastases from colorectal cancer  
Patients referred between March 2004 and Nov 2005 for surgery for suspected or verified metastases 
16 men, 19 women 
median age 62 (range 33-74) 
Interventions  
PETCT 
SPIO-MRI 
PET 
CT 
 
Readers of the imaging studies were ‘blinded’ to the results of other imaging studies but were informed of the 
date for the primary colorectal cancer surgery. 
Reference standard was intra-operative ultrasound scan and histological result of the resected specimen. 
Outcomes  
Sensitivity (true positives/[true positives+false negatives] 
Specificity (true negatives/[true negatives+false positives] 
Accuracy (true positives +true negatives) / all lesions 
Positive predictive value PPV (true positives / [true positives +false positives]) 
Negative predictive value NPV (true negatives / [true negatives +false negatives]) 
Results  
 
Per patient 
 Liver mets + Liver mets - total 
CT+ 28 2 30 
CT - 0 1 1 
total 28 3 31 
 
Sensitivity 100%  (CI NA) 
Specificity 33%    (CI NA) 
PPV 93%    (CI NA) 
NPV 100%  (CI NA) 
Accuracy 94%    (CI NA) 
 
 Liver mets + Liver mets - total 
PET+ 23 0 23 
PET - 5 3 8 
total 28 3 31 
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Sensitivity 82%   (CI NA) 
Specificity 100% (CI NA) 
PPV 100% (CI NA) 
NPV 38%   (CI NA) 
Accuracy 84%   (CI NA) 
 
 Liver mets + Liver mets - total 
PETCT+ 26 0 28 
PETCT - 2 3 3 
total 28 3 31 
 
Sensitivity 93%    (CI NA) 
Specificity 100%  (CI NA) 
PPV 93%    (CI NA) 
NPV 100%  (CI NA) 
Accuracy 94% 
 
 Liver mets + Liver mets - total 
SPIO MRI+ 28 2 30 
SPIO MRI - 0 1 1 
total 28 3 31 
 
Sensitivity 100%  (CI NA) 
Specificity 33%    (CI NA) 
PPV 93%    (CI NA) 
NPV 100%  (CI NA) 
Accuracy 94 
 
Per lesion analysis 
 Liver mets + Liver mets - total 
CT+ 43 25 68 
CT - 28 50 78 
total 71 75 146 
 
Sensitivity 61%  (CI NA) 
Specificity 67%  (CI NA) 
PPV 72%  (CI NA) 
NPV 86%  (CI NA) 
Accuracy 77%  (CI NA) 
 
 Liver mets + Liver mets - total 
PET+ 38 1 39 
PET - 33 74 107 
total 71 75 146 
 
Sensitivity 54%  (CI NA) 
Specificity 99%  (CI NA) 
PPV 97%  (CI NA) 
NPV 69%  (CI NA) 
Accuracy 77%  (CI NA) 
 
 Liver mets + Liver mets - total 
PETCT+ 47 1 48 
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PETCT - 24 74 98 
total 71 75 146 
 
Sensitivity 66%  (CI NA) 
Specificity 99%  (CI NA) 
PPV 98%  (CI NA) 
NPV 76%  (CI NA) 
Accuracy 83%  (CI NA) 
 
 Liver mets + Liver mets - total 
SPIO MRI+ 58 14 72 
SPIO MRI - 13 61 74 
total 71 75 146 
 
Sensitivity 82%  (CI NA) 
Specificity 81%  (CI NA) 
PPV 81%  (CI NA) 
NPV 82%  (CI NA) 
Accuracy 82%  (CI NA) 
 
Both CT and SPIO MRI were significantly more sensitive than PET alone. P<0.0001, p<0.0001 respectively and 
PET CT p<0.001, p<0.05 respectively. 
There was no difference between SPIO MRI and CT 
All modalities were more sensitive in detecting liver metastases larger than 1cm compared with liver 
metastases of up to 1cm. Of the 19 liver metastases that were less than 1cm in size PET diagnosed 1, PETCT 
5, SPIO MRI 10 and CT 13. 
There were 4 patients who had chemotherapy less than 1 month prior to PETCT. Even when these patients 
were excluded from the analysis CT and SPIO were significantly more sensitive than PET. (p=0.001) 
General comments  
PET alone was significantly less sensitive than CT and SPIO MRI in the detection of liver metastases. This 
conflicts with the conclusions from meta-analyses. Only some of the studies reported in the meta-analysis 
reported lesion by lesion sensitivity. 
PETCT equalled MRI imaging in accuracy for liver metastasis detection.  
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Design: prospective. Country: Italy 
Aim: to compare the diagnostic accuracy of single section spiral CT and MRI with and without tissue-specific 
contrast agent MnDPDP in the detection of colorectal liver metastases. 
Inclusion criteria: Consecutive patients referred to one institution undergoing surgery for primary and / or 
metastatic colorectal cancer. 
>18 years of age. Histologically confirmed diagnosis of CRC. Surgical indication for either resection of the 
primary and/or liver resection of metastases according to colonoscopy and CT of chest and abdomen. Life 
expectancy of at least 12 weeks. Normal renal function (creatinine <1.5mg/dl). 
Exclusion criteria: Pregnancy or lactation, contraindication to CT or MRI or laparoscopic surgery, CT-MRI 
interval > 4 weeks, CT or MRI imaging of poor quality due to movement artifact 
Population  
125 consecutive patients from one institution considered (Dec 2000-Mar 2003), 61 men (48.8%), Median age 
64.4 (41-86). 82/125 had resection of primary. 19/82 also had synchronous metastases. 43/125 had resection 
of metachronous metastases. 19/125 had received neoadjuvant chemotherapy prior to inclusion in the study. 
Interventions  
Dual phase spiral single section CT with contrast. (Triple phase (delayed phase – done only when required by 
radiologist to differentiate between slowly filling haemangioma and metastasis). 
MRI with and without MnDPDP contrast. 
Reference Standard: IOUS combined with palpation and surgical inspection together with histopathologic  
reliefs (intra-operative frozen section histology when needed and histology on resected specimens). 
2 radiologists assessed CT images and 2 the MRI images. Disagreement between readers was resolved by 
consensus re-evaluation. The readers were aware that the patient had CRC but were unaware of the result of 
other investigations and of the other readers. IOUS was performed by 1 of 2 radiologists and they were aware 
of the results of the CT and MRI. 
Outcomes  
Primary outcome 
 sum of TP, sum of TN for all patients for CT, unenhanced MRI, MnDPDP MRI (per patient analysis) 
TP = when the procedure detected the same metastases as the reference standard 
TN = when the procedure correctly diagnosed no metastases.  
Secondary outcome 
 Sensitivity / specificity -  per patient basis 
 Sensitivity / PPV – per lesion basis 
 The level of diagnostic confidence and inter-observer agreement 
Per patient basis analysis definitions 
Sensitivity = number of TP cases / number of patients with at least one metastasis. 
Specificity = number of TN cases / all cases in whom the reference standard did not detect any metastases. 
Results  
MnDPDP MRI is more accurate than CT on a per patient basis. There is no difference between CT and MRI 
and only a trend of higher accuracy for MnDPDP MRI compared to unenhanced MRI.  
MnDPDP MRI has a significantly higher sensitivity on a per lesion basis than both CT (OR 2.6; 95% CI 1.44, 
4.92) and unenhanced MRI (OR 2.1; 95% CI 1.11, 3.84); (multiple logistic model accounting for lesion 
dimensions and intra-patient variability). 
Kappa for inter-observer variability was 0.85 for CT, 0.77 for both enhanced and unenhanced MRI. Overall 
Kappa was 0.75 suggesting excellent agreement.  
Diagnostic confidence levels not included in this evidence table as not a relevant outcome to PICO. 
No serious side effects were reported from any of the investigations. 
 
 CT MRI MnDPDP MRI CT v MRI CT v 
MnDPDP 
MRI 
MRI v 
MnDPDP 
MRI 
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Per patient 
analysis 
      
Accuracy 91/125(72.8%) 98/125(78.4%) 103/125(82.4%) p=0.071 p=0.005 P=0.059 
Sensitivity 30/62(48.4%) 36/62(58.1%) 41/62(66.1%) p=0.083 p=0.004 p=0.059 
Specificity 61/63(96.8%) 62/63(98.4%) 62/63(98.4%)    
Per lesion 
analysis 
      
Sensitivity 137/191(71.7%) 143/191(74.9%) 158/191(82.7%)    
Sensitivity 
per lesion 
size 
      
≤ 10mm 31/65(47.7%) 35/65(53.8%) 44/65(67.7%)    
11-20mm 39/53(73.6%) 40/53(75.5%) 46/54(86.8%)    
>20mm 67/73(91.8%) 68/73(93.2%) 68/73(93.2%)    
PPV 137/163(84%) 143/149(96%) 158/165(95.8%)    
 
Per patient analysis 
 
 Liver mets + Liver mets - total 
MnDPDP MRI+ 41 1 42 
MnDPDP MRI - 21 62 83 
total 62 63 125 
Sensitivity 66.1% 
Specificity 98.4%   
PPV 97.6%   
NPV 74.7%   
Accuracy 82.4% 
 
 Liver mets + Liver mets - total 
MRI+ 36 1 37 
MRI - 26 62 88 
total 62 63 125 
Sensitivity 58.1% 
Specificity 98.4%  
PPV 97.3%   
NPV 70.5%   
Accuracy 78.4% 
 
 Liver mets + Liver mets - total 
CT+ 30 2 32 
CT - 32 61 93 
total 62 63 125 
Sensitivity 48.4% 
Specificity 96.8% 
PPV 94%   
NPV 66%   
Accuracy 72.8% 
 
There was no difference between CT and MRI 
MnDPDP MRI was more accurate and more sensitive than CT 
There was a higher accuracy and sensitivity tendency for MnDPDP MRI v unenhanced MRI but not statistically 
significant. 
 
Per lesion analysis 
 
 Liver mets + Liver mets - total 
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MnDPDP MRI+ 158 7 165 
MnDPDP MRI - 33 67 100 
total 191 74 265 
 
Sensitivity 82.7% 
Specificity 90.5% 
PPV 95.8% 
NPV 67.0 % 
Accuracy 84.9%  
 
 Liver mets + Liver mets - total 
MRI+ 143 6 149 
MRI - 48 68 116 
total 191 74 265 
 
Sensitivity 74.9% 
Specificity 91.9%   
PPV 96% 
NPV 58.6% 
Accuracy 79.6% 
 
 Liver mets + Liver mets - total 
CT+ 137 26 163 
CT - 54 48 102 
total 191 74 265 
 
Sensitivity 71.7% 
Specificity 64.9%   
PPV 84% 
NPV 47.1%   
Accuracy 69.8%  
 
CT and unenhanced MRI showed no difference in sensitivity in the per lesion analysis (OR 1.3, CI 0.73-2.27) 
The sensitivity of MnDPDP MRI was significantly higher than both CT (OR 2.6 CI 1.44-4.92), and unenhanced 
MRI (OR 2.1 CI 1.11-3.84) 
General comments: On a per patient basis MnDPDP MRI is significantly more accurate and sensitive than CT 
in the detection of colorectal liver metastases. Specificity was similar. However MnDPDP MRI failed to be more 
accurate and sensitive than unenhanced MRI for both comparisons. There was no difference between CT and 
unenhanced MRI. 
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Citation 17: Ruers TJM. Improved selection of patients for hepatic surgery of colorectal liver metastases with 
18F-FDG PET: A randomized study. J.Nucl.Med. 2009; 50:1036-1041 
Design: randomised phase III multicentre trial. Country: the Netherlands 
Aim: to investigate whether the addition of FDG PET to conventional CT-based pre-operative screening of 
colorectal liver metastases is beneficial and reduces the number of futile laparotomies. 
Inclusion criteria: Histologically documented colorectal cancer treated by R0 resection, 1-4 suspected 
potentially resectable liver metastases. No evidence of extra-hepatic metastatic disease (except up to a 
maximum of 2 resectable lung mets on CT). No evidence of recurrent or second colorectal carcinoma on 
barium enema or colonoscopy. WHO performance status of 0-2. Age 18 - 75 
Exclusion criteria: Previous malignancies (except in situ carcinoma of the cervix, non-melanoma cancer of the 
skin, or a cancer where there had been a disease-free interval of at least 10 years). Liver dysfunction (bilirubin, 
ALP x3 times upper limit if normal). Active infection. Poorly regulated diabetes mellitus. 
Population: 150 patients with CRC liver mets selected for surgery by CT. Multicentre. May 2002 –Feb 2006. 
Interventions: FDG PET and CT versus CT only 
Outcomes: Primary=Number of futile laparotomies (any laparotomy that did not result in complete tumour 
treatment, that revealed benign disease, or that did not result in disease-free survival period > 6 months. 
Secondary=Disease-free survival (DFS), Overall survival (OS) 
Results 
Futile laparotomies  
Variable Control arm (no PET) n=75 Experimental arm (PET) n=75 
No laparotomy 0 5 (7%) 
Confirmed benign disease - 2 
Confirmed extra-hepatic disease - 3 
laparotomy 75 (100%) 70(93%) 
Futile laparotomy 34 (45%) 21(28%) 
Extra-hepatic disease at 
laparotomy – not resectable 
6 2 
Too extensive liver disease at 
laparotomy – not resectable 
8 3 
Benign disease at laparotomy 3 2 
Benign disease after resection 1 1 
Disease recurrence in <6 months 16 13 
 A significantly higher proportion of patients underwent futile laparotomies in the control-no PET arm 
than in the experimental arm (45% v 28%) p=0.042 
 The relative risk reduction was 38% (CI 4%-60%) 
 The absolute difference of 17% means that 6 patients need to undergo PET to avoid 1 futile 
laparotomy. 
 Futile laparotomy was not found to be associated with other prognostic factors as measured by the 
Fong score (p=0.539) 
Survival 
All patients were followed up for at least 3 years after randomization. For all patients randomized 
3 year survival Control arm (no PET) Experimental arm (PET) 
Overall survival OS 65.8% 61.3% 
Disease free survival DFS 29.8% 35.5% 
Both OS and DFS were not significantly different between the experimental and the control groups. 
General Comments: 
The introduction of PET in the pre-operative work-up of patients with suspected liver mets from colorectal 
cancer significantly reduces the number of futile laparotomies due to unexpected unresectable disease. 
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Citation 18: Schwartz L, Brody L, Brown K, Covey A, Tuorto S, Mazumdar M, Riedel E, Jarnagin W, 
Getrajdman G, Fong Y. Prospective, blinded comparison of helical CT and CT arterial 
portography in the assessment of hepatic metastasis from colorectal carcinoma. World J.Surg. 
2006; 30:1892-1901 
Design: prospective 
Country: Memorial Sloan Kettering Cancer Centre - USA 
Aim: To compare helical CT with helical CT with arterial portography aimed at detecting liver metastases from 
colorectal carcinoma. 
Cannot obtain 2X2 table as only ROC curve presented. 
Inclusion criteria  
Exclusion criteria  
Patients with evidence of extra-hepatic disease on imaging (37 patients) 
Population  
87 consecutive patients between April 1999 and April 2001 with suspected colorectal liver metastases . 
all imaging done at a single institution 
no evidence of extra-hepatic disease (final population analysed n=50) 
Interventions  
Helical CT 
Helical CTAP – results not presented as not relevant to PICO 
Outcomes 
Sensitivity from ROC curve 
Results  
Only CT results are presented as they are relevant to the PICO. 
 
 CT using cut-off 1 
0-1 benign 2-3-4 malignant 
CT using cut-off 2  
0-1-2 benign 3-4 malignant 
Sensitivity 76% 69% 
Specificity 56%   82% 
PPV 61% 78% 
NPV 73%   75% 
Accuracy 65%  76% 
 
General comments  
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Citation 19: Selzner MK, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PETCT 
imaging modality impact on the treatment of patients with metastatic colorectal cancer of the 
liver? Ann.Surg. 2004; 240:1027-1036 
Design: prospective. Country: Switzerland 
Aim: To compare the diagnostic value of contrast enhanced CT with that of FDG PETCT in patients with 
metastatic colorectal cancer to the liver. 
Inclusion criteria: All patients referred for consideration for liver resection between Jan 2002 and July 2003. 
CT and PETCT must have occurred within 2 weeks of each other. 
Exclusion criteria: Synchronous metastatic lesions (metastatic liver disease coincident with the primary CRC). 
Population: 76 patients, 52 men, 24 women, median age of 63 years (range 35-78), 62 patients received 
chemotherapy after their initial bowel resection. Median interval between chemotherapy and PETCT = 3 
months (range 7 days to 15 months). Median follow up 16 months (range 6 months to 3 years). 
Interventions: Contrast-enhanced CT, FDG PETCT 
Follow up was at 3 and 6 months for those patients that did not proceed to surgery. 
Separate CT radiologist and PET radiologist. Both ‘blinded’ to the results of other findings. 
Outcomes  
Primary outcome: Does PETCT alter the indications for surgery compared with CT. 
Secondary outcome: True positives/negatives, false positives/negatives for PETCT. 
The diagnostic ability of the modality in patients with a previous hepatectomy. 
The influence of previous chemotherapy on the detection of tumours by PETCT. 
Results  
Per patient analysis 
 Liver mets + Liver mets - total 
CT+ 63 3 66 
CT - 3 7 10 
total 66 10 76 
Sensitivity 95% 
Specificity 70% 
PPV 95%   
NPV 70%   
Accuracy 92% 
 
 Liver mets + Liver mets - total 
PETCT+ 60 1 61 
PETCT - 6 9 15 
total 66 10 76 
Sensitivity 91% 
Specificity 90% 
PPV 98%   
NPV 60%   
Accuracy 91% 
 
No difference between CT and PETCT with regard to specificity p=0.58 
General comments  
Comparable results between PETCT and CT with regard to the diagnosis of hepatic metastases. 
Management is altered by PETCT but purely on the identification of extra-hepatic disease. 
PETCT is also better at diagnosing recurrent liver disease in patients with prior hepatectomy. 
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Citation 20: Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, Pruvot FR. Prospective evaluation of the 
impact of 18Ffluoro-2-deoxy D glucose positron emission tomography of resectable colorectal 
liver metastases. The British Journal of Surgery 2005; 92:362-369 
Design: prospective double blind 
Country: France 
Aim: to assess the additional value of information provided by FDG PET over that provided by CT in patients 
with resectable liver metastases from colorectal cancer. 
Inclusion criteria  
 Oct 2001-Nov 2002 
Those patients whom on CT were thought to be eligible for liver resection. 
If the PET was discordant with the CT this did not alter the decision to proceed to laparotomy. 
Exclusion criteria  
Population 
All 53 patients underwent laparotomy 
40 men, 13 women 
mean age 63, range 44-78 
27 patients presented with synchronous liver metastases. 26 had metachronous liver metastases. 
Interventions  
FDG PET 
Helical CT, dual phase, 5mm slices, with iodinated contrast 
Mean time between PET and CT was 24 days (range 0-61 days) 
All PET scan performed within 2 months of laparotomy 
Outcomes  
Results  
Per patient analysis: Unable to extract 2x2 table from descriptive statistics of the per patient analysis. 
 
Per lesion analysis 
 Liver mets + Liver mets - total 
CT+ 78 3 81 
CT - 21 1 22 
total 99 4 103 
Sensitivity 79% 
Specificity 25% 
PPV 96%   
NPV 5%   
Accuracy 77% 
 
 Liver mets + Liver mets - total 
PET+ 78 1 79 
PET- 21 4 25 
total 99 5 104 
Sensitivity 79% 
Specificity 80% 
PPV 99%   
NPV 16%   
Accuracy 79% 
 
Comments: Comparable results for PET and CT regarding liver mets. Extra lesions identified are extra-hepatic. 
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Citation 21: Vidiri A, Carpanese L, D'Annibale M, Caterino M, Cosimelli M, Zeuli M, David V, Crecco M. 
Evaluation of hepatic metastases from colorectal carcinoma with MR-superparamagnetic iron 
oxide. Journal of Experimental & Clinical Cancer Research 2004; 23:53-60 
Design: prospective. Country: Italy 
Aim: To compare the results obtained with SPIO-MRI and unenhanced MRI with that of spiral CT in order to 
select those patients suitable for liver resection.  
Inclusion criteria  
Patients with known colorectal neoplasm who were candidates for liver resection 
Exclusion criteria 
age <18 
pregnancy and or lactation 
hypersensitivity to administration of Dextran  
stage C liver cirrhosis (Child-Pugh classification) 
serious kidney insufficiency 
haematological disease with splenomegaly 
administration of a different contrast within 24 hours. 
Population  
35 patients, mean age 65, 20 men, 15 women, all potentially suitable for hepatic resection of metastatic lesions 
Interventions  
All patients had all the investigations. 
spiral CT 
SPIO-MRI (with body coil) 
unenhanced MRI 
All imaging was performed within 7 days 
Pre- and post-op evaluation time period with a maximum of 30 days 
Gold standard: IOUS combined with palpation and surgical inspection together with histopathology reliefs on 
resected specimens. 
Outcomes  
Sensitivity on a per lesion basis 
Change in overall decision on a per patient basis 
Results  
Singularly difficult to make sense of their descriptive statistics to construct a 2x2 table. 
Of the 35 patients included, 26 went to surgery and 9 did not (unresectable). Of the 9 unresectable cases 8 had 
chemotherapy and 1 had radiofrequency ablation. 
 
Of patients submitted for surgery: 
dimensions No of lesions CT MRI SPIO-MRI IOUS 
 48 34 32 41 48 
<1cm 13 4 2 9 13 
1-2cm 14 10 10 12 14 
>2cm 21 20 20 20 21 
 
3 FP on CT 
2 FP on MRI 
2 FP on SPIO-MRI (same as above) 
5 patients were found to have unresectable disease at operation (missed by both CT and MRIs) 
2 lesions considered by CT to be metastases were correctly identified by MRIs to be non-metastatic. 
1 lesion identified by MRI as a metastasis and not picked up by CT at all was not a metastasis (angioma). 
 
 
Of patients not submitted for surgery: 
dimensions CT MRI SPIO-MRI 
 8 8 15 
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<1cm   4 
1-2cm 2 2 5 
>2cm 6 6 6 
 
Per patient 
In 5 cases SPIO-MRI concluded that surgery was contraindicated – the opposite to the CT conclusion 
(in 4 cases SPIO-MRI showed a greater number of lesions per segment, in 1 case it identified the lesion as 
benign and not metastatic). 
 
Statistics 
Kappa  CT v MRI  0.9  good agreement 
Kappa  CT v SPIO-MRI 0.59 mild agreement 
Kappa  MRI v  SPIO-MRI 0.51 mild agreement 
 
Per patient analysis 
 Liver mets + Liver mets - total 
CT+ 9+ 3  
CT - 5   
total   35 
 
Sensitivity NA 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA 
 
 Liver mets + Liver mets - total 
MRI+ 9+ 2  
MRI - 5   
total   35  
 
Sensitivity NA 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA  
 
 Liver mets + Liver mets - total 
SPIO MRI+ 9+ 2  
SPIO MRI - 5   
total   35  
 
Sensitivity NA 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA  
 
Per lesion analysis 
 Liver mets + Liver mets - total 
CT+ 34 3 37 
CT - 14   
total 48   
 
Sensitivity 71% 
Specificity NA   
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PPV NA 
NPV NA   
Accuracy NA 
 
 Liver mets + Liver mets - total 
MRI+ 32 2 34 
MRI - 16   
total 48   
 
Sensitivity 66.6% 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA  
 
 Liver mets + Liver mets - total 
SPIO MRI+ 41 2 43 
SPIO MRI - 7   
total 48   
 
Sensitivity 85.4% 
Specificity NA   
PPV NA 
NPV NA   
Accuracy NA  
McNemar test: significantly greater number lesions identified with SPIRO-MRI v MRI (p=0.008) 
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Citation 22: Wiering B, Ruers TJM, Krabbe PFM, Dekker HM, Oyen WJG. Comparison of multiphase CT, FDG 
PET and intra-operative ultrasound in patients with colorectal liver metastases selected for 
surgery. Ann.Surg.Oncol. 2007; 14:818-826 
Design: prospective 
Country: The Netherlands 
Aim: to evaluate the predictive value of CT and FDG PET of the liver and extra-hepatic findings compared with 
findings at laparotomy and at 6 months follow-up. 
Inclusion criteria  
Consecutive patients between Jan 1999 and Nov 2004. 
Suitable for liver resection of hepatic metastases from colorectal cancer on CT imaging. 
Exclusion criteria  
Presence of local recurrence on colonoscopy or colonography 
No previous liver surgery 
Poorly regulated diabetes 
Population  
131 consecutive patients thought suitable for liver resection of hepatic metastases on CT imaging. 
Interventions  
CT dual phase helical with intravenous contrast – iodine 
PET 
Outcomes  
Diagnostic 2x2 tables for each modality for liver metastases, extra-hepatic, intra-abdominal and other sites. 
Only liver-related results presented. 
Results  
Per patient analysis 
 
 Liver mets + Liver mets - total 
CT+ 127 3 130 
CT - 1 0 1 
total 128 3 131 
 
Sensitivity 99.2% 
Specificity NA 
PPV 97% 
NPV NA   
Accuracy 97%  
 
 Liver mets + Liver mets - total 
PET+ 126 0 126 
PET- 2 3 5 
total 128 3 131 
 
 
Sensitivity 98.4% 
Specificity 100%   
PPV 100% 
NPV 60%   
Accuracy 98.5%  
 
Per lesion analysis 
 
 
 Liver mets + Liver mets - total 
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CT+ 257 3 260 
CT - 106 0 106 
total 363 3 366 
 
Sensitivity 70.8% 
Specificity NA   
PPV 98.8% 
NPV NA   
Accuracy 70.2%  
 
 
 Liver mets + Liver mets - total 
PET+ 260 0 260 
PET- 103 3 106 
total 363 3 366 
 
Sensitivity 71.6% 
Specificity 100%   
PPV 100% 
NPV 2.8%   
Accuracy 71.8%  
 
 
PET and CT both missed the majority of lesions that were smaller than 10mm. Many were only a few mm in 
diameter. 
 
Detection rate of histologically-proven liver metastases 
Lesion size IOUS CT PET CT and/or PET 
<10mm 63 10 (16%) 10 (16%) 12 (19%) 
10-20mm 172 123 (72%) 129 (75%) 142 (83%) 
>20mm 128 124 (97%) 121 (95%) 125 (98%) 
All  363 257 (71%) 260 (72%) 279 (77%) 
 
Results from CT and PET may not be congruent and thus are complementary for the detection of metastases. 
 
After 6 months follow up 42 new lesions developed in 15 patients. CT and PET had previously detected all the 
lesions though it had not been possible to identify them at laparotomy with palpation and IOUS.  
General comments  
CT and PET have similar diagnostic yield for the detection of liver metastases; both modalities are adequate on 
a patient basis but inadequate to detect the smallest of liver lesions. The latter finding is of limited clinical 
significance. 
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NICE methodology checklist for Systematic Reviews and Meta-
Analyses 
 
 
Study identification: 
 
Guideline topic:   Key question no: 
Checklist completed by:  
SECTION 1 : INTERNAL VALIDITY  
In a well-conducted systematic review  
In this study the criterion is 
(highlight the correct responses in yellow):  
1.1 
The study addresses an appropriate and clearly focused 
question 
Well covered Not addressed 
Adequately 
addressed 
Not reported 
Poorly addressed Not applicable 
1.2 A description of the methodology used is included  
Well covered Not addressed 
Adequately 
addressed 
Not reported 
Poorly addressed Not applicable 
1.3 
The literature search is sufficiently rigorous to identify all 
relevant studies 
Well covered Not addressed 
Adequately 
addressed 
Not reported 
Poorly addressed Not applicable 
1.4 Study quality is assessed and taken into account 
Well covered Not addressed 
Adequately 
addressed 
Not reported 
Poorly addressed Not applicable 
1.5 
There are enough similarities between the studies selected to 
make combining them reasonable 
Well covered Not addressed 
Adequately 
addressed 
Not reported 
Poorly addressed Not applicable 
   
SECTION 2: OVERALL ASSESSMENT OF THE STUDY 
2.1  How well was the study done to minimise bias 
 
 
2.2 
If coded as + or – what is the likely direction in which bias might 
affect the study results 
 
 
 
 
SECTION 3: DESCRIPTION OF THE STUDY  
3.1 What types of studies are included on the review?  
3.2 
How does the review help to answer your key question? 
Summarise the main conclusions to the review and how it 
relates to the relevant key question. Comment on the particular 
strength or weakness of the review as a source of evidence. 
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NICE methodology checklist for Randomised Controlled Trials 
 
 
Study identification: 
 
Guideline topic:   Key question no: 
Checklist completed by:  
 
SECTION 1 : INTERNAL VALIDITY  
In a well-conducted RCT:  
In this study the criterion is  
(highlight the correct response in yellow) :  
1.1 
The study addresses an appropriate and clearly focused 
question 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.2 
The assignment of subjects to treatment groups is 
randomised. 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.3 
An adequate concealment method is used. 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.4 
Subjects and investigators are kept ‘blind’ about treatment 
allocation. 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.5 
The treatment and control groups are similar at the start of 
the trial. 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.6 
The only difference between groups is the treatment under 
investigation. 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.7 
All relevant outcomes are measured in a standard, valid and 
reliable way. 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.8 
What percentage of the individuals or clusters recruited into 
each treatment arm of the study dropped out before the 
study was completed? 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.9 
All the subjects are analysed in the groups to which they 
were randomly allocated (often referred to as intention-to-
treat analysis). 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.10 
Where the study is carried out at more than one site, results 
are comparable for all sites. 
 
Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
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SECTION 2: OVERALL ASSESSMENT OF THE STUDY 
2.1  
How well was the study done to minimise the risk of bias or 
confounding and to establish a causal relationship between exposure 
and effect? (select ++, + or -) 
 
 
2.2 
If coded as + or – what is the likely direction in which bias might affect 
the study results? 
 
 
2.3 
Taking into account clinical considerations, your evaluation of the 
methodology used and the statistical power of the study, are you 
certain that the overall effect is due to the study exposure?  
 
2.4 
Are the results of this study directly applicable to the patient group 
targeted by this guideline? 
 
   
SECTION 3: DESCRIPTION OF THE STUDY (responses can be referred to the Evidence Table) 
3.1 How many patients are included in this study?  
3.2 What are the main characteristics of the patient population?  
3.3 What environmental or prognostic factor is being investigated?  
3.4 What comparisons are made in the study?  
3.5 How long are participants followed up in the study?   
3.6 What outcome measure(s) are used in the study?  
3.7 What size of effect is identified in the study?  
3.8 How was the study funded?   
3.9 Does this study help to answer your key question?  
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Evidence tables for the SR on CRC follow up 
 
Citation 1: Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic 
colorectal cancer. Cochrane Database of Systematic Reviews. 2007. Issue 1. 2007 
Design: Systematic Review and Meta-analysis. Country: New Zealand 
Aim: To review the available evidence concerning the benefits of intensive follow-up of colorectal cancer 
patients with respect to survival. Secondary endpoints included: time to diagnosis of recurrence, quality of life 
(QoL) and the harms and costs of surveillance and investigations. 
Inclusion criteria: Only randomised controlled trials comparing different follow up strategies for patients with 
non-matastatic colorectal cancer (CRC) treated with curative intent were included.  
Exclusion criteria: Non-randomised studies. Ongoing randomised trials (COLFOL, FACS, GILDA) 
Population: Patients with non-matastatic colorectal cancer (CRC) treated with curative intent +/- adjuvant 
treatment. Males and females of any age with histologically proven adenocarcinoma of the colon or rectum 
staged as T1,2,3,4; N0,1,2; M0. Duke’s stage A, B and C. 
Interventions: Strategies of follow-up. 
This included comparisons of  
follow-up versus no follow up 
follow-up strategies of varying intensity 
follow-up in different healthcare settings. 
 
Follow up visits with health professionals included: 
symptom enquiry 
clinical examination 
procedures (e.g. colonoscopy) 
blood tests 
faecal analysis 
radiological examinations. 
Outcomes  
Primary: Overall Survival (OS) 
Secondary: 
Disease specific survival 
Time to diagnosis of recurrence 
Incidence of surgery(with curative intent) for recurrence 
Interval recurrences (between planned visits) 
Quality of life 
Harms 
Cost of surveillance and investigations 
Results  
 
Eight studies were included (2141 patients in total): 
 Overall survival benefit at five years exists for patients undergoing more intensive follow up 
 The absolute number of recurrences was similar 
 For disease free survival there is no significant survival benefit between intensive follow up and less 
intensive. 
 There is a mortality benefit for performing more tests versus fewer tests 
 There is a mortality benefit for performing liver imaging versus no liver imaging 
 The weighted mean difference for the time to recurrence was significantly reduced but there was 
significant heterogeneity amongst the studies. 
 There was significantly more curative surgical procedures in the intensively followed arm 
 No useful data on quality of life, harms or cost-effectiveness were available. 
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Comparison Studies 
included 
 
No of 
patients 
Overall survival at 5 years 
expressed as odds ratio (OR)  
and risk difference (RD) 
S = significant 
NS = not significant 
No of recurrences 
expressed as odds ratio (OR)  
and risk difference (RD) 
S = significant 
NS = not significant 
Intensive FU 
v 
minimalist FU 
6 of 8 
 
1601 OR 0.73 (CI 0.59, 0.91) S 
 
RD -0.06 ( CI -0.11,  -0.02) S 
 
 7 of 8 1938  OR 0.91 (CI 0.71, 1.1) NS 
 
RD -0.02 ( CI -0.06,  0.02) NS 
Clinic visit 
v 
No clinic visit 
1 of 8  
 
107 OR 0.57 (CI 0.26, 1.29) NS 
 
RD -0.12 ( CI -0.3,  0.05) NS 
 
 2 of 8 444  OR 0.85 (CI 0.58, 1.25) NS 
 
RD -0.04 ( CI -0.13,  0.05) NS 
More clinic visits 
v 
Fewer clinic visits 
2 of 8 804 OR 0.78 (CI 0.58, 1.05) NS 
 
RD -0.05 ( CI -012 , 0.01) NS 
OR 0.93 (CI 0.69, 1.26) NS 
 
RD -0.02 ( CI -0.08, 0.05) NS 
More tests 
v 
Fewer tests 
5 of 8  1004 OR 0.64 (CI 0.49, 0.85) S 
 
RD -0.09 ( CI -0.14, 0.03) S 
OR 0.90 (CI 0.69, 1.16) NS 
 
RD -0.02 ( CI -0.08,  0.03) NS 
CEA 
v 
No CEA 
1 of 8  107 OR 0.57 (CI 0.26, 1.29) NS 
 
RD -0.12 ( CI -0.3,  0.05) NS 
 
 2 of 8 444  OR 0.85 (CI 0.58, 1.25) NS 
 
RD -0.04 ( CI -0.13,  0.05) NS 
Liver imaging 
V 
No liver imaging 
5 of 8  1004 OR 0.64 (CI 0.49, 0.85) S 
 
RD -0.09 ( CI -0.14,  0.03) S 
 
 6 of 8 1341  OR 0.88 (CI 0.70, 1.10) NS 
 
RD -0.03 ( CI -0.08,  0.02) NS 
 
Comparison Studies 
included 
 
No of 
patients 
Time to recurrence 
Expressed as odds ratio 
(OR) in months 
Curative surgery at 
recurrence 
Expressed as odds ratio (OR) 
Intensive FU 
v 
minimalist FU 
3 of 8 420 OR -6.75 (-11.06, -2.44) S 
But significant heterogeneity  
 
 6 of 8 1613  OR 2.41 (1.62, 3.53) S 
 
RD 0.06 (0.04, 0.09) S 
 
Disease-free survival (DFS): 
2 studies reported on DFS and their pooled result shows no significant difference in survival benefit between 
intensive follow up and less intensive. OR 0.92, CI (0.64, 1.31), RD-0.01 CI (-0.08, 0.05) NS. 
Metachronous tumours:  
7 studies reported a total of 15 metachronous tumours in the experimental arms and 9 in the control arms of the 
studies. 1 study reported interval tumours and noted 8 in the control and 2 in the experimental arm. 
 
 
 
Complications: 
1 study reported adverse events from follow up. 2 perforations and 2 GI bleeds from a total of 731 
colonoscopies. 
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Quality of life: 
1 study (597 patients) reported a small but significant increase in the quality of life of patients associated with 
more frequent follow up visits.(Kjeldsen 1997 – separate publication 1999) 
A different study (203 patients) reported no difference in quality of life, anxiety, depression, and patient 
satisfaction in patients followed up in different settings; GP / hospital. (Wattchow 2006) 
 
General comments  
 This meta-analysis supports the general principle of follow up for patients with CRC after curative 
treatment. There is also a clear message that the use of liver imaging is associated with improved 
survival and this should be included in any follow up programme. 
 However there is the limitation that the combined studies span a long time-frame during which clinical 
care and surgical technique have changed considerably. These factors may have an effect on survival 
and question the validity of applying the results of earlier studies to modern practice. 
 Although there was no statistical heterogeneity amongst the studies the intensity of follow up was 
varied. For example the follow up intensity in the experimental arm of one study was the same as the 
intensity of follow up in the control arm of another study. Therefore a precise indication of frequency, 
type or setting of follow up cannot be extracted from the data. 
 Time to recurrence was significantly less and significantly more surgical procedures were carried out in 
the intensively followed arms of the studies. Although this suggests that recurrences were detected 
earlier leading to salvage surgery that lead to the improved survival this result is subject to intervention 
bias. The decision for salvage surgery in these studies was made by clinicians that were not blinded. 
In addition there was significant heterogeneity amongst the studies that reported on time to recurrence 
and this result is not reliable. 
 No useful data on quality of life, harms or cost-effectiveness were available. 
References of Included Studies (For systematic reviews): 
1. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomised study of follow up after 
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2. Makela JT, Seppo OL, Kairaluoma MI. Five year follow up after radical surgery for colorectal cancer. 
Archives of Surgery 1995;130:1062-1067 
3. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg K. Follow up after curative surgery for colorectal 
carcinoma. Diseases of colon and rectum 1995;38(6):619-626 
4. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of 
local recurrences of colorectal cancer. Diseases of colon and rectum 1998;41:1127-1133 
5. Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X et al. Postoperative surveillance in 
patients  with colorectal cancer who have undergone  curative resection: A prospective, multicentre, 
randomised, controlled trial. Journal of clinical oncology 2005;24(3):1-8 
6. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT and chest radiography do not 
influence 5-year survival of colorectal cancer patients. Gastroenterology 1998;114:7-14 
7. Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al. Efficacy and cost of risk 
adapted follow up in patients after colorectal cancer surgery: a prospective, randomised and controlled 
trial. European Journal of Surgical Oncology 2002;28:418-423 
8. Wattchow DA, Weller DP, Esterman A, Pilotto LS, McGorm K, Hammett Z, et al. General practice 
versus surgical-based follow-up for patients with colon cancer: randomised controlled trial. British 
Journal of Cancer 2006;94:1116-1121 
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Citation 2: Tjandra JJ, Chan MKY. Follow-up after curative resection of colorectal cancer: a meta-analysis. 
Diseases Colon & Rectum. 2007 50(11):1783-1799 
Design: Systematic review and meta-analysis. Country: Australia 
Aim: To evaluate the impact of various follow-up intensities and strategies on the outcome of patients after 
curative surgery for colorectal cancer.  
Inclusion criteria : All RCT that randomised at or shortly after surgery and comparing different intensities of 
surveillance on colorectal cancer after curative resection. 
Exclusion criteria: Studies considered to have bias ( studies that did not report on their randomization, 
inclusion and exclusion criteria,patient selection, allocation, study design)  
Population: Patients with colorectal cancers that were treated surgically with curative intent. Local excision, 
distant metastases, inflammatory bowel disease and polyposis were excluded. Patients with co-morbidities that 
could not comply with follow up or in whom treatment of recurrent disease would be contraindicated were also 
excluded. 
Interventions: Intensive follow-up strategies as defined by the different trials. The clinical assessment, the 
investigations as well as who delivered the follow up were to be clearly stated. 
Outcomes  
 
Mortality Number of Asymptomatic recurrences 
Cancer-related mortality Time to recurrence 
Other cause of death Method of detection of recurrence 
Total recurrence rate Reoperation rate 
Local recurrence rate (all and isolated) Curative reoperation rate 
hepatic recurrence rate (all and isolated) Setting of follow up 
lung recurrence rate  Compliance to protocol 
Number of Intramural recurrence Complications from follow-up investigations 
Number of Metachronous recurrences  
Results  
A total of 2,923 patients were pooled from 8 RCTs 
 Overall survival benefit at five years exists for patients undergoing more intensive follow up OR 0.74 
(CI 0.59, 0.93) P value = 0.01 
 Cancer related mortality did not show any significant difference between intensive and non-intensive 
follow up arms. (11.5% v 12.5%; OR 0.91; P=0.52) – grade not done. 
 The number of all site recurrences was similar between the two groups. OR 0.97 (CI 0.82, 1.14)p=0.68 
 However there is a significantly higher number of asymptomatic recurrences being picked up in the 
intensively followed up group. OR 3.42 (CI 2.17,5.41) 
 There was no difference between the two groups with regard to different types of recurrence being 
diagnosed i.e. local,  distant, intramural, metachronous, hepatic.(p>0.05) 
 The weighted mean time to recurrence detection was reduced by 6 months with intensive follow up but 
there was significant heterogeneity among the studies pooled. 
 The number of curative operations done for recurrence was significantly higher with intensive follow up. 
OR 2.81 (CI 1.65, 4.75) 
 There was a significant survival benefit with CEA and colonoscopy. Liver USS had a significant survival 
benefit but CT was not found to make a significant difference to survival. Neither made a difference to 
recurrence detection. 
 Although the number of recurrences was not significantly different more curative operations were 
performed for recurrence and this was the case whichever test was used for follow up.  
 As far as frequency of the testing is concerned, more frequently done CEA levels was the only test 
associated with an improvement in overall mortality. 
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Comparison Studies 
included 
 
No of 
patients 
Overall survival at 5 years 
expressed as odds ratio 
(OR)  
S = significant 
NS = not significant 
No of recurrences 
expressed as odds ratio (OR)  
S = significant 
NS = not significant 
Intensive FU 
v 
minimalist FU 
8 of 8 
 
2,923 OR 0.74 (CI 0.59, 0.93) S 
 
P value = 0.01 
 
 all site 
8 of 8 
Asymptomatic 
6 of 8 
 
2,923 
 
1,679 
 All site  
OR 0.97 (CI 0.82, 1.14) NS 
P value=0.68 
Asymptomatic 
OR 3.42 (CI 2.17,5.41) S 
P value<0.00001 
CEA 
v 
No CEA 
2 of 8  444 OR 0.57* forest plot CI S 
P value= 0.003 
*OR calculation end of table 
 
 2 of 8 444  OR 0.85 (CI 0.58, 1.25) NS 
More CEA  
v 
Less CEA 
1 of 8 207 OR 0.51* forest plot CI S 
P value=0.03 
 
 1 of 8 207  OR 0.83 (CI 0.61, 1.13) NS 
Overall CEA  
V 
No/less CEA 
3 651 OR* 0.56 forest plot CI S 
P value= 0.0002 
 
 3 651  0.83 (CI 0.61, 1.13) NS 
Colonoscopy  
v 
no colonoscopy 
4 of 8 875 OR 0.63* forest plot CI S 
P value=0.0006 
 
 ? 538  OR 0.94 (0.39, 2.27) NS 
More colonoscopy 
V 
Less colonoscopy 
3of 8 1841 OR 0.96* forest plot CI NS 
P value 0.86 
 
 3 of 8 1841  OR 1.22 (0.45, 3.29) NS 
Overall 
colonoscopy 
V 
No/less 
colonoscopy 
7 of 8 2716 OR*0.84 forest plot CI S 
P value=0.04 
 
 
 ? 432  0.87 (CI 0.37, 2.04) 
USS Liver imaging 
V 
No USS liver 
imaging 
3 of 8  702 OR 0.70* forest plot CI S 
P value=0.008 
 
 
 1 of 8 107  OR 2.77 (CI 0.51, 14.94) NS 
More USS liver 
V 
Less USS liver 
2 of 8 1192 OR* 0.90 forest plot CI NS 
P value 0.73 
 
 2 of 8 1192  OR 0.69 (0.44, 1.09) NS 
Overall USS liver 
V 
No/less USS liver 
5 of 8 1894 OR*0.84 forest plot CI NS 
P value 0.11 
 
 ? 1298  0.81 (0.44, 1.5) 
CT liver imaging 
V 
No CT liver 
imaging 
6 of 8 1989 OR*0.79 forest plot CI NS 
P value= 0.06 
 
 6 of 8 1989  OR 0.99 (0.8, 1.22) NS 
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Comparison Studies 
included 
 
No of 
patients 
Time to recurrence 
Expressed as odds ratio 
(OR) in months 
Curative surgery at 
recurrence 
Expressed as odds ratio (OR) 
Intensive FU 
v 
minimalist FU 
5 of 8 1276 OR -5.91 (-8.74, -3.09) S 
But significant heterogeneity 
P<0.00001 
 
 7 of 8 707  OR 2.81 (1.65, 4.79) S 
CEA 
v 
No CEA 
2 of 8 444  OR* 2.06 forest plot CI S 
P value=0.02 
More CEA  
v 
Less CEA 
1 of 8 207  OR*9.86 forest plot CI S 
P value=0.0006 
Overall CEA 
V 
No/less CEA 
3 of 8 651  OR*2.99 forest plot CI S 
P value=0.03 
Colonoscopy  
V 
No colonoscopy 
4 of 8 875  OR* 1.85 forest plot CI S 
P value=0.01 
More colonoscopy 
V 
Less colonoscopy 
2 of 8 856  OR* 2.48 forest plot CI S 
P value=0.01 
Overall 
colonoscopy 
V 
No/less 
colonoscopy 
6 of 8 1731  OR*2.10 forest plot CI S 
P value=0.0006 
USS Liver 
imaging 
V 
No USS liver 
imaging 
3 of 8 702  OR* 1.99 forest plot CI S 
P value=0.002 
More USS liver 
V 
Less USS liver 
1 of 8 207  OR*9.87 forest plot CI S 
P value=0.0006 
Overall USS liver 
V 
No/less USS liver 
4 of 8 909  OR*2.54 forest plot CI  S 
P=0.002 
CT liver imaging 
V 
No CT liver 
imaging 
5 of 8 1004  OR*2.03 forest plot CI  S 
P=0.01 
 
Complication: 
1 study (Schoemaker 1998) reported complications. 4 patients (1.23%) had complications as a result of 
colonoscopy (2 perforations – 1 requiring laparotomy, 2 haemorrhages) 
 
Cost: 
1 study (Rodriguez 2006) included a cost analysis. Overall cost of follow up was higher with intensive follow up 
(300,315 euro v 188,630 euro). However, intensive follow up was more cost-effective when the respectability of 
recurrent disease was taken into account (16,684 euro v 18,863 euro). 
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General comments  
  This meta-analysis supports the general principle of follow up for patients with CRC after curative 
treatment.  
 However there is the limitation that the combined studies span a long time-frame during which clinical 
care and surgical technique have changed considerably. These factors may have an effect on survival 
and question the validity of applying the results of earlier studies to modern practice. 
 Although there was no statistical heterogeneity amongst the studies the intensity of follow up was 
varied. For example the follow up intensity in the experimental arm of one study was the same as the 
intensity of follow up in the control arm of another study. Therefore a precise indication of frequency, 
type or setting of follow up cannot be extracted from the data. 
 Time to recurrence was significantly less and significantly more surgical procedures were carried out in 
the intensively followed arms of the studies. Although this suggests that recurrences were detected 
earlier leading to salvage surgery that lead to the improved survival this result is subject to intervention 
bias. The decision for salvage surgery in these studies was made by clinicians that were not blinded. 
In addition there was significant heterogeneity amongst the studies that reported on time to recurrence 
and this result is not reliable. 
 When looking at particular test used for follow up CEA levels and colonoscopy are the only ones that 
offer a significant survival benefit. The use of liver USS significantly reduced overall mortality but CT 
had an insignificant effect. Increasing the frequency did not improve survival or recurrence detection 
for any of the tests apart from CEA 
 However because the contribution of individual surveillance tests varied considerably among studies 
and no study directly compared specific tests the optimal investigation strategy remains unclear. 
References of Included Studies (For systematic reviews): 
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2. Makela JT, Seppo OL, Kairaluoma MI. Five year follow up after radical surgery for colorectal cancer. 
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3. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg K. Follow up after curative surgery for colorectal 
carcinoma. Diseases of colon and rectum 1995;38(6):619-626 
4. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of 
local recurrences of colorectal cancer. Diseases of colon and rectum 1998;41:1127-1133 
5. Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X et al. Postoperative surveillance in 
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randomised, controlled trial. Journal of clinical oncology 2005;24(3):1-8 
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after resection with curative intent: the GILDA trial. Surg Oncol 2004;13:119-24 
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Citation 3:Wang T, Cui Y, Huang WS, Deng YH, Gong W, Li CJ, Wang JP. The role of postoperative colonoscopic 
surveillance after radical surgery for colorectal cancer: a prospective randomised clinical study. Gastrointestinal 
endoscopy 2009;69(3):609-615. 
Design: Randomised controlled trial 
Country: China 
Aim: To compare the efficacy of 2 different colonoscopic surveillance strategies in terms of survival and recurrence 
resectability. 
Inclusion criteria  
All patients undergoing curative resection for newly diagnosed colorectal cancer between January 1995 and March 
2001. (curative resection was defined as one in which no macroscopic tumour remained at the end of the operation 
and histology of the specimen confirmed no tumour at the margins of resection) 
 
Exclusion criteria  
Duke’s stage D, inflammatory bowel disease, familial adenomatous polyposis, hereditary non-polyposis colorectal 
cancer, patients over the age of 80, medical co-morbidity(making follow up difficult or 5 year survival unlikely), 
residence in remote area, refusal of consent. 
 
Population  
326 consecutive patients under the age of 80, undergoing curative resection for newly diagnosed colorectal cancer 
between Jan 1995 and Mar 2001 at a teaching hospital in China who consented to the trial, did not live in a remote 
area and did not have co-morbidities that made follow up difficult or 5 year survival unlikely. 
7 patients were lost to follow up so there were 319 patients in the final statistical analysis. 
Interventions  
Colonoscopic strategy of follow up. Intensive colonoscopic surveillance (ICS) versus routine colonoscopic surveillance 
(RCS). 
 
The intensive colonoscopy surveillance group (n=165)had colonoscopy at every follow-up visit i.e. 3 monthly for the 
first year, 6 monthly for the next 2 years and annually for the next two years. 
 
The routine colonoscopy surveillance group (n=161) had colonoscopy performed at 6, 30 and 60 months. If 
colonoscopy had been preformed pre-operatively then it was not done at 6 months. 
 
All patients were seen 3 monthly for the first year, 6 monthly for the next 2 years and annually for the next two years. 
At each visit they all had 
Medical history 
Clinical examination 
CEA levels 
CXR 
Liver imaging (CT or USS) 
Outcomes  
5 year survival rate 
Numbers of post operative colorectal cancer (anastomotic recurrence and metachronous tumours) 
Time to recurrence 
Curative surgery for recurrence 
Complications 
Results  
Overall survival was no different between the ICS and the RCS groups. 
Patients in the ICS group had more curative operations for postoperative colorectal cancer and survived significantly 
longer following the detection of the postoperative colorectal cancer. 
76.9% of postoperative colorectal cancers (anastomotic and metachronous) occurred within the first 2 pos-op years. 
Survival 
 42 patients (26.1%) in the ICS v 50 patients (31.6%) in the RCS group died.  
 No significant difference in survival seen between the two groups P=0.27 
 No difference in stage or location distribution seen. 
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 5 year survival (%) 5 year survival (%) P HR (95% CI) 
 ICS RCS   
All patients 77 73 0.25 1.41 (0.92, 2.14) 
Colon cancer 81 76 0.31 1.52 (0.80, 2.87) 
Rectal cancer 72 70 0.49 1.32 (0.75, 2.34) 
Duke’s A 91 86 0.29 1.84 (0.58, 5.84) 
Duke’s B 76 75 0.40 1.19 (0.62,2.27) 
Duke’s C 63 54 0.51 1.35 (0.70, 2.59) 
 
Postoperative colorectal cancer 
 13 patients (8.1%) in the ICS group and 18 patients (11.4%) in the RCS group had postoperative colorectal 
cancer detected. No significant difference between the two groups.p=0.32 
 Anastomotic recurrence was diagnosed in 10 patients (6.2%) of the ICS group and 12 patients (7.6%) of the 
RCS group 
 Metachronous tumours were diagnosed in 3 patients (1.9%) of the ICS group and 6 patients (3.8%) of the 
RCS group. 
 76.9% of postoperative colorectal cancers occurred within the first 2 years. 
 
Postoperative 
colorectal 
cancer 
Year 1 
No / % 
Year 2 
No / % 
Year 3 
No / % 
Year 4 
No / % 
Year 5 
No / % 
Later 
No / % 
ICS (n=13) 5 (38.5%) 
anastomotic  
5 (38.5%) 
4 anastomotic 
1metachronous 
1 (7.7%) 
Anastomotic 
1(7.7%) 
Metachronous 
0 1(7.7%) 
Metachronous 
RCS (n=18) - - 14 (77.8%) 
10anastomotic 
1metachronous 
- 3 (16.7%) 
2anastomotic 
1metachronous 
1 (5.6%) 
metachronous 
 
 Significantly more patients in the ICS group were asymptomatic at the time of detection of their postoperative 
colorectal cancer. (OR 5.24 (1.06, 26.0) p=0.43) 
 Significantly more patients in the ICS group had curative surgery for their postoperative cancer. (OR 0.12 
(0.02, 0.91) p=0.31) 
 Survival after recurrence was detected was significantly longer in the ICS group compared to the RCS group. 
(HR 2.97 (1.05,8.44) p=0.41) 
 More patients that were asymptomatic were able to have curative surgery for their recurrence. 76.5% v 35.7%  
 Patients with asymptomatic recurrence survived significantly longer than those who were 
symptomatic.p=0.005 
Outcome of 
postoperative 
colorectal cancer 
ICS 
No 
ICS  
% 
RCS 
No 
RCS 
% 
P value 
Time to 
recurrence(months) 
Mean 22 
SD 17.6 
 Mean 35 
SD 23.9 
 0.49 
No of 
asymptomatic 
10 76.9% 7 38.9% 0.04 
Curative surgery 
for tumour 
recurrence 
9 69.2% 6 33.3% 0.48 
Survival after 
recurrence(months) 
Mean 69.1 
SD 12.3 
 Mean 24.4 
SD 5.7 
  
 
Complications. 
 3 complications occurred in the ICS group (2 bleeds, 1 perforation) 
 None in the RCS group. 
General comments  
 Well conducted, reasonable size RCT. 
 Supports the view that intensive colonoscopic surveillance does not improve overall survival even though 
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meta-analysis have shown that intensive follow up in general does improve survival. 
 Shows that what intensive colonoscopic surveillance does achieve is earlier detection of postoperative 
colorectal cancer, more curative surgery for this and a longer survival following its detection. 
 The study also reported a large number of postoperative cancers detected in the first 2 years post op and 
suggests based on this finding that colonoscopy should be undertaken annually in the first two years following 
colorectal cancer resection. 
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Calculations for Tjandra 2007: 
 
1. OR for overall survival; CEA v no CEA  from forest plot. Tjandra 2007  
Secco and Ohlsson (444 in total, 192+53=245 intensive arm, 145+54=199 non-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  86  
B = intensive arm no events  245-86=159 
C=events in control arm 97  
D= control arm no events  199-97=102 
OR = ad/bc  OR = 0.57 
 
2. OR for overall survival; more CEA v less CEA  from forest plot. Tjandra 2007  
Pietra (207 in total, 104 intensive arm, 103 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  28  
B = intensive arm no events  104-28=76 
C=events in control arm 43  
D= control arm no events  103-43=60 
OR = ad/bc  OR = 0.51 
 
3. OR for overall survival; CEA v less or no CEA  from forest plot. Tjandra 2007  
Secco, Ohlsson, Pietra (651 in total, 349 intensive arm, 302 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  114  
B = intensive arm no events  349-114=235 
C=events in control arm 140  
D= control arm no events  302-140=162 
OR = ad/bc  OR = 0.56 
 
4. OR for curative reoperation; CEA v no CEA  from forest plot. Tjandra 2007  
Secco and Ohlsson (444 in total, 192+53=245 intensive arm, 145+54=199 non-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  33  
B = intensive arm no events  245-33=212 
C=events in control arm 14  
D= control arm no events  199-14=185 
OR = ad/bc  OR = 2.06 
 
5. OR for curative reoperation; more CEA v less CEA  from forest plot. Tjandra 2007  
Pietra (207 in total, 104 intensive arm, 103 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  17  
B = intensive arm no events  104-17=87 
C=events in control arm 2  
D= control arm no events  103-2=101 
OR = ad/bc  OR = 9.86 
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6. OR for curative reoperation; CEA v less / no CEA  from forest plot. Tjandra 2007  
Secco, Ohlsson, Pietra (651 in total, 349 intensive arm, 302 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  50  
B = intensive arm no events  349-50=299 
C=events in control arm 16  
D= control arm no events  302-16=286 
OR = ad/bc  OR = 2.99 
 
7. OR for overall survival; colonoscopy v no colonoscopy  from forest plot. Tjandra 2007  
Makela, Ohlsson, Schoemaker, Secco (875 in total, 464 intensive arm, 411 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  152  
B = intensive arm no events  464-152=312 
C=events in control arm 179  
D= control arm no events  411-179=232 
OR = ad/bc  OR = 0.63 
 
8. OR for curative reoperation; colonoscopy v no colonoscopy  from forest plot. Tjandra 2007  
Makela, Ohlsson, Schoemaker, Secco (875 in total, 464 intensive arm, 411 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  44  
B = intensive arm no events  464-44=420 
C=events in control arm 22  
D= control arm no events  411-22=389 
OR = ad/bc  OR = 1.85 
 
9. OR for overall survival; more colonoscopy v less colonoscopy  from forest plot. Tjandra 2007  
Kjedsen, Grossmann, Rodriguez ( 1841 in total, 906 intensive arm, 935 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  141  
B = intensive arm no events  906-141=765 
C=events in control arm 151  
D= control arm no events  935-151=784 
OR = ad/bc  OR = 0.96 
 
10. OR for overall survival; colonoscopy v less / no colonoscopy  from forest plot. Tjandra 2007  
Kjedsen, Grossmann, Rodriguez Makela, Ohlsson, Schoemaker, Secco 
(2716 in total, 1370 intensive arm, 1346 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  293  
B = intensive arm no events  1370-293=1077 
C=events in control arm 330  
D= control arm no events  1346-330=1016 
OR = ad/bc  OR = 0.84 
 
11. OR for curative reoperation; more colonoscopy v less colonoscopy  from forest plot. Tjandra 2007  
Kjedsen, Rodriguez (856 in total, 417 intensive arm, 439 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  25  
B = intensive arm no events  417-25=392 
C=events in control arm 11  
D= control arm no events  439-11=428 
OR = ad/bc  OR = 2.48 
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12. OR for curative reoperation; colonoscopy v less /no colonoscopy  from forest plot. Tjandra 2007  
Makela, Ohlsson, Schoemaker, Secco, Kjedsen, Rodriguez  
(1731 in total, 881 intensive arm, 850 less-intensive arm) 
 
 Detail given Detail calculated 
A=events in intensive arm  69  
B = intensive arm no events  881-69=812 
C=events in control arm 33  
D= control arm no events  850-33=817 
OR = ad/bc  OR = 2.10 
 
13. OR for overall survival; US liver v no US liver  from forest plot. Tjandra 2007  
Makela, Secco, Rodriguez (702 in total, 371 intensive arm, 331 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  115  
B = intensive arm no events  371-115=256 
C=events in control arm 129  
D= control arm no events  331-129=202 
OR = ad/bc  OR = 0.70 
 
14. OR for curative reoperation;  US liver v no US liver  from forest plot. Tjandra 2007  
Makela, Secco,  Rodriguez (702 in total,  371 intensive arm, 331 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  54  
B = intensive arm no events  371-54=317 
C=events in control arm 26  
D= control arm no events  331-26=305 
OR = ad/bc  OR = 1.99 
 
15. OR for overall survival; more USS liver v less USS liver  from forest plot. Tjandra 2007  
Pietra, Grossmann (1192 in total, 593 intensive arm, 599 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  60  
B = intensive arm no events  593-60=533 
C=events in control arm 67  
D= control arm no events  599-67=532 
OR = ad/bc  OR = 0.90 
 
16. OR for overall survival;  USS liver v less /no USS liver  from forest plot. Tjandra 2007  
Makela, Secco,  Rodriguez, Pietra, Grossmann (1894 in total, 964 intensive arm, 930 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  175  
B = intensive arm no events  964-175=789 
C=events in control arm 196  
D= control arm no events  930-196=734 
OR = ad/bc  OR = 0.84 
 
17. OR for curative reoperation;  more USS liver v less USS liver  from forest plot. Tjandra 2007  
Pietra (207 in total,  104 intensive arm, 103 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  17  
B = intensive arm no events  104-17=87 
C=events in control arm 2  
D= control arm no events  103-2=101 
OR = ad/bc  OR = 9.87 
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18. OR for curative reoperation; USS liver v less / no USS liver  from forest plot. Tjandra 2007  
Makela, Secco,  Rodriguez, Pietra (909 in total,  475 intensive arm, 434 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  71  
B = intensive arm no events  475-71=404 
C=events in control arm 28  
D= control arm no events  434-28=406 
OR = ad/bc  OR = 2.54 
 
19. OR for overall survival; CT liver v no CT liver  from forest plot. Tjandra 2007  
Makela, Ohlsson, Pietra, Schoemaker, Grossmann, Rodriguez (1989 in total, 992 intensive arm, 997 less-
intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  162  
B = intensive arm no events  992-162=830 
C=events in control arm 198  
D= control arm no events  997-198=799 
OR = ad/bc  OR = 0.79 
 
20. OR for curative reoperation;  CT liver v no CT liver  from forest plot. Tjandra 2007  
Makela, Ohlsson, Pietra, Schoemaker, Rodriguez (1004 in total, 503 intensive arm, 501 less-intensive arm) 
 Detail given Detail calculated 
A=events in intensive arm  48  
B = intensive arm no events  503-48=455 
C=events in control arm 21  
D= control arm no events  501-21=480 
OR = ad/bc  OR = 2.41 
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GRADE tables for follow up recommendation 
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Quality assessment Summary of findings 
Importance 
Number of patients Effect 
Quality Number of 
studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
Intensive 
follow-up 
Less 
intensive or 
no follow-up  
Relative 
(95% CI) 
Absolute 
Overall survival at 5 years Jeffery et al 2007 (follow-up mean 5 years) 
6 randomised trials serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
218/793 
(27.5%) 
274/808 
(33.9%) 
OR 0.73 
(0.59 to 
0.91) 
67 fewer per 
1000 (from 21 
fewer to 107 
fewer)  
MODERATE 
CRITICAL 
33.9% 
67 fewer per 
1000 (from 21 
fewer to 107 
fewer) 
Overall survival at 5 years Tjandra 2007 (follow-up mean 5 years) 
8 randomised trials serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
321/1474 
(21.8%) 
373/1449 
(25.7%) 
OR 0.74 
(0.59 to 
0.93) 
53 fewer per 
1000 (from 14 
fewer to 88 
fewer)  
MODERATE 
CRITICAL 
25.7% 
53 fewer per 
1000 (from 14 
fewer to 88 
fewer) 
Number of recurrences Jeffery 2007 (follow-up mean 5 years) 
7 randomised trials serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
354/985 
(35.9%) 
351/953 
(36.8%) 
OR 0.91 
(0.75 to 
1.1) 
22 fewer per 
1000 (from 64 
fewer to 22 
more)  
MODERATE 
CRITICAL 
36.8% 
22 fewer per 
1000 (from 64 
fewer to 22 
more) 
Number of recurrences (all sites) Tjandra 2007 (follow-up mean 5 years) 
8 randomised 
trials 
serious1 no serious 
inconsistency2 
no serious 
indirectness 
no serious 
imprecision 
none 
429/1474 
(29.1%) 
417/1449 
(28.8%) OR 0.97 
(0.82 to 
1.14) 
6 fewer per 1000 (from 
39 fewer to 28 more)  
MODERATE 
CRITICAL 
28.8% 
6 fewer per 1000 (from 
39 fewer to 28 more) 
Question: Should intensive follow-up versus less intensive or no follow-up be recommended for non metastatic colorectal cancer? 
 
1 the majority of studies in this comparison had unclear reporting of allocation concealment. This could introduce significant bias to the randomisation process and the results 
overall. 
2 heterogeneity not reported 
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Number of asymptomatic recurrences Tjandra 2007 (follow-up mean 5 years) 
6 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
162/858 
(18.9%) 
52/821 
(6.3%) OR 3.42 (2.17 to 
5.41) 
124 more per 1000 (from 65 more to 
205 more)  
LOW 
CRITICAL 
6.3% 
124 more per 1000 (from 64 more to 
204 more) 
Time to recurrence Jeffery 2007 (follow-up mean 5 years; measured with: months from primary surgery to recurrence; Better indicated by lower values) 
3 randomised 
trials 
serious1 serious4 no serious 
indirectness 
no serious 
imprecision 
none 
209 211 - MD 6.75 lower (11.06 to 2.44 lower) 
 
LOW 
CRITICAL 
Time to recurrence Tjandra 2007 (follow-up mean 5 years; measured with: months from primary surgery to recurrence; Better indicated by lower values) 
5 randomised 
trials 
serious1 serious5 no serious 
indirectness 
no serious 
imprecision 
none 
626 650 - MD 5.91 lower (8.74 to 3.09 lower) 
 
LOW 
CRITICAL 
Curative surgery attempted for recurrence Jeffery 2007 (follow-up mean 5 years) 
6 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
95/818 
(11.6%) 
40/795 (5%) 
OR 2.41 (1.63 to 
3.54) 
63 more per 1000 (from 29 more to 
108 more)  
LOW 
CRITICAL 
5% 
63 more per 1000 (from 29 more to 
107 more) 
Curative surgery attempted for recurrence Tjandra 2007 (follow-up mean 5 years) 
7 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
86/354 
(24.3%) 
35/353 
(9.9%) OR 2.81 (1.65 to 
4.79) 
137 more per 1000 (from 55 more to 
246 more)  
LOW 
CRITICAL 
9.9% 
137 more per 1000 (from 54 more to 
246 more) 
Disease specific survival Jeffery 2007 (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3,6 none 
73/343 
(21.3%) 
82/361 
(22.7%) OR 0.92 (0.64 to 
1.31) 
14 fewer per 1000 (from 69 fewer to 
51 more)  
LOW 
CRITICAL 
22.7% 
14 fewer per 1000 (from 69 fewer to 
51 more) 
 
1 the majority of studies in this comparison had unclear reporting of allocation concealment. This could introduce significant bias to the randomisation process and the results 
overall. 
2 heterogeneity not reported 
3 The total number of event is low (less than the 300 rule of thumb). This can introduce imprecision to the result.  
4 heterogeneity: p=0.00002, I squared=91%, all 3 studies favour intensive follow -up. 
5 heterogeneity: p<0.00001, I squared not given, 4 out of 5 studies favour intensive follow-up.  
6 The CI includes 1 and the lower limit is <than 0.75 and the upper limit is > 1.25 
 
Question continued: Should intensive follow -up versus less intensive or no follow-up be recommended for non metastatic colorectal cancer? 
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Quality assessment Summary of findings 
Importance 
Number of patients Effect 
Quality Number of 
studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
CEA No CEA 
Relative 
(95% CI) 
Absolute 
Overall survival at 5 years Jeffery 2007 (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
15/53 
(28.3%) 
22/54 
(40.7%) OR 0.57 (0.26 
to 1.29) 
126 fewer per 1000 (from 
256 fewer to 63 more)  
LOW 
CRITICAL 
40.7% 
126 fewer per 1000 (from 
256 fewer to 63 more) 
Overall survival at 5 years Tjandra 2007 (follow-up mean 5 years) 
2 randomised 
trials 
very 
serious1,3 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
86/245 
(35.1%) 
97/199 
(48.7%) OR 0.57 (0 to 
0)4,5 
136 fewer per 1000 (from 
487 fewer to 487 fewer)  
VERY 
LOW 
 
48.7% 
136 fewer per 1000 (from 
487 fewer to 487 fewer) 
Number of recurrences Jefferey 2007 (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
118/245 
(48.2%) 
101/199 
(50.8%) OR 0.85 (0.58 
to 1.25) 
41 fewer per 1000 (from 
133 fewer to 55 more)  
LOW 
CRITICAL 
50.8% 
41 fewer per 1000 (from 
133 fewer to 55 more) 
Number of recurrences Tjandra 2007 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
118/245 
(48.2%) 
101/199 
(50.8%) OR 0.85 (0.58 
to 1.25) 
41 fewer per 1000 (from 
133 fewer to 55 more)  
LOW 
CRITICAL 
50.8% 
41 fewer per 1000 (from 
133 fewer to 55 more) 
Number of curative re-operations (Tjandra 2007) (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
33/245 
(13.5%) 
14/199 
(7%) OR 2.06 (0 to 
0)4,5 
65 more per 1000 (from 
70 fewer to 70 fewer)  
LOW 
CRITICAL 
7% 
64 more per 1000 (from 
70 fewer to 70 fewer) 
Question: Should CEA testing versus no CEA testing be recommended for non metastatic colorectal cancer follow-up ? 
1 unclear allocation concealment. 2 the total number of event is low (less than 300 rule of thumb) 
3 Secco trial included in the survival data though it is unclear how survival data has been extracted from this trial.  
4 for ease of comparison this OR value is my calculation based on other relevant information provided by the authors in their forest plot. Please see page of calculations in the 
evidence tables document for more detailed explanation of how this calculation was done. The authors reported p value and not OR. 
5 No numerical confidence interval was given but forest plot indicates that this is a statistically significant result as the diamond does not cross the line of no effect (1). 
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Quality assessment 
Summary of findings 
Importance 
Number of patients Effect 
Quality Number of 
studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
Liver 
imaging 
No liver 
imaging 
Relative 
(95% CI) 
Absolute 
Overall survival at 5 years Jeffery 2007 (follow-up mean 5 years) 
5 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
130/503 
(25.8%) 
174/501 
(34.7%) 
OR 0.64 
(0.49 to 0.85) 
93 fewer per 1000 
(from 36 fewer to 140 
fewer)  
MODERATE 
CRITICAL 
34.7% 
93 fewer per 1000 
(from 36 fewer to 140 
fewer) 
Number of recurrences Jeffery 2007 (follow-up mean 5 years) 
6 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 
278/695 
(40%) 
271/646 
(42%) 
OR 0.88 (0.7 
to 1.1) 
31 fewer per 1000 
(from 84 fewer to 23 
more)  
MODERATE 
CRITICAL 
42% 
31 fewer per 1000 
(from 84 fewer to 23 
more) 
Ultrasonography overall survival at 5 years Tjandra 
3 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
115/371 
(31%) 
129/331 
(39%) 
OR 0.7 (0 to 
0)4,5 
81 fewer per 1000 
(from 390 fewer to 390 
fewer)  
LOW 
CRITICAL 
39% 
81 fewer per 1000 
(from 390 fewer to 390 
fewer) 
CT overall survival Tjandra 2007 
6 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
162/992 
(16.3%) 
198/997 
(19.9%) 
OR 0.79 (0 to 
0)4,6 
35 fewer per 1000 
(from 199 fewer to 199 
fewer)  
MODERATE 
CRITICAL 
19.9% 
35 fewer per 1000 
(from 199 fewer to 199 
fewer) 
Ultrasonography number of recurrences Tjandra 2007 (follow-up mean 5 years) 
3 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
5/52 
(9.6%) 
2/54 
(3.7%) OR 2.77 
(0.51 to 
14.94) 
59 more per 1000 
(from 18 fewer to 328 
more)  
LOW 
 
3.7% 
59 more per 1000 
(from 18 fewer to 328 
more) 
Question: Should liver imaging versus no liver imaging be recommended for non metastatic colorectal cancer follow-up? 
1 most studies had unclear allocation concealment 
2 i do not think this comparison has significant imprecision. The total number of events is large (>300) and althought the CI includes 1 the upper limit is not >1.25 
3 the total number of event was low (less than 300 rule of thumb) 
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CT number of recurrences (follow-up mean 5 years) 
5 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
252/992 
(25.4%) 
254/997 
(25.5%) 
OR 0.99 (0.8 
to 1.22) 
2 fewer per 1000 
(from 40 fewer to 40 
more)  
MODERATE 
CRITICAL 
25.5% 
2 fewer per 1000 
(from 40 fewer to 40 
more) 
Ultrasonography number of curative re-operations 
3 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
54/371 
(14.6%) 
26/331 
(7.9%) 
OR 1.99 (0 to 
0)4,5 
66 more per 1000 
(from 79 fewer to 79 
fewer)  
LOW 
CRITICAL 
7.9% 
67 more per 1000 
(from 79 fewer to 79 
fewer) 
CT number of curative re-operations Tjandra 2007 (follow-up mean 5 years) 
5 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
48/503 
(9.5%) 
21/501 
(4.2%) 
OR 2.41 (0 to 
0)4,5 
53 more per 1000 
(from 42 fewer to 42 
fewer)  
LOW 
CRITICAL 
4.2% 
54 more per 1000 
(from 42 fewer to 42 
fewer) 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 most studies had unclear allocation concealment 
2 i do not think this comparison has significant imprecision. The total number of events is large (>300) and althought the CI includes 1 the upper limit is not >1.25 
3 the total number of event was low (less than 300 rule of thumb) 
4 for ease of comparison this OR value is my calculation based on other relevant information provided by the authors in the forest plot. Please see page of calculations in the 
evidence tables document for more detailed explanations of how this calculation was done. 
5 No numerical confidence interval was given but forest plot indicates that this is a statistically significant result as the diamond does not cross the line of no effect(1). 
6 No numerical confidence interval was given but forest plot indicates that this is not a statistically significant result as the diamond does cross the line of no effect (1). 
 
Question continued: Should liver imaging versus no liver imaging be recommended for non metastatic colorectal cancer follow-up? 
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Quality assessment Summary of findings 
Importance 
Number of patients Effect 
Quality Number 
of studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
Intensive 
colonoscopic 
surveillance 
No 
colonoscopic 
surveillance 
Relative 
(95% CI) 
Absolute 
Number of recurrences (Tjandra 2007) (follow-up 5 years) 
4 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
11/272 (4%) 
11/266 (4.1%) 
OR 0.94 
(0.39 to 
2.27) 
2 fewer per 1000 
(from 25 fewer to 
48 more)  
LOW 
 
4.1% 
2 fewer per 1000 
(from 25 fewer to 
47 more) 
Overall survival at 5 years Tjandra (follow-up mean 5 years) 
4 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
152/464 (32.8%) 
179/411 (43.6%) 
OR 0.63 (0 
to 0)3,4 
108 fewer per 
1000 (from 436 
fewer to 436 
fewer)  
MODERATE 
CRITICAL 
43.6% 
108 fewer per 
1000 (from 436 
fewer to 436 
fewer) 
Curative operations for recurrence (Tjandra 2007) (follow-up mean 5 years) 
4 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
44/464 (9.5%) 
22/411 (5.4%) 
OR 1.85 (0 
to 0)3,4 
41 more per 
1000 (from 54 
fewer to 54 
fewer)  
LOW 
CRITICAL 
5.4% 
42 more per 
1000 (from 54 
fewer to 54 
fewer) 
 
 
 
 
 
 
 
Question: Should intensive colonoscopic surveillance versus no colonoscopic surveillance be recommended for non metastatic colorectal cancer follow-up? 
 
1 most studies have unclear allocation concealment 
2 the total number of events is less than 300 (rule of thumb) 
3 No numerical confidence interval was given but forest plot indicates that this is a statistically significant result as the diamond does not cross the line of no effect (1).  
4 for ease of comparison this OR value is my calculation based on other relevant information provided by the authors in their forest plot. Please see page of calculations in the 
evidence tables document for more detailed explanation of how this calculation was done. The authors reported p value and not OR. 
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Quality assessment Summary of findings 
Importance 
Number of patients Effect 
Quality Number of 
studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
More 
tests 
Fewer 
tests 
Relative 
(95% CI) 
Absolute 
Overall survival at 5 years (follow-up mean 5 years) 
5 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
130/503 
(25.8%) 
174/501 
(34.7%) OR 0.64 
(0.49 to 
0.85) 
93 fewer per 1000 
(from 36 fewer to 140 
fewer)  
MODERATE 
CRITICAL 
89.1% 
51 fewer per 1000 
(from 17 fewer to 91 
fewer) 
Number of recurrences Jeffery 2007 (follow-up mean 5 years) 
5 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 
177/503 
(35.2%) 
188/501 
(37.5%) OR 0.90 
(0.69 to 
1.16) 
24 fewer per 1000 
(from 82 fewer to 35 
more)  
MODERATE 
CRITICAL 
37.5% 
24 fewer per 1000 
(from 82 fewer to 35 
more) 
More CEA testing versus less CEA testing for overall survival (Tjandra 2007) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
28/104 
(26.9%) 
43/103 
(41.7%) 
OR 0.51 (0 
to 0)4,5 
150 fewer per 1000 
(from 417 fewer to 417 
fewer)  
LOW 
CRITICAL 
41.7% 
150 fewer per 1000 
(from 417 fewer to 417 
fewer) 
More CEA testing versus less CEA testing for recurrence (Tjandra 2007) (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
47/104 
(45.2%) 
53/103 
(51.5%) OR 0.83 
(0.61 to 
1.13) 
47 fewer per 1000 
(from 122 fewer to 30 
more)  
LOW 
CRITICAL 
51.5% 
47 fewer per 1000 
(from 122 fewer to 30 
more) 
More CEA testing versus less CEA testing for curative re-operation (Tjandra 2007) (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
17/104 
(16.3%) 
2/103 
(1.9%) 
OR 9.86 (0 
to 0)4,5 
144 more per 1000 
(from 19 fewer to 19 
fewer)  
LOW 
CRITICAL 
1.9% 
141 more per 1000 
(from 19 fewer to 19 
fewer) 
Question: Should more tests versus fewer tests be recommended for non metastatic colorectal cancer follow-up? 
 
1 unclear allocation concealment 
2 I do not think this result has significant imprecision. The CI includes 1 but the number of total events is large (>300). 
3 the total number of events is very low (less than 300 rule of thumb). 
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More versus less colonoscopy for overall survival (Tjandra 2007) (follow-up mean 5 years) 
3 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
141/906 
(15.6%) 
151/935 
(16.1%) 
OR 0.96 (0 to 0)4,6 
5 fewer per 1000 (from 161 fewer to 161 
fewer)  
LOW 
CRITICAL 
16.1% 
5 fewer per 1000 (from 161 fewer to 161 
fewer) 
More versus less colonoscopy for overall survival (Wang 2009) (follow-up mean 5 years) 
1 randomised 
trials 
serious7 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
42/165 
(25.5%) 
50/161 
(31.1%) HR 1.41 (0.92 to 
2.14) 
97 more per 1000 (from 21 fewer to 238 
more)  
LOW 
CRITICAL 
31.1% 
98 more per 1000 (from 21 fewer to 238 
more) 
More versus less colonoscopy for recurrence (Tjandra 2007) (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
33/906 (3.6%) 
32/935 (3.4%) 
OR 1.22 (0.45 to 
3.29) 
7 more per 1000 (from 19 fewer to 70 
more)  
LOW 
CRITICAL 
3.4% 
7 more per 1000 (from 18 fewer to 70 
more) 
More versus less colonoscopy for recurrence (anastomotic and metachronous) Wang 2009 (follow-up mean 5 years) 
1 randomised 
trials 
serious7 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
13/165 (7.9%) 
18/161 
(11.2%) p value 0.32 (0 to 
0) 
76 fewer per 1000 (from 112 fewer to 112 
fewer)  
LOW 
CRITICAL 
11.2% 
76 fewer per 1000 (from 112 fewer to 112 
fewer) 
More versus less colonoscopy for anastomotic recurrence Wang 2009 (follow-up mean 5 years) 
1 randomised 
trials 
serious7 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
10/13 (76.9%) 
7/18 (38.9%) 
OR 5.24 (1.06 to 
26) 
380 more per 1000 (from 14 more to 554 
more)  
LOW 
CRITICAL 
38.9% 
380 more per 1000 (from 14 more to 554 
more) 
1 unclear allocation concealment 
3 the total number of events is very low (less than 300 rule of thumb).  
7 there was no blinding in the study introducing high risk of performance and detection bias. 
Question continued: Should more tests versus fewer tests be recommended for non metastatic colorectal cancer follow-up? 
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More versus less colonoscopy for time to recurrence Wang 2009 (follow-up mean 5 years; Better indicated by lower values) 
1 randomised 
trials 
serious7 no serious 
inconsistency 
no serious 
indirectness 
serious8 none 
13 18 - 0.49 higher (0 to 0 higher) 
 
LOW 
CRITICAL 
More versus less colonoscopy for curative operations attempted for recurrence (Tjandra 2007) (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
25/417 (6%) 
11/439 (2.5%) 
OR 2.48 (0 to 0)4,5 
35 more per 1000 (from 25 fewer to 25 
fewer)  
LOW 
CRITICAL 
2.5% 
35 more per 1000 (from 25 fewer to 25 
fewer) 
More versus less colonoscopy for curative surgery attempted for recurrence (Wang 2009) (follow-up mean 5) 
1 randomised 
trials 
serious7 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
9/13 (69.2%) 
8/18 (44.4%) 
OR 0.12 (0.02 to 
0.91) 
357 fewer per 1000 (from 23 fewer to 429 
fewer)  
LOW 
CRITICAL 
44.4% 
357 fewer per 1000 (from 23 fewer to 428 
fewer) 
More versus less colonoscopy for time of survival after recurrence(Wang 2009) (follow-up mean 5 years; Better indicated by lower values) 
1 randomised 
trials 
serious7 no serious 
inconsistency 
no serious 
indirectness 
serious8 none 
13 18 - 2.97 higher (1.05 to 8.44 higher) 
 
LOW 
CRITICAL 
More versus less ultrasonography for overall survival Tjandra 2007 (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
60/593 
(10.1%) 
67/599 
(11.2%) 
OR 0.90 (0 to 0)4,6 
10 fewer per 1000 (from 112 fewer to 112 
fewer)  
LOW 
CRITICAL 
11.2% 
10 fewer per 1000 (from 112 fewer to 112 
fewer) 
More versus less ultrasonography for recurrence Tjandra 2007 (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
39/593 (6.6%) 
53/599 (8.8%) 
OR 0.69 (0.44 to 
1.09) 
26 fewer per 1000 (from 48 fewer to 7 
more)  
LOW 
CRITICAL 
8.8% 
26 fewer per 1000 (from 47 fewer to 7 
more) 
More versus less ultrasonography for curative re-operation for recurrence Tjandra 2007 (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 
17/104 
(16.3%) 
2/103 (1.9%) 
OR 9.87 (0 to 0)4,5 
144 more per 1000 (from 19 fewer to 19 
fewer)  
LOW 
CRITICAL 
1.9% 
141 more per 1000 (from 19 fewer to 19 
fewer) 
 
 
 
 
1 unclear allocation concealment 
3 the total number of events is very low (less than 300 rule of thumb).  
7 there was no blinding in the study introducing high risk of performance and detection bias. 
8 the total population size is very low (less than 400 rule of thumb for continuous outcomes) 
 
Question continued: Should more tests versus fewer tests be recommended for non metastatic colorectal cancer follow-up? 
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Quality assessment 
Summary of findings 
Importance 
Number of patients Effect 
Quality Number of 
studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
More tests 
Fewer or 
no tests 
Relative 
(95% CI) 
Absolute 
CEA testing versus less or no CEA testing for overall recurrence Tjandra 2007 (follow-up mean 5 years) 
3 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
114/349 
(32.7%) 
140/302 
(46.4%) 
OR 0.56  (0 
to 0)3,4 
137 fewer per 1000 
(from 464 fewer to 
464 fewer)  
LOW 
CRITICAL 
46.4% 
138 fewer per 1000 
(from 464 fewer to 
464 fewer) 
CEA testing versus less or no CEA testing for number of recurrences Tjandra 2007 (follow-up mean 5 years) 
3 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
165/349 
(47.3%) 
154/302 
(51%) OR 0.83 
(0.61 to 
1.13) 
47 fewer per 1000 
(from 122 fewer to 30 
more)  
MODERATE 
CRITICAL 
51% 
47 fewer per 1000 
(from 122 fewer to 30 
more) 
CEA testing versus less or no CEA testing for curative re-operation Tjandra 2007 (follow-up mean 5 years) 
3 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
50/349 
(14.3%) 
16/302 
(5.3%) 
OR 2.99  (0 
to 0)3,4 
90 more per 1000 
(from 53 fewer to 53 
fewer)  
LOW 
CRITICAL 
5.3% 
90 more per 1000 
(from 53 fewer to 53 
fewer) 
Colonoscopy versus less or no colonoscopy for overall survival Tjandra 2007 (follow-up mean 5 years) 
7 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
293/1370 
(21.4%) 
330/1346 
(24.5%) 
OR 0.84 (0 
to 0)3,4 
31 fewer per 1000 
(from 245 fewer to 
245 fewer)  
MODERATE 
CRITICAL 
024.5% 
31 fewer per 1000 
(from 245 fewer to 
245 fewer) 
Question: Should more tests versus fewer or no tests be recommended for follow-up for colorectal cancer?  
1 Allocation concealment unclear in the majority of studies. 
2 total number of events is less than 300 (rule of thumb) 
3 for ease of comparison the OR value is my own calculation based on other relevant information provided by the authors in their forest plot. Please see page of caluclations in the 
evidence tables document for more detailed explanation of how this calculation was made. The authors reported p-value not OR. 
4 No numerical confidence interval was given but forest plot indicates that this is a statistically significant result as the diamond does not cross the line of no effect (1). 
5 No numerical confidence interval was given but forest plot indicates that this is not a statistically significant result as the diamond does cross the line of no effect (1). 
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Colonoscopy versus less or no colonoscopy for number of recurrences Tjandra 2007 (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
44/1178 
(3.7%) 
43/1201 
(3.6%) OR 1.09 (0.6 to 
1.98) 
3 more per 1000 (from 14 fewer to 
33 more)  
LOW 
CRITICAL 
3.6% 
3 more per 1000 (from 14 fewer to 
33 more) 
Colonoscopy versus less or no colonoscopy for curative re-operation Tjandra 2007 (follow-up mean 5 years) 
6 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
69/881 
(7.8%) 
33/850 
(3.9%) OR 2.10 (0 to 
0)3,4 
39 more per 1000 (from 39 fewer 
to 39 fewer)  
LOW 
CRITICAL 
3.9% 
40 more per 1000 (from 39 fewer 
to 39 fewer) 
Ultrasonography versus less or no ultrasonography of the liver for overall survival Tjandra 2007 (follow-up mean 5 years) 
5 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 
175/964 
(18.2%) 
196/930 
(21.1%) OR 0.84 (0 to 
0)3,5 
28 fewer per 1000 (from 211 fewer 
to 211 fewer)  
MODERATE 
CRITICAL 
21.1% 
28 fewer per 1000 (from 211 fewer 
to 211 fewer) 
Ultrasonography versus less or no ultrasonography for number of recurrences Tjandra 2007 (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
44/645 
(6.8%) 
55/653 
(8.4%) OR 0.81 (0.44 
to 1.5) 
15 fewer per 1000 (from 45 fewer 
to 37 more)  
LOW 
CRITICAL 
8.4% 
15 fewer per 1000 (from 45 fewer 
to 37 more) 
Ultrasonography versus less or no ultrasonography for curative re-operations Tjandra 2007 
4 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2 none 
71/475 
(14.9%) 
28/434 
(6.5%) OR 2.54 (0 to 
0)3,4 
85 more per 1000 (from 65 fewer 
to 65 fewer)  
LOW 
CRITICAL 
6.5% 
85 more per 1000 (from 65 fewer 
to 65 fewer) 
 
 
 
 
 
 
 
1 Allocation concealment unclear in the majority of studies. 
2 total number of events is less than 300 (rule of thumb) 
3 for ease of comparison the OR value is my own calculation based on other relevant information provided by the authors in their forest plot. Please see page of caluclations in the 
evidence tables document for more detailed explanation of how this calculation was made. The authors reported p-value not OR. 
4 No numerical confidence interval was given but forest plot indicates that this is a statistically significant result as the diamond does not cross the line of no effect (1). 
5 No numerical confidence interval was given but forest plot indicates that this is not a statistically significant result as the diamond does cross the line of no effect (1). 
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Quality assessment Summary of findings 
Importance 
Number of patients Effect 
Quality Number of 
studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
Clinic visit 
No clinic 
visit 
Relative 
(95% CI) 
Absolute 
Overall survival at 5 years Jeffery 2007 (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2,3 none 
15/53 
(28.3%) 
22/54 
(40.7%) OR 0.57 (0.26 
to 1.29) 
126 fewer per 1000 (from 
256 fewer to 63 more)  
LOW 
CRITICAL 
40.7% 
126 fewer per 1000 (from 
256 fewer to 63 more) 
Number of recurrences Jeffery 2007 (follow-up mean 5 years) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious2,3 none 
118/245 
(48.2%) 
101/199 
(50.8%) OR 0.85 (0.58 
to 1.25) 
41 fewer per 1000 (from 
133 fewer to 55 more)  
LOW 
CRITICAL 
50.8% 
41 fewer per 1000 (from 
133 fewer to 55 more) 
 
 
 
 
 
 
1 unclear reporting of allocation concealment 
2 the number of total events is low (less than 300) 
3 the CI crosses the line of no effect (includes 1) plus its lower limit is < than 0.75 and its upper limit is > than 1.25. In addition the total number of events is much lower than the 
rule of thumb of 300. 
 
Question: Should follow -up clinic  visits versus no follow -up clinic visit be recommended in non metastatic colorectal cancer suveillance? 
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Quality assessment Summary of findings 
Importance 
Number of patients Effect 
Quality Number of 
studies 
Design Limitations Inconsistency Indirectness Imprecision 
Other 
considerations 
More clinic 
visits 
Fewer 
clinic visits 
Relative 
(95% CI) 
Absolute 
Overall survival at 5 years Jeffery 2007 (follow-up mean 5 years) 
2 randomised 
trials 
serious1 serious2 no serious 
indirectness 
serious3,4 none 
116/394 
(29.4%) 
143/410 
(34.9%) OR 0.78 (0.58 
to 1.05) 
54 fewer per 1000 (from 
112 fewer to 11 more)  
VERY 
LOW 
CRITICAL 
34.9% 
54 fewer per 1000 (from 
112 fewer to 11 more) 
Number of recurrences Jeffery 2007 (follow-up mean 5 years) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3,5 none 
123/394 
(31.2%) 
133/410 
(32.4%) OR 0.93 (0.69 
to 1.26) 
16 fewer per 1000 (from 
76 fewer to 53 more)  
LOW 
CRITICAL 
32.4% 
16 fewer per 1000 (from 
75 fewer to 53 more) 
 
 
 
 
 
 
 
 
 
1 unclear allocation concealment 
2 p value 0.1, I squared 62% 
3 the total number of events is low (less than 300) 
4 CI includes 1 and the lower limit is < 0.75 
5 CI includes 1, the lower limit is < 0.75 and the upper limit is > 
 
Question: Should more follow-up clinic visits versus fewer follow-up clinic visits be recommended for non metastatic colorectal cancer surveillance? 
 
  329 
Appendix 8 
 
Publication 1 
 
Kontoyannis A, Hargest R. How Guidelines influence modern surgical 
practice. In: Taylor I, Johnson CD (Editors). Recent Advances in Surgery. 
New Delhi: Jaypee Brothers Medical Publishers; 2011. p 20-33  
(ISBN 978-93-5025-355-7) 
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Publication 2 
 
Kontoyannis A, Hargest R. The importance of understanding guideline 
methodology and the principles of evidence based medicine. BMJ online 
rapid response. 2011. http://www.bmj.com/rapid-
response/2011/11/03/importance-understanding-guideline-development-
methodology-and-principles- 
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Response
The importance of understanding guideline development
methodology and the principles of evidence­based
medicine.
We enjoyed reading the article by Carthey et al. regarding the use of
guidelines in clinical practice. The authors have presented an important
issue and their frustration is undoubtedly shared by many clinicians.
To accept the recommendations of any guideline and potentially change
practice individual clinicians need the skills to appraise the validity of
the guideline.
The current confusion of many healthcare professionals with regard to
guidelines that has been reported by the authors, is accentuated by a lack
of appraisal skills.
We may eagerly read the recommendations, but this is incomplete if we
don't read or understand the methodology in order to assess the quality
and validity of the guideline.
Our research shows that there is very poor reporting of methodology
by the majority of UK learned medical societies that produce guidelines.
The methodology is often absent from the guideline document and the
society website.[1] Even when the methodology is reported, has been
assessed and is sound, clinicians need to be able to assess the strengths
and weaknesses of individual recommendations. Contradictory statements
between different guidelines are likely to arise when the evidence is of
low quality and the recommendation has been developed by consensus
methods. If the evidence is of high quality there may be subtle
differences in the development framework because focusing on subtly
different end points can produce a very different search result and
therefore recommendation.
Differences between international guidelines may reflect the
different healthcare settings and culture of both the patient population
and the guideline development group. These should be accounted for when
assessing the applicability of the guideline to our own patients.
We agree with the authors that guidelines should be a means to
improve patient care. To streamline the use of what we consider a valuable
new tool and navigate through this currently ever­increasing ocean of
information we would also like to see:
1.better reporting of methodology by learned medical societies on
production of their guidelines.
2.education in guideline development, appraisal and the principles of
evidence­based medicine as a core curriculum topic in medical schools and
postgraduate training programmes.
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